<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002352</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>2</s160></s100><s200><s210>1</s210><s211>20</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthetic</s223></s220></s200><s400> 1Gly Gly Asp Tyr Lys Asp Asp Asp Asp Lys Gly Gly His His His His1               5                   10                  15His His His His            20</s400><s200><s210>2</s210><s211>29</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>synthetic</s223></s220></s200><s400> 2Asp Tyr Lys Asp Asp Asp Asp Lys His His His His His His Gly Leu1               5                   10                  15Asn Asp Ile Phe Glu Ala Gln Lys Ile Glu Trp His Glu            20                  25</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002353A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221220" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002353</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17138309</doc-number><date>20201230</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>401</main-group><subgroup>14</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>401</main-group><subgroup>10</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>213</main-group><subgroup>82</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>401</main-group><subgroup>04</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>401</main-group><subgroup>12</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>403</main-group><subgroup>04</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>405</main-group><subgroup>14</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>409</main-group><subgroup>14</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>417</main-group><subgroup>04</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>417</main-group><subgroup>14</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>401</main-group><subgroup>14</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>401</main-group><subgroup>10</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>213</main-group><subgroup>82</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>401</main-group><subgroup>04</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>417</main-group><subgroup>14</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>403</main-group><subgroup>04</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>405</main-group><subgroup>14</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>409</main-group><subgroup>14</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>417</main-group><subgroup>04</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>401</main-group><subgroup>12</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>16141044</doc-number><date>20180925</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>10947215</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>17138309</doc-number></document-id></child-doc></relation></continuation><division><relation><parent-doc><document-id><country>US</country><doc-number>15253773</doc-number><date>20160831</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>10125118</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>16141044</doc-number></document-id></child-doc></relation></division><us-provisional-application><document-id><country>US</country><doc-number>62212520</doc-number><date>20150831</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Dong-A Socio Holdings Co., Ltd.</orgname><address><city>Seoul</city><country>KR</country></address></addressbook><residence><country>KR</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>KIM</last-name><first-name>Myeong-Seop</first-name><address><city>Gyeonggi-do</city><country>KR</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>KIM</last-name><first-name>Sumin</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>KIM</last-name><first-name>Jin Kwan</first-name><address><city>Gyeonggi-do</city><country>KR</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>KIM</last-name><first-name>Hadong</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>RYU</last-name><first-name>Ki Moon</first-name><address><city>Gyeonggi-do</city><country>KR</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>PARK</last-name><first-name>Seong Jin</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="06" designation="us-only"><addressbook><last-name>PARK</last-name><first-name>Taesun</first-name><address><city>Gyeonggi-do</city><country>KR</country></address></addressbook></inventor><inventor sequence="07" designation="us-only"><addressbook><last-name>SHEEN</last-name><first-name>Joon-Ho</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="08" designation="us-only"><addressbook><last-name>YOON</last-name><first-name>Taeyoung</first-name><address><city>Seoul</city><country>KR</country></address></addressbook></inventor><inventor sequence="09" designation="us-only"><addressbook><last-name>JANG</last-name><first-name>Mi Yeon</first-name><address><city>Gyeonggi-do</city><country>KR</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament.</p><p id="p-0002" num="0000">The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.</p></abstract><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">RELATED APPLICATION</heading><p id="p-0003" num="0001">This application claims the benefit of priority under U.S.C. &#xa7; 119(e) to U.S. Provisional Patent Application Ser. No. 62/212,520 filed Aug. 31, 2015, which is incorporated herein by reference.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0002" level="1">TECHNICAL FIELD</heading><p id="p-0004" num="0002">The present invention relates to novel heterocyclic compounds having Mer kinase inhibitory activity, a stereoisomer thereof, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, the use for preparing pharmaceutical compositions, pharmaceutical compositions comprising the same, methods of treating diseases using these compositions.</p><heading id="h-0003" level="1">BACKGROUND ART</heading><p id="p-0005" num="0003">Transmembrane receptor tyrosine kinases (RTKs) comprise an evolutionarily conserved family of structurally related proteins. The gene Mer is a member of the Tyro3/Axl/Mer (TAM) receptor kinase family and a proto-oncogene. Its abnormal expression and activation is found in conjunction with human cancers such as pituitary adenomas, mantle cell lymphomas, and T-cell acute lymphoblastic leukemia.</p><p id="p-0006" num="0004">The ATP-binding site is similar for all protein kinases. For this reason, it is challenging to find an inhibitor that is specific for the Mer. Compound-52, a 2,6,9-trisubstituted purine that occupies the ATP-binding site, was actually the first molecule that was found to be successful in inhibiting Mer (J Struct Biol. 2009 February; 165(2): 88-96). This inhibitor has, however, limited potency and lack of selectivity. Lately, several compounds have been unveiled mostly by modifying Compound-52 including UNC-569, UNC-1062, and UNC-2025 (ACS Med Chem Lett. 2012 Feb. 9; 3(2):129-134, Eur J Med Chem. 2013 July; 65:83-93, J Med Chem. 2014 Aug. 28; 57(16):7031-41).</p><p id="p-0007" num="0005">It is an object of the invention to provide reagents and methods of regulating a receptor tyrosine kinase Mer. This and other objects of the invention are provided by one or more of the embodiments described below.</p><heading id="h-0004" level="1">DISCLOSURE</heading><heading id="h-0005" level="1">Technical Problem</heading><p id="p-0008" num="0006">Several Mer kinase inhibitors have been previously described, but they have different moieties onto the scaffold from the present invention. Highly potent and selective Mer kinase inhibitors based on aminopyridine or aminopyrimidine scaffolds are described.</p><p id="p-0009" num="0007">The present invention relates to compounds capable of inhibiting the activity of Mer, which compounds are useful for the prevention and/or the treatment of cancer and other immune-related diseases such as infection and sepsis.</p><heading id="h-0006" level="1">Technical Solution</heading><p id="p-0010" num="0008">Novel Mer Kinase Inhibitors</p><p id="p-0011" num="0009">The present invention relates to a heterocyclic compound represented by the following Formula I, a stereoisomer thereof, an enantiomer thereof, or a pharmaceutically acceptable salt thereof:</p><p id="p-0012" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="30.56mm" wi="63.84mm" file="US20230002353A1-20230105-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0013" num="0010">wherein:</p><p id="p-0014" num="0011">X is CR<sup>7</sup>, or N;</p><p id="p-0015" num="0012">Y is CHR<sup>8</sup>, NR<sup>8</sup>, or O;</p><p id="p-0016" num="0013">Z is CH<sub>2</sub>, CH<sub>2</sub>O, C(&#x2550;O), C(&#x2550;O)O, C(&#x2550;O)NH, NR<sup>8</sup>, NHC(&#x2550;O), O or O(C&#x2550;O);</p><p id="p-0017" num="0014">R<sup>1 </sup>is H, halogen, C<sub>1-3 </sub>alkyl, NHR<sup>8 </sup>or OR<sup>8</sup>;</p><p id="p-0018" num="0015">R<sup>2 </sup>is H, halogen, C<sub>1-4 </sub>alkyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, C<sub>1-2 </sub>alkylheterocyclyl or -L-aryl, which C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, C<sub>1-2 </sub>alkylheterocyclyl or -L-aryl may optionally be substituted with one or more R<sup>9</sup>;</p><p id="p-0019" num="0016">R<sup>3 </sup>is H, halogen, CN, C<sub>1-3 </sub>alkyl, cycloalkenyl, C<sub>2-6 </sub>alkenyl, aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, or C<sub>1-2 </sub>alkylheterocyclyl which aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, or C<sub>1-2 </sub>alkylheterocyclyl may optionally be substituted with one or more R<sup>9</sup>;</p><p id="p-0020" num="0017">R<sup>4 </sup>and R<sup>5 </sup>each independently is H, C<sub>1-6 </sub>alkyl, C<sub>1-6 </sub>alkoxy, C<sub>3-10 </sub>cycloalkyl, C(&#x2550;O) R<sup>6</sup>, C<sub>1-2 </sub>alkylaryl, aryl; or</p><p id="p-0021" num="0018">R<sup>4 </sup>and R<sup>5 </sup>may be combined with each other to form a 3-7 membered cyclic ring or heterocyclic ring containing 1 or 2 of NR<sup>8</sup>, O or S, and the cyclic or heterocyclic ring may optionally be substituted with 1 or 2 halogen(s), C<sub>1-4 </sub>alkyl or C<sub>1-4 </sub>alkoxy;</p><p id="p-0022" num="0019">R<sup>5&#x2032;</sup> is H or R<sup>5 </sup>and R<sup>5&#x2032;</sup> may be combined with each other to form carbonyl;</p><p id="p-0023" num="0020">R<sup>6 </sup>is H, C<sub>1-4 </sub>alkyl, C<sub>1-6 </sub>alkoxy, &#x2014;NR<sup>15</sup>R<sup>16</sup>, aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, C<sub>1-2 </sub>alkylheterocyclyl, C<sub>1-2 </sub>alkylbiaryl, -L-aryl or -L-biaryl, which C<sub>1-4 </sub>alkyl, aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, C<sub>1-2 </sub>alkylheterocyclyl, C<sub>1-2 </sub>alkylbiaryl, -L-aryl or -L-biaryl, may optionally be substituted with one or more R<sup>9</sup>;</p><p id="p-0024" num="0021">R<sup>7 </sup>is H, halogen or C<sub>1-3 </sub>alkyl;</p><p id="p-0025" num="0022">R<sup>8 </sup>is H, C<sub>1-6 </sub>alkyl, C<sub>1-4 </sub>fluoroalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-3 </sub>alkylaryl or C(&#x2550;O)R<sup>10 </sup>which C<sub>1-6 </sub>alkyl or C<sub>1-3 </sub>alkylaryl may optionally be substituted with one or more R<sup>9</sup>;</p><p id="p-0026" num="0023">when Z is NR<sup>8</sup>, R<sup>8 </sup>and R<sup>6 </sup>may be combined with each other to form a 3-7 membered heterocyclic ring comprising 1 to 2 N or 0 to 2 O heteroatoms;</p><p id="p-0027" num="0024">R<sup>9 </sup>is halogen, hydroxyl, &#x2014;CN, &#x2014;NO<sub>2</sub>, &#x2014;COOH, &#x2014;(C&#x2550;O)H, C<sub>1-6 </sub>alkyl, C<sub>2-6 </sub>alkenyl, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-6 </sub>alkoxy, cycloalkenyl, aryl, heterocyclyl, heteroaryl, &#x2014;NR<sup>15</sup>R<sup>16</sup>, -L-NR<sup>15</sup>R<sup>16</sup>, -L-COOR<sup>17</sup>, -L-alkyl, -L-C<sub>3-10 </sub>cycloalkyl, -L-heterocyclyl, -L-heteroaryl, or -L-aryl which C<sub>1-6 </sub>alkyl, C<sub>2-6 </sub>alkenyl, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-6 </sub>alkoxy, cycloalkenyl, aryl, heterocyclyl, heteroaryl, -L-alkyl, -L-C<sub>3-10 </sub>cycloalkyl, -L-heterocyclyl, -L-heteroaryl, or -L-aryl may substituted with halogen, hydroxyl, &#x2014;CN, &#x2014;NR<sup>15</sup>R<sup>16</sup>, C<sub>1-6 </sub>alkyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>2-6 </sub>alkenyl, aryl, heterocyclyl, -L-heterocyclyl, or &#x2014;(CH<sub>2</sub>)&#x2014;C(&#x2550;O)&#x2014;NR<sup>15</sup>R<sup>16</sup>;</p><p id="p-0028" num="0025">R<sup>10 </sup>is C<sub>1-3 </sub>alkyl or C<sub>1-3 </sub>alkylaryl;</p><p id="p-0029" num="0026">R<sup>15 </sup>and R<sup>16 </sup>each independently is H, C<sub>1-6 </sub>alkyl, C<sub>3-10 </sub>cycloalkyl or SO<sub>2</sub>R<sup>17</sup>;</p><p id="p-0030" num="0027">R<sup>17 </sup>is H, C<sub>1-3</sub>alkyl or C<sub>1-3 </sub>alkylaryl;</p><p id="p-0031" num="0028">L is C<sub>1-3 </sub>alkyl, C<sub>1-3 </sub>alkylO, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, C(&#x2550;O)O, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)NH&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;NHC(&#x2550;O)&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, NR<sup>8</sup>, &#x2014;NH&#x2014;C(&#x2550;O)&#x2014;CR<sup>15</sup>R<sup>16</sup>&#x2014;NH&#x2014;C(&#x2550;O)&#x2014;, NHC(&#x2550;O), O, O(C&#x2550;O) S, S(&#x2550;O), or SO<sub>2</sub>; and</p><p id="p-0032" num="0029">l and m each independently is an integer of 0 to 2.</p><p id="p-0033" num="0030">In accordance with a second embodiment of the present invention, there are provided the heterocyclic compound represented formula I is represented by the following Formula Ia:</p><p id="p-0034" num="0000"><chemistry id="CHEM-US-00002" num="00002"><img id="EMI-C00002" he="34.88mm" wi="65.45mm" file="US20230002353A1-20230105-C00002.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0035" num="0031">wherein:</p><p id="p-0036" num="0032">X is CH, or N;</p><p id="p-0037" num="0033">Y is NR<sup>8</sup>, or O;</p><p id="p-0038" num="0034">W is CH<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub>, NR<sup>11</sup>, or O;</p><p id="p-0039" num="0035">Z is CH<sub>2</sub>, CH<sub>2</sub>O, C(&#x2550;O), C(&#x2550;O)O, C(&#x2550;O)NH, NR<sup>8</sup>, NHC(&#x2550;O), O or O(C&#x2550;O);</p><p id="p-0040" num="0036">R<sup>3 </sup>is H, halogen, CN, C<sub>1-3 </sub>alkyl, cycloalkenyl, C<sub>2-6 </sub>alkenyl, aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, or C<sub>1-2 </sub>alkylheterocyclyl which aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, or C<sub>1-2 </sub>alkylheterocyclyl may optionally be substituted with one or more R<sup>9</sup>;</p><p id="p-0041" num="0037">R<sup>6 </sup>is H, C<sub>1-4 </sub>alkyl, C<sub>1-6 </sub>alkoxy, &#x2014;NR<sup>15</sup>R<sup>16</sup>, aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, C<sub>1-2 </sub>alkylheterocyclyl, C<sub>1-2 </sub>alkylbiaryl, -L-aryl or -L-biaryl, which C<sub>1-4 </sub>alkyl, aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, C<sub>1-2 </sub>alkylheterocyclyl, C<sub>1-2 </sub>alkylbiaryl, -L-aryl or -L-biaryl, may optionally be substituted with one or more R<sup>9</sup>;</p><p id="p-0042" num="0038">R<sup>8 </sup>is H, C<sub>1-6 </sub>alkyl, C<sub>1-4 </sub>fluoroalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-3 </sub>alkylaryl or C(&#x2550;O)R<sup>10 </sup>which C<sub>1-6 </sub>alkyl or C<sub>1-3 </sub>alkylaryl may optionally be substituted with one or more R<sup>9</sup>;</p><p id="p-0043" num="0039">when Z is NR<sup>8</sup>, R<sup>8 </sup>and R<sup>6 </sup>may be combined with each other to form a 3-7 membered heterocyclic ring comprising 1 to 2 N or 0 to 2 O heteroatoms;</p><p id="p-0044" num="0040">R<sup>9 </sup>is halogen, hydroxyl, &#x2014;CN, &#x2014;NO<sub>2</sub>, &#x2014;COOH, &#x2014;(C&#x2550;O)H, C<sub>1-6 </sub>alkyl, C<sub>2-6 </sub>alkenyl, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-6 </sub>alkoxy, cycloalkenyl, aryl, heterocyclyl, heteroaryl, &#x2014;NR<sup>15</sup>R<sup>16</sup>, -L-NR<sup>15</sup>R<sup>16</sup>, -L-COOR<sup>17</sup>, -L-alkyl, -L-C<sub>3-10 </sub>cycloalkyl, -L-heterocyclyl, -L-heteroaryl, or -L-aryl which C<sub>1-6 </sub>alkyl, C<sub>2-6 </sub>alkenyl, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-6 </sub>alkoxy, cycloalkenyl, aryl, heterocyclyl, heteroaryl, -L-alkyl, -L-C<sub>3-10 </sub>cycloalkyl, -L-heterocyclyl, -L-heteroaryl, or -L-aryl may substituted with halogen, hydroxyl, &#x2014;CN, &#x2014;NR<sup>15</sup>R<sup>16</sup>, C<sub>1-6 </sub>alkyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>2-6 </sub>alkenyl, aryl, heterocyclyl, -L-heterocyclyl, or &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)&#x2014;NR<sup>15</sup>R<sup>16</sup>;</p><p id="p-0045" num="0041">R<sup>10 </sup>is C<sub>1-3 </sub>alkyl or C<sub>1-3 </sub>alkylaryl;</p><p id="p-0046" num="0042">R<sup>11 </sup>is H, C<sub>1-6 </sub>alkyl, C<sub>1-4 </sub>fluoroalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-3 </sub>alkylaryl or C(&#x2550;O)R<sup>10 </sup>which C<sub>1-6 </sub>alkyl or C<sub>1-3 </sub>alkylaryl may optionally be substituted with one or more R<sup>9</sup>;</p><p id="p-0047" num="0043">R<sup>15 </sup>and R<sup>16 </sup>each independently is H, C<sub>1-6 </sub>alkyl, C<sub>3-10 </sub>cycloalkyl or SO<sub>2</sub>R<sup>17</sup>;</p><p id="p-0048" num="0044">R<sup>17 </sup>is H, C<sub>1-3 </sub>alkyl or C<sub>1-3 </sub>alkylaryl;</p><p id="p-0049" num="0045">R<sup>18 </sup>to R<sup>21 </sup>are the same as or different from each other, and are each independently H or halogen; or</p><p id="p-0050" num="0046">R<sup>18 </sup>and R<sup>19</sup>; or R<sup>20 </sup>and R<sup>21 </sup>may be combined with each other to form a 3-7 membered cyclic ring or heterocyclic ring containing 1 or 2 of NR<sup>8</sup>, O or S, and the cyclic or heterocyclic ring may optionally be substituted with 1 or 2 halogen(s), C<sub>1-4 </sub>alkyl or C<sub>1-4 </sub>alkoxy;</p><p id="p-0051" num="0047">L is C<sub>1-3 </sub>alkyl, C<sub>1-3 </sub>alkylO, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, C(&#x2550;O)O, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)NH&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;NHC(&#x2550;O)&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, NR<sup>8</sup>, &#x2014;NH&#x2014;C(&#x2550;O)&#x2014;CR<sup>15</sup>R<sup>16</sup>&#x2014;NH&#x2014;C(&#x2550;O)&#x2014;NHC(&#x2550;O), O, O(C&#x2550;O) S, S, S(&#x2550;O), or SO<sub>2</sub>; and</p><p id="p-0052" num="0048">l and m each independently is an integer of 0 to 2.</p><p id="p-0053" num="0049">In accordance with a third embodiment of the present invention, there are provided the heterocyclic compound represented formula I is represented by the following Formula Ib:</p><p id="p-0054" num="0000"><chemistry id="CHEM-US-00003" num="00003"><img id="EMI-C00003" he="34.46mm" wi="71.29mm" file="US20230002353A1-20230105-C00003.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0055" num="0050">wherein:</p><p id="p-0056" num="0051">X is CH, or N;</p><p id="p-0057" num="0052">W is CH<sub>2</sub>, NR<sup>11</sup>, or O;</p><p id="p-0058" num="0053">V<sup>1 </sup>and V<sup>2 </sup>each independently is CR<sup>13</sup>R<sup>13&#x2032;</sup>, NR<sup>13</sup>, or O;</p><p id="p-0059" num="0054">at least one of V<sub>1 </sub>and V<sub>2 </sub>is CR<sup>13</sup>R<sup>13&#x2032;</sup>;</p><p id="p-0060" num="0055">X<sup>1 </sup>to X<sup>5 </sup>are the same as or different from each other, and are each independently CR<sup>14 </sup>or N;</p><p id="p-0061" num="0056">at least one of X<sup>1 </sup>to X<sup>5 </sup>is CR<sup>14</sup>;</p><p id="p-0062" num="0057">R<sup>3 </sup>is H, halogen, CN, C<sub>1-3 </sub>alkyl, cycloalkenyl, C<sub>2-6 </sub>alkenyl, aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, or C<sub>1-2 </sub>alkylheterocyclyl which aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, or C<sub>1-2 </sub>alkylheterocyclyl may optionally be substituted with one or more R<sup>9</sup>;</p><p id="p-0063" num="0058">R<sup>9 </sup>is halogen, hydroxyl, &#x2014;CN, &#x2014;NO<sub>2</sub>, &#x2014;COOH, &#x2014;(C&#x2550;O)H, C<sub>1-6 </sub>alkyl, C<sub>2-6 </sub>alkenyl, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-6 </sub>alkoxy, cycloalkenyl, aryl, heterocyclyl, heteroaryl, &#x2014;NR<sup>15</sup>R<sup>16</sup>, -L-NR<sup>15</sup>R<sup>16</sup>, -L-COOR<sup>17</sup>, -L-alkyl, -L-C<sub>3-10 </sub>cycloalkyl, -L-heterocyclyl, -L-heteroaryl, or -L-aryl which C<sub>1-6 </sub>alkyl, C<sub>2-6 </sub>alkenyl, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-6 </sub>alkoxy, cycloalkenyl, aryl, heterocyclyl, heteroaryl, -L-alkyl, -L-C<sub>3-10</sub>cycloalkyl, -L-heterocyclyl, -L-heteroaryl, or -L-aryl may substituted with halogen, hydroxyl, &#x2014;CN, &#x2014;NR<sup>15</sup>R<sup>16</sup>, C<sub>1-6 </sub>alkyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>2-6 </sub>alkenyl, aryl, heterocyclyl, -L-heterocyclyl, or &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)&#x2014;NR<sup>15</sup>R<sup>16</sup>;</p><p id="p-0064" num="0059">R<sup>10 </sup>is C<sub>1-3 </sub>alkyl or C<sub>1-3 </sub>alkylaryl;</p><p id="p-0065" num="0060">R<sup>11 </sup>is H, C<sub>1-6 </sub>alkyl, C<sub>1-4 </sub>fluoroalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-3 </sub>alkylaryl or C(&#x2550;O)R<sup>10 </sup>which C<sub>1-6 </sub>alkyl or C<sub>1-3 </sub>alkylaryl may optionally be substituted with one or more R<sup>9</sup>;</p><p id="p-0066" num="0061">R<sup>13 </sup>and R<sup>13&#x2032;</sup> each independently is H, C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>hydroxyalkyl;</p><p id="p-0067" num="0062">each R<sup>14 </sup>is independently selected from H, halogen, hydroxyl, &#x2014;CN, &#x2014;NO<sub>2</sub>, C<sub>1-6 </sub>alkyl, C<sub>2-6 </sub>alkenyl, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, &#x2014;NR<sup>15</sup>R<sup>16</sup>, -L-alkyl, -L-heterocyclyl, -L-heteroaryl, or -L-aryl which C<sub>1-6 </sub>alkyl, aryl, heteroaryl, heterocycyl may optionally be substituted with one or more R<sup>9</sup>; or adjacent groups among a plurality of R<sup>14</sup>s are bonded to each other to form a 3-7 membered cyclic ring or heterocyclic ring containing 1 or 2 of NR<sup>11 </sup>O or S, and the cyclic or heterocyclic ring may optionally be substituted with 1 or 2 halogen(s), C<sub>1-4 </sub>alkyl or C<sub>1-4 </sub>alkoxy;</p><p id="p-0068" num="0063">R<sup>15 </sup>and R<sup>16 </sup>each independently is H, C<sub>1-6 </sub>alkyl, C<sub>3-10 </sub>cycloalkyl or SO<sub>2</sub>R<sup>17</sup>;</p><p id="p-0069" num="0064">R<sup>17 </sup>is H, C<sub>1-3 </sub>alkyl or C<sub>1-3 </sub>alkylaryl;</p><p id="p-0070" num="0065">L is C<sub>1-3 </sub>alkyl, C<sub>1-3 </sub>alkylO, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, C(&#x2550;O)O, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)NH&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;NHC(&#x2550;O)&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, NR<sup>8</sup>, &#x2014;NH&#x2014;C(&#x2550;O)&#x2014;CR<sup>15</sup>R<sup>16</sup>&#x2014;NH&#x2014;C(&#x2550;O)&#x2014;, NHC(&#x2550;O), O, O(C&#x2550;O) S, S, S(&#x2550;O), or SO<sub>2</sub>; and</p><p id="p-0071" num="0066">l and m each independently is an integer of 0 to 2.</p><p id="p-0072" num="0067">In the present disclosure, a halogen may be fluorine, chlorine, bromine or iodine.</p><p id="p-0073" num="0068">In the present disclosure, the alkyl may be straight or branched, and the number of carbon atoms thereof is not particularly limited, but is preferably 1 to 6. Specific examples thereof include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a pentyl group, a hexyl group, and the like, or a branched chain thereof, but are not limited thereto.</p><p id="p-0074" num="0069">In the present disclosure, the cycloalkyl is not particularly limited, but has preferably 3 to 10 carbon atoms. Specific examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, a norbornyl group, an adamantly group, and the like, but are not limited thereto.</p><p id="p-0075" num="0070">In the present disclosure, the alkoxy may be straight, branched, or cyclic. The number of carbon atoms of the alkoxy group is not particularly limited, but is preferably 1 to 6. Specific examples thereof include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, and the like, but are not limited thereto.</p><p id="p-0076" num="0071">In the present disclosure, the alkenyl may be straight or branched, and the number of carbon atoms thereof is not particularly limited, but is preferably 2 to 6. Specific examples thereof include vinyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 3-methyl-1-butenyl, 1,3-butadienyl, and the like, but are not limited thereto.</p><p id="p-0077" num="0072">In the present disclosure, the aryl may be monocyclic, or polycyclic and the number of carbon atoms is not particularly limited, but is preferably 6 to 60. Specific examples of the aryl group include a monocyclic aromatic group, such as a phenyl group and a polycyclic aromatic group, such as a naphthyl group, an anthracenyl group, a phenanthrenyl group, a pyrenyl group, a perylenyl group, a tetracenyl group, a chrysenyl group, a fluorenyl group, an acenaphthacenyl group, a triphenylene group, and a fluoranthene group, and the like, but are not limited thereto.</p><p id="p-0078" num="0073">In the present disclosure, the biaryl may two or more monocyclics and/or polycyclics linked each other.</p><p id="p-0079" num="0074">In the present disclosure, the aryl in the alkylaryl and biaryl is the same as the above-described examples of the aryl group.</p><p id="p-0080" num="0075">In the present disclosure, a heterocyclic or a heteroaryl including one or more hetero atom, for example, a heterocyclic group including one or more of O, N, S, Si, Se and the like. Examples of the heterocyclic group include a thiophene group, a furan group, a pyrrole group, an, imidazole group, a thiazole group, an oxazole group, an oxadiazole group, a triazole group, a pyridyl group, a bipyridyl group, a triazine group, an acridyl group, a pyridazine group, a pyrrolidine group, a morpholine group, a piperazin group, a piperidine group, a tetrahydrofuran group, a pyrazole group, a quinolinyl group, an isoquinoline group, an indole group, a carbazole group, a benzoxazole group, a benzimidazole group, a benzothiazole group, a benzocarbazole group, a benzothiophene group, a dibenzothiophene group, a benzofuranyl group, a phenanthroline group, a dibenzofuranyl group, and the like, but are not limited thereto.</p><p id="p-0081" num="0076">In the present disclosure, the &#x201c;adjacent&#x201d; group may mean a substituent substituted with an atom directly linked to an atom in which the corresponding substituent is substituted, a substituent disposed sterically closest to the corresponding substituent, or another substituent substituted with an atom in which the corresponding substituent is substituted. For example, two substituents substituted at the ortho position in a benzene ring and two substituents substituted with the same carbon in an aliphatic ring may be interpreted as groups &#x201c;adjacent&#x201d; to each other.</p><p id="p-0082" num="0077">In the present disclosure, the cyclic ring or heterocyclic ring formed by binding two or more R<sup>14</sup>s comprises cycloalkyl, cycloalkenyl, aryl, heterocycle, heteroaryl. In accordance with a forth embodiment of the present invention, there are provided the heterocyclic compound represented formula I is represented by any one of the following compounds.</p><p id="p-0083" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="210pt" align="left"/><thead><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>Example 1</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 2</entry><entry>2-amino-N-((1R,2R)-2-(benzyloxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 3</entry><entry>2-amino-N-(trans-2-(benzyloxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 4</entry><entry>2-amino-N-((1R,2S)-2-(benzyloxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 5</entry><entry>2-amino-N-(cis-2-(benzyloxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 6</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((2-</entry></row><row><entry/><entry>methylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 7</entry><entry>2-amino-N-((1S,2S)-2-((3-ethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 8</entry><entry>2-amino-N-((1S,2S)-2-((4-ethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 9</entry><entry>2-amino-N-(trans-2-((4-ethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 10</entry><entry>2-amino-N-((1S,2S)-2-((4-isopropylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 11</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 12</entry><entry>2-amino-N-((1R,2R)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 13</entry><entry>2-amino-N-(trans-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 14</entry><entry>2-amino-N-((1S,2S)-2-((2,3-dimethylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 15</entry><entry>2-amino-N-((1S,2S)-2-((2,6-dimethylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 16</entry><entry>2-amino-N-((1S,2S)-2-((2,5-dimethylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 17</entry><entry>2-amino-N-((1S,2S)-2-((3,5-dimethylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 18</entry><entry>2-amino-N-((1S,2S)-2-((2,4-dimethylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 19</entry><entry>2-amino-N-((1S,2S)-2-((4-ethyl-3-methylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 20</entry><entry>2-amino-N-((1S,2S)-2-((3,4-diethylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 21</entry><entry>2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 22</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3-</entry></row><row><entry/><entry>propylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 23</entry><entry>2-amino-N-((1S,2S)-2-((3-cyclopentylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 24</entry><entry>2-amino-N-((1S,2S)-2-((3-isopropylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 25</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3-(prop-1-en-2-</entry></row><row><entry/><entry>yl)benzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 26</entry><entry>2-amino-N-((1S,2S)-2-((3-cyclopropylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 27</entry><entry>2-amino-N-((1S,2S)-2-((3-cyclobutylbenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 28</entry><entry>2-amino-N-((1S,2S)-2-((3-ethynylbenzyl)oxy)cyclopentyl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 29</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-</entry></row><row><entry/><entry>(trifluoromethyl)benzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 30</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3-</entry></row><row><entry/><entry>nitrobenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 31</entry><entry>2-amino-N-((1S,2S)-2-((3-cyanobenzyl)oxy)cyclopentyl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 32</entry><entry>2-amino-N-((1S,2S)-2-((3-hydroxybenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 33</entry><entry>2-amino-N-((1S,2S)-2-((3-methyloxybenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 34</entry><entry>2-amino-N-((1R,2R)-2-((3-methoxybenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 35</entry><entry>2-amino-N-((1S,2S)-2-((4-methoxybenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 36</entry><entry>2-amino-N-((1R,2R)-2-((4-methoxybenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 37</entry><entry>2-amino-N-(trans-2-((3,5-dimethoxybenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 38</entry><entry>2-amino-N-((1S,2S)-2-((2,3-dimethoxybenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 39</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3-</entry></row><row><entry/><entry>phenoxybenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 40</entry><entry>2-amino-N-((1S,2S)-2-(benzo[d][1,3]dioxol-5-ylmethoxy)cyclopentyl)-</entry></row><row><entry/><entry>5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 41</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-</entry></row><row><entry/><entry>(methylthio)benzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 42</entry><entry>methyl 3-((((1S,2S)-2-(2-amino-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamido)cyclopentyl)oxy)methyl)benzoate</entry></row><row><entry>Example 43</entry><entry>2-amino-N-((1S,2S)-2-((3-chlorobenzyl)oxy)cyclopentyl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 44</entry><entry>2-amino-N-(trans-2-((3-chlorobenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 45</entry><entry>2-amino-N-(trans-2-((4-chlorobenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 46</entry><entry>2-amino-N-(trans-2-((3,4-dichlorobenzyl)oxy)cyclopentyl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamid</entry></row><row><entry>Example 47</entry><entry>2-amino-N-(trans-2-((2-fluorobenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 48</entry><entry>2-amino-N-((1S,2S)-2-((3-fluorobenzyl)oxy)cyclopentyl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 49</entry><entry>2-amino-N-(trans-2-((4-bromo-2-fluorobenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 50</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(trans-2-((2,4,5-</entry></row><row><entry/><entry>trifluorobenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 51</entry><entry>2-amino-N-((1S,2S)-2-((3-bromobenzyl)oxy)cyclopentyl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 52</entry><entry>2-amino-N-(trans-2-((3-bromo-4-fluorobenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 53</entry><entry>2-amino-N-((1R,2R)-2-((3-bromo-4-fluorobenzyl)oxy)cyclopentyl)-5-</entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 54</entry><entry>2-amino-N-((1S,2S)-2-(1-(4-bromophenyl)ethoxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 55</entry><entry>methyl (3-((((1S,2S)-2-(2-amino-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamido)cyclopentyl)oxy)methyl)benzoyl)glycinate</entry></row><row><entry>Example 56</entry><entry>2-amino-N-((1S,2S)-2-((3-((2-</entry></row><row><entry/><entry>hydroxyethyl)carbamoyl)benzyl)oxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 57</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3-(piperidine-4-</entry></row><row><entry/><entry>carboxamido)benzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 58</entry><entry>2-amino-N-((1S,2S)-2-((3-((S)-2-</entry></row><row><entry/><entry>aminopropanamido)benzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 59</entry><entry>N-((1S,2S)-2-((3-((S)-2-</entry></row><row><entry/><entry>acetamidopropanamido)benzyl)oxy)cyclopentyl)-2-amino-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 60</entry><entry>2-amino-N-((1S,2S)-2-((3-(3-aminopropanamido)benzyl)oxy)-</entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 61</entry><entry>N-((1S,2S)-2-((3-(2H-1,2,3-triazol-2-yl)benzyl)oxy)cyclopentyl)-2-</entry></row><row><entry/><entry>amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 62</entry><entry>N-((1S,2S)-2-((4-(2H-1,2,3-triazol-2-yl)benzyl)oxy)cyclopentyl)-2-</entry></row><row><entry/><entry>amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 63</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-(naphthalen-2-</entry></row><row><entry/><entry>ylmethoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 64</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-(quinolin-8-</entry></row><row><entry/><entry>ylmethoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 65</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((2&#x2032;,3&#x2032;,4&#x2032;,5&#x2032;-</entry></row><row><entry/><entry>tetrahydro-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 66</entry><entry>N-(trans-2-([1,1&#x2032;-biphenyl]-2-ylmethoxy)cyclopentyl)-2-amino-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 67</entry><entry>N-((1S,2S)-2-([1,1&#x2032;-biphenyl]-3-ylmethoxy)cyclopentyl)-2-amino-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 68</entry><entry>N-((1S,2S)-2-([1,1&#x2032;-biphenyl]-4-ylmethoxy)cyclopentyl)-2-amino-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 69</entry><entry>2-amino-N-((1S,2S)-2-hydroxycyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 70</entry><entry>2-amino-N-(cis-2-hydroxycyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 71</entry><entry>N-((1S,2S)-2-(benzyloxy)cyclopentyl)-2-(ethylamino)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 72</entry><entry>N-((1S,2S)-2-(benzyloxy)cyclopentyl)-2-((3,4-dimethylbenzyl)amino)-</entry></row><row><entry/><entry>5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 73</entry><entry>2-amino-N-((6R,7S)-6-(benzyloxy)-1,4-dioxaspiro[4.4]nonan-7-yl)-5-</entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 74</entry><entry>2-amino-N-(trans-2-(benzyloxy)cyclohexyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 75</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclohexyl)-5-(1-methyl-1H-pyrazol-</entry></row><row><entry/><entry>4-yl)nicotinamide</entry></row><row><entry>Example 76</entry><entry>2-amino-N-(trans-2-(benzyl(methyl)amino)cyclopentyl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 77</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-</entry></row><row><entry/><entry>(phenoxymethyl)cyclopentyl)nicotinamide</entry></row><row><entry>Example 78</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylphenoxy)methyl)cyclopentyl)-5-</entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 79</entry><entry>2-amino-N-(trans-2,2-difluoro-5-(phenoxymethyl)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 80</entry><entry>2-amino-N-((1S,2S)-2-(((2,3-dihydro-1H-inden-5-</entry></row><row><entry/><entry>yl)oxy)methyl)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 81</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3,4,5-</entry></row><row><entry/><entry>trimethylphenoxy)methyl)cyclopentyl)nicotinamide</entry></row><row><entry>Example 82</entry><entry>2-amino-N-((1S,2S)-2-((3-(dimethylamino)phenoxy)methyl)-</entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 83</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3-(piperidine-1-</entry></row><row><entry/><entry>carbonyl)phenoxy)methyl)cyclopentyl)nicotinamide</entry></row><row><entry>Example 84</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-</entry></row><row><entry/><entry>phenoxyphenoxy)methyl)cyclopentyl)nicotinamide</entry></row><row><entry>Example 85</entry><entry>2-amino-N-((1S,2S)-2-((benzyloxy)methyl)cyclopentyl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 86</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-(((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)oxy)methyl)cyclopentyl)nicotinamide</entry></row><row><entry>Example 87</entry><entry>(1S,2S)-2-(benzyloxy)cyclopentyl 2-amino-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinate</entry></row><row><entry>Example 88</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2R)-2-</entry></row><row><entry/><entry>phenethylcyclopentyl)nicotinamide</entry></row><row><entry>Example 89</entry><entry>2-amino-N-(trans-4-(benzyloxy)tetrahydrofuran-3-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 90</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(trans-4-</entry></row><row><entry/><entry>morpholinotetrahydrofuran-3-yl)nicotinamide</entry></row><row><entry>Example 91</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(trans-4-(pyrrolidin-1-</entry></row><row><entry/><entry>yl)tetrahydrofuran-3-yl)nicotinamide</entry></row><row><entry>Example 92</entry><entry>2-amino-N-(cis-4-hydroxytetrahydrofuran-3-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 93</entry><entry>2-amino-N-(4-(benzyloxy)-1-methylpyrrolidin-3-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 94</entry><entry>2-amino-N-(trans-4-(benzyloxy)-1-isopropylpyrrolidin-3-yl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 95</entry><entry>(R)-2-amino-N-(2-(benzyloxy)propyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 96</entry><entry>(S)-2-amino-N-(2-(benzyloxy)propyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 97</entry><entry>(S)-2-amino-N-(1-(benzyloxy)propan-2-yl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 98</entry><entry>(R)-2-amino-N-(1-(benzyloxy)propan-2-yl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 99</entry><entry>2-amino-N-(1-(benzyloxy)-2-methylpropan-2-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 100</entry><entry>(R)-2-amino-N-(1-((3,4-dimethylbenzyl)oxy)propan-2-yl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 101</entry><entry>(S)-2-amino-N-(2-((3,4-dimethylbenzyl)oxy)propyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 102</entry><entry>(R)-2-amino-N-(1-((4-chlorobenzyl)oxy)propan-2-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 103</entry><entry>(S)-2-amino-N-(2-((4-chlorobenzyl)oxy)propyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 104</entry><entry>(R)-2-amino-N-(1-((3,4-dichlorobenzyl)oxy)propan-2-yl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 105</entry><entry>(S)-2-amino-N-(2-((3,4-dichlorobenzyl)oxy)propyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 106</entry><entry>(R)-2-amino-N-(1-((3-methoxybenzyl)oxy)propan-2-yl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 107</entry><entry>(S)-2-amino-N-(2-((3-methoxybenzyl)oxy)propyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 108</entry><entry>(R)-2-amino-N-(1-(benzyloxy)butan-2-yl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 109</entry><entry>(S)-2-amino-N-(1-(benzyloxy)-3-methylbutan-2-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 110</entry><entry>(R)-2-amino-N-(1-(benzyloxy)-3-methylbutan-2-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 111</entry><entry>(S)-2-amino-N-(1-(benzyloxy)-4-methylpentan-2-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 112</entry><entry>(R)-2-amino-N-(1-(benzyloxy)-4-methylpentan-2-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 113</entry><entry>(R)-2-amino-N-(2-(benzyloxy)-1-cyclohexylethyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 114</entry><entry>(R)-2-amino-N-(1-cyclohexyl-2-hydroxyethyl)-5-(1-methyl-1H-pyrazol-</entry></row><row><entry/><entry>4-yl)nicotinamide</entry></row><row><entry>Example 115</entry><entry>(S)-2-amino-N-(2-(benzyloxy)-1-phenylethyl)-5-(1-methyl-1H-pyrazol-</entry></row><row><entry/><entry>4-yl)nicotinamide</entry></row><row><entry>Example 116</entry><entry>(R)-2-amino-N-(2-(benzyloxy)-1-phenylethyl)-5-(1-methyl-1H-pyrazol-</entry></row><row><entry/><entry>4-yl)nicotinamide</entry></row><row><entry>Example 117</entry><entry>(S)-2-amino-N-(1-(benzyloxy)-3-phenylpropan-2-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 118</entry><entry>(R)-2-amino-N-(1-(benzyloxy)-3-phenylpropan-2-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 119</entry><entry>(R)-2-amino-N-(1-(cyclobutylmethoxy)propan-2-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 120</entry><entry>methyl N-(2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinoyl)-O-benzyl-</entry></row><row><entry/><entry>L-serinate</entry></row><row><entry>Example 121</entry><entry>methyl N-(2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinoyl)-O-benzyl-</entry></row><row><entry/><entry>L-threoninate</entry></row><row><entry>Example 122</entry><entry>2-amino-N-((2S,3R)-3-(benzyloxy)-1-(methylamino)-1-oxobutan-2-yl)-</entry></row><row><entry/><entry>5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 123</entry><entry>2-amino-N-((2S,3R)-3-(benzyloxy)-1-oxo-1-(propylamino)butan-2-yl)-</entry></row><row><entry/><entry>5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 124</entry><entry>2-amino-N-((2S,3R)-3-(benzyloxy)-1-(cyclopentylamino)-1-oxobutan-2-</entry></row><row><entry/><entry>yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 125</entry><entry>2-amino-N-((2S,3R)-3-(benzyloxy)-1-oxo-1-(pyrrolidin-1-yl)butan-2-</entry></row><row><entry/><entry>yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 126</entry><entry>benzyl (2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinoyl)-L-alaninate</entry></row><row><entry>Example 127</entry><entry>benzyl (2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinoyl)-L-valinate</entry></row><row><entry>Example 128</entry><entry>benzyl (2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinoyl)-L-serinate</entry></row><row><entry>Example 129</entry><entry>3-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)pyrazine-2-carboxamide</entry></row><row><entry>Example 130</entry><entry>3-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-6-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)pyrazine-2-carboxamide</entry></row><row><entry>Example 131</entry><entry>(S)-3-amino-6-(1-methyl-1H-pyrazol-4-yl)-N-(1,2,3,4-</entry></row><row><entry/><entry>tetrahydronaphthalen-1-yl)pyrazine-2-carboxamide</entry></row><row><entry>Example 132</entry><entry>3-amino-N-(trans-4-(benzyloxy)tetrahydrofuran-3-yl)-6-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)pyrazine-2-carboxamide</entry></row><row><entry>Example 133</entry><entry>3-amino-N-(cis-4-(benzyloxy)tetrahydrofuran-3-yl)-6-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)pyrazine-2-carboxamide</entry></row><row><entry>Example 134</entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-amino-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 135</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-amino-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 136</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-</entry></row><row><entry/><entry>(methylamino)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 137</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(dimethylamino)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 138</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((dimethylamino)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 139</entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-amino-2&#x2032;-methyl-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 140</entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-hydroxy-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 141</entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-(hydroxymethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 142</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(hydroxymethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 143</entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-(aminomethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 144</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(aminomethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 145</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(2-aminoethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 146</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)-</entry></row><row><entry/><entry>cyclopentyl)nicotinamide</entry></row><row><entry>Example 147</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(6-(piperazin-</entry></row><row><entry/><entry>1-yl)pyridin-3-yl)benzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 148</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(6-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)pyridin-3-yl)benzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 149</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3&#x2032;-(piperazin-1-</entry></row><row><entry/><entry>yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinainide</entry></row><row><entry>Example 150</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3&#x2032;-(4-methyl-</entry></row><row><entry/><entry>piperazin-1-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 151</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3&#x2032;-((4-methyl-</entry></row><row><entry/><entry>piperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-</entry></row><row><entry/><entry>nicotinamide</entry></row><row><entry>Example 152</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(morpholine-</entry></row><row><entry/><entry>4-carbonyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 153</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-ethyl-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 154</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(cyanomethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 155</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-carbamoyl-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 156</entry><entry>2-amino-N-((1S,2S)-2-((3-fluoro-4&#x2032;-((4-methylpiperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 157</entry><entry>2-amino-N-((1S,2S)-2-((3-fluoro-4&#x2032;-((cis-3,4,5-trimethylpiperazin-1-</entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 158</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 159</entry><entry>2-amino-N-((1S,2S)-2-((2-chloro-4&#x2032;-((4-methylpiperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 160</entry><entry>2-amino-N-((1S,2S)-2-((3-fluoro-4&#x2032;-((cis-4-(2-hydroxyethyl)-3,5-</entry></row><row><entry/><entry>dimethylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 161</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(2-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 162</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(1-(piperidin-</entry></row><row><entry/><entry>4-yl)-1H-pyrazol-4-yl)benzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 163</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(1-(1-</entry></row><row><entry/><entry>methylpiperidin-4-yl)-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)benzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 164</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2R)-2-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 165</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1R,2S)-2-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 166</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclohexyl)nicotinamide</entry></row><row><entry>Example 167</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(2-(4-methylpiperazin-1-yl)propan-2-yl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 168</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-3-</entry></row><row><entry/><entry>(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 169</entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-hydroxy-[1,1&#x2032;-biphenyl]-3-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 170</entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-amino-[1,1&#x2032;-biphenyl]-3-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 171</entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-(hydroxymethyl)-[1,1&#x2032;-biphenyl]-3-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 172</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 173</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(((2-hydroxyethyl)amino)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 174</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-</entry></row><row><entry/><entry>(morpholinomethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 175</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((3,3-difluoropiperidin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 176</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperidin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 177</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(piperazin-1-</entry></row><row><entry/><entry>ylmethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 178</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-</entry></row><row><entry/><entry>phenylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 179</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-</entry></row><row><entry/><entry>(pyrrolidin-1-yl)piperidin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 180</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-hydroxypiperidin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 181</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 182</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-(2-hydroxy-2-methylpropyl)piperazin-1-</entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 183</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-ethylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 184</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-cyclopropylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 185</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(((R)-3-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 186</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(((R)-3,4-dimethylpiperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 187</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(((R)-2,4-dimethylpiperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 188</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((3-ethyl-4-methylpiperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 189</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((cis-3,5-dimethylpiperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 190</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((cis-3,4,5-</entry></row><row><entry/><entry>trimethylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 191</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((trans-2,5-dimethylpiperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 192</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(((2R,5S)-</entry></row><row><entry/><entry>2,4,5-trimethylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 193</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 194</entry><entry>3-amino-6-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)pyrazine-2-carboxamide</entry></row><row><entry>Example 195</entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-fluoro-4&#x2032;-((4-methylpiperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 196</entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;,5&#x2032;-difluoro-4&#x2032;-((4-methylpiperazin-1-</entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 197</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 198</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3&#x2032;-methyl-4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 199</entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-hydroxy-4&#x2032;-((4-methylpiperazin-1-</entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 200</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-3&#x2032;-nitro-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 201</entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-methoxy-4&#x2032;-((4-methylpiperazin-1-</entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 202</entry><entry>2-amino-N-((1S,2S)-2-((2&#x2032;-chloro-4&#x2032;-((4-methylpiperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 203</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(6-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)pyridin-3-</entry></row><row><entry/><entry>yl)benzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 204</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(5-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)pyridin-2-</entry></row><row><entry/><entry>yl)benzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 205</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-</entry></row><row><entry/><entry>3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 206</entry><entry>2-amino-N-((1S,2S)-2-((2&#x2032;-chloro-4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-</entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 207</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-3&#x2032;-</entry></row><row><entry/><entry>(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 208</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(1-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 209</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(1-((3S,5R)-</entry></row><row><entry/><entry>3,4,5-trimethylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 210</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 211</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(1-((3S,5R)-4-(2-hydroxyethyl)-3,5-</entry></row><row><entry/><entry>dimethylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 212</entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;,5&#x2032;-difluoro-4&#x2032;-(1-(4-(2-</entry></row><row><entry/><entry>hydroxyethyl)piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 213</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((R)-1-</entry></row><row><entry/><entry>(piperazin-1-yl)ethyl)-[1,1-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 214</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((R)-1-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 215</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((S)-1-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 216</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(1-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)cyclopropyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 217</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(2-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 218</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((R)-1-(4-(2-hydroxyethyl)piperazin-1-</entry></row><row><entry/><entry>yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 219</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((S)-1-(4-(2-hydroxyethyl)piperazin-1-</entry></row><row><entry/><entry>yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 220</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl)piperazin-1-</entry></row><row><entry/><entry>yl)cyclopropyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 221</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(2-(4-(2-hydroxyethyl)piperazin-1-yl)propan-</entry></row><row><entry/><entry>2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 222</entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((S)-1-(4-methylpiperazin-1-</entry></row><row><entry/><entry>yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-</entry></row><row><entry/><entry>carboxamide</entry></row><row><entry>Example 223</entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((R)-1-(4-methylpiperazin-1-</entry></row><row><entry/><entry>yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-</entry></row><row><entry/><entry>carboxamide</entry></row><row><entry>Example 224</entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-</entry></row><row><entry/><entry>yl)cyclopropyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-</entry></row><row><entry/><entry>bipyridine]-5-carboxamide</entry></row><row><entry>Example 225</entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(2-(4-methylpiperazin-1-yl)propan-</entry></row><row><entry/><entry>2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-</entry></row><row><entry/><entry>carboxamide</entry></row><row><entry>Example 226</entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((S)-1-(4-(2-</entry></row><row><entry/><entry>hydroxyethyl)piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</entry></row><row><entry>Example 227</entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((R)-1-(4-(2-</entry></row><row><entry/><entry>hydroxyethyl)piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</entry></row><row><entry>Example 228</entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl)piperazin-1-</entry></row><row><entry/><entry>yl)cyclopropyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-</entry></row><row><entry/><entry>bipyridine]-5-carboxamide</entry></row><row><entry>Example 229</entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(2-(4-(2-hydroxyethyl)piperazin-1-</entry></row><row><entry/><entry>yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopenty])-[3,3&#x2032;-</entry></row><row><entry/><entry>bipyridine]-5-carboxamide</entry></row><row><entry>Example 230</entry><entry>6-amino-5&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)ethyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-</entry></row><row><entry/><entry>carboxamide</entry></row><row><entry>Example 231</entry><entry>2-amino-5-chloro-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)ethyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 232</entry><entry>2-amino-5-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)ethyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 233</entry><entry>2-amino-5-cyano-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)ethyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 234</entry><entry>2-amino-6-chloro-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)ethyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 235</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 236</entry><entry>6-amino-5&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl)piperazin-1-</entry></row><row><entry/><entry>yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-</entry></row><row><entry/><entry>carboxamide</entry></row><row><entry>Example 237</entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl)piperazin-1-</entry></row><row><entry/><entry>yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-</entry></row><row><entry/><entry>carboxamide</entry></row><row><entry>Example 238</entry><entry>6-amino-2&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl)piperazin-1-</entry></row><row><entry/><entry>yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-</entry></row><row><entry/><entry>carboxamide</entry></row><row><entry>Example 239</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((1-</entry></row><row><entry/><entry>methylpiperidin-4-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 240</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((1-(2-hydroxyethyl)piperidin-4-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 241</entry><entry>methyl 2-(4-((4&#x2032;-((((1S,2S)-2-(2-amino-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamido)cyclopentyl)oxy)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methyl)piperidin-1-yl)acetate</entry></row><row><entry>Example 242</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((1-(2-amino-2-oxoethyl)piperidin-4-</entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 243</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(3-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)propyl)benzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 244</entry><entry>2-amino-N-((1S,2S)-2-((4-(3-(dimethylamino)propyl)benzyl)oxy)-</entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 245</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(2-(dimethylamino)ethoxy)-[1,1&#x2032;-biphenyl]-</entry></row><row><entry/><entry>4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 246</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(3-(dimethylamino)propoxy)-[1,1&#x2032;-biphenyl]-</entry></row><row><entry/><entry>4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 247</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((1-</entry></row><row><entry/><entry>methylpiperidin-4-yl)oxy)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 248</entry><entry>2-amino-N-((1S,2S)-2-((4-(3-(dimethylamino)prop-1-yn-1-</entry></row><row><entry/><entry>yl)benzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 249</entry><entry>2-amino-N-((1S,2S)-2-((4-(4-hydroxybut-1-yn-1-</entry></row><row><entry/><entry>yl)benzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 250</entry><entry>2-amino-N-((1S,2S)-2-((4-(5-hydroxypent-1-yn-1-</entry></row><row><entry/><entry>yl)benzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 251</entry><entry>2-amino-N-((1S,2S)-2-((4-(6-hydroxyhex-1-yn-1-</entry></row><row><entry/><entry>yl)benzyl)oxy)cyclopentyl)-5-(1-methy1-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 252</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(4-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)but-1-yn-1-</entry></row><row><entry/><entry>yl)benzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 253</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(4-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 254</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(1-(piperidin-4-yl)-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 255</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(1-(1-</entry></row><row><entry/><entry>methylpiperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 256</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(1-(1-ethylpiperidin-</entry></row><row><entry/><entry>4-yl)-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 257</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(1-(1-</entry></row><row><entry/><entry>isopropylpiperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 258</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(1-(1-(pyrrolidin-3-</entry></row><row><entry/><entry>ylmethyl)piperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 259</entry><entry>2-amino-N-((1R,2R)-2-(benzyloxy)cyclopentyl)-5-(1-(piperidin-4-yl)-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 260</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dichlorobenzyl)oxy)cyclopentyl)-5-(1-</entry></row><row><entry/><entry>(piperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 261</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(3-(hydroxymethyl)-</entry></row><row><entry/><entry>1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 262</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(3-(((2-</entry></row><row><entry/><entry>hydroxyethyl)amino)methyl)-1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 263</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(3-((3-</entry></row><row><entry/><entry>hydroxypiperidin-1-yl)methyl)-1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 264</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>cyanophenyl)nicotinamide</entry></row><row><entry>Example 265</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(3-</entry></row><row><entry/><entry>cyanophenyl)nicotinamide</entry></row><row><entry>Example 266</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>(cyanomethyl)phenyl)nicotinamide</entry></row><row><entry>Example 267</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>phenoxyphenyl)nicotinamide</entry></row><row><entry>Example 268</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(3-((1-</entry></row><row><entry/><entry>methylpiperidin-4-yl)carbamoyl)phenyl)nicotinamide</entry></row><row><entry>Example 269</entry><entry>6-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6&#x2032;-(hydroxymethyl)-</entry></row><row><entry/><entry>[3,3-bipyridine]-5-carboxamide</entry></row><row><entry>Example 270</entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 271</entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(3-(4-</entry></row><row><entry/><entry>methylpiperazine-1-carbonyl)phenyl)nicotinamide</entry></row><row><entry>Example 272</entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(3-(4-</entry></row><row><entry/><entry>(pyrrolidin-1-yl)piperidine-1-carbonyl)phenyl)nicotinamide</entry></row><row><entry>Example 273</entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(3-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 274</entry><entry>2-amino-5-(3-fluoro-4-((4-methylpiperazin-1-yl)methyl)phenyl)-N-</entry></row><row><entry/><entry>((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 275</entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-((4-</entry></row><row><entry/><entry>(pyrrolidin-1-yl)piperidin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 276</entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-(4-</entry></row><row><entry/><entry>methylpiperazine-1-carbonyl)phenyl)nicotinamide</entry></row><row><entry>Example 277</entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-(4-</entry></row><row><entry/><entry>(pyrrolidin-1-yl)piperidine-1-carbonyl)phenyl)nicotinamide</entry></row><row><entry>Example 278</entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-(2-((1-</entry></row><row><entry/><entry>methylpiperidin-4-yl)amino)-2-oxoethyl)phenyl)nicotinamide</entry></row><row><entry>Example 279</entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-(2-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)acetyl)phenyl)nicotinamide</entry></row><row><entry>Example 280</entry><entry>2-amino-5-(3-fluoro-4-((4-(pyrrolidin-1-yl)piperidin-1-yl)methyl)-</entry></row><row><entry/><entry>phenyl)-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 281</entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-(4-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)piperidine-1-carbonyl)phenyl)nicotinamide</entry></row><row><entry>Example 282</entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>(piperazin-1-ylmethyl)phenyl)nicotinamide</entry></row><row><entry>Example 283</entry><entry>2-amino-N-((1S,2S)-2-((4-methylbenzyl)oxy)cyclopentyl)-5-(4-(4-</entry></row><row><entry/><entry>methylpiperazine-1-carbonyl)phenyl)nicotinamide</entry></row><row><entry>Example 284</entry><entry>2-amino-N-((1S,2S)-2-((4-methylbenzyl)oxy)cyclopentyl)-5-(4-(4-</entry></row><row><entry/><entry>(pyrrolidin-1-yl)piperidine-1-carbonyl)phenyl)nicotinamide</entry></row><row><entry>Example 285</entry><entry>2-amino-5-(1,5-dimethyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 286</entry><entry>2-amino-5-(1,3-dimethyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 287</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(2-(2-</entry></row><row><entry/><entry>hydroxypropan-2-yl)-4-methylthiazol-5-yl)nicotinamide</entry></row><row><entry>Example 288</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(2-(3-</entry></row><row><entry/><entry>hydroxytetrahydrofuran-3-yl)-4-methylthiazol-5-yl)nicotinamide</entry></row><row><entry>Example 289</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 290</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-(2-</entry></row><row><entry/><entry>(4-methylpiperazin-1-yl)-2-oxoethyl)phenyl)nicotinamide</entry></row><row><entry>Example 291</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>(morpholinomethyl)phenyl)nicotinamide</entry></row><row><entry>Example 292</entry><entry>2-amino-5-(4-((dimethylamino)methyl)phenyl)-N-((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 293</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((4-</entry></row><row><entry/><entry>(2-hydroxyethyl)piperazin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 294</entry><entry>6-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-2&#x2032;-</entry></row><row><entry/><entry>methoxy-[3,3&#x2032;-bipyridine]-5-carboxamide</entry></row><row><entry>Example 295</entry><entry>2-amino-5-(4-(dimethylamino)phenyl)-N-((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 296</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-</entry></row><row><entry/><entry>hydroxyphenyl)nicotinamide</entry></row><row><entry>Example 297</entry><entry>2-amino-5-(3-aminophenyl)-N-((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 298</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-</entry></row><row><entry/><entry>(methylsulfonamido)phenyl)nicotinamide</entry></row><row><entry>Example 299</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-</entry></row><row><entry/><entry>(hydroxymethyl)phenyl)nicotinamide</entry></row><row><entry>Example 300</entry><entry>2-amino-5-(3-(aminomethyl)phenyl)-N-((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 301</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-(3-</entry></row><row><entry/><entry>hydroxypropyl)phenyl)nicotinamide</entry></row><row><entry>Example 302</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-</entry></row><row><entry/><entry>((((1r,4S)-4-hydroxycyclohexyl)amino)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 303</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-(((1-</entry></row><row><entry/><entry>methylpiperidin-4-yl)amino)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 304</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-</entry></row><row><entry/><entry>((((S)-piperidin-3-yl)amino)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 305</entry><entry>3-(6-amino-5-(((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-</entry></row><row><entry/><entry>carbamoyl)pyridin-3-yl)-5-hydroxybenzoic acid</entry></row><row><entry>Example 306</entry><entry>4-(6-amino-5-(((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-</entry></row><row><entry/><entry>carbamoyl)pyridin-3-yl)-2-methylbenzoic acid</entry></row><row><entry>Example 307</entry><entry>2-amino-5-(4-aminophenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)-</entry></row><row><entry/><entry>cyclopentyl)nicotinamide</entry></row><row><entry>Example 308</entry><entry>3-(6-amino-5-(((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)carbamoyl)pyridin-3-yl)benzoic acid</entry></row><row><entry>Example 309</entry><entry>3-amino-5-(6-amino-5-(((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)carbamoyl)pyridin-3-yl)benzoic acid</entry></row><row><entry>Example 310</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(2-</entry></row><row><entry/><entry>methyl-5-(4-(pyrrolidin-1-yl)piperidine-1-carbonyl)phenyl)nicotinamide</entry></row><row><entry>Example 311</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-</entry></row><row><entry/><entry>methyl-4-(4-methylpiperazine-1-carbonyl)phenyl)nicotinamide</entry></row><row><entry>Example 312</entry><entry>2-amino-5-(3-amino-5-(4-(pyrrolidin-1-yl)piperidine-1-carbonyl)-</entry></row><row><entry/><entry>phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-</entry></row><row><entry/><entry>nicotinamide</entry></row><row><entry>Example 313</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>(hydroxymethyl)phenyl)nicotinamide</entry></row><row><entry>Example 314</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>formylphenyl)nicotinamide</entry></row><row><entry>Example 315</entry><entry>4-(6-amino-5-(((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)carbamoyl)pyridin-3-yl)benzoic acid</entry></row><row><entry>Example 316</entry><entry>3-(4-(6-amino-5-(((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)carbamoyl)pyridin-3-</entry></row><row><entry/><entry>yl)phenyl)propanoic acid</entry></row><row><entry>Example 317</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(2-</entry></row><row><entry/><entry>hydroxyphenyl)nicotinamide</entry></row><row><entry>Example 318</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((1-</entry></row><row><entry/><entry>methylpiperidin-4-yl)carbamoyl)phenyl)nicotinamide</entry></row><row><entry>Example 319</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>(dimethylcarbamoyl)phenyl)nicotinamide</entry></row><row><entry>Example 320</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-(((1-</entry></row><row><entry/><entry>methylpiperidin-4-yl)amino)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 321</entry><entry>6-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-6&#x2032;-</entry></row><row><entry/><entry>(hydroxymethyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</entry></row><row><entry>Example 322</entry><entry>2-amino-4-(6-amino-5-(((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)carbamoyl)pyridin-3-yl)benzoic acid</entry></row><row><entry>Example 323</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>(hydroxymethyl)-3-methoxyphenyl)nicotinamide</entry></row><row><entry>Example 324</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-</entry></row><row><entry/><entry>fluoro-4-(hydroxymethyl)phenyl)nicotinamide</entry></row><row><entry>Example 325</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-</entry></row><row><entry/><entry>fluoro-4-((4-(pyrrolidin-1-yl)piperidin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 326</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-(1-</entry></row><row><entry/><entry>hydroxyethyl)phenyl)nicotinamide</entry></row><row><entry>Example 327</entry><entry>2-amino-5-(4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)phenyl)-N-</entry></row><row><entry/><entry>((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 328</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((4-</entry></row><row><entry/><entry>hydroxypiperidin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 329</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>((((1-methylpiperidin-4-yl)methyl)amino)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 330</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-</entry></row><row><entry/><entry>methyl-4-(4-(pyrrolidin-1-yl)piperidine-1-carbonyl)phenyl)nicotinamide</entry></row><row><entry>Example 331</entry><entry>2-amino-5-(3-amino-4-(4-(pyrrolidin-1-yl)piperidine-1-</entry></row><row><entry/><entry>carbonyl)phenyl)-N-((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 332</entry><entry>2-amino-5-(3-amino-4-((4-(pyrrolidin-1-yl)piperidin-1-</entry></row><row><entry/><entry>yl)methyl)phenyl)-N-((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 333</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>(hydroxymethyl)-3-methylphenyl)nicotinamide</entry></row><row><entry>Example 334</entry><entry>2-amino-5-(3-chlorophenyl)-N-((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 335</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(m-</entry></row><row><entry/><entry>tolyl)nicotinamide</entry></row><row><entry>Example 336</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3,5-</entry></row><row><entry/><entry>dimethylphenyl)nicotinamide</entry></row><row><entry>Example 337</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((3-</entry></row><row><entry/><entry>morpholinopyrrolidin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 338</entry><entry>2-amino-5-(4-((4-aminopiperidin-1-yl)methyl)phenyl)-N-((1S,2S)-2-</entry></row><row><entry/><entry>((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 339</entry><entry>2-amino-5-(4-((3-aminopiperidin-1-yl)methyl)phenyl)-N-((1S,2S)-2-</entry></row><row><entry/><entry>((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 340</entry><entry>2-amino-5-(4-((3-aminopyrrolidin-1-yl)methyl)phenyl)-N-((1S,2S)-2-</entry></row><row><entry/><entry>((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 341</entry><entry>2-amino-5-(4-((3-aminopyrrolidin-1-yl)methyl)-3-fluorophenyl)-N-</entry></row><row><entry/><entry>((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 342</entry><entry>2-amino-5-(4-((3-aminopyrrolidin-1-yl)methyl)-3-fluorophenyl)-N-</entry></row><row><entry/><entry>((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 343</entry><entry>2-amino-5-(3-((3-(dimethylamino)pyrrolidin-1-yl)methyl)phenyl)-N-</entry></row><row><entry/><entry>((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 344</entry><entry>2-amino-5-(3-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-4-</entry></row><row><entry/><entry>methoxyphenyl)-N-((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 345</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((3-</entry></row><row><entry/><entry>hydroxyazetidin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 346</entry><entry>2-amino-5-(4-(((R)-3-(dimethylamino)pyrrolidin-1-yl)methyl)phenyl)-</entry></row><row><entry/><entry>N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 347</entry><entry>2-amino-5-(4-(((S)-3-(dimethylamino)pyrrolidin-1-yl)methyl)phenyl)-</entry></row><row><entry/><entry>N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 348</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>(((R)-3-hydroxypyrrolidin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 349</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>(((S)-3-hydroxypyrrolidin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 350</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((3-</entry></row><row><entry/><entry>hydroxypiperidin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 351</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>hydroxyphenyl)nicotinamide</entry></row><row><entry>Example 352</entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>hydroxy-3-methoxyphenyl)nicotinamide</entry></row><row><entry>Example 353</entry><entry>2-amino-5-(3,4-dimethoxyphenyl)-N-((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 354</entry><entry>amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-</entry></row><row><entry/><entry>(pyrrolidin-1-yl)phenyl)nicotinamide</entry></row><row><entry>Example 355</entry><entry>2-amino-5-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3,4-</entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 356</entry><entry>2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>(hydroxymethyl)phenyl)nicotinamide</entry></row><row><entry>Example 357</entry><entry>2-amino-5-(4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)phenyl)-N-</entry></row><row><entry/><entry>((1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 358</entry><entry>2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>((3-hydroxypyrrolidin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 359</entry><entry>2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>(2-(piperazin-1-yl)propan-2-yl)phenyl)nicotinamide</entry></row><row><entry>Example 360</entry><entry>2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>(2-(4-(2-hydroxyethyl)piperazin-1-yl)propan-2-yl)phenyl)nicotinamide</entry></row><row><entry>Example 361</entry><entry>3-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6-(1-(piperidin-4-yl)-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)pyrazine-2-carboxamide</entry></row><row><entry>Example 362</entry><entry>(S)-3-amino-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-N-(1,2,3,4-</entry></row><row><entry/><entry>tetrahydronaphthalen-1-yl)pyrazine-2-carboxamide</entry></row><row><entry>Example 363</entry><entry>2-amino-5-(4-fluorophenyl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-</entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 364</entry><entry>2-amino-5-(3,4-difluorophenyl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-</entry></row><row><entry/><entry>1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 365</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>(trifluoromethyl)phenyl)nicotinamide</entry></row><row><entry>Example 366</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-(1-methylpiperidin-4-yl)-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 367</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(4-(4-methylpiperazin-1-</entry></row><row><entry/><entry>yl)phenyl)nicotinamide</entry></row><row><entry>Example 368</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(4-((4-methylpiperazin-1-</entry></row><row><entry/><entry>yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 369</entry><entry>2-amino-5-(4-(hydroxymethyl)phenyl)-N-((1S,2S)-2-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 370</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(m-tolyl)nicotinamide</entry></row><row><entry>Example 371</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-phenylnicotinamide</entry></row><row><entry>Example 372</entry><entry>2-amino-5-(4-hydroxyphenyl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-</entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 373</entry><entry>2-amino-5-(4-chloro-3-fluorophenyl)-N-((1S,2S)-2-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 374</entry><entry>2-amino-5-methyl-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 375</entry><entry>6-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</entry></row><row><entry>Example 376</entry><entry>2-amino-5-(4-methoxyphenyl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-</entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 377</entry><entry>6-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-[3,4&#x2032;-bipyridine]-5-carboxamide</entry></row><row><entry>Example 378</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(4-((4-methylpiperidin-1-</entry></row><row><entry/><entry>yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 379</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>(morpholinomethyl)phenyl)nicotinamide</entry></row><row><entry>Example 380</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-(tetrahydro-2H-pyran-4-yl)-</entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 381</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(4-</entry></row><row><entry/><entry>morpholinophenyl)nicotinamide</entry></row><row><entry>Example 382</entry><entry>2-amino-5-(cyclohex-1-en-1-yl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-</entry></row><row><entry/><entry>1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 383</entry><entry>2-amino-5-(3,4-dimethoxyphenyl)-N-((1S,2S)-2-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide</entry></row><row><entry>Example 384</entry><entry>6-amino-2&#x2032;,6&#x2032;-difluoro-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-</entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,4&#x2032;-bipyridine]-</entry></row><row><entry/><entry>5-carboxamide</entry></row><row><entry>Example 385</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(4-methylthiophen-3-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 386</entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-</entry></row><row><entry/><entry>carboxamide</entry></row><row><entry>Example 387</entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-(1,1,2,2-tetrafluoroethyl)-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 388</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 389</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(4-(hydroxymethyl)phenyl)nicotinamide</entry></row><row><entry>Example 390</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(4-((4-methylpiperazin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 391</entry><entry>2-amino-5-(4-carbamoylphenyl)-N-((3S,4S)-4-((3-ethyl-4-</entry></row><row><entry/><entry>methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</entry></row><row><entry>Example 392</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(m-tolyl)nicotinamide</entry></row><row><entry>Example 393</entry><entry>4-(6-amino-5-(((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-</entry></row><row><entry/><entry>yl)carbamoyl)pyridin-3-yl)benzoic acid</entry></row><row><entry>Example 394</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>phenylnicotinamide</entry></row><row><entry>Example 395</entry><entry>6-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-</entry></row><row><entry/><entry>[3,4&#x2032;-bipyridine]-5-carboxamide</entry></row><row><entry>Example 396</entry><entry>6-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-</entry></row><row><entry/><entry>[3,3&#x2032;-bipyridine]-5-carboxamide</entry></row><row><entry>Example 397</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>vinylnicotinamide</entry></row><row><entry>Example 398</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(4-fluorophenyl)nicotinamide</entry></row><row><entry>Example 399</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(4-formylphenyl)nicotinamide</entry></row><row><entry>Example 400</entry><entry>2-amino-5-(4-cyanophenyl)-N-((3S,4S)-4-((3-ethyl-4-</entry></row><row><entry/><entry>methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</entry></row><row><entry>Example 401</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(4-(methylsulfonamido)phenyl)nicotinamide</entry></row><row><entry>Example 402</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(4-phenoxyphenyl)nicotinamide</entry></row><row><entry>Example 403</entry><entry>5-([1,1&#x2032;-biphenyl]-4-yl)-2-amino-N-((3S,4S)-4-((3-ethyl-4-</entry></row><row><entry/><entry>methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</entry></row><row><entry>Example 404</entry><entry>2-amino-5-(4-(benzyloxy)phenyl)-N-((3S,4S)-4-((3-ethyl-4-</entry></row><row><entry/><entry>methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</entry></row><row><entry>Example 405</entry><entry>2-amino-5-(4-(dimethylamino)phenyl)-N-((3S,4S)-4-((3-ethyl-4-</entry></row><row><entry/><entry>methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</entry></row><row><entry>Example 406</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(quinolin-3-yl)nicotinamide</entry></row><row><entry>Example 407</entry><entry>2-amino-5-(benzofuran-2-yl)-N-((3S,4S)-4-((3-ethyl-4-</entry></row><row><entry/><entry>methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</entry></row><row><entry>Example 408</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(naphthalen-1-yl)nicotinamide</entry></row><row><entry>Example 409</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(4-(trifluoromethyl)phenyl)nicotinamide</entry></row><row><entry>Example 410</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(2,4,5-trifluorophenyl)nicotinamide</entry></row><row><entry>Example 411</entry><entry>2-amino-5-(4-(cyanomethyl)phenyl)-N-((3S,4S)-4-((3-ethyl-4-</entry></row><row><entry/><entry>methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</entry></row><row><entry>Example 412</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(1-(piperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 413</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 414</entry><entry>2-amino-N-((3S,4S)-4-(benzyloxy)pyrrolidin-3-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 415</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)-4-((4-</entry></row><row><entry/><entry>methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</entry></row><row><entry>Example 416</entry><entry>2-amino-N-((3S,4S)-4-((3-ethylbenzyl)oxy)pyrrolidin-3-yl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 417</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-fluorobenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 418</entry><entry>2-amino-N-((3S,4S)-4-((4-chloro-3-ethylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 419</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(4-((1-methylpiperidin-4-yl)carbamoyl)phenyl)nicotinamide</entry></row><row><entry>Example 420</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(4-((4-methylcyclohexyl)carbamoyl)phenyl)nicotinamide</entry></row><row><entry>Example 421</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(4-(4-methylpiperidine-1-carbonyl)phenyl)nicotinamide</entry></row><row><entry>Example 422</entry><entry>2-amino-5-(4-(dimethylcarbamoyl)phenyl)-N-((3S,4S)-4-((3-ethyl-4-</entry></row><row><entry/><entry>methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</entry></row><row><entry>Example 423</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(4-((4-methylpiperidin-1-yl)methyl)phenyl)nicotinamide</entry></row><row><entry>Example 424</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-</entry></row><row><entry/><entry>(4-(morpholinomethyl)phenyl)nicotinamide</entry></row><row><entry>Example 425</entry><entry>2-amino-5-(4-((3,3-difluoropiperidin-1-yl)methyl)phenyl)-N-((3S,4S)-4-</entry></row><row><entry/><entry>((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</entry></row><row><entry>Example 426</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)-1-</entry></row><row><entry/><entry>methylpyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 427</entry><entry>2-amino-N-((3S,4S)-1-benzyl-4-((3-ethyl-4-</entry></row><row><entry/><entry>methylbenzyl)oxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 428</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)-1-(3-</entry></row><row><entry/><entry>phenylpropyl)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 429</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)-1-</entry></row><row><entry/><entry>phenethylpyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 430</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)-1-</entry></row><row><entry/><entry>isobutylpyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 431</entry><entry>2-amino-N-((3S,4S)-1-butyl-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-</entry></row><row><entry/><entry>3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 432</entry><entry>2-amino-N-((3S,4S)-1-ethyl-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-</entry></row><row><entry/><entry>3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 433</entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)-1-</entry></row><row><entry/><entry>methylpyrrolidin-3-yl)-5-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 434</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)-4-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-</entry></row><row><entry/><entry>3-yl)nicotinamide</entry></row><row><entry>Example 435</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)-1-methyl-4-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-</entry></row><row><entry/><entry>3-yl)nicotinamide</entry></row><row><entry>Example 436</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)-4-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)pyrrolidin-3-yl)nicotinamid</entry></row><row><entry>Example 437</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)-1-methyl-4-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)pyrrolidin-3-yl)nicotinamide</entry></row><row><entry>Example 438</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)-4-((4&#x2032;-(1-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-3-</entry></row><row><entry/><entry>yl)nicotinamide</entry></row><row><entry>Example 439</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)-1-methyl-4-((4&#x2032;-(1-</entry></row><row><entry/><entry>(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-</entry></row><row><entry/><entry>3-yl)nicotinamide</entry></row><row><entry>Example 440</entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-(2-(4-(2-hydroxyethyl)piperazin-1-yl)propan-</entry></row><row><entry/><entry>2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 441</entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-(2-(4-(2-hydroxyethyl)piperazin-1-yl)propan-</entry></row><row><entry/><entry>2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)-1-methylpyrrolidin-3-yl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 442</entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-(1-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-</entry></row><row><entry/><entry>4-yl)nicotinamide</entry></row><row><entry>Example 443</entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-(1-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)-1-methylpyirolidin-3-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 444</entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-</entry></row><row><entry/><entry>3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)-5-(1-</entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 445</entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-</entry></row><row><entry/><entry>3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)-1-methylpyrrolidin-</entry></row><row><entry/><entry>3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 446</entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-</entry></row><row><entry/><entry>4-yl)nicotinamide</entry></row><row><entry>Example 447</entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)-1-methylpyrrolidin-3-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 448</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4R)-4-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)tetrahydrofuran-3-yl)nicotinamide</entry></row><row><entry>Example 449</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4R)-4-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)tetrahydrofuran-3-yl)nicotinamide</entry></row><row><entry>Example 450</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4R)-4-((4&#x2032;-(2-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)tetrahydrofuran-3-yl)nicotinamide</entry></row><row><entry>Example 451</entry><entry>2-amino-N-((3S,4R)-4-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-</entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl)-5-(1-methyl-1H-</entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 452</entry><entry>2-amino-N-((3S,4R)-4-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-</entry></row><row><entry/><entry>3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl)-</entry></row><row><entry/><entry>5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 453</entry><entry>2-amino-N-((3S,4R)-4-((4&#x2032;-(2-(4-(2-hydroxyethyl)piperazin-1-</entry></row><row><entry/><entry>yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl)-5-</entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide</entry></row><row><entry>Example 454</entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(trans-4-((4&#x2032;-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-</entry></row><row><entry/><entry>yl)methoxy)tetrahydrofuran-3-yl)nicotinamide</entry></row><row><entry>Example 455</entry><entry>2-amino-N-(trans-4-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-</entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl)nicotinamide</entry></row><row><entry>Example 456</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6-((4-((4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)phenyl)amino)nicotinamide</entry></row><row><entry>Example 457</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6-</entry></row><row><entry/><entry>(phenylamino)nicotinamide</entry></row><row><entry>Example 458</entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6-((4-(4-</entry></row><row><entry/><entry>methylpiperazin-1-yl)phenyl)amino)nicotinamide</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0007" level="1">Pharmaceutical Compositions Comprising of Novel Mer Kinase Inhibitors</heading><p id="p-0084" num="0078">The present invention provides pharmaceutical compositions comprising the heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt thereof together with pharmaceutically acceptable carriers.</p><p id="p-0085" num="0079">The carriers that are used in the present invention may be those that are conventionally used in the art, and examples thereof include, but are not limited to, sugar, starch, microcrystalline cellulose, lactose (lactose hydrate), glucose, di-mannitol, alginate, alkaline earth metal salts, clay, polyethylene glycol, anhydrous dibasic calcium phosphate, or mixtures thereof.</p><p id="p-0086" num="0080">Further, according to another embodiment of the present invention, the pharmaceutical compositions may contain additives such as binders, disintegrants, lubricants, pH-adjusting agents, antioxidants, and the like.</p><p id="p-0087" num="0081">Examples of the binders that may be used in the present invention include, but are not limited to, starch, microcrystalline cellulose, highly dispersed silica, mannitol, di-mannitol, sucrose, lactose hydrate, polyethylene glycol, polyvinylpyrrolidone (povidone), polyvinylpyrrolidone copolymer (copovidone), hypromellose, hydroxypropyl cellulose, natural gum, synthetic gum, copovidone, gelatin, or mixtures thereof.</p><p id="p-0088" num="0082">Examples of the disintegrants that may be used in the present invention include, but are not limited to, starches or modified starches such as sodium starch glyconate, maize starch, potato starch or pregelatinized starch; clays such as bentonite, montmorillonite, or veegum; celluloses such as microcrystalline cellulose, hydroxypropylcellulose or carboxymethylcellulose; algins such as sodium alginate or alginic acid; crosslinked celluloses such as croscarmellose sodium; gums such as guar gum or xanthan gum; crosslinked polymers such as crosslinked polyvinylpyrrolidone (crospovidone); effervescent formulations such as sodium bicarbonate or citric acid; or mixtures thereof.</p><p id="p-0089" num="0083">Examples of the lubricants that may be used in the present invention include, but are not limited to, talc, stearic acid, magnesium stearate, calcium stearate, sodium lauryl sulfate, hydrogenated vegetable oil, sodium benzoate, sodium stearyl fumarate, glyceryl behenate, glyceryl monooleate, glyceryl monostearate, glyceryl palmitostearate, colloidal silicon dioxide, or mixtures thereof.</p><p id="p-0090" num="0084">Examples of the pH-adjusting agents that may be used in the present invention include, but are not limited to, acidifying agents such as acetic acid, adipic acid, ascorbic acid, sodium ascorbate, sodium etherate, malic acid, succinic acid, tartaric acid, fumaric acid or citric acid, and basifying agents such as precipitated calcium carbonate, ammonia water, meglumine, sodium carbonate, magnesium oxide, magnesium carbonate, sodium citrate, or tribasic calcium phosphate.</p><p id="p-0091" num="0085">Examples of the antioxidants that may be used in the present invention include, but are not limited to, dibutyl hydroxytoluene, butylated hydroxyanisole, tocopherol acetate, tocopherol, propyl gallate, sodium hydrogen sulfite, sodium pyrosulfite, and the like.</p><p id="p-0092" num="0086">The present invention provides the pharmaceutical compositions comprise, as active ingredients, the heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt thereof and are used for prevention or treatment of a disease which is influenced by inhibition of Mer kinase.</p><p id="p-0093" num="0087">The present invention provides the disease which is influenced by inhibition of Mer kinase is cancer or immune-related diseases.</p><p id="p-0094" num="0088">The cancer is selected from the group consisting of: glioma, gliosarcoma, anaplastic astrocytoma, medulloblastoma, lung cancer, small cell lung carcinoma, cervical carcinoma, colon cancer, rectal cancer, chordoma, throat cancer, Kaposi's sarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, colorectal cancer, endometrium cancer, ovarian cancer, breast cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, hepatic carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, testicular tumor, Wilms' tumor, Ewing's tumor, bladder carcinoma, angiosarcoma, endotheliosarcoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland sarcoma, papillary sarcoma, papillary adenosarcoma, cystadenosarcoma, bronchogenic carcinoma, medullary carcinoma, mastocytoma, mesotheliorma, synovioma, melanoma, leiomyosarcoma, rhabdomyosarcoma, neuroblastoma, retinoblastoma, oligodentroglioma, acoustic neuroma, hemangioblastoma, meningioma, pinealoma, ependymoma, craniopharyngioma, epithelial carcinoma, embryonal carcinoma, squamous cell carcinoma, base cell carcinoma, fibrosarcoma, myxoma, myxosarcoma, liposarcorna, chondrosarcoma, osteogenic sarcoma, leukemia and metastatic lesions secondary to these primary tumors.</p><p id="p-0095" num="0089">The immune-related disease is selected from the group consisting of infection and sepsis.</p><p id="p-0096" num="0090">The term &#x201c;treatment&#x201d; is used to refer to both prevention of diseases and treatment of pre-existing conditions.</p><p id="p-0097" num="0091">The therapeutic amount varies according to the specific disease and can be determined by the person skilled in the art without undue effort.</p><p id="p-0098" num="0092">In addition, the subject in the prevention or treatment method of the present invention includes mammals, particularly humans.</p><p id="p-0099" num="0093">The dose varies depending on the specific compound used, the specific disease, the patient status, etc. A therapeutic dose is typically sufficient considerably to reduce the undesired cell population in the target tissue while the viability of the patient is maintained. The treatment is generally continued until a considerable reduction has occurred, for example an at least about 50% reduction in the cell burden, and may be continued until essentially no more undesired cells are detected in the body.</p><heading id="h-0008" level="1">Method for Prevention or Treatment of Immune-Related Diseases or Cancer</heading><p id="p-0100" num="0094">The present invention provides a method of treating or preventing immune-related diseases or cancer, the method comprising administering to a mammals including humans in need thereof compositions comprising, as active ingredients, the heterocyclic compounds, isomers thereof or pharmaceutically acceptable salts thereof.</p><p id="p-0101" num="0095">The composition that is used in the inventive method for preventing or treating immune-related diseases or cancer includes the pharmaceutical composition described in the specification</p><p id="p-0102" num="0096">The present invention provides use of compositions comprising, as active ingredients, the heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt thereof for preparation of medicaments for preventing or treating cancer or immune-related diseases.</p><p id="p-0103" num="0097">Methods for Preparing of Novel Mer Kinase Inhibitors</p><p id="p-0104" num="0098">The compounds of this invention can be prepared in accordance with one or more of schemes discussed below.</p><p id="p-0105" num="0099">These methods can be used either directly or with obvious variations to trained chemists to prepare key intermediates and certain compounds of this invention.</p><p id="p-0106" num="0100">Suitable synthetic sequences are readily selected per specific structures of this invention, but within the art known to individuals practicing organic synthesis, such as methods summarized in available chemistry data bases, as in CAS Scifinder and Elesevier Reaxys. Based on these general methods, the enablement for making the compounds of this invention is straightforward and can be practiced within a common professional knowledge. Some general synthetic methods to prepare the compounds of this invention are illustrated below in Schemes 1-2 (non-limiting, for illustration only).</p><p id="p-0107" num="0101">One general approach to the compounds of this invention is illustrated in general Scheme 1.</p><p id="p-0108" num="0000"><chemistry id="CHEM-US-00004" num="00004"><img id="EMI-C00004" he="137.16mm" wi="75.86mm" file="US20230002353A1-20230105-C00004.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0109" num="0102">Another general approach to the compounds of this invention is illustrated in general Scheme 2.</p><p id="p-0110" num="0000"><chemistry id="CHEM-US-00005" num="00005"><img id="EMI-C00005" he="120.14mm" wi="75.86mm" file="US20230002353A1-20230105-C00005.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><heading id="h-0009" level="1">Advantageous Effects</heading><p id="p-0111" num="0103">Novel heterocyclic compounds according to the present invention, a stereoisomer thereof, an enantiomer thereof, or a pharmaceutically acceptable salt thereof exhibit the effect of effectively inhibiting Mer kinase.</p><p id="p-0112" num="0104">Novel heterocyclic compounds according to the present invention, a stereoisomer thereof, an enantiomer thereof, or a pharmaceutically acceptable salt can be used for the prevention or treatment of cancer or immune-related disease.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0010" level="1">MODE FOR INVENTION</heading><p id="p-0113" num="0105">Based on the studies conducted and the results obtained so far, it is believed that the following compounds (numbered 1 to 458), including isomers, mixtures of isomer as well as pharmaceutically acceptable salts and solvates thereof, are particularly interesting.</p><heading id="h-0011" level="1">General Synthetic Methods</heading><heading id="h-0012" level="1">Examples</heading><p id="p-0114" num="0106">Embodiments of the present invention are described in the following examples, which are meant to illustrate and not limit the scope of this invention. Common abbreviations well known to those with ordinary skills in the synthetic art used throughout.</p><p id="p-0115" num="0107">All chemical reagents were commercially available. Flash column chromatography means silica gel chromatography unless specified otherwise, which was performed on Teledyne Combiflash-RF200 System. <sup>1</sup>H NMR spectra (&#x3b4;, ppm) are recorded on 400 MHz or 600 MHz instrument. Mass spectroscopy data for a positive ionization method are provided. Preparative HPLC was performed on Agilent technologies G1361A.</p><heading id="h-0013" level="1">Example 1. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0116" num="0108">Scheme for the Preparation of the Compound of Example 1:</p><p id="p-0117" num="0000"><chemistry id="CHEM-US-00006" num="00006"><img id="EMI-C00006" he="118.87mm" wi="75.86mm" file="US20230002353A1-20230105-C00006.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0118" num="0109">Intermediate 1. To a mixture of methyl 2-amino-5-bromonicotinate (1.5 g, 6.5 mmol) and 1-Methylpyrazole-4-boronic acid pinacol ester (1.76 g, 8.5 mmol) in 24 ml of 1,4-dioxane was added 8 ml of aq. 2N K<sub>3</sub>PO<sub>4 </sub>followed by Pd(PPh<sub>3</sub>)<sub>4 </sub>(370 mg, 0.32 mmol). The reaction mixture was heated at 100&#xb0; C. for 3 hrs, cooled to room temperature, and extracted with EtOAc, dried over anhydrous MgSO<sub>4 </sub>and concentrated under vacuum. The crude product was purified by silicagel column chromatography to give 1.25 g of off-white solid.</p><p id="p-0119" num="0110"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; 3.90 (s, 3H), 3.91 (s, 3H), 7.74 (s, 1H), 7.91 (s, 1H), 8.29 (d, J=2.4 Hz, 1H), 8.35 (d, J=2.4 Hz, 1H);</p><p id="p-0120" num="0111">MS (ESI, m/z): 233.1 [M+H]<sup>+</sup></p><p id="p-0121" num="0112">Intermediate 2. To a suspension of intermediate 1 (1.2 g, 5.17 mmol) in 26 ml of MeOH was added 2N NaOH (4.3 ml, 8.63 mmol) and the mixture was heated at 65&#xb0; C. for 1 hr, cooled to room temperature, neutralized (4.3 ml of 2N HCl), and the resulting precipitate was filtered, washed with MeOH, and dried to give 0.97 g of off-white solid.</p><p id="p-0122" num="0113"><sup>1</sup>H NMR (600 MHz, DMSO-d<sub>6</sub>) &#x3b4; ppm 3.82 (s, 3H), 5.73 (s, 2H), 7.77 (s, 1H), 8.05 (s, 1H), 8.13 (d, J=2.4 Hz, 1H), 8.42 (d, J=2.4 Hz, 1H);</p><p id="p-0123" num="0114">MS (ESI, m/z): 219.1 [M+H]<sup>+</sup></p><heading id="h-0014" level="1">Example 1. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0124" num="0115">To a mixture of intermediate 2 (43 mg, 0.2 mmol) and triethylamine (24 mg, 0.24 mmol) in 2 ml of DMF was added HATU (91 mg, 0.24 mmol) followed by (1S,2S)-2-(benzyloxy)cyclopentan-1-amine (38 mg, 0.2 mmol). The mixture was stirred at room temperature for 1 hr and then saturated sodium bicarbonate solution was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude residue was purified by preparative HPLC to afford 46 mg of the title compound.</p><p id="p-0125" num="0116"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.57-1.69 (m, 1H) 1.72-1.86 (m, 3H) 1.90-2.08 (m, 1H) 2.11-2.21 (m, 1H) 3.93 (s, 3H) 3.96 (dt, J=6.75, 4.26 Hz, t H) 4.39 (td, J=7.34, 4.11 Hz, 1H) 4.61 (s, 2H) 7.13-7.24 (m, 1H) 7.27 (t, J=7.46 Hz, 2H) 7.32 (d, J=7.04 Hz, 2H) 7.79-7.90 (m, 1H) 8.00 (s, 1H) 8.23 (d, J=1.76 Hz, 1H) 8.46 (d, J=2.35 Hz, 1H);</p><p id="p-0126" num="0117">MS (ESI, m/z): 392.2 [M+H]<sup>+</sup></p><heading id="h-0015" level="1">Example 2. 2-amino-N-((1R,2R)-2-(benzyloxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0127" num="0118">Using (1R,2R)-2-(benzyloxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0128" num="0119">MS (ESI, m/z): 392.2 [M+H]<sup>+</sup></p><heading id="h-0016" level="1">Example 3. 2-amino-N-(trans-2-(benzyloxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0129" num="0120">Using trans-2-(benzyloxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0130" num="0121">MS (ESI, m/z): 392.2 [M+H]<sup>+</sup></p><heading id="h-0017" level="1">Example 4. 2-amino-N-((1R,2S)-2-(benzyloxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0131" num="0122">Using (1R,2S)-2-(benzyloxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0132" num="0000"><chemistry id="CHEM-US-00007" num="00007"><img id="EMI-C00007" he="28.19mm" wi="64.85mm" file="US20230002353A1-20230105-C00007.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0133" num="0123">MS (ESI, m/z): 392.2 [M+H]<sup>+</sup></p><heading id="h-0018" level="1">Example 5. 2-amino-N-(cis-2-(benzyloxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0134" num="0124">Using cis-2-(benzyloxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0135" num="0000"><chemistry id="CHEM-US-00008" num="00008"><img id="EMI-C00008" he="28.19mm" wi="64.85mm" file="US20230002353A1-20230105-C00008.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0136" num="0125">MS (ESI, m/z): 392.2 [M+H]<sup>+</sup></p><heading id="h-0019" level="1">Example 6. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((2-methylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0137" num="0126">Using (1S,2S)-2-((2-methylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0138" num="0000"><chemistry id="CHEM-US-00009" num="00009"><img id="EMI-C00009" he="28.19mm" wi="64.85mm" file="US20230002353A1-20230105-C00009.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0139" num="0127">MS (ESI, m/z): 406.2 [M+H]<sup>+</sup></p><heading id="h-0020" level="1">Example 7. 2-amino-N-((1S,2S)-2-((3-ethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0140" num="0128">Using (1S,2S)-2-((3-ethylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0141" num="0000"><chemistry id="CHEM-US-00010" num="00010"><img id="EMI-C00010" he="28.19mm" wi="74.17mm" file="US20230002353A1-20230105-C00010.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0142" num="0129">MS (ESI, m/z): 420.2 [M+H]<sup>+</sup></p><heading id="h-0021" level="1">Example 8. 2-amino-N-((1S,2S)-2-((4-ethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0143" num="0130">Using (1S,2S)-2-((4-ethylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0144" num="0000"><chemistry id="CHEM-US-00011" num="00011"><img id="EMI-C00011" he="29.29mm" wi="72.39mm" file="US20230002353A1-20230105-C00011.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0145" num="0131">MS (ESI, m/z): 420.2 [M+H]<sup>+</sup></p><heading id="h-0022" level="1">Example 9. 2-amino-N-(trans-2-((4-ethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0146" num="0132">Using trans-2-((4-ethylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0147" num="0000"><chemistry id="CHEM-US-00012" num="00012"><img id="EMI-C00012" he="34.04mm" wi="72.39mm" file="US20230002353A1-20230105-C00012.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0148" num="0133">MS (ESI, m/z): 420.2 [M+H]<sup>+</sup></p><heading id="h-0023" level="1">Example 10. 2-amino-N-((1S,2S)-2-((4-isopropylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0149" num="0134">Using (1S,2S)-2-((4-isopropylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0150" num="0000"><chemistry id="CHEM-US-00013" num="00013"><img id="EMI-C00013" he="34.54mm" wi="72.39mm" file="US20230002353A1-20230105-C00013.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0151" num="0135">MS (ESI, m/z): 434.3 [M+H]<sup>+</sup></p><heading id="h-0024" level="1">Example 11. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0152" num="0136">Using (1S,2S)-2-((2,3-dimethylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0153" num="0000"><chemistry id="CHEM-US-00014" num="00014"><img id="EMI-C00014" he="29.21mm" wi="70.36mm" file="US20230002353A1-20230105-C00014.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0154" num="0137">MS (ESI, m/z): 420.2 [M+H]<sup>+</sup></p><heading id="h-0025" level="1">Example 12. 2-amino-N-((1R,2R)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0155" num="0138">Using (1R,2R)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0156" num="0000"><chemistry id="CHEM-US-00015" num="00015"><img id="EMI-C00015" he="29.21mm" wi="70.36mm" file="US20230002353A1-20230105-C00015.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0157" num="0139">MS (ESI, m/z): 420.2 [M+H]<sup>+</sup></p><heading id="h-0026" level="1">Example 13. 2-amino-N-(trans-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0158" num="0140">Using trans-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0159" num="0000"><chemistry id="CHEM-US-00016" num="00016"><img id="EMI-C00016" he="33.95mm" wi="70.36mm" file="US20230002353A1-20230105-C00016.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0160" num="0141">MS (ESI, m/z): 420.2 [M+H]<sup>+</sup></p><heading id="h-0027" level="1">Example 14. 2-amino-N-((1S,2S)-2-((2,3-dimethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0161" num="0142">Using (1S,2S)-2-((2,3-dimethylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0162" num="0000"><chemistry id="CHEM-US-00017" num="00017"><img id="EMI-C00017" he="28.19mm" wi="70.36mm" file="US20230002353A1-20230105-C00017.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0163" num="0143">MS (ESI, m/z): 420.2 [M+H]<sup>+</sup></p><heading id="h-0028" level="1">Example 15. 2-amino-N-((1S,2S)-2-((2,6-dimethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0164" num="0144">Using (1S,2S)-2-((2,6-dimethylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0165" num="0000"><chemistry id="CHEM-US-00018" num="00018"><img id="EMI-C00018" he="27.52mm" wi="63.92mm" file="US20230002353A1-20230105-C00018.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0166" num="0145">MS (ESI, m/z): 420.2 [M+H]<sup>+</sup></p><heading id="h-0029" level="1">Example 16. 2-amino-N-((1S,2S)-2-((2,5-dimethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0167" num="0146">Using (1S,2S)-2-((2,5-dimethylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0168" num="0000"><chemistry id="CHEM-US-00019" num="00019"><img id="EMI-C00019" he="30.31mm" wi="64.26mm" file="US20230002353A1-20230105-C00019.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0169" num="0147">MS (ESI, m/z): 420.2 [M+H]<sup>+</sup></p><heading id="h-0030" level="1">Example 17. 2-amino-N-((1S,2S)-2-((3,5-dimethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0170" num="0148">Using (1S,2S)-2-((3,5-dimethylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0171" num="0000"><chemistry id="CHEM-US-00020" num="00020"><img id="EMI-C00020" he="30.31mm" wi="69.60mm" file="US20230002353A1-20230105-C00020.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0172" num="0149">MS (ESI, m/z): 420.2 [M+H]<sup>+</sup></p><heading id="h-0031" level="1">Example 18. 2-amino-N-((1S,2S)-2-((2,4-dimethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0173" num="0150">Using (1S,2S)-2-((2,4-dimethylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0174" num="0000"><chemistry id="CHEM-US-00021" num="00021"><img id="EMI-C00021" he="27.60mm" wi="66.97mm" file="US20230002353A1-20230105-C00021.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0175" num="0151">MS (ESI, m/z): 420.2 [M+H]<sup>+</sup></p><heading id="h-0032" level="1">Example 19. 2-amino-N-((1S,2S)-2-((4-ethyl-3-methylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0176" num="0152">Using (1S,2S)-2-((4-ethyl-3-methylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0177" num="0000"><chemistry id="CHEM-US-00022" num="00022"><img id="EMI-C00022" he="27.60mm" wi="72.31mm" file="US20230002353A1-20230105-C00022.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0178" num="0153">MS (ESI, m/z): 434.3 [M+H]<sup>+</sup></p><heading id="h-0033" level="1">Example 20. 2-amino-N-((1S,2S)-2-((3,4-diethylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0179" num="0154">Using (1S,2S)-2-((3,4-diethylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0180" num="0000"><chemistry id="CHEM-US-00023" num="00023"><img id="EMI-C00023" he="27.60mm" wi="73.74mm" file="US20230002353A1-20230105-C00023.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0181" num="0155">MS (ESI, m/z): 448.3 [M+H]<sup>+</sup></p><heading id="h-0034" level="1">Example 21. 2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0182" num="0156">Using (1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0183" num="0000"><chemistry id="CHEM-US-00024" num="00024"><img id="EMI-C00024" he="27.60mm" wi="73.74mm" file="US20230002353A1-20230105-C00024.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0184" num="0157">MS (ESI, m/z): 434.3 [M+H]<sup>+</sup></p><heading id="h-0035" level="1">Example 22. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3-propylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0185" num="0158">Using (1S,2S)-2-((3-propylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0186" num="0000"><chemistry id="CHEM-US-00025" num="00025"><img id="EMI-C00025" he="26.33mm" wi="75.44mm" file="US20230002353A1-20230105-C00025.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0187" num="0159">MS (ESI, m/z): 434.3 [M+H]<sup>+</sup></p><heading id="h-0036" level="1">Example 23. 2-amino-N-((1S,2S)-2-((3-cyclopentylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0188" num="0160">Using (1S,2S)-2-((3-cyclopentylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0189" num="0000"><chemistry id="CHEM-US-00026" num="00026"><img id="EMI-C00026" he="26.25mm" wi="75.27mm" file="US20230002353A1-20230105-C00026.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0190" num="0161">MS (ESI, m/z): 460.3 [M+H]<sup>+</sup></p><heading id="h-0037" level="1">Example 24. 2-amino-N-((1S,2S)-2-((3-isopropylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0191" num="0162">Using (1S,2S)-2-((3-isopropylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0192" num="0000"><chemistry id="CHEM-US-00027" num="00027"><img id="EMI-C00027" he="27.60mm" wi="73.74mm" file="US20230002353A1-20230105-C00027.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0193" num="0163">MS (ESI, m/z): 434.3 [M+H]<sup>+</sup></p><heading id="h-0038" level="1">Example 25. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3-(prop-1-en-2-yl)benzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0194" num="0164">Using (1S,2S)-2-((3-(prop-1-en-2-yl)benzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0195" num="0000"><chemistry id="CHEM-US-00028" num="00028"><img id="EMI-C00028" he="27.52mm" wi="73.74mm" file="US20230002353A1-20230105-C00028.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0196" num="0165">MS (ESI, m/z): 432.2 [M+H]<sup>+</sup></p><heading id="h-0039" level="1">Example 26. 2-amino-N-((1S,2S)-2-((3-cyclopropylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0197" num="0166">Using (1S,2S)-2-((3-cyclopropylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0198" num="0000"><chemistry id="CHEM-US-00029" num="00029"><img id="EMI-C00029" he="27.52mm" wi="75.27mm" file="US20230002353A1-20230105-C00029.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0199" num="0167">MS (ESI, m/z): 432.2 [M+H]<sup>+</sup></p><heading id="h-0040" level="1">Example 27. 2-amino-N-((1S,2S)-2-((3-cyclobutylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0200" num="0168">Using (1S,2S)-2-((3-cyclobutylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0201" num="0000"><chemistry id="CHEM-US-00030" num="00030"><img id="EMI-C00030" he="27.52mm" wi="75.27mm" file="US20230002353A1-20230105-C00030.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0202" num="0169">MS (ESI, m/z): 446.3 [M+H]<sup>+</sup></p><heading id="h-0041" level="1">Example 28. 2-amino-N-((1S,2S)-2-((3-ethynylbenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0203" num="0170">Using (1S,2S)-2-((3-ethynylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0204" num="0000"><chemistry id="CHEM-US-00031" num="00031"><img id="EMI-C00031" he="27.52mm" wi="75.44mm" file="US20230002353A1-20230105-C00031.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0205" num="0171">MS (ESI, m/z): 416.2 [M+H]<sup>+</sup></p><heading id="h-0042" level="1">Example 29. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(trifluoromethyl)benzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0206" num="0172">Using (1S,2S)-2-((4-(trifluoromethyl)benzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0207" num="0000"><chemistry id="CHEM-US-00032" num="00032"><img id="EMI-C00032" he="28.79mm" wi="70.02mm" file="US20230002353A1-20230105-C00032.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0208" num="0173">MS (ESI, m/z): 460.2 [M+H]<sup>+</sup></p><heading id="h-0043" level="1">Example 30. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3-nitrobenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0209" num="0174">Using (1S,2S)-2-((3-nitrobenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0210" num="0000"><chemistry id="CHEM-US-00033" num="00033"><img id="EMI-C00033" he="27.52mm" wi="73.58mm" file="US20230002353A1-20230105-C00033.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0211" num="0175">MS (ESI, m/z): 437.2 [M+H]<sup>+</sup></p><heading id="h-0044" level="1">Example 31. 2-amino-N-((1S,2S)-2-((3-cyanobenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0212" num="0176">Using 3-((((1S,2S)-2-aminocyclopentyl)oxy)methyl)benzonitrile, the title compound was obtained as described for the example 1.</p><p id="p-0213" num="0000"><chemistry id="CHEM-US-00034" num="00034"><img id="EMI-C00034" he="27.52mm" wi="72.47mm" file="US20230002353A1-20230105-C00034.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0214" num="0177"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.58-1.70 (m, 1H) 1.73-1.90 (m, 3H) 1.95-2.07 (m, 1H) 2.11-2.22 (m, 1H) 3.88-3.98 (m, 4H) 4.36-4.44 (m, 1H) 4.61-4.72 (m, 2H) 7.43-7.51 (m, 1H) 7.57 (br d, J=7.43 Hz, 1H) 7.63 (br d, J=7.43 Hz, 1H) 7.70 (s, 1H) 7.85 (s, 1H) 7.99 (s, 1H) 8.23 (d, J=1.96 Hz, 1H) 8.45 (d, J=1.96 Hz, 1H);</p><p id="p-0215" num="0178">MS (ESI, m/z): 417.2 [M+H]<sup>+</sup></p><heading id="h-0045" level="1">Example 32. 2-amino-N-((1S,2S)-2-(3-hydroxybenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0216" num="0179">Using (1S,2S)-2-((3-hydroxybenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0217" num="0000"><chemistry id="CHEM-US-00035" num="00035"><img id="EMI-C00035" he="27.52mm" wi="72.56mm" file="US20230002353A1-20230105-C00035.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0218" num="0180">MS (ESI, m/z): 408.2 [M+H]<sup>+</sup></p><heading id="h-0046" level="1">Example 33. 2-amino-N-((1S,2S)-2-((3-methyloxybenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0219" num="0181">Using (1S,2S)-2-((3-methyloxybenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0220" num="0000"><chemistry id="CHEM-US-00036" num="00036"><img id="EMI-C00036" he="27.52mm" wi="74.17mm" file="US20230002353A1-20230105-C00036.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0221" num="0182"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.54-1.65 (m, 1H) 1.68-1.88 (m, 3H) 1.95-2.07 (m, 1H) 2.09-2.22 (m, 1H) 3.65-3.74 (m, 3H) 3.88-3.98 (m, 4H) 4.33-4.43 (m, 1H) 4.51-4.66 (m, 2H) 6.74 (dd, J=8.41, 1.76 Hz, 1H) 6.83-6.93 (m, 2H) 7.12-7.22 (m, 1H) 7.85 (s, 1H) 7.99 (s, 1H) 8.22 (d, J=1.96 Hz, 1H) 8.45 (d, J=1.96 Hz, 1H);</p><p id="p-0222" num="0183">MS (ESI, m/z): 422.2 [M+H]<sup>+</sup></p><heading id="h-0047" level="1">Example 34. 2-amino-N-((1R,2R)-2-((3-methoxybenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0223" num="0184">Using (1R,2R)-2-((3-methoxybenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0224" num="0000"><chemistry id="CHEM-US-00037" num="00037"><img id="EMI-C00037" he="27.52mm" wi="71.46mm" file="US20230002353A1-20230105-C00037.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0225" num="0185">MS (ESI, m/z): 422.2 [M+H]<sup>+</sup></p><heading id="h-0048" level="1">Example 35. 2-amino-N-((1S,2S)-2-((4-methoxybenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0226" num="0186">Using (1S,2S)-2-((4-methoxybenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0227" num="0000"><chemistry id="CHEM-US-00038" num="00038"><img id="EMI-C00038" he="27.52mm" wi="72.98mm" file="US20230002353A1-20230105-C00038.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0228" num="0187">MS (ESI, m/z): 422.2 [M+H]<sup>+</sup></p><heading id="h-0049" level="1">Example 36. 2-amino-N-((1R,2R)-2-((4-methoxybenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0229" num="0188">Using (1R,2R)-2-((4-methoxybenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0230" num="0000"><chemistry id="CHEM-US-00039" num="00039"><img id="EMI-C00039" he="27.52mm" wi="72.98mm" file="US20230002353A1-20230105-C00039.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0231" num="0189">MS (ESI, m/z): 422.2 [M+H]<sup>+</sup></p><heading id="h-0050" level="1">Example 37. 2-amino-N-(trans-2-((3,5-dimethoxybenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0232" num="0190">Using trans-2-((3,5-dimethoxybenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0233" num="0000"><chemistry id="CHEM-US-00040" num="00040"><img id="EMI-C00040" he="39.12mm" wi="75.44mm" file="US20230002353A1-20230105-C00040.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0234" num="0191">MS (ESI, m/z): 452.2 [M+H]<sup>+</sup></p><heading id="h-0051" level="1">Example 38. 2-amino-N-((1S,2S)-2-((2,3-dimethoxybenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0235" num="0192">Using (1S,2S)-2-((2,3-dimethoxybenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0236" num="0000"><chemistry id="CHEM-US-00041" num="00041"><img id="EMI-C00041" he="27.52mm" wi="74.08mm" file="US20230002353A1-20230105-C00041.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0237" num="0193">MS (ESI, m/z): 452.2 [M+H]<sup>+</sup></p><heading id="h-0052" level="1">Example 39. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3-phenoxybenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0238" num="0194">Using (1S,2S)-2-((3-phenoxybenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0239" num="0000"><chemistry id="CHEM-US-00042" num="00042"><img id="EMI-C00042" he="27.52mm" wi="73.41mm" file="US20230002353A1-20230105-C00042.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0240" num="0195">MS (ESI, m/z): 484.2 [M+H]<sup>+</sup></p><heading id="h-0053" level="1">Example 40. 2-amino-N-((1S,2S)-2-(benzo[d][1,3]dioxol-5-yl-methoxy)-cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0241" num="0196">Using (1S,2S)-2-(benzo[d][1,3]dioxol-5-ylmethoxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0242" num="0000"><chemistry id="CHEM-US-00043" num="00043"><img id="EMI-C00043" he="27.52mm" wi="72.56mm" file="US20230002353A1-20230105-C00043.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0243" num="0197">MS (ESI, m/z): 436.2 [M+H]<sup>+</sup></p><heading id="h-0054" level="1">Example 41. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(methylthio)benzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0244" num="0198">Using (1S,2S)-2-((4-(methylthio)benzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0245" num="0000"><chemistry id="CHEM-US-00044" num="00044"><img id="EMI-C00044" he="27.52mm" wi="71.54mm" file="US20230002353A1-20230105-C00044.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0246" num="0199">MS (ESI, m/z): 438.2 [M+H]<sup>+</sup></p><heading id="h-0055" level="1">Example 42. methyl 3-((((1S,2S)-2-(2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinamido)cyclopentyl)oxy)methyl)benzoate</heading><p id="p-0247" num="0200">Using methyl 3-((((1S,2S)-2-aminocyclopentyl)oxy)methyl)benzoate, the title compound was obtained as described for the example 1.</p><p id="p-0248" num="0000"><chemistry id="CHEM-US-00045" num="00045"><img id="EMI-C00045" he="25.91mm" wi="74.51mm" file="US20230002353A1-20230105-C00045.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0249" num="0201">MS (ESI, m/z): 450.2 [M+H]<sup>+</sup></p><heading id="h-0056" level="1">Example 43. 2-amino-N-((1S,2S)-2-((3-chlorobenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0250" num="0202">Using (1S,2S)-2-((3-chlorobenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0251" num="0000"><chemistry id="CHEM-US-00046" num="00046"><img id="EMI-C00046" he="27.52mm" wi="71.46mm" file="US20230002353A1-20230105-C00046.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0252" num="0203"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.62 (br dd, J=13.50, 6.46 Hz, 1H) 1.72-1.87 (m, 3H) 1.94-2.05 (m, 1H) 2.16 (br d, J=6.65 Hz, 1H) 3.89-3.97 (m, 4H) 4.38 (br d, J=4.70 Hz, 1H) 4.55-4.66 (m, 2H) 7.20 (br s, 1H) 7.22-7.28 (m, 2H) 7.34 (s, 1H) 7.85 (s, 1H) 7.99 (s, 1H) 8.22 (d, J=2.35 Hz, 1H) 8.44 (br d, J=2.35 Hz, 1H);</p><p id="p-0253" num="0204">MS (ESI, m/z): 426.2 [M+H]<sup>+</sup></p><heading id="h-0057" level="1">Example 44. 2-amino-N-(trans-2-((3-chlorobenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0254" num="0205">Using trans-2-((3-chlorobenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0255" num="0000"><chemistry id="CHEM-US-00047" num="00047"><img id="EMI-C00047" he="33.10mm" wi="74.08mm" file="US20230002353A1-20230105-C00047.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0256" num="0206">MS (ESI, m/z): 426.2 [M+H]<sup>+</sup></p><heading id="h-0058" level="1">Example 45. 2-amino-N-(trans-2-((4-chlorobenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0257" num="0207">Using trans-2-((4-chlorobenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0258" num="0000"><chemistry id="CHEM-US-00048" num="00048"><img id="EMI-C00048" he="33.02mm" wi="68.75mm" file="US20230002353A1-20230105-C00048.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0259" num="0208">MS (ESI, m/z): 426.2 [M+H]<sup>+</sup></p><heading id="h-0059" level="1">Example 46. 2-amino-N-(trans-2-((3,4-dichlorobenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0260" num="0209">Using trans-2-((3,4-dichlorobenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0261" num="0000"><chemistry id="CHEM-US-00049" num="00049"><img id="EMI-C00049" he="33.02mm" wi="71.80mm" file="US20230002353A1-20230105-C00049.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0262" num="0210">MS (ESI, m/z): 460.1 [M+H]<sup>+</sup></p><heading id="h-0060" level="1">Example 47. 2-amino-N-(trans-2-((2-fluorobenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0263" num="0211">Using trans-2-((2-fluorobenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0264" num="0000"><chemistry id="CHEM-US-00050" num="00050"><img id="EMI-C00050" he="33.02mm" wi="64.94mm" file="US20230002353A1-20230105-C00050.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0265" num="0212">MS (ESI, m/z): 410.2 [M+H]<sup>+</sup></p><heading id="h-0061" level="1">Example 48. 2-amino-N-((1S,2S)-2-((3-fluorobenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0266" num="0213">Using (1S,2S)-2-((3-fluorobenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0267" num="0000"><chemistry id="CHEM-US-00051" num="00051"><img id="EMI-C00051" he="33.02mm" wi="71.04mm" file="US20230002353A1-20230105-C00051.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0268" num="0214"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.63 (dq, J=13.69, 7.17 Hz, 1H) 1.70-1.88 (m, 3H) 1.93-2.06 (m, 1H) 2.15 (dt, J=13.69, 6.85 Hz, 1H) 3.87-4.00 (m, 4H) 4.34-4.42 (m, 1H) 4.62 (s, 2H) 6.92 (td, J=8.61, 1.96 Hz, 1H) 7.03-7.16 (m, 2H) 7.27 (dd, J=8.02, 6.06 Hz, 1H) 7.85 (s, 1H) 8.00 (s, 1H) 8.22 (d, J=1.96 Hz, 1H) 8.49 (d, J=1.96 Hz, 1H); MS (ESI, m/z): 410.2 [M+H]<sup>+</sup></p><heading id="h-0062" level="1">Example 49. 2-amino-N-(trans-2-((4-bromo-2-fluorobenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0269" num="0215">Using trans-2-((4-bromo-2-fluorobenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0270" num="0000"><chemistry id="CHEM-US-00052" num="00052"><img id="EMI-C00052" he="33.02mm" wi="68.92mm" file="US20230002353A1-20230105-C00052.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0271" num="0216">MS (ESI m/z): 488.1/490.1 [M+H]<sup>+</sup></p><heading id="h-0063" level="1">Example 50. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(trans-2-((2,4,5-trifluorobenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0272" num="0217">Using trans-2-((2,4,5-trifluorobenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0273" num="0000"><chemistry id="CHEM-US-00053" num="00053"><img id="EMI-C00053" he="33.02mm" wi="67.90mm" file="US20230002353A1-20230105-C00053.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0274" num="0218">MS (ESI, m/z): 446.2 [M+H]<sup>+</sup></p><heading id="h-0064" level="1">Example 51. 2-amino-N-((1S,2S)-2-((3-bromobenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0275" num="0219">Using (1S,2S)-2-((3-bromobenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0276" num="0000"><chemistry id="CHEM-US-00054" num="00054"><img id="EMI-C00054" he="27.43mm" wi="72.05mm" file="US20230002353A1-20230105-C00054.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0277" num="0220">MS (ESI, m/z): 470.1/472.1 [M+H]<sup>+</sup></p><heading id="h-0065" level="1">Example 52. 2-amino-N-(trans-2-((3-bromo-4-fluorobenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0278" num="0221">Using trans-2-((3-bromo-4-fluorobenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0279" num="0000"><chemistry id="CHEM-US-00055" num="00055"><img id="EMI-C00055" he="33.02mm" wi="72.05mm" file="US20230002353A1-20230105-C00055.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0280" num="0222">MS (ESI, m/z): 488.1/490.1 [M+H]<sup>+</sup></p><heading id="h-0066" level="1">Example 53. 2-amino-N-((1R,2R)-2-((3-bromo-4-fluorobenzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0281" num="0223">Using (1R,2R)-2-((3-bromo-4-fluorobenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0282" num="0000"><chemistry id="CHEM-US-00056" num="00056"><img id="EMI-C00056" he="28.28mm" wi="72.05mm" file="US20230002353A1-20230105-C00056.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0283" num="0224">MS (ESI, m/z): 488.1/490.1 [M+H]<sup>+</sup></p><heading id="h-0067" level="1">Example 54. 2-amino-N-((1S,2S)-2-(1-(4-bromophenyl)ethoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0284" num="0225">Using (1S,2S)-2-(1-(4-bromophenyl)ethoxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0285" num="0000"><chemistry id="CHEM-US-00057" num="00057"><img id="EMI-C00057" he="28.28mm" wi="68.92mm" file="US20230002353A1-20230105-C00057.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0286" num="0226">MS (ESI, m/z): 484.1/486.1 [M+H]<sup>+</sup></p><heading id="h-0068" level="1">Example 55. methyl (3-((((1S,2S)-2-(2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinamido)cyclopentyl)oxy)methyl)benzoyl)glycinate</heading><p id="p-0287" num="0227">Using methyl (3-((((1S,2S)-2-aminocyclopentyl)oxy)methyl)benzoyl)glycinate, the title compound was obtained as described for the example 1.</p><p id="p-0288" num="0000"><chemistry id="CHEM-US-00058" num="00058"><img id="EMI-C00058" he="25.99mm" wi="75.01mm" file="US20230002353A1-20230105-C00058.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0289" num="0228"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.58-1.70 (m, 1H) 1.73-1.90 (m, 3H) 1.95-2.07 (m, 1H) 2.11-2.22 (m, 1H) 3.88-3.98 (m, 4H) 4.36-4.44 (m, 1H) 4.61-4.72 (m, 2H) 7.43-7.51 (m, 1H) 7.57 (br d, J=7.43 Hz, 1H) 7.63 (br d, J=7.43 Hz, 1H) 7.70 (s, 1H) 7.85 (s, 1H) 7.99 (s, 1H) 8.23 (d, J=1.96 Hz, 1H) 8.45 (d, J=1.96 Hz, 1H);</p><p id="p-0290" num="0229">MS (ESI, m/z): 507.2[M+H]<sup>+</sup></p><heading id="h-0069" level="1">Example 56. 2-amino-N-((1S,2S)-2-((3-((2-hydroxyethyl)carbamoyl)benzyl)-oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0291" num="0230">Using methyl (3-((((1S,2S)-2-aminocyclopentyl)oxy)methyl)-N-(2-hydroxyethyl)-benzamide, the title compound was obtained as described for the example 1.</p><p id="p-0292" num="0000"><chemistry id="CHEM-US-00059" num="00059"><img id="EMI-C00059" he="22.44mm" wi="74.68mm" file="US20230002353A1-20230105-C00059.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0293" num="0231">MS (ESI, m/z): 479.2[M+H]<sup>+</sup></p><heading id="h-0070" level="1">Example 57. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3-(piperidine-4-carboxamido)benzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0294" num="0232">Using tert-butyl 4-((3-((((1S,2S)-2-aminocyclopentyl)oxy)methyl)phenyl)carbamoyl)-piperidine-1-carboxylate, the title compound was obtained as described for the example 1 and following deprotection with TFA.</p><p id="p-0295" num="0000"><chemistry id="CHEM-US-00060" num="00060"><img id="EMI-C00060" he="23.03mm" wi="75.01mm" file="US20230002353A1-20230105-C00060.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0296" num="0233">MS (ESI, m/z): 518.3[M+H]<sup>+</sup></p><heading id="h-0071" level="1">Example 58. 2-amino-N-((1S,2S)-2-((3-((S)-2-aminopropanamido)benzyl)oxy)-cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0297" num="0234">Using tert-butyl ((S)-1-((3-((((1S,2S)-2-aminocyclopentyl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)carbamate, the title compound was obtained as described for the example 1 and following deprotection with TFA.</p><p id="p-0298" num="0000"><chemistry id="CHEM-US-00061" num="00061"><img id="EMI-C00061" he="24.47mm" wi="72.39mm" file="US20230002353A1-20230105-C00061.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0299" num="0235">MS (EST, m/z): 478.3 [M+H]<sup>+</sup></p><heading id="h-0072" level="1">Example 59. N-((1S,2S)-2-((3-((S)-2-acetamidopropanamido)benzyl)oxy)-cyclopentyl)-2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0300" num="0236">Using (S)-2-acetamido-N-(3-((((1S,2S)-2-aminocyclopentyl)oxy)methyl)phenyl)-propanamide, the title compound was obtained as described for the example 1.</p><p id="p-0301" num="0000"><chemistry id="CHEM-US-00062" num="00062"><img id="EMI-C00062" he="24.47mm" wi="75.01mm" file="US20230002353A1-20230105-C00062.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0302" num="0237">MS (ESI, m/z): 520.3[M+H]<sup>+</sup></p><heading id="h-0073" level="1">Example 60. 2-amino-N-((1S,2S)-2-((3-(3-aminopropanamido)benzyl)oxy)-cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0303" num="0238">Using tert-butyl (3-((3-((((1S,2S)-2-aminocyclopentyl)oxy)methyl)phenyl)amino)-3-oxopropyl)carbamate, the title compound was obtained as described for the example 1 and following deprotection with TFA.</p><p id="p-0304" num="0000"><chemistry id="CHEM-US-00063" num="00063"><img id="EMI-C00063" he="23.62mm" wi="75.35mm" file="US20230002353A1-20230105-C00063.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0305" num="0239">MS (ESI, m/z): 478.3[M+H]<sup>+</sup></p><heading id="h-0074" level="1">Example 61. N-((1S,2S)-2-((3-(2H-1,2,3-triazol-2-yl)benzyl)oxy)cyclopentyl)-2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0306" num="0240">Using (1S,2S)-2-((3-(2H-1,2,3-triazol-2-yl)benzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0307" num="0000"><chemistry id="CHEM-US-00064" num="00064"><img id="EMI-C00064" he="26.75mm" wi="75.52mm" file="US20230002353A1-20230105-C00064.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0308" num="0241">MS (ESI, m/z): 459.2 [M+H]<sup>+</sup></p><heading id="h-0075" level="1">Example 62. N-(1S,2S)-2-((4-(2H-1,2,3-triazol-2-yl)benzyl)oxy)cyclopentyl)-2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0309" num="0242">Using (1S,2S)-2-((4-(2H-1,2,3-triazol-2-yl)benzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0310" num="0000"><chemistry id="CHEM-US-00065" num="00065"><img id="EMI-C00065" he="37.59mm" wi="74.85mm" file="US20230002353A1-20230105-C00065.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0311" num="0243">MS (ESI, m/z): 459.2 [M+H]<sup>+</sup></p><heading id="h-0076" level="1">Example 63. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-(naphthalen-2-ylmethoxy)cyclopentyl)nicotinamide</heading><p id="p-0312" num="0244">Using (1S,2S)-2-(naphthalen-2-ylmethoxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0313" num="0000"><chemistry id="CHEM-US-00066" num="00066"><img id="EMI-C00066" he="29.21mm" wi="74.17mm" file="US20230002353A1-20230105-C00066.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0314" num="0245">MS (ESI, m/z): 442.2 [M+H]<sup>+</sup></p><heading id="h-0077" level="1">Example 64. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-(quinolin-8-ylmethoxy)cyclopentyl)nicotinamide</heading><p id="p-0315" num="0246">Using (1S,2S)-2-(quinolin-8-ylmethoxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0316" num="0000"><chemistry id="CHEM-US-00067" num="00067"><img id="EMI-C00067" he="28.11mm" wi="72.14mm" file="US20230002353A1-20230105-C00067.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0317" num="0247">MS (ESI, m/z): 443.2 [M+H]<sup>+</sup></p><heading id="h-0078" level="1">Example 65. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((2&#x2032;,3&#x2032;,4&#x2032;,5&#x2032;-tetrahydro-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0318" num="0248">Using (1S,2S)-2-((2&#x2032;,3&#x2032;,4&#x2032;,5&#x2032;-tetrahydro-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0319" num="0000"><chemistry id="CHEM-US-00068" num="00068"><img id="EMI-C00068" he="37.85mm" wi="74.25mm" file="US20230002353A1-20230105-C00068.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0320" num="0249"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.62 (br d, J=5.87 Hz, 2H) 1.67-1.87 (m, 5H) 1.93-2.09 (m, 2H) 2.14 (br s, 3H) 2.28 (br s, 2H) 3.92 (s, 3H) 4.37 (br d, J=5.48 Hz, 1H) 4.49-4.65 (m, 2H) 6.00 (br s, 1H) 7.18-7.30 (m, 2H) 7.54 (br s, 1H) 7.59-7.69 (m, 1H) 7.84 (s, 1H) 7.98 (s, 1H) 8.23 (s, 1H) 8.38 (s, 1H);</p><p id="p-0321" num="0250">MS (ESI, m/z): 472.3 [M+H]<sup>+</sup></p><heading id="h-0079" level="1">Example 66. N-(trans-2-([1,1&#x2032;-biphenyl]-2-ylmethoxy)cyclopentyl)-2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0322" num="0251">Using trans-2-([1,1&#x2032;-biphenyl]-2-ylmethoxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0323" num="0000"><chemistry id="CHEM-US-00069" num="00069"><img id="EMI-C00069" he="33.78mm" wi="70.10mm" file="US20230002353A1-20230105-C00069.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0324" num="0252">MS (ESI, m/z): 468.2 [M+H]<sup>+</sup></p><heading id="h-0080" level="1">Example 67. N-((1S,2S)-2-([1,1&#x2032;-biphenyl]-3-ylmethoxy)cyclopentyl)-2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0325" num="0253">Using (1S,2S)-2-([1,1&#x2032;-biphenyl]-3-ylmethoxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0326" num="0000"><chemistry id="CHEM-US-00070" num="00070"><img id="EMI-C00070" he="25.74mm" wi="74.34mm" file="US20230002353A1-20230105-C00070.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0327" num="0254">MS (ESI, m/z): 468.2 [M+H]<sup>+</sup></p><heading id="h-0081" level="1">Example 68. N-((1S,2S)-2-([1,1&#x2032;-biphenyl]-4-ylmethoxy)cyclopentyl)-2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0328" num="0255">Using (1S,2S)-3-([1,1&#x2032;-biphenyl]-4-ylmethoxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0329" num="0000"><chemistry id="CHEM-US-00071" num="00071"><img id="EMI-C00071" he="37.85mm" wi="74.25mm" file="US20230002353A1-20230105-C00071.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0330" num="0256"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.59 (br d, J=1.17 Hz, 1H) 1.79 (br s, 3H) 1.97 (br s, 1H) 2.11-2.21 (m, 1H) 3.62 (s, 2H) 3.87 (s, 3H) 3.97 (br s, 1H) 4.39 (br s, 1H) 4.65 (br d, J=13.69 Hz, 2H) 7.34-7.42 (m, 2H) 7.50 (br t, J=7.43 Hz, 2H) 7.80 (s, 1H) 7.90 (s, 1H) 8.17 (br s, 1H) 8.29-8.34 (m, 1H);</p><p id="p-0331" num="0257">MS (ESI, m/z): 468.2 [M+H]<sup>+</sup></p><heading id="h-0082" level="1">Example 69. 2-amino-N-((1S,2S)-2-hydroxycyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0332" num="0258">Using (1S,2S)-2-aminocyclopentan-1-ol, the title compound was obtained as described for the example 1.</p><p id="p-0333" num="0000"><chemistry id="CHEM-US-00072" num="00072"><img id="EMI-C00072" he="28.11mm" wi="48.85mm" file="US20230002353A1-20230105-C00072.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0334" num="0259">MS (ESI, m/z): 302.2 [M+H]<sup>+</sup></p><heading id="h-0083" level="1">Example 70. 2-amino-N-(cis-2-hydroxycyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0335" num="0260">Using cis-2-aminocyclopentan-1-ol, the title compound was obtained as described for the example 1.</p><p id="p-0336" num="0000"><chemistry id="CHEM-US-00073" num="00073"><img id="EMI-C00073" he="28.11mm" wi="48.85mm" file="US20230002353A1-20230105-C00073.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0337" num="0261">MS (ESI, m/z): 302.2 [M+H]<sup>+</sup></p><heading id="h-0084" level="1">Example 71. N-((1S,2S)-2-(benzyloxy)cyclopentyl)-2-(ethylamino)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0338" num="0262">Using 2-(ethylamino)-5-(1-methyl-1H-pyrazol-4-yl)nicotinic acid, the title compound was obtained as described for the example 1.</p><p id="p-0339" num="0000"><chemistry id="CHEM-US-00074" num="00074"><img id="EMI-C00074" he="30.06mm" wi="64.85mm" file="US20230002353A1-20230105-C00074.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0340" num="0263">MS (ESI, m/z): 420.2 [M+H]<sup>+</sup></p><heading id="h-0085" level="1">Example 72. N-((1S,2S)-2-(benzyloxy)cyclopentyl)-2-((3,4-dimethylbenzyl-)amino)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0341" num="0264">Using 2-((3,4-dimethylbenzyl)amino)-5-(1-methyl-1H-pyrazol-4-yl)nicotinic acid, the title compound was obtained as described for the example 1.</p><p id="p-0342" num="0000"><chemistry id="CHEM-US-00075" num="00075"><img id="EMI-C00075" he="35.90mm" wi="64.85mm" file="US20230002353A1-20230105-C00075.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0343" num="0265">MS (ESI, m/z): 510.3 [M+H]<sup>+</sup></p><heading id="h-0086" level="1">Example 73. 2-amino-N-((6R,7S)-6-(benzyloxy)-1,4-dioxaspiro[4.4]nonan-7-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0344" num="0266">Using (6R,7S)-6-(benzyloxy)-1,4-dioxaspiro[4.4]nonan-7-amine, the title compound was obtained as described for the example 1.</p><p id="p-0345" num="0000"><chemistry id="CHEM-US-00076" num="00076"><img id="EMI-C00076" he="32.77mm" wi="60.79mm" file="US20230002353A1-20230105-C00076.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0346" num="0267">MS (ESI, m/z): 450.2 [M+H]<sup>+</sup></p><heading id="h-0087" level="1">Example 74. 2-amino-N-(trans-2-(benzyloxy)cyclohexyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0347" num="0268">Using trans-2-(benzyloxy)cyclohexan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0348" num="0000"><chemistry id="CHEM-US-00077" num="00077"><img id="EMI-C00077" he="30.23mm" wi="65.02mm" file="US20230002353A1-20230105-C00077.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0349" num="0269">MS (ESI, m/z): 406.2 [M+H]<sup>+</sup></p><heading id="h-0088" level="1">Example 75. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclohexyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0350" num="0270">Using (1S,2S)-2-(benzyloxy)cyclohexan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0351" num="0000"><chemistry id="CHEM-US-00078" num="00078"><img id="EMI-C00078" he="31.41mm" wi="64.09mm" file="US20230002353A1-20230105-C00078.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0352" num="0271"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.28-1.47 (m, 4H) 1.77 (br s, 1H) 1.83 (br s, 1H) 1.97 (s, 1H) 2.29 (br s, 1H) 3.38 (br d, J=9.39 Hz, 1H) 3.92 (s, 3H) 3.99 (br d, J=10.17 Hz, 1H) 4.41-4.47 (m, 1H) 4.68 (br d, J=12.13 Hz, 1H) 7.13 (dt, J=14.57, 6.99 Hz, 3H) 7.25 (br d, J=7.43 Hz, 2H) 7.77 (s, 1H) 7.89 (s, 1H) 8.21 (s, 1H) 8.25 (br s, 1H);</p><p id="p-0353" num="0272">MS (ESI, m/z): 406.2 [M+H]<sup>+</sup></p><heading id="h-0089" level="1">Example 76. 2-amino-N-(trans-2-(benzyl(methyl)amino)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0354" num="0273">Using trans-N1-benzyl-N1-methylcyclopentane-1,2-diamine, the title compound was obtained as described for the example 1.</p><p id="p-0355" num="0000"><chemistry id="CHEM-US-00079" num="00079"><img id="EMI-C00079" he="28.87mm" wi="63.92mm" file="US20230002353A1-20230105-C00079.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0356" num="0274">MS (ESI, m/z): 405.2 [M+H]<sup>+</sup></p><heading id="h-0090" level="1">Example 77. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-(phenoxymethyl)cyclopentyl)nicotinamide</heading><p id="p-0357" num="0275">Using (1S,2S)-2-(phenoxymethyl)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0358" num="0000"><chemistry id="CHEM-US-00080" num="00080"><img id="EMI-C00080" he="29.63mm" wi="64.09mm" file="US20230002353A1-20230105-C00080.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0359" num="0276">MS (ESI, m/z): 392.2 [M+H]<sup>+</sup></p><heading id="h-0091" level="1">Example 78. 2-amino-N-((1S,2S)-2-((3,4-dimethylphenoxy)methyl)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0360" num="0277">Using (1S,2S)-2-((3,4-dimethylphenoxy)methyl)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0361" num="0000"><chemistry id="CHEM-US-00081" num="00081"><img id="EMI-C00081" he="29.63mm" wi="69.51mm" file="US20230002353A1-20230105-C00081.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0362" num="0278">MS (ESI, m/z): 420.2 [M+H]<sup>+</sup></p><heading id="h-0092" level="1">Example 79. 2-amino-N-(trans-2,2-difluoro-5-(phenoxymethyl)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0363" num="0279">Using (trans-2,2-difluoro-5-(phenoxymethyl)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0364" num="0000"><chemistry id="CHEM-US-00082" num="00082"><img id="EMI-C00082" he="31.67mm" wi="64.09mm" file="US20230002353A1-20230105-C00082.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0365" num="0280">MS (ESI, m/z): 428.2 [M+H]<sup>+</sup></p><heading id="h-0093" level="1">Example 80. 2-amino-N-((1S,2S)-2-(((2,3-dihydro-1H-inden-5-yl)oxy)-methyl)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0366" num="0281">Using (1S,2S)-2-(((2,3-dihydro-1H-inden-5-yl)oxy)methyl)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0367" num="0000"><chemistry id="CHEM-US-00083" num="00083"><img id="EMI-C00083" he="29.63mm" wi="71.71mm" file="US20230002353A1-20230105-C00083.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0368" num="0282">MS (ESI, m/z): 432.2 [M+H]<sup>+</sup></p><heading id="h-0094" level="1">Example 81. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3,4,5-trimethylphenoxy)methyl)cyclopentyl)nicotinamide</heading><p id="p-0369" num="0283">Using (1S,2S)-2-((3,4,5-trimethylphenoxy)methyl)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0370" num="0000"><chemistry id="CHEM-US-00084" num="00084"><img id="EMI-C00084" he="32.43mm" wi="69.51mm" file="US20230002353A1-20230105-C00084.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0371" num="0284">MS (ESI, m/z): 434.3 [M+H]<sup>+</sup></p><heading id="h-0095" level="1">Example 82. 2-amino-N-((1S,2S)-2-((3-(dimethylamino)phenoxy)-methyl)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0372" num="0285">Using 3-(((1S,2S)-2-aminocyclopentyl)methoxy)-N,N-dimethylaniline, the title compound was obtained as described for the example 1.</p><p id="p-0373" num="0000"><chemistry id="CHEM-US-00085" num="00085"><img id="EMI-C00085" he="29.55mm" wi="73.49mm" file="US20230002353A1-20230105-C00085.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0374" num="0286">MS (ESI, m/z): 435.2 [M+H]<sup>+</sup></p><heading id="h-0096" level="1">Example 83. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3-(piperidine-1-carbonyl)phenoxy)methyl)cyclopentyl)nicotinamide</heading><p id="p-0375" num="0287">Using (3-(((1S,2S)-2-aminocyclopentyl)methoxy)phenyl)(piperidin-1-yl)methanone, the title compound was obtained as described for the example 1.</p><p id="p-0376" num="0000"><chemistry id="CHEM-US-00086" num="00086"><img id="EMI-C00086" he="28.11mm" wi="72.56mm" file="US20230002353A1-20230105-C00086.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0377" num="0288">MS (ESI, m/z): 503.3 [M+H]<sup>+</sup></p><heading id="h-0097" level="1">Example 84. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-phenoxyphenoxy)methyl)cyclopentyl)nicotinamide</heading><p id="p-0378" num="0289">Using (1S,2S)-2-((4-phenoxyphenoxy)methyl)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0379" num="0000"><chemistry id="CHEM-US-00087" num="00087"><img id="EMI-C00087" he="30.31mm" wi="70.02mm" file="US20230002353A1-20230105-C00087.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0380" num="0290">MS (ESI, m/z): 484.2 [M+H]<sup>+</sup></p><heading id="h-0098" level="1">Example 85. 2-amino-N-((1S,2S)-2-((benzyloxy)methyl)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0381" num="0291">Using (1S,2S)-2-((benzyloxy)methyl)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0382" num="0000"><chemistry id="CHEM-US-00088" num="00088"><img id="EMI-C00088" he="29.55mm" wi="71.04mm" file="US20230002353A1-20230105-C00088.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0383" num="0292">MS (ESI, m/z): 406.2 [M+H]<sup>+</sup></p><heading id="h-0099" level="1">Example 86. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-(((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)oxy)methyl)cyclopentyl)nicotinamide</heading><p id="p-0384" num="0293">Using (1S,2S)-2-(((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)oxy)methyl)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0385" num="0000"><chemistry id="CHEM-US-00089" num="00089"><img id="EMI-C00089" he="31.92mm" wi="72.22mm" file="US20230002353A1-20230105-C00089.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0386" num="0294"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.56-1.65 (m, 1H) 1.67-1.75 (m, 1H) 1.79 (br d, J=6.46 Hz, 1H) 1.85 (br d, J=8.80 Hz, 1H) 2.03-2.12 (m, 1H) 2.16 (br dd, J=12.91, 5.87 Hz, 1H) 2.43-2.51 (m, 1H) 2.84 (s, 3H) 3.75 (s, 2H) 3.89 (s, 3H) 4.10 (d, J=5.87 Hz, 2H) 4.30-4.38 (m, 1H) 6.96 (d, J=8.80 Hz, 2H) 7.38 (br d, J=8.22 Hz, 2H) 7.50 (dd, J=16.43, 8.22 Hz, 4H) 7.86 (s, 1H) 7.98 (s, 1H) 8.21 (d, J=2.35 Hz, 1H) 8.51 (d, J=2.35 Hz, 1H);</p><p id="p-0387" num="0295">MS (ESI m/z): 580.3 [M+H]<sup>+</sup></p><heading id="h-0100" level="1">Example 87. (1S,2S)-2-(benzyloxyl)cyclopentyl 2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinate</heading><p id="p-0388" num="0296">Using (1S,2S)-2-(benzyloxy)cyclopentan-1-ol, the title compound was obtained as described for the example 1.</p><p id="p-0389" num="0000"><chemistry id="CHEM-US-00090" num="00090"><img id="EMI-C00090" he="27.52mm" wi="64.69mm" file="US20230002353A1-20230105-C00090.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0390" num="0297">MS (ESI, m/z): 393.2 [M+H]<sup>+</sup></p><heading id="h-0101" level="1">Example 88. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2R)-2-phenethylcyclopentyl)nicotinamide</heading><p id="p-0391" num="0298">Using (1S,2R)-2-phenethylcyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0392" num="0000"><chemistry id="CHEM-US-00091" num="00091"><img id="EMI-C00091" he="27.52mm" wi="64.69mm" file="US20230002353A1-20230105-C00091.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0393" num="0299">MS (ESI, m/z): 390.2 [M+H]<sup>+</sup></p><heading id="h-0102" level="1">Example 89. 2-amino-N-(trans-4-(benzyloxy)tetrahydrofuran-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0394" num="0300">Using trans-4-(benzyloxy)tetrahydrofuran-3-amine, the title compound was obtained as described for the example 1.</p><p id="p-0395" num="0000"><chemistry id="CHEM-US-00092" num="00092"><img id="EMI-C00092" he="28.36mm" wi="64.69mm" file="US20230002353A1-20230105-C00092.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0396" num="0301">MS (ESI, m/z): 394.2 [M+H]<sup>+</sup></p><heading id="h-0103" level="1">Example 90. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(trans-4-morpholino-tetrahydrofuran-3-yl)nicotinamide</heading><p id="p-0397" num="0302">Using trans-4-morpholinotetrahydrofuran-3-amine, the title compound was obtained as described for the example 1.</p><p id="p-0398" num="0000"><chemistry id="CHEM-US-00093" num="00093"><img id="EMI-C00093" he="30.40mm" wi="52.07mm" file="US20230002353A1-20230105-C00093.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0399" num="0303">MS (ESI, m/z): 373.2 [M+H]<sup>+</sup></p><heading id="h-0104" level="1">Example 91. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(trans-4-(pyrrolidin-1-yl)tetrahydrofuran-3-yl)nicotinamide</heading><p id="p-0400" num="0304">Using trans-4-(pyrrolidin-1-yl)tetrahydrofuran-3-amine, the title compound was obtained as described for the example 1.</p><p id="p-0401" num="0000"><chemistry id="CHEM-US-00094" num="00094"><img id="EMI-C00094" he="30.40mm" wi="50.38mm" file="US20230002353A1-20230105-C00094.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0402" num="0305">MS (ESI, m/z): 357.2 [M+H]<sup>+</sup></p><heading id="h-0105" level="1">Example 92. 2-amino-N-(cis-4-hydroxytetrahydrofuran-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0403" num="0306">Using cis-4-aminotetrahydrofuran-3-ol, the title compound was obtained as described for the example 1.</p><p id="p-0404" num="0000"><chemistry id="CHEM-US-00095" num="00095"><img id="EMI-C00095" he="30.40mm" wi="47.84mm" file="US20230002353A1-20230105-C00095.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0405" num="0307">MS (ESI, m/z): 304.1 [M+H]<sup>+</sup></p><heading id="h-0106" level="1">Example 93. 2-amino-N-(4-(benzyloxy)-1-methylpyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0406" num="0308">Using trans-4-(benzyloxy)-1-methylpyrrolidin-3-amine, the title compound was obtained as described for the example 1.</p><p id="p-0407" num="0000"><chemistry id="CHEM-US-00096" num="00096"><img id="EMI-C00096" he="37.25mm" wi="64.69mm" file="US20230002353A1-20230105-C00096.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0408" num="0309">MS (ESI, m/z): 407.2 [M+H]<sup>+</sup></p><heading id="h-0107" level="1">Example 94. 2-amino-N-(trans-4-(benzyloxy)-1-isopropylpyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0409" num="0310">Using trans-4-(benzyloxy)-1-isopropylpyrrolidin-3-amine, the title compound was obtained as described for the example 1.</p><p id="p-0410" num="0000"><chemistry id="CHEM-US-00097" num="00097"><img id="EMI-C00097" he="37.17mm" wi="64.69mm" file="US20230002353A1-20230105-C00097.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0411" num="0311">MS (ESI, m/z): 435.2 [M+H]<sup>+</sup></p><heading id="h-0108" level="1">Example 95. (R)-2-amino-N-(2-(benzyloxy)propyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0412" num="0312">Using (R)-2-(benzyloxy)propan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0413" num="0000"><chemistry id="CHEM-US-00098" num="00098"><img id="EMI-C00098" he="24.21mm" wi="64.69mm" file="US20230002353A1-20230105-C00098.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0414" num="0313">MS (ESI, m/z): 366.2 [M+H]<sup>+</sup></p><heading id="h-0109" level="1">Example 96. (S)-2-amino-N-(2-(benzyloxy)propyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0415" num="0314">Using (S)-2-(benzyloxy)propan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0416" num="0000"><chemistry id="CHEM-US-00099" num="00099"><img id="EMI-C00099" he="24.21mm" wi="64.69mm" file="US20230002353A1-20230105-C00099.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0417" num="0315">MS (ESI, m/z): 366.2 [M+H]<sup>+</sup></p><heading id="h-0110" level="1">Example 97. (S)-2-amino-N-(1-(benzyloxy)propan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0418" num="0316">Using (S)-1-(benzyloxy)propan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0419" num="0000"><chemistry id="CHEM-US-00100" num="00100"><img id="EMI-C00100" he="26.08mm" wi="64.69mm" file="US20230002353A1-20230105-C00100.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0420" num="0317">MS (ESI, m/z): 366.2 [M+H]<sup>+</sup></p><heading id="h-0111" level="1">Example 98. (R)-2-amino-N-(1-(benzyloxy)propan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0421" num="0318">Using (R)-1-(benzyloxy)propan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0422" num="0000"><chemistry id="CHEM-US-00101" num="00101"><img id="EMI-C00101" he="26.08mm" wi="64.69mm" file="US20230002353A1-20230105-C00101.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0423" num="0319">MS (ESI, m/z): 366.2 [M+H]<sup>+</sup></p><heading id="h-0112" level="1">Example 99. 2-amino-N-(1-(benzyloxy)-2-methylpropan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0424" num="0320">Using 1-(benzyloxy)-2-methylpropan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0425" num="0000"><chemistry id="CHEM-US-00102" num="00102"><img id="EMI-C00102" he="26.08mm" wi="64.69mm" file="US20230002353A1-20230105-C00102.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0426" num="0321">MS (ESI, m/z): 380.2 [M+H]<sup>+</sup></p><heading id="h-0113" level="1">Example 100. (R)-2-amino-N-(1-((3,4-dimethylbenzyl)oxy)propan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0427" num="0322">Using (R)-1-((3,4-dimethylbenzyl)oxy)propan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0428" num="0000"><chemistry id="CHEM-US-00103" num="00103"><img id="EMI-C00103" he="26.25mm" wi="69.93mm" file="US20230002353A1-20230105-C00103.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0429" num="0323">MS (ESI, m/z): 394.2 [M+H]<sup>+</sup></p><heading id="h-0114" level="1">Example 101. (S)-2-amino-N-(2-((3,4-dimethylbenzyl)oxy)propyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0430" num="0324">Using (S)-2-((3,4-dimethylbenzyl)oxy)propan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0431" num="0000"><chemistry id="CHEM-US-00104" num="00104"><img id="EMI-C00104" he="26.25mm" wi="69.93mm" file="US20230002353A1-20230105-C00104.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0432" num="0325">MS (ESI, m/z): 394.2 [M+H]<sup>+</sup></p><heading id="h-0115" level="1">Example 102. (R)-2-amino-N-(1-((4-chlorobenzyl)oxy)propan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0433" num="0326">Using (R)-1-((4-chlorobenzyl)oxy)propan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0434" num="0000"><chemistry id="CHEM-US-00105" num="00105"><img id="EMI-C00105" he="27.09mm" wi="69.09mm" file="US20230002353A1-20230105-C00105.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0435" num="0327">MS (ESI, m/z): 400.2 [M+H]<sup>+</sup></p><heading id="h-0116" level="1">Example 103. (S)-2-amino-N-(2-((4-chlorobenzyl)oxy)propyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0436" num="0328">Using (S)-2-((4-chlorobenzyl)oxy)propan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0437" num="0000"><chemistry id="CHEM-US-00106" num="00106"><img id="EMI-C00106" he="27.09mm" wi="69.09mm" file="US20230002353A1-20230105-C00106.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0438" num="0329">MS (ESI, m/z): 400.2 [M+H]<sup>+</sup></p><heading id="h-0117" level="1">Example 104. (R)-2-amino-N-(1-((3,4-dichlorobenzyl)oxy)propan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0439" num="0330">Using (R)-1-((3,4-dichlorobenzyl)oxy)propan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0440" num="0000"><chemistry id="CHEM-US-00107" num="00107"><img id="EMI-C00107" he="27.09mm" wi="71.46mm" file="US20230002353A1-20230105-C00107.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0441" num="0331">MS (ESI, m/z): 434.1 [M+H]<sup>+</sup></p><heading id="h-0118" level="1">Example 105. (S)-2-amino-N-(2-((3,4-dichlorobenzyl)oxy)propyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0442" num="0332">Using (S)-2-((3,4-dichlorobenzyl)oxy)propan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0443" num="0000"><chemistry id="CHEM-US-00108" num="00108"><img id="EMI-C00108" he="27.77mm" wi="71.29mm" file="US20230002353A1-20230105-C00108.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0444" num="0333">MS (ESI, m/z): 419.1 [M+H]<sup>+</sup></p><heading id="h-0119" level="1">Example 106. (R)-2-amino-N-(1-((3-methoxybenzyl)oxy)propan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0445" num="0334">Using (R)-1-((3-methoxybenzyl)oxy)propan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0446" num="0000"><chemistry id="CHEM-US-00109" num="00109"><img id="EMI-C00109" he="26.33mm" wi="74.00mm" file="US20230002353A1-20230105-C00109.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0447" num="0335">MS (ESI, m/z): 396.2 [M+H]<sup>+</sup></p><heading id="h-0120" level="1">Example 107. (S)-2-amino-N-(2-((3-methoxybenzyl)oxy)propyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0448" num="0336">Using (S)-2-((3-methoxybenzyl)oxy)propan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0449" num="0000"><chemistry id="CHEM-US-00110" num="00110"><img id="EMI-C00110" he="26.08mm" wi="74.00mm" file="US20230002353A1-20230105-C00110.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0450" num="0337">MS (ESI, m/z): 396.2 [M+H]<sup>+</sup></p><heading id="h-0121" level="1">Example 108. (R)-2-amino-N-(1-(benzyloxy)butan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0451" num="0338">Using (R)-1-(benzyloxy)butan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0452" num="0000"><chemistry id="CHEM-US-00111" num="00111"><img id="EMI-C00111" he="29.63mm" wi="64.60mm" file="US20230002353A1-20230105-C00111.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0453" num="0339">MS (ESI, m/z): 380.2 [M+H]<sup>+</sup></p><heading id="h-0122" level="1">Example 109. (S)-2-amino-N-(1-(benzyloxy)-3-methylbutan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0454" num="0340">Using (S)-1-(benzyloxy)-3-methylbutan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0455" num="0000"><chemistry id="CHEM-US-00112" num="00112"><img id="EMI-C00112" he="29.63mm" wi="64.60mm" file="US20230002353A1-20230105-C00112.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0456" num="0341">MS (ESI, m/z): 394.2 [M+H]<sup>+</sup></p><heading id="h-0123" level="1">Example 110. (R)-2-amino-N-(1-(benzyloxy)-3-methylbutan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0457" num="0342">Using (R)-1-(benzyloxy)-3-methylbutan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0458" num="0000"><chemistry id="CHEM-US-00113" num="00113"><img id="EMI-C00113" he="29.63mm" wi="64.60mm" file="US20230002353A1-20230105-C00113.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0459" num="0343">MS (ESI, m/z): 394.2 [M+H]<sup>+</sup></p><heading id="h-0124" level="1">Example 111. (S)-2-amino-N-(1-(benzyloxy)-4-methylpentan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0460" num="0344">Using (S)-1-(benzyloxy)-4-methylpentan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0461" num="0000"><chemistry id="CHEM-US-00114" num="00114"><img id="EMI-C00114" he="35.22mm" wi="64.60mm" file="US20230002353A1-20230105-C00114.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0462" num="0345">MS (ESI, m/z): 408.2 [M+H]<sup>+</sup></p><heading id="h-0125" level="1">Example 112. (R)-2-amino-N-(1-(benzyloxy)-4-methylpentan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0463" num="0346">Using (R)-1-(benzyloxy)-4-methylpentan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0464" num="0000"><chemistry id="CHEM-US-00115" num="00115"><img id="EMI-C00115" he="35.14mm" wi="64.60mm" file="US20230002353A1-20230105-C00115.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0465" num="0347">MS (ESI, m/z): 408.2 [M+H]<sup>+</sup></p><heading id="h-0126" level="1">Example 113. (R)-2-amino-N-(2-(benzyloxy)-1-cyclohexylethyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0466" num="0348">Using (R)-2-(benzyloxy)-1-cyclohexylethan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0467" num="0000"><chemistry id="CHEM-US-00116" num="00116"><img id="EMI-C00116" he="37.68mm" wi="64.60mm" file="US20230002353A1-20230105-C00116.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0468" num="0349">MS (ESI, m/z): 434.3 [M+H]<sup>+</sup></p><heading id="h-0127" level="1">Example 114. (R)-2-amino-N-(1-cyclohexyl-2-hydroxyethyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0469" num="0350">Using (R)-2-amino-2-cyclohexylethan-1-ol, the title compound was obtained as described for the example 1.</p><p id="p-0470" num="0000"><chemistry id="CHEM-US-00117" num="00117"><img id="EMI-C00117" he="37.68mm" wi="48.85mm" file="US20230002353A1-20230105-C00117.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0471" num="0351">MS (ESI, m/z): 344.3 [M+H]<sup>+</sup></p><heading id="h-0128" level="1">Example 115. (S)-2-amino-N-(2-(benzyloxy)-1-phenylethyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0472" num="0352">Using (S)-2-(benzyloxy)-1-phenylethan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0473" num="0000"><chemistry id="CHEM-US-00118" num="00118"><img id="EMI-C00118" he="37.59mm" wi="64.60mm" file="US20230002353A1-20230105-C00118.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0474" num="0353">MS (ESI, m/z): 428.2 [M+H]<sup>+</sup></p><heading id="h-0129" level="1">Example 116. (R)-2-amino-N-(2-(benzyloxy)-1-phenylethyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0475" num="0354">Using (R)-2-(benzyloxy)-1-phenylethan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0476" num="0000"><chemistry id="CHEM-US-00119" num="00119"><img id="EMI-C00119" he="37.68mm" wi="64.60mm" file="US20230002353A1-20230105-C00119.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0477" num="0355">MS (ESI, m/z): 428.2 [M+H]<sup>+</sup></p><heading id="h-0130" level="1">Example 117. (S)-2-amino-N-(1-(benzyloxy)-3-phenylpropan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0478" num="0356">Using (S)-1-(benzyloxy)-3-phenylpropan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0479" num="0000"><chemistry id="CHEM-US-00120" num="00120"><img id="EMI-C00120" he="38.52mm" wi="64.60mm" file="US20230002353A1-20230105-C00120.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0480" num="0357">MS (ESI m/z): 442.2 [M+H]<sup>+</sup></p><heading id="h-0131" level="1">Example 118. (R)-2-amino-N-(1-(benzyloxy)-3-phenylpropan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0481" num="0358">Using (R)-1-(benzyloxy)-3-phenylpropan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0482" num="0000"><chemistry id="CHEM-US-00121" num="00121"><img id="EMI-C00121" he="38.52mm" wi="64.60mm" file="US20230002353A1-20230105-C00121.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0483" num="0359">MS (ESI, m/z): 442.2 [M+H]<sup>+</sup></p><heading id="h-0132" level="1">Example 119. (R)-2-amino-N-(1-(cyclobutylmethoxy)propan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0484" num="0360">Using (R)-1-(cyclobutylmethoxy)propan-2-amine, the title compound was obtained as described for the example 1.</p><p id="p-0485" num="0000"><chemistry id="CHEM-US-00122" num="00122"><img id="EMI-C00122" he="26.25mm" wi="61.04mm" file="US20230002353A1-20230105-C00122.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0486" num="0361">MS (ESI, m/z): 344.2 [M+H]<sup>+</sup></p><heading id="h-0133" level="1">Example 120. methyl N-(2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinoyl)-O-benzyl-L-serinate</heading><p id="p-0487" num="0362">Using methyl O-benzyl-L-serinate, the title compound was obtained as described for the example 1.</p><p id="p-0488" num="0000"><chemistry id="CHEM-US-00123" num="00123"><img id="EMI-C00123" he="36.75mm" wi="64.09mm" file="US20230002353A1-20230105-C00123.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0489" num="0363">MS (ESI, m/z): 410.2 [M+H]<sup>+</sup></p><heading id="h-0134" level="1">Example 121. methyl N-(2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinoyl)-O-benzyl-L-threoninate</heading><p id="p-0490" num="0364">Using methyl O-benzyl-L-threoninate, the title compound was obtained as described for the example 1.</p><p id="p-0491" num="0000"><chemistry id="CHEM-US-00124" num="00124"><img id="EMI-C00124" he="36.75mm" wi="64.09mm" file="US20230002353A1-20230105-C00124.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0492" num="0365">MS (ESI, m/z): 424.2 [M+H]<sup>+</sup></p><heading id="h-0135" level="1">Example 122 2-amino-N-((2S,3R)-3-(benzyloxy)-1-(methylamino)-1-oxobutan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0493" num="0366">Using (2S,3R)-2-amino-3-(benzyloxy)-N-methylbutanamide, the title compound was obtained as described for the example 1.</p><p id="p-0494" num="0000"><chemistry id="CHEM-US-00125" num="00125"><img id="EMI-C00125" he="36.75mm" wi="64.09mm" file="US20230002353A1-20230105-C00125.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0495" num="0367">MS (ESI m/z): 423.2 [M+H]<sup>+</sup></p><heading id="h-0136" level="1">Example 123. 2-amino-N-((2S,3R)-3-(benzyloxy)-1-oxo-1-(propylamino)butan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0496" num="0368">Using (2S,3R)-2-amino-3-(benzyloxy)-N-propylbutanamide, the title compound was obtained as described for the example 1.</p><p id="p-0497" num="0000"><chemistry id="CHEM-US-00126" num="00126"><img id="EMI-C00126" he="46.14mm" wi="64.09mm" file="US20230002353A1-20230105-C00126.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0498" num="0369">MS (ESI, m/z): 451.2 [M+H]<sup>+</sup></p><heading id="h-0137" level="1">Example 124. 2-amino-N-((2S,3R)-3-(benzyloxy)-1-(cyclopentylamino)-1-oxobutan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0499" num="0370">Using (2S,3R)-2-amino-3-(benzyloxy)-N-cyclopentylbutanamide, the title compound was obtained as described for the example 1.</p><p id="p-0500" num="0000"><chemistry id="CHEM-US-00127" num="00127"><img id="EMI-C00127" he="45.89mm" wi="64.09mm" file="US20230002353A1-20230105-C00127.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0501" num="0371">MS (ESI, m/z): 477.3 [M+H]<sup>+</sup></p><heading id="h-0138" level="1">Example 125. 2-amino-N-((2S,3R)-3-(benzyloxy)-1-oxo-1-(pyrrolidin-1-yl)butan-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0502" num="0372">Using (2S,3R)-2-amino-3-(benzyloxy)-1-(pyrrolidin-1-yl)butan-1-one, the title compound was obtained as described for the example 1.</p><p id="p-0503" num="0000"><chemistry id="CHEM-US-00128" num="00128"><img id="EMI-C00128" he="39.54mm" wi="64.09mm" file="US20230002353A1-20230105-C00128.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0504" num="0373">MS (ESI, m/z): 463.2 [M+H]<sup>+</sup></p><heading id="h-0139" level="1">Example 126. benzyl (2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinoyl)-L-alaninate</heading><p id="p-0505" num="0374">Using benzyl L-alaninate, the title compound was obtained as described for the example 1.</p><p id="p-0506" num="0000"><chemistry id="CHEM-US-00129" num="00129"><img id="EMI-C00129" he="27.43mm" wi="64.09mm" file="US20230002353A1-20230105-C00129.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0507" num="0375"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.51 (d, J=7.43 Hz, 3H) 3.92 (s, 3H) 4.64 (d, J=7.43 Hz, 1H) 5.12-5.25 (m, 2H) 7.21-7.42 (m, 5H) 7.84 (s, 1H) 7.96-8.00 (m, 1H) 8.21-8.27 (m, 1H) 8.54 (d, J=2.35 Hz, 1H);</p><p id="p-0508" num="0376">MS (ESI, m/z): 380.2 [M+H]<sup>+</sup></p><heading id="h-0140" level="1">Example 127. benzyl (2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinoyl)-L-valinate</heading><p id="p-0509" num="0377">Using benzyl L-valinate, the title compound was obtained as described for the example 1.</p><p id="p-0510" num="0000"><chemistry id="CHEM-US-00130" num="00130"><img id="EMI-C00130" he="30.40mm" wi="64.09mm" file="US20230002353A1-20230105-C00130.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0511" num="0378"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.00 (dd, J=9.19, 6.85 Hz, 6H) 2.16-2.36 (m, 1H) 4.46-4.55 (m, 1H) 5.10-5.30 (m, 2H) 7.22-7.41 (m, 5H) 7.84 (d, J=0.78 Hz, 1H) 7.98 (s, 1H) 8.24 (d, J=1.96 Hz, 1H) 8.48 (d, J=2.35 Hz, 1H);</p><p id="p-0512" num="0379">MS (ESI, m/z): 408.2 [M+H]<sup>+</sup></p><heading id="h-0141" level="1">Example 128. benzyl (2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinoyl)-L-serinate</heading><p id="p-0513" num="0380">Using benzyl L-serinate, the title compound was obtained as described for the example 1.</p><p id="p-0514" num="0000"><chemistry id="CHEM-US-00131" num="00131"><img id="EMI-C00131" he="31.16mm" wi="64.09mm" file="US20230002353A1-20230105-C00131.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0515" num="0381"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 3.94-4.07 (m, 2H) 4.78 (dd, J=5.48, 4.30 Hz, 1H) 5.21 (s, 2H) 7.23-7.43 (m, 5H) 7.86 (d, J=0.78 Hz, 1H) 8.01 (s, 1H) 8.24 (d, J=1.96 Hz, 1H) 8.64 (d, J=1.96 Hz, 1H);</p><p id="p-0516" num="0382">MS (ESI, m/z): 396.2 [M+H]<sup>+</sup></p><heading id="h-0142" level="1">Example 129. 3-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxamide</heading><p id="p-0517" num="0383">Using 3-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxylic acid and (1S,2S)-2-(benzyloxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0518" num="0000"><chemistry id="CHEM-US-00132" num="00132"><img id="EMI-C00132" he="28.11mm" wi="64.85mm" file="US20230002353A1-20230105-C00132.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0519" num="0384">MS (ESI, m/z): 393.2 [M+H]<sup>+</sup></p><heading id="h-0143" level="1">Example 130. 3-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxamide</heading><p id="p-0520" num="0385">Using 3-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxylic acid and (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0521" num="0000"><chemistry id="CHEM-US-00133" num="00133"><img id="EMI-C00133" he="29.21mm" wi="70.36mm" file="US20230002353A1-20230105-C00133.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0522" num="0386">MS (ESL, m/z): 421.2 [M+H]<sup>+</sup></p><heading id="h-0144" level="1">Example 131. (S)-3-amino-6-(1-methyl-1H-pyrazol-4-yl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazine-2-carboxamide</heading><p id="p-0523" num="0387">Using 3-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxylic acid and (S)-1,2,3,4-tetrahydronaphthalen-1-amine, the title compound was obtained as described for the example 1.</p><p id="p-0524" num="0000"><chemistry id="CHEM-US-00134" num="00134"><img id="EMI-C00134" he="37.68mm" wi="48.94mm" file="US20230002353A1-20230105-C00134.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0525" num="0388">MS (ESI, m/z): 349.2 [M+H]<sup>+</sup></p><heading id="h-0145" level="1">Example 132. 3-amino-N-(trans-4-(benzyloxy)tetrahydrofuran-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxamide</heading><p id="p-0526" num="0389">Using 3-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxylic acid and trans-4-(benzyloxy)tetrahydrofuran-3-amine, the title compound was obtained as described for the example 1.</p><p id="p-0527" num="0000"><chemistry id="CHEM-US-00135" num="00135"><img id="EMI-C00135" he="28.87mm" wi="64.85mm" file="US20230002353A1-20230105-C00135.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0528" num="0390">MS (ESI, m/z): 395.2 [M+H]<sup>+</sup></p><heading id="h-0146" level="1">Example 133. 3-amino-N-(cis-4-(benzyloxy)tetrahydrofuran-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxamide</heading><p id="p-0529" num="0391">Using 3-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxylic acid and cis-4-(benzyloxy)tetrahydrofuran-3-amine, the title compound was obtained as described for the example 1.</p><p id="p-0530" num="0000"><chemistry id="CHEM-US-00136" num="00136"><img id="EMI-C00136" he="28.87mm" wi="64.85mm" file="US20230002353A1-20230105-C00136.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0531" num="0392">MS (ESI, m/z): 395.2 [M+H]<sup>+</sup></p><heading id="h-0147" level="1">Example 134. 2-amino-N-((1S,2S)-2-((3&#x2032;-amino-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0532" num="0393">Scheme for the Preparation of the Compound of Example 134:</p><p id="p-0533" num="0000"><chemistry id="CHEM-US-00137" num="00137"><img id="EMI-C00137" he="142.92mm" wi="102.95mm" file="US20230002353A1-20230105-C00137.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0534" num="0394">Intermediate 3. To a solution of methyl 2-amino-5-bromonicotinate (560 mg, 2.42 mmol) in 10 ml of MeOH was added 2N NaOH (2 ml, 4 mmol) and the mixture was heated at 65&#xb0; C. for 1 hr, cooled to room temperature, neutralized (2 ml of 2N HCl), and the resulting precipitate was filtered, washed with MeOH, and dried to give 0.35 g of white solid.</p><p id="p-0535" num="0395"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 8.17 (d, J=2.4 Hz, 1H), 8.23 (d, J=2.4 Hz, 1H);</p><p id="p-0536" num="0396">MS (ESI, m/z): 217.0 [M+H]<sup>+</sup></p><p id="p-0537" num="0397">Intermediate 2. To a mixture of intermediate 3 (4.48 g, 20.6 mmol) and 1-methylpyrazole-4-boronic acid pinacol ester (5.5 g, 26.8 mmol) in 100 ml of 1,4-dioxane/water (3/1) was added K<sub>2</sub>CO<sub>3 </sub>(8.5 g, 61.9 mmol) followed by Pd(PPh<sub>3</sub>)<sub>4 </sub>(1.19 g, 1.03 mmol). The reaction mixture was heated at 100&#xb0; C. for 3 hrs, cooled to room temperature, and partitioned between water and EtOAc. Water layer was separated and adjusted to pH value between 4 and 5. The precipitate was collected by filtration and dried to afford 4 g of the title compound. The crude product was used for the next step without further purification.</p><p id="p-0538" num="0398"><sup>1</sup>H NMR (600 MHz, DMSO-d<sub>6</sub>) &#x3b4; ppm 3.82 (s, 3H), 5.73 (s, 2H), 7.77 (s, 1H), 8.05 (s, 1H), 8.13 (d, J=2.4 Hz, 1H), 8.42 (d, J=2.4 Hz, 1H);</p><p id="p-0539" num="0399">MS (ESI, m/z): 219.1 [M+H]<sup>+</sup></p><p id="p-0540" num="0400">Intermediate 4. To a mixture of intermediate 2 (350 mg, 1.60 mmol) and triethylamine (0.34 ml, 2.41 mmol) in 4 ml of DMF was added HATU (732 mg, 1.92 mmol) followed by (1S,2S)-2-((4-bromobenzyl)oxy)cyclopentan-1-amine (475 mg, 1.76 mmol). The mixture was stirred at room temperature for 1 hr and then saturated sodium bicarbonate solution was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude product was purified through silicagel column chromatography to give 650 mg of off-white solid.</p><p id="p-0541" num="0401"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.59-1.69 (m, 1H) 1.72-1.78 (m, 1H) 1.78-1.86 (m, 2H) 1.96-2.07 (m, 1H) 2.16 (dq, J=13.50, 6.85 Hz, 1H) 3.94 (s, 3H) 3.95 (br d, J=1.76 Hz, 1H) 4.33-4.42 (m, 1H) 4.53-4.62 (m, 2H) 7.25 (m, J=8.22 Hz, 2H) 7.41 (m, J=8.22 Hz, 2H) 7.87 (s, 1H) 8.01 (s, 1H) 8.22 (d, J=1.76 Hz, 1H) 8.52 (d, J=1.76 Hz, 1H);</p><p id="p-0542" num="0402">MS (ESI, m/z): 470.1/472.1 [M+H]<sup>+</sup></p><heading id="h-0148" level="1">Example 134. 2-amino-N-(1S,2S)-2-((3&#x2032;-amino-[1,1&#x2032;-biphenyl]-4-yl)-methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0543" num="0403">To a mixture of intermediate 4 (33 mg, 0.07 mmol) and (3-aminophenyl)boronic acid (11 mg, 0.08 mmol) in 0.4 ml of 1,4-dioxane/water (3/1) was added K<sub>2</sub>CO<sub>3 </sub>(29 mg, 0.21 mmol) followed by Pd(PPh<sub>3</sub>)<sub>4 </sub>(4 mg, 0.003 mmol). The reaction mixture was heated at 100&#xb0; C. for 3 hrs, cooled to room temperature, and extracted with EtOAc, dried over anhydrous MgSO<sub>4 </sub>and concentrated under vacuum. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 30 mg of the title compound.</p><p id="p-0544" num="0404"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.60-1.69 (m, 1H) 1.73-1.90 (m, 3H) 2.05 (br d, J=7.04 Hz, 1H) 2.17 (s, 1H) 3.89 (s, 3H) 4.00 (br d, J=4.30 Hz, 1H) 4.36-4.46 (m, 2H) 4.67 (s, 2H) 7.24 (br d, J=7.43 Hz, 1H) 7.42-7.59 (m, 7H) 7.84 (s, 1H) 7.97 (s, 1H) 8.20 (d, J=2.35 Hz, 1H) 8.48 (d, J=2.35 Hz, 1H);</p><p id="p-0545" num="0405">MS (ESI, m/z): 483.2 [M+H]<sup>+</sup></p><heading id="h-0149" level="1">Example 135. 2-amino-N-((1S,2S)-2-((4&#x2032;-amino-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0546" num="0406">Using (4-aminophenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0547" num="0000"><chemistry id="CHEM-US-00138" num="00138"><img id="EMI-C00138" he="39.88mm" wi="75.52mm" file="US20230002353A1-20230105-C00138.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0548" num="0407">MS (ESI, m/z): 483.2 [M+H]<sup>+</sup></p><heading id="h-0150" level="1">Example 136. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(methylamino)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0549" num="0408">Using (4-(methylamino)phenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0550" num="0000"><chemistry id="CHEM-US-00139" num="00139"><img id="EMI-C00139" he="38.02mm" wi="75.61mm" file="US20230002353A1-20230105-C00139.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0551" num="0409"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.64 (br d, J=5.87 Hz, 1H) 1.73-1.94 (m, 3H) 2.05 (br s, 1H) 2.17 (br s, 1H) 3.55 (br t, J=11.15 Hz, 3H) 3.90 (s, 3H) 4.00 (br s, 1H) 4.43 (s, 4H) 4.67 (s, 2H) 7.45 (br d, J=8.22 Hz, 2H) 7.55 (br d, J=7.83 Hz, 2H) 7.60 (br d, J=7.83 Hz, 2H) 7.71 (br d, J=7.83 Hz, 2H) 7.85 (s, 1H) 7.98 (s, 1H) 8.21 (s, 1H) 8.52 (s, 1H);</p><p id="p-0552" num="0410">MS (ESI, m/z): 497.3 [M+H]<sup>+</sup></p><heading id="h-0151" level="1">Example 137. 2-amino-N-((1S,2S)-2-((4&#x2032;-(dimethylamino)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0553" num="0411">Using (4-(dimethylamino)phenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0554" num="0000"><chemistry id="CHEM-US-00140" num="00140"><img id="EMI-C00140" he="40.05mm" wi="75.44mm" file="US20230002353A1-20230105-C00140.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0555" num="0412">MS (ESI, m/z): 511.3 [M+H]<sup>+</sup></p><heading id="h-0152" level="1">Example 138. 2-amino-N-((1S,2S)-2-((4&#x2032;-((dimethylamino)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0556" num="0413">Using ((4-((dimethylamino)methyl)phenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0557" num="0000"><chemistry id="CHEM-US-00141" num="00141"><img id="EMI-C00141" he="36.07mm" wi="75.69mm" file="US20230002353A1-20230105-C00141.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0558" num="0414"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.55-1.68 (m, 1H) 1.80 (br s, 3H) 2.04 (br d, J=7.43 Hz, 1H) 2.15 (br s, 1H) 3.49 (br s, 3H) 3.62 (br s, 3H) 3.75 (br s, 2H) 3.89 (s, 3H) 3.97 (br s, 1H) 4.39 (br s, 1H) 4.62 (br d, J=12.91 Hz, 1H) 4.66-4.73 (m, 1H) 7.44 (br t, J=9.19 Hz, 4H) 7.56 (br d, J=8.22 Hz, 2H) 7.62 (br d, J=7.83 Hz, 2H) 7.82 (s, 1H) 7.94 (s, 1H) 8.16 (s, 1H) 8.42 (s, 1H);</p><p id="p-0559" num="0415">MS (ESI, m/z): 525.3 [M+H]<sup>+</sup></p><heading id="h-0153" level="1">Example 139. 2-amino-N-((1S,2S)-2-((3&#x2032;-amino-2&#x2032;-methyl-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0560" num="0416">Using (3-amino-2-methylphenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0561" num="0000"><chemistry id="CHEM-US-00142" num="00142"><img id="EMI-C00142" he="32.43mm" wi="75.52mm" file="US20230002353A1-20230105-C00142.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0562" num="0417">MS (ESI, m/z): 497.2 [M+H]<sup>+</sup></p><heading id="h-0154" level="1">Example 140. 2-amino-N-((1S,2S)-2-((3&#x2032;-hydroxy-[1,1&#x2032;-biphenyl]-4-yl)-methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0563" num="0418">Using (3-hydroxyphenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0564" num="0000"><chemistry id="CHEM-US-00143" num="00143"><img id="EMI-C00143" he="32.94mm" wi="75.61mm" file="US20230002353A1-20230105-C00143.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0565" num="0419"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.61 (br d, J=7.43 Hz, 1H) 1.72-1.86 (m, 3H) 1.95-2.08 (m, 1H) 2.09-2.20 (m, 1H) 3.87 (s, 3H) 3.97 (br s, 1H) 4.40 (br d, J=18.00 Hz, 1H) 4.56-4.71 (m, 2H) 6.70-6.75 (m, 1H) 6.90 (br s, 1H) 6.95 (br d, J=7.83 Hz, 1H) 7.14-7.21 (m, 1H) 7.32-7.41 (m, 2H) 7.42-7.50 (m, 2H) 7.78-7.83 (m, 1H) 7.88-7.93 (m, 1H) 8.16 (br d, J=1.96 Hz, 1H) 8.36 (br d, J=2.35 Hz, 1H);</p><p id="p-0566" num="0420">MS (ESI, m/z): 484.2 [M+H]<sup>+</sup></p><heading id="h-0155" level="1">Example 141. 2-amino-N-((1S,2S)-2-((3&#x2032;-(hydroxymethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0567" num="0421">Using (3-(hydroxymethyl)phenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0568" num="0000"><chemistry id="CHEM-US-00144" num="00144"><img id="EMI-C00144" he="31.41mm" wi="75.61mm" file="US20230002353A1-20230105-C00144.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0569" num="0422">MS (ESI, m/z): 498.2 [M+H]<sup>+</sup></p><heading id="h-0156" level="1">Example 142. 2-amino-N-((1S,2S)-2-(4&#x2032;-(hydroxymethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0570" num="0423">Using ((4-(hydroxymethyl)phenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0571" num="0000"><chemistry id="CHEM-US-00145" num="00145"><img id="EMI-C00145" he="34.12mm" wi="75.44mm" file="US20230002353A1-20230105-C00145.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0572" num="0424">MS (ESI, m/z): 498.2 [M+H]<sup>+</sup></p><heading id="h-0157" level="1">Example 143. 2-amino-N-((1S,2S)-2-((3&#x2032;-(aminomethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0573" num="0425">Using (3-(aminomethyl)phenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0574" num="0000"><chemistry id="CHEM-US-00146" num="00146"><img id="EMI-C00146" he="30.99mm" wi="75.44mm" file="US20230002353A1-20230105-C00146.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0575" num="0426"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.54-1.67 (m, 1H) 1.71-1.90 (m, 3H) 2.03 (br dd, J=12.33, 7.04 Hz, 1H) 2.11-2.21 (m, 1H) 3.88 (s, 3H) 3.96-4.03 (m, 1H) 4.16 (s, 2H) 4.35-4.47 (m, 1H) 4.67 (s, 2H) 7.40 (br d, J=7.63 Hz, 1H) 7.44 (d, J=8.22 Hz, 1H) 7.49 (br t, J=7.63 Hz, 2H) 7.58 (d, J=7.63 Hz, 1H) 7.59-7.62 (m, 2H) 7.61 (br d, J=7.63 Hz, 1H) 7.66 (s, 1H) 7.80 (s, 1H) 7.92 (s, 1H) 8.21 (d, J=2.35 Hz, 1H) 8.29 (br s, 1H);</p><p id="p-0576" num="0427">MS (ESI, m/z): 497.3 [M+H]<sup>+</sup></p><heading id="h-0158" level="1">Example 144. 2-amino-N-((1S,2S)-2-((4&#x2032;-(aminomethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0577" num="0428">Using (4-(aminomethyl)phenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0578" num="0000"><chemistry id="CHEM-US-00147" num="00147"><img id="EMI-C00147" he="33.78mm" wi="75.61mm" file="US20230002353A1-20230105-C00147.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0579" num="0429"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.64 (br dd, J=14.09, 7.04 Hz, 1H) 1.72-1.90 (m, 3H) 2.03 (br dd, J=13.21, 6.16 Hz, 1H) 2.14-2.23 (m, 1H) 3.90 (s, 3H) 4.01 (br d, J=7.04 Hz, 1H) 4.14 (s, 2H) 4.40-4.45 (m, 1H) 4.63-4.70 (m, 2H) 7.43 (d, J=8.22 Hz, 2H) 7.49 (d, J=7.63 Hz, 2H) 7.57 (d, J=7.63 Hz, 2H) 7.65 (d, J=8.22 Hz, 2H) 7.85 (s, 1H) 7.97 (s, 1H) 8.21 (d, J=1.76 Hz, 1H) 8.49 (br s, 1H);</p><p id="p-0580" num="0430">MS (ESI, m/z): 497.3 [M+H]<sup>+</sup></p><heading id="h-0159" level="1">Example 145. 2-amino-N-((1S,2S)-2-((4&#x2032;-(2-aminoethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0581" num="0431">Using (4-(2-aminoethyl)phenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0582" num="0000"><chemistry id="CHEM-US-00148" num="00148"><img id="EMI-C00148" he="35.73mm" wi="75.61mm" file="US20230002353A1-20230105-C00148.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0583" num="0432">MS (ESI, m/z): 511.3 [M+H]<sup>+</sup></p><heading id="h-0160" level="1">Example 146. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(4-methylpiperazin-1-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0584" num="0433">Using (4-(4-methylpiperazin-1-yl)phenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0585" num="0000"><chemistry id="CHEM-US-00149" num="00149"><img id="EMI-C00149" he="42.84mm" wi="75.61mm" file="US20230002353A1-20230105-C00149.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0586" num="0434">MS (ESI, m/z): 566.3 [M+H]<sup>+</sup></p><heading id="h-0161" level="1">Example 147. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(6-(piperazin-1-yl)pyridin-3-yl)benzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0587" num="0435">Using (6-(piperazin-1-yl)pyridin-3-yl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0588" num="0000"><chemistry id="CHEM-US-00150" num="00150"><img id="EMI-C00150" he="41.06mm" wi="75.61mm" file="US20230002353A1-20230105-C00150.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0589" num="0436"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.64 (br d, J=7.83 Hz, 1H) 1.81 (br d, J=7.83 Hz, 3H) 2.04 (br s, 1H) 2.18 (br s, 1H) 3.32-3.40 (m, 4H) 3.84 (br s, 4H) 3.90 (s, 3H) 3.98 (br s, 1H) 4.40 (br s, 1H) 4.65 (s, 2H) 6.98-7.02 (m, 1H) 7.41 (br d, J=7.04 Hz, 2H) 7.50 (br d, J=7.83 Hz, 2H) 7.83-7.89 (m, 2H) 7.96 (s, 1H) 8.20 (s, 1H) 8.35 (s, 1H) 8.48 (s, 1H);</p><p id="p-0590" num="0437">MS (ESI, m/z): 553.3 [M+H]<sup>+</sup></p><heading id="h-0162" level="1">Example 148. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0591" num="0438">Using (6-(4-methylpiperazin-1-yl)pyridin-3-yl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0592" num="0000"><chemistry id="CHEM-US-00151" num="00151"><img id="EMI-C00151" he="42.76mm" wi="75.61mm" file="US20230002353A1-20230105-C00151.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0593" num="0439"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.58-1.66 (m, 1H) 1.73-1.87 (m, 3H) 2.04 (dq, J=13.72, 6.77 Hz, 1H) 2.16 (dt, J=13.35, 6.53 Hz, 1H) 2.96 (s, 3H) 3.90 (s, 3H) 3.96-4.01 (m, 1H) 4.37-4.45 (m, 1H) 4.60-4.69 (m, 2H) 6.99 (d, J=8.80 Hz, 1H) 7.41 (d, J=8.22 Hz, 2H) 7.50 (d, J=8.22 Hz, 2H) 7.83 (s, 1H) 7.85 (d, J=2.35 Hz, 1H) 7.96 (s, 1H) 8.20 (d, J=2.35 Hz, 1H) 8.36 (d, J=2.35 Hz, 1H) 8.45 (s, 1H);</p><p id="p-0594" num="0440">MS (ESI, m/z): 567.3 [M+H]<sup>+</sup></p><heading id="h-0163" level="1">Example 149. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3&#x2032;-(piperazin-1-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0595" num="0441">Using (3-(piperazin-1-yl)phenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0596" num="0000"><chemistry id="CHEM-US-00152" num="00152"><img id="EMI-C00152" he="30.65mm" wi="75.44mm" file="US20230002353A1-20230105-C00152.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0597" num="0442"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.62 (br d, J=5.87 Hz, 2H) 1.81 (br d, J=6.65 Hz, 3H) 1.96-2.07 (m, 1H) 2.17 (br s, 1H) 3.40 (br dd, J=19.95, 5.87 Hz, 8H) 3.88 (s, 3H) 4.00 (br s, 1H) 4.40 (br s, 1H) 4.65 (s, 2H) 6.99 (br d, J=7.43 Hz, 1H) 7.10 (br d, J=6.65 Hz, 1H) 7.16 (s, 1H) 7.32 (t, J=7.60 Hz, 1H) 7.40 (d, J=7.83 Hz, 2H) 7.53 (d, J=8.61 Hz, 2H) 7.84 (s, 1H) 7.95 (s, 1H) 8.19 (s, 1H) 8.46 (s, 1H);</p><p id="p-0598" num="0443">MS (ESI, m/z): 552.3 [M+H]<sup>+</sup></p><heading id="h-0164" level="1">Example 150, 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(1S,2S)-2-((3&#x2032;-(4-methylpiperazin-1-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0599" num="0444">Using (3-(4-methylpiperazin-1-yl)phenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0600" num="0000"><chemistry id="CHEM-US-00153" num="00153"><img id="EMI-C00153" he="29.97mm" wi="75.10mm" file="US20230002353A1-20230105-C00153.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0601" num="0445"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.66 (s, 1H) 1.73-1.88 (m, 3H) 1.99-2.08 (m, 1H) 2.17 (br dd, J=13.50, 5.87 Hz, 1H) 2.97 (s, 3H) 3.06 (br s, 2H) 3.60 (br s, 2H) 3.88 (s, 3H) 3.96-4.03 (m, 1H) 4.41 (br d, J=4.70 Hz, 1H) 4.61-4.70 (m, 2H) 6.99 (br d, J=8.80 Hz, 1H) 7.10 (br d, J=7.63 Hz, 1H) 7.16 (s, 1H) 7.32 (t, J=7.92 Hz, 1H) 7.41 (d, J=8.22 Hz, 2H) 7.53 (d, J=8.22 Hz, 2H) 7.82 (s, 1H) 7.93 (s, 1H) 8.19 (d, J=1.76 Hz, 1H) 8.35-8.41 (m, 1H);</p><p id="p-0602" num="0446">MS (ESI, m/z): 566.3 [M+H]<sup>+</sup></p><heading id="h-0165" level="1">Example 151. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0603" num="0447">Using (3-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 134.</p><p id="p-0604" num="0000"><chemistry id="CHEM-US-00154" num="00154"><img id="EMI-C00154" he="37.51mm" wi="75.61mm" file="US20230002353A1-20230105-C00154.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0605" num="0448"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.65 (br dd, J=13.30, 6.26 Hz, 1H) 1.76-1.90 (m, 3H) 1.99-2.10 (m, 1H) 2.18 (br dd, J=14.09, 6.65 Hz, 1H) 2.85 (s, 3H) 3.78 (s, 2H) 3.91 (s, 3H) 4.02 (br s, 1H) 4.43 (br dd, J=10.96, 7.83 Hz, 1H) 4.68 (s, 2H) 7.34 (br d, J=7.43 Hz, 1H) 7.38-7.45 (m, 3H) 7.51 (br d, J=7.83 Hz, 1H) 7.54-7.60 (m, 3H) 7.86 (s, 1H) 7.99 (s, 1H) 8.21 (d, J=1.96 Hz, 1H) 8.51 (d, J=1.96 Hz, 1H);</p><p id="p-0606" num="0449">MS (ESI, m/z): 579.3 [M+H]<sup>+</sup></p><heading id="h-0166" level="1">Example 152. 2-amino-5-(1-methyl-1-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(morpholine-4-carbonyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0607" num="0450">Using (4-(morpholine-4-carbonyl)phenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0608" num="0000"><chemistry id="CHEM-US-00155" num="00155"><img id="EMI-C00155" he="37.93mm" wi="74.93mm" file="US20230002353A1-20230105-C00155.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0609" num="0451">MS (ESI, m/z): 581.3 [M+H]<sup>+</sup></p><heading id="h-0167" level="1">Example 153. 2-amino-N-((1S,2S)-2-((4&#x2032;-ethyl-[1,1&#x2032;-biphenyl]-4-yl)-methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0610" num="0452">Using (4-ethylphenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0611" num="0000"><chemistry id="CHEM-US-00156" num="00156"><img id="EMI-C00156" he="37.76mm" wi="75.27mm" file="US20230002353A1-20230105-C00156.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0612" num="0453"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.24 (t, J=7.63 Hz, 3H) 1.55-1.67 (m, 1H) 1.73-1.86 (m, 3H) 2.01-2.08 (m, 1H) 2.16 (br dd, J=13.21, 5.58 Hz, 1H) 2.66 (q, J=7.63 Hz, 2H) 3.87 (s, 3H) 3.93-3.99 (m, 1H) 4.38-4.42 (m, 1H) 4.61 (d, J=12.91 Hz, 1H) 4.65-4.71 (m, 1H) 7.21 (d, J=7.63 Hz, 2H) 7.38 (d, J=8.22 Hz, 2H) 7.41 (d, J=8.22 Hz, 2H) 7.50 (d, J=8.22 Hz, 2H) 7.82 (s, 1H) 7.91 (s, 1H) 8.16 (d, J=1.76 Hz, 1H) 8.42 (d, J=2.35 Hz, 1H);</p><p id="p-0613" num="0454">MS (ESI, m/z): 496.3 [M+H]<sup>+</sup></p><heading id="h-0168" level="1">Example 154. 2-amino-N-((1S,2S)-2-((4&#x2032;-(cyanomethyl)-[1,1&#x2032;-biphenyl]-4-yl)-methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0614" num="0455">Using (4-(cyanomethyl)phenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0615" num="0000"><chemistry id="CHEM-US-00157" num="00157"><img id="EMI-C00157" he="34.29mm" wi="75.69mm" file="US20230002353A1-20230105-C00157.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0616" num="0456">MS (ESI, m/z): 507.2 [M+H]<sup>+</sup></p><heading id="h-0169" level="1">Example 155. 2-amino-N-((1S,2S)-2-((4&#x2032;-carbamoyl-[1,1&#x2032;-biphenyl]-4-yl)-methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0617" num="0457">Using (4-carbamoylphenyl)boronic acid, the title compound was obtained as described for the example 134.</p><p id="p-0618" num="0000"><chemistry id="CHEM-US-00158" num="00158"><img id="EMI-C00158" he="39.03mm" wi="75.44mm" file="US20230002353A1-20230105-C00158.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0619" num="0458"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.62 (s, 1H) 1.70-1.88 (m, 3H) 2.05 (s, 1H) 2.16 (td, J=13.06, 7.92 Hz, 1H) 3.88 (s, 3H) 3.98 (br d, J=6.46 Hz, 1H) 4.40 (br d, J=4.70 Hz, 1H) 4.63 (d, J=12.33 Hz, 1H) 4.70 (d, J=12.91 Hz, 1H) 7.44 (d, J=8.22 Hz, 2H) 7.58 (d, J=8.22 Hz, 2H) 7.61 (d, J=8.80 Hz, 2H) 7.81 (s, 1H) 7.89 (d, J=8.22 Hz, 2H) 7.92 (s, 1H) 8.17 (d, J=2.35 Hz, 1H) 8.38 (d, J=1.76 Hz, 1H);</p><p id="p-0620" num="0459">MS (ESI, m/z): 511.2 [M+H]<sup>+</sup></p><heading id="h-0170" level="1">Example 156. 2-amino-N-((1S,2S)-2-((3-fluoro-4&#x2032;-((4-methylpiperazin-1-yl)-methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-0621" num="0460">Using (1S,2S)-2-((4-bromo-2-fluorobenzyl)oxy)cyclopentan-1-amine and 4-(4-methylpiperazino)methylphenylboronic acid pinacol ester, the title compound was obtained as described for the example 134.</p><p id="p-0622" num="0000"><chemistry id="CHEM-US-00159" num="00159"><img id="EMI-C00159" he="33.78mm" wi="74.93mm" file="US20230002353A1-20230105-C00159.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0623" num="0461"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.64 (br dd, J=13.30, 7.04 Hz, 1H) 1.74-1.92 (m, 3H) 2.04 (br dd, J=12.72, 6.06 Hz, 1H) 2.17 (br dd, J=13.50, 6.46 Hz, 1H) 2.91 (s, 3H) 3.25 (br s, 4H) 3.47 (br s, 4H) 3.90 (s, 3H) 3.96-4.08 (m, 1H) 4.12 (s, 2H) 4.34-4.45 (m, 1H) 4.64-4.78 (m, 2H) 5.47 (s, 1H) 7.32 (br d, J=11.35 Hz, 1H) 7.40 (br d, J=7.83 Hz, 1H) 7.47-7.57 (m, 3H) 7.62 (br d, J=7.83 Hz, 2H) 7.85 (s, 1H) 7.99 (s, 1H) 8.18 (s, 1H) 8.55 (s, 1H);</p><p id="p-0624" num="0462">MS (ESI, m/z): 598.4 [M+H]<sup>+</sup></p><heading id="h-0171" level="1">Example 157. 2-amino-N-((1S,2S)-2-((3-fluoro-4&#x2032;-((cis-3,4,5-trimethylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-0625" num="0463">Using (1S,2S)-2-((4-bromo-2-fluorobenzyl)oxy)cyclopentan-1-amine and (4-((cis-3,4,5-trimethylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 134.</p><p id="p-0626" num="0000"><chemistry id="CHEM-US-00160" num="00160"><img id="EMI-C00160" he="35.90mm" wi="74.93mm" file="US20230002353A1-20230105-C00160.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0627" num="0464">MS (ESI, m/z): 626.4 [M+H]<sup>+</sup></p><heading id="h-0172" level="1">Example 158. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)-methoxy)cyclopentyl)nicotinamide</heading><p id="p-0628" num="0465">Using (1S,2S)-2-((4-bromo-2-(trifluoromethyl)benzyl)oxy)cyclopentan-1-amine and 4-(4-methylpiperazino)methylphenylboronic acid pinacol ester, the title compound was obtained as described for the example 134.</p><p id="p-0629" num="0000"><chemistry id="CHEM-US-00161" num="00161"><img id="EMI-C00161" he="33.78mm" wi="74.93mm" file="US20230002353A1-20230105-C00161.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0630" num="0466"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.69 (dt, J=13.89, 6.75 Hz, 1H) 1.77-1.93 (m, 3H) 2.01-2.12 (m, 1H) 2.13-2.30 (m, 1H) 2.87 (s, 3H) 3.75 (s, 2H) 3.92 (s, 3H) 4.00-4.08 (m, 1H) 4.45 (br dd, J=11.54, 7.24 Hz, 1H) 7.47 (d, J=8.22 Hz, 2H) 7.62 (m, J=8.22 Hz, 2H) 7.81-7.84 (m, 2H) 7.86 (d, J=5.09 Hz, 2H) 8.00 (s, 1H) 8.23 (d, J=1.96 Hz, 1H) 8.56 (d, J=2.35 Hz, 1H);</p><p id="p-0631" num="0467">MS (ESI, m/z): 648.3[M+H]<sup>+</sup></p><heading id="h-0173" level="1">Example 159. 2-amino-N-((1S,2S)-2-((2-chloro-4&#x2032;-((4-methylpiperazin-1-yl)-methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-0632" num="0468">Using (1S,2S)-2-((4-bromo-3-chlorobenzyl)oxy)cyclopentan-1-amine and 4-(4-methylpiperazino)methylphenylboronic acid pinacol ester, the title compound was obtained as described for the example 134.</p><p id="p-0633" num="0000"><chemistry id="CHEM-US-00162" num="00162"><img id="EMI-C00162" he="33.78mm" wi="74.93mm" file="US20230002353A1-20230105-C00162.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0634" num="0469"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.65 (br dd, J=13.50, 7.04 Hz, 1H) 1.74-1.89 (m, 3H) 1.97-2.11 (m, 1H) 2.15-2.22 (m, 1H) 2.85 (s, 3H) 3.72 (s, 2H) 3.92 (s, 3H) 3.98 (dt, J=6.46, 4.11 Hz, 1H) 4.42 (td, J=7.34, 4.11 Hz, 1H) 4.66 (d, J=2.35 Hz, 2H) 7.27 (d, J=7.63 Hz, 1H) 7.30-7.37 (m, 3H) 7.40 (d, J=8.22 Hz, 2H) 7.47 (d, J=1.17 Hz, 1H) 7.86 (s, 1H) 7.99 (s, 1H) 8.22 (d, J=2.35 Hz, 1H) 8.49 (d, J=2.35 Hz, 1H);</p><p id="p-0635" num="0470">MS (ESI, m/z): 614.3[M+H]<sup>+</sup></p><heading id="h-0174" level="1">Example 160. 2-amino-N-((1S,2S)-2-((3-fluoro-4&#x2032;-((cis-4-(2-hydroxyethyl)-3,5-dimethylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0636" num="0471">Using (1S,2S)-2-((4-bromo-2-fluorobenzyl)oxy)cyclopentan-1-amine and (4-((cis-4-(2-hydroxyethyl)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 134.</p><p id="p-0637" num="0000"><chemistry id="CHEM-US-00163" num="00163"><img id="EMI-C00163" he="47.67mm" wi="112.18mm" file="US20230002353A1-20230105-C00163.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0638" num="0472">MS (ESI, m/z): 656.4 [M+H]<sup>+</sup></p><heading id="h-0175" level="1">Example 161. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(2-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0639" num="0473">Using 4-(2-(4-methylpiperazino)ethyl)phenylboronic acid pinacol ester, the title compound was obtained as described for the example 134.</p><p id="p-0640" num="0000"><chemistry id="CHEM-US-00164" num="00164"><img id="EMI-C00164" he="43.69mm" wi="74.93mm" file="US20230002353A1-20230105-C00164.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0641" num="0474"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.63 (br dd, J=13.79, 6.75 Hz, 1H) 1.74-1.87 (m, 3H) 2.00-2.11 (m, 1H) 2.11-2.23 (m, 1H) 2.79-2.96 (m, 2H) 3.02 (br s, 2H) 3.24 (s, 2H) 3.41 (br s, 4H) 3.89 (s, 3H) 3.97-4.03 (m, 1H) 4.41 (br s, 1H) 4.61-4.71 (m, 2H) 7.31 (br d, J=8.22 Hz, 2H) 7.40 (d, J=7.63 Hz, 2H) 7.50 (br d, J=8.22 Hz, 2H) 7.51-7.57 (m, 2H) 7.84 (br d, J=2.93 Hz, 1H) 7.96 (s, 1H) 8.16-8.21 (m, 1H) 8.50 (br d, J=4.70 Hz, 1H);</p><p id="p-0642" num="0475">MS (ESI, m/z): 594.4 [M+H]<sup>+</sup></p><heading id="h-0176" level="1">Example 162. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)benzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0643" num="0476">Using tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate, the title compound was obtained as described for the example 134 and following deprotection with TFA.</p><p id="p-0644" num="0000"><chemistry id="CHEM-US-00165" num="00165"><img id="EMI-C00165" he="33.19mm" wi="75.27mm" file="US20230002353A1-20230105-C00165.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0645" num="0477"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.62 (br s, 1H) 1.80 (br d, J=6.65 Hz, 3H) 2.03 (br s, 1H) 2.15 (br s, 1H) 2.28 (br d, J=13.69 Hz, 4H) 3.14-3.25 (m, 2H) 3.56 (br d, J=11.35 Hz, 2H) 3.90 (s, 3H) 3.97 (br s, 1H) 4.39 (br s, 1H) 4.53 (br s, 1H) 4.60 (s, 2H) 7.32 (br d, J=7.83 Hz, 2H) 7.47 (br d, J=7.83 Hz, 2H) 7.79 (s, 1H) 7.85 (s, 1H) 7.97 (br s, 2H) 8.20 (br s, 1H) 8.48 (s, 1H);</p><p id="p-0646" num="0478">MS (ESI, m/z): 541.3 [M+H]<sup>+</sup></p><heading id="h-0177" level="1">Example 163. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)benzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0647" num="0479">Using (1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)-piperidine, the title compound was obtained as described for the example 134.</p><p id="p-0648" num="0000"><chemistry id="CHEM-US-00166" num="00166"><img id="EMI-C00166" he="32.09mm" wi="74.93mm" file="US20230002353A1-20230105-C00166.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0649" num="0480"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.57-1.66 (m, 1H) 1.72-1.87 (m, 3H) 2.03 (br dd, J=12.62, 6.75 Hz, 1H) 2.17 (br s, 1H) 2.24-2.42 (m, 4H) 2.94 (s, 3H) 3.19-3.27 (m, 2H) 3.48 (br s, 1H) 3.90 (s, 3H) 3.98 (br d, J=6.46 Hz, 1H) 4.36-4.45 (m, 1H) 4.46-4.55 (m, 1H) 4.57-4.64 (m, 2H) 7.33 (br d, J=8.22 Hz, 2H) 7.47 (br d, J=8.22 Hz, 2H) 7.79 (br s, 1H) 7.84 (s, 1H) 7.97 (d, J=5.87 Hz, 2H) 8.20 (br d, J=1.76 Hz, 1H) 8.47 (s, 1H);</p><p id="p-0650" num="0481">MS (ESI, m/z): 555.3 [M+H]<sup>+</sup></p><heading id="h-0178" level="1">Example 164. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2R)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0651" num="0482">Using (1S,2R)-2-((4-bromobenzyl)oxy)cyclopentan-1-amine and (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 134.</p><p id="p-0652" num="0000"><chemistry id="CHEM-US-00167" num="00167"><img id="EMI-C00167" he="36.58mm" wi="103.55mm" file="US20230002353A1-20230105-C00167.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0653" num="0483"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.58-1.69 (m, 1H) 1.82-1.97 (m, 4H) 2.00-2.07 (m, 1H) 2.83-2.90 (m, 3H) 3.79 (s, 3H) 3.80-3.87 (m, 2H) 4.11-4.18 (m, 1H) 4.36-4.43 (m, 1H) 4.45 (d, J=11.74 Hz, 1H) 4.67 (d, J=11.74 Hz, 1H) 7.38 (d, J=8.22 Hz, 2H) 7.40-7.44 (m, 2H) 7.46 (d, J=8.22 Hz, 2H) 7.49 (d, J=8.22 Hz, 2H) 7.78 (s, 1H) 7.83 (s, 1H) 8.12-8.19 (m, 1H) 8.44 (s, 1H);</p><p id="p-0654" num="0484">MS (ESI, m/z): 580.3 [M+H]<sup>+</sup></p><heading id="h-0179" level="1">Example 165. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1R,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0655" num="0485">Using (1R,2S)-2-((4-bromobenzyl)oxy)cyclopentan-1-amine and (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 134.</p><p id="p-0656" num="0000"><chemistry id="CHEM-US-00168" num="00168"><img id="EMI-C00168" he="33.87mm" wi="75.27mm" file="US20230002353A1-20230105-C00168.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0657" num="0486"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.60-1.70 (m, 1H) 1.81-1.98 (m, 4H) 2.00-2.09 (m, 1H) 2.87 (s, 3H) 3.79 (s, 3H) 3.80-3.85 (m, 2H) 4.15 (d, J=4.70 Hz, 1H) 4.36-4.42 (m, 1H) 4.45 (d, J=11.74 Hz, 1H) 4.67 (d, J=12.33 Hz, 1H) 7.38 (d, J=8.22 Hz, 2H) 7.42 (d, J=7.04 Hz, 2H) 7.46 (d, J=8.22 Hz, 2H) 7.48-7.50 (m, 2H) 7.78 (s, 1H) 7.83 (s, 1H) 8.15 (d, J=1.76 Hz, 1H) 8.44 (d, J=2.35 Hz, 1H);</p><p id="p-0658" num="0487">MS (ESI, m/z): 580.3 [M+H]<sup>+</sup></p><heading id="h-0180" level="1">Example 166. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclohexyl)nicotinamide</heading><p id="p-0659" num="0488">Using (1S,2S)-2-((4-bromobenzyl)oxy)cyclohexan-1-amine and (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 134.</p><p id="p-0660" num="0000"><chemistry id="CHEM-US-00169" num="00169"><img id="EMI-C00169" he="31.16mm" wi="72.81mm" file="US20230002353A1-20230105-C00169.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0661" num="0489"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.43 (br s, 4H) 1.97-2.07 (m, 2H) 2.18 (br s, 2H) 2.32 (s, 3H) 3.40-3.48 (m, 1H) 3.58 (s, 2H) 3.80-3.89 (m, 1H) 3.90 (s, 3H) 4.61 (s, 2H) 7.41 (dd, J=14.09, 8.22 Hz, 4H) 7.55-7.62 (m, 4H) 7.78 (s, 1H) 7.89 (s, 1H) 8.03 (d, J=1.76 Hz, 1H) 8.23 (br s, 1H);</p><p id="p-0662" num="0490">MS (ESI m/z): 594.4 [M+H]<sup>+</sup></p><heading id="h-0181" level="1">Example 167. 2-amino-N-((1S,2S)-2-((4&#x2032;-(2-(4-methylpiperazin-1-yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0663" num="0491">Using 2-aminonicotinic acid and (4-(2-(4-methylpiperazin-1-yl)propan-2-yl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 134.</p><p id="p-0664" num="0000"><chemistry id="CHEM-US-00170" num="00170"><img id="EMI-C00170" he="37.25mm" wi="72.31mm" file="US20230002353A1-20230105-C00170.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0665" num="0492"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.47 (s, 6H) 1.55-1.70 (m, 1H) 1.82 (br d, J=7.04 Hz, 3H) 2.03 (br s, 1H) 2.12-2.25 (m, 1H) 2.86 (s, 3H) 4.00 (br s, 1H) 4.40 (br s, 1H) 4.66 (s, 2H) 6.90-6.99 (m, 1H) 7.38-7.46 (m, 2H) 7.59 (br dd, J=10.96, 7.83 Hz, 6H) 8.01 (d, J=5.09 Hz, 1H) 8.33 (d, J=7.83 Hz, 1H);</p><p id="p-0666" num="0493">MS (ESI, m/z): 528.3 [M+H]<sup>+</sup></p><heading id="h-0182" level="1">Example 168. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0667" num="0494">Using 2-aminonicotinic acid, (1S,2S)-2-((4-bromo-2-(trifluoromethyl)benzyl)oxy)cyclopentan-1-amine and 4-(4-methylpiperazino)methylphenylboronic acid pinacol ester, the title compound was obtained as described for the example 134.</p><p id="p-0668" num="0000"><chemistry id="CHEM-US-00171" num="00171"><img id="EMI-C00171" he="35.22mm" wi="72.31mm" file="US20230002353A1-20230105-C00171.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0669" num="0495"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.66 (dt, J=13.60, 6.70 Hz, 1H) 1.78-1.93 (m, 3H) 1.97-2.12 (m, 1H) 2.13-2.26 (m, 1H) 2.87 (s, 3H) 3.77 (s, 2H) 4.00-4.05 (m, 1H) 4.43 (br dd, J=10.76, 7.63 Hz, 1H) 6.98 (dd, J=7.43, 6.26 Hz, 1H) 7.48 (d, J=8.22 Hz, 2H) 7.65 (d, J=8.22 Hz, 2H) 7.77-7.93 (m, 3H) 8.02 (br dd, J=6.26, 1.57 Hz, 1H) 8.37 (dd, J7.43, 1.57 Hz, 1H):</p><p id="p-0670" num="0496">MS (ESI, m/z): 568.3[M+H]<sup>+</sup></p><heading id="h-0183" level="1">Example 169. amino-N-((1S,2S)-2-((3&#x2032;-hydroxy-[1,1&#x2032;-biphenyl]-3-yl)methoxy)-cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0671" num="0497">Scheme for the Preparation of the Compound of Example 169:</p><p id="p-0672" num="0000"><chemistry id="CHEM-US-00172" num="00172"><img id="EMI-C00172" he="96.27mm" wi="105.24mm" file="US20230002353A1-20230105-C00172.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0673" num="0498">Intermediate 5. To a mixture of intermediate 2 (350 mg, 1.60 mmol) and triethylamine (0.34 ml, 2.41 mmol) in 4 ml of DMF was added HATU (732 mg, 1.92 mmol) followed by (1S,2S)-2-((3-bromobenzyl)oxy)cyclopentan-1-amine (475 mg, 1.76 mmol). The mixture was stirred at room temperature for 1 hr and then saturated sodium bicarbonate solution was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude product was purified through silicagel column chromatography to give 680 mg of off-white solid.</p><p id="p-0674" num="0499"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.58-1.69 (m, 1H) 1.72-1.88 (m, 3H) 1.96-2.08 (m, 1H) 2.16 (td, J=13.35, 7.92 Hz, 1H) 3.86-4.00 (m, 3H) 4.39 (td, J=7.48, 4.40 Hz, 1H) 4.60 (q, J=12.72 Hz, 2H) 7.20 (t, J=7.92 Hz, 1H) 7.29 (d, J=7.63 Hz, 1H) 7.35 (d, J=7.63 Hz, 1H) 7.50 (s, 1H) 7.45-7.53 (m, 1H) 7.86 (s, 1H) 8.00 (s, 1H) 8.23 (d, J=2.35 Hz, 1H) 8.46 (d, J=1.76 Hz, 1H):</p><p id="p-0675" num="0500">MS (ESI, m/z): 470.1/472.1 [M+H]<sup>+</sup></p><heading id="h-0184" level="1">Example 169. 2-amino-N-((1S,2S)-2-((3&#x2032;-hydroxy-[1,1&#x2032;-biphenyl]-3-yl)-methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0676" num="0501">To a mixture of intermediate 5 (33 mg, 0.07 mmol) and (3-hydroxyphenyl)boronic acid (11 mg, 0.08 mmol) in 0.4 ml of 1,4-dioxane/water (3/1) was added K<sub>2</sub>CO<sub>3 </sub>(29 mg, 0.21 mmol) followed by Pd(PPh<sub>3</sub>)<sub>4 </sub>(4 mg, 0.003 mmol). The reaction mixture was heated at 100&#xb0; C. for 3 hrs, cooled to room temperature, and extracted with EtOAc, dried over anhydrous MgSO<sub>4 </sub>and concentrated under vacuum. The crude residue was dissolved with 0.5 ml of CH<sub>2</sub>Cl<sub>2</sub>/TFA (10/1) and the mixture was stirred for 2 hrs. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 27 mg of the title compound.</p><p id="p-0677" num="0502"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.62 (br dd, J=12.62, 6.75 Hz, 1H) 1.81 (br d, J=4.70 Hz, 3H) 2.03 (br d, J=11.74 Hz, 1H) 2.16 (br s, 1H) 3.92 (s, 3H) 3.94-4.01 (m, 1H) 4.43 (br s, 1H) 4.64-4.74 (m, 2H) 7.13 (br d, J=6.46 Hz, 2H) 7.34-7.43 (m, 3H) 7.47 (br d, J=7.63 Hz, 2H) 7.58-7.62 (m, 1H) 7.81 (s, 1H) 7.96 (s, 1H) 8.17 (br d, J=1.76 Hz, 1H) 8.36 (br d, J=2.35 Hz, 1H);</p><p id="p-0678" num="0503">MS (ESI, m/z): 484.2 [M+H]<sup>+</sup></p><heading id="h-0185" level="1">Example 170. 2-amino-N-((1S,2S)-2-((3&#x2032;-amino-[1,1&#x2032;-biphenyl]-3-yl)methoxy)-cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0679" num="0504">Using (3-aminophenyl)boronic acid, the title compound was obtained as described for the example 169.</p><p id="p-0680" num="0000"><chemistry id="CHEM-US-00173" num="00173"><img id="EMI-C00173" he="24.13mm" wi="71.29mm" file="US20230002353A1-20230105-C00173.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0681" num="0505">MS (ESI, m/z): 483.2 [M+H]<sup>+</sup></p><heading id="h-0186" level="1">Example 171. 2-amino-N-((1S,2S)-2-((3&#x2032;-(hydroxymethyl)-[1,1&#x2032;-biphenyl]-3-yl)-methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0682" num="0506">Using (3-(hydroxymethyl)phenyl)boronic acid, the title compound was obtained as described for the example 169.</p><p id="p-0683" num="0000"><chemistry id="CHEM-US-00174" num="00174"><img id="EMI-C00174" he="24.21mm" wi="75.35mm" file="US20230002353A1-20230105-C00174.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0684" num="0507">MS (ESI, m/z): 498.2 [M+H]<sup>+</sup></p><heading id="h-0187" level="1">Example 172. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0685" num="0508">Scheme for the Preparation of the Compound of Example 172:</p><p id="p-0686" num="0000"><chemistry id="CHEM-US-00175" num="00175"><img id="EMI-C00175" he="123.95mm" wi="110.57mm" file="US20230002353A1-20230105-C00175.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0687" num="0509">Intermediate 6. To a mixture of intermediate 4 (33 mg, 0.07 mmol) and (4-formylphenyl)boronic acid (12 mg, 0.08 mmol) in 0.4 ml of 1,4-dioxane/water (3/1) was added K<sub>2</sub>CO<sub>3 </sub>(29 mg, 0.21 mmol) followed by Pd(PPh<sub>3</sub>)<sub>4 </sub>(4 mg, 0.003 mmol). The reaction mixture was heated at 100&#xb0; C. for 3 hrs, cooled to room temperature, and extracted with EtOAc, dried over anhydrous MgSO<sub>4</sub>. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 30 mg of the title compound.</p><p id="p-0688" num="0510"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; ppm 1.52-1.62 (m, 1H) 1.74-1.85 (m, 3H) 1.85-1.93 (m, 1H) 1.97-2.06 (m, 1H) 2.27 (br dd, J=13.30, 5.48 Hz, 1H) 3.87 (s, 3H) 3.97-4.03 (m, 1H) 4.36-4.46 (m, 1H) 4.69 (s, 2H) 6.90 (br s, 1H) 7.12 (br s, 1H) 7.16-7.19 (m, 1H) 7.43-7.48 (m, 2H) 7.50 (s, 1H) 7.54-7.60 (m, 2H) 7.68 (m, J=8.22 Hz, 2H) 7.79 (s, 1H) 7.90 (m, J=8.22 Hz, 2H) 7.98 (s, 1H) 10.02 (s, 1H); MS (ESI, m/z): 496.2 [M+H]<sup>+</sup></p><heading id="h-0188" level="1">Example 172. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0689" num="0511">To intermediate 6 (30 mg, 0.06 mmol) in 0.4 ml of dichloroethane was added 1-methylpiperazine (12 mg, 0.12 mmol) followed by NaBH(OAc)<sub>3 </sub>(26 mg, 0.18 mmol). The mixture was stirred at room temperature for 4 hr and then water was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 27 mg of the title compound.</p><p id="p-0690" num="0512"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.52-1.67 (m, 1H) 1.69-1.86 (m, 3H) 2.01 (br dd, J=12.52, 5.87 Hz, 1H) 2.08-2.21 (m, 1H) 2.28 (s, 3H) 2.51 (br s, 8H) 3.54 (s, 2H) 3.84 (s, 3H) 3.91-3.99 (m, 1H) 4.40 (br d, J=4.70 Hz, 1H) 4.64 (br d, J=3.13 Hz, 2H) 7.34 (br d, J=7.83 Hz, 2H) 7.39 (br d, J=8.22 Hz, 2H) 7.47 (br d, J=7.83 Hz, 1H) 7.50 (br d, J=7.83 Hz, 2H) 7.73 (s, 1H) 7.81 (s, 1H) 7.96 (s, 1H) 8.23 (s, 1H);</p><p id="p-0691" num="0513">MS (ESI, m/z): 580.3 [M+H]<sup>+</sup></p><heading id="h-0189" level="1">Example 173. 2-amino-N-((1S,2S)-2-((4&#x2032;-(((2-hydroxyethyl)amino)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0692" num="0514">Using 2-aminoethan-1-ol, the title compound was obtained as described for the example 172.</p><p id="p-0693" num="0000"><chemistry id="CHEM-US-00176" num="00176"><img id="EMI-C00176" he="30.06mm" wi="74.85mm" file="US20230002353A1-20230105-C00176.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0694" num="0515"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.59-1.69 (m, 1H) 1.74-1.88 (m, 3H) 1.99-2.11 (m, 1H) 2.18 (td, J=12.91, 7.04 Hz, 1H) 3.11-3.12 (m, 1H) 3.11-3.16 (m, 1H) 3.77-3.86 (m, 2H) 3.90 (s, 3H) 3.93 (br d, J=5.87 Hz, 1H) 3.97-4.05 (m, 1H) 4.26 (s, 2H) 4.39-4.48 (m, 1H) 4.67 (s, 2H) 7.44 (d, J=8.22 Hz, 2H) 7.53 (m, J=8.22 Hz, 2H) 7.55-7.62 (m, 2H) 7.66 (d, J=8.22 Hz, 2H) 7.85 (s, 1H) 7.97 (s, 1H) 8.20 (s, 1H) 8.49 (br s, 1H);</p><p id="p-0695" num="0516">MS (ESI, m/z): 541.3 [M+H]<sup>+</sup></p><heading id="h-0190" level="1">Example 174. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(morpholinomethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0696" num="0517">Using morpholine, the title compound was obtained as described for the example 172.</p><p id="p-0697" num="0000"><chemistry id="CHEM-US-00177" num="00177"><img id="EMI-C00177" he="29.46mm" wi="73.15mm" file="US20230002353A1-20230105-C00177.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0698" num="0518"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.57-1.69 (m, 1H) 1.74-1.90 (m, 3H) 2.04 (s, 1H) 2.14-2.23 (m, 1H) 2.19 (br d, J=7.63 Hz, 1H) 3.31-3.46 (m, 2H) 3.90 (s, 3H) 3.99-4.03 (m, 1H) 4.39 (s, 2H) 4.42 (br d, J=5.28 Hz, 1H) 4.67 (d, J=3.52 Hz, 2H) 7.45 (d, J=8.22 Hz, 2H) 7.56 (d, J=8.22 Hz, 2H) 7.59 (d, J=8.22 Hz, 2H) 7.71 (d, J=7.63 Hz, 2H) 7.85 (s, 1H) 7.98 (s, 1H) 8.21 (d, J=1.76 Hz, 1H) 8.49 (br s, 1H);</p><p id="p-0699" num="0519">MS (ESI, m/z): 567.3 [M+H]<sup>+</sup></p><heading id="h-0191" level="1">Example 175. 2-amino-N-((1S,2S)-2-((4&#x2032;-((3,3-difluoropiperidin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0700" num="0520">Using 3,3-difluoropiperidine, the title compound was obtained as described for the example 172.</p><p id="p-0701" num="0000"><chemistry id="CHEM-US-00178" num="00178"><img id="EMI-C00178" he="29.46mm" wi="74.59mm" file="US20230002353A1-20230105-C00178.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0702" num="0521">MS (ESI, m/z): 601.3 [M+H]<sup>+</sup></p><heading id="h-0192" level="1">Example 176. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperidin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0703" num="0522">Using 4-methylpiperidine, the title compound was obtained as described for the example 172.</p><p id="p-0704" num="0000"><chemistry id="CHEM-US-00179" num="00179"><img id="EMI-C00179" he="28.28mm" wi="73.15mm" file="US20230002353A1-20230105-C00179.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0705" num="0523">MS (ESI, m/z): 579.3 [M+H]<sup>+</sup></p><heading id="h-0193" level="1">Example 177. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(piperazin-1-ylmethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0706" num="0524">Using piperazine, the title compound was obtained as described for the example 172.</p><p id="p-0707" num="0000"><chemistry id="CHEM-US-00180" num="00180"><img id="EMI-C00180" he="29.46mm" wi="74.93mm" file="US20230002353A1-20230105-C00180.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0708" num="0525"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.63 (br dd, J=13.50, 7.04 Hz, 1H) 1.73-1.88 (m, 3H) 2.00-2.08 (m, 1H) 2.13-2.22 (m, 1H) 2.96 (br s, 4H) 3.32 (br d, J=9.98 Hz, 4H) 3.50 (s, 1H) 3.84-3.89 (m, 2H) 3.90 (s, 3H) 4.00 (br s, 1H) 4.38-4.44 (m, 1H) 4.66 (d, J=2.93 Hz, 2H) 7.38-7.47 (m, 4H) 7.52-7.60 (m, 4H) 7.85 (s, 1H) 7.97 (s, 1H) 8.19 (d, J=2.35 Hz, 1H) 8.50 (d, J=2.35 Hz, 1H);</p><p id="p-0709" num="0526">MS (ESI, m/z): 566.3 [M+H]<sup>+</sup></p><heading id="h-0194" level="1">Example 178. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-phenylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0710" num="0527">Using 1-phenylpiperazine, the title compound was obtained as described for the example 172.</p><p id="p-0711" num="0000"><chemistry id="CHEM-US-00181" num="00181"><img id="EMI-C00181" he="39.03mm" wi="112.44mm" file="US20230002353A1-20230105-C00181.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0712" num="0528"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.61-1.69 (m, 1H) 1.76-1.87 (m, 3H) 2.00-2.07 (m, 1H) 2.15-2.23 (m, 1H) 3.90 (s, 3H) 3.98-4.04 (m, 1H) 4.39-4.44 (m, 1H) 4.45 (s, 2H) 4.68 (s, 2H) 6.92 (t, J=7.34 Hz, 1H) 7.00 (d, J=8.22 Hz, 2H) 7.27 (t, J=7.92 Hz, 2H) 7.45 (d, J=8.22 Hz, 2H) 7.60 (dd, J=9.68, 8.51 Hz, 4H) 7.72 (br d, J=8.22 Hz, 2H) 7.85 (s, 1H) 7.98 (s, 1H) 8.21 (d, J=1.76 Hz, 1H) 8.51 (d, J=1.76 Hz, 1H);</p><p id="p-0713" num="0529">MS (ESI, m/z): 642.4 [M+H]<sup>+</sup></p><heading id="h-0195" level="1">Example 179. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-(pyrrolidin-1-yl)piperidin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-nicotinamide</heading><p id="p-0714" num="0530">Using 4-(pyrrolidin-1-yl)piperidine, the title compound was obtained as described for the example 172.</p><p id="p-0715" num="0000"><chemistry id="CHEM-US-00182" num="00182"><img id="EMI-C00182" he="39.03mm" wi="110.83mm" file="US20230002353A1-20230105-C00182.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0716" num="0531"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.60-1.69 (m, 1H) 1.74-1.88 (m, 3H) 1.96-2.23 (m, 8H) 2.43 (br d, J=13.50 Hz, 2H) 3.06-3.21 (m, 4H) 3.44 (br s, 2H) 3.66 (br d, J=12.91 Hz, 4H) 3.90 (s, 3H) 3.99-4.03 (m, 1H) 4.37 (s, 2H) 4.39-4.45 (m, 1H) 4.67 (s, 2H) 7.41-7.48 (m, 2H) 7.51-7.57 (m, 2H) 7.58 (d, J=8.22 Hz, 2H) 7.68 (br d, J=8.22 Hz, 2H) 7.85 (s, 1H) 7.98 (s, 1H) 8.20 (d, J=2.35 Hz, 1H) 8.50 (d, J=1.76 Hz, 1H);</p><p id="p-0717" num="0532">MS (ESI, m/z): 634.4 [M+H]<sup>+</sup></p><heading id="h-0196" level="1">Example 180. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-hydroxypiperidin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0718" num="0533">Using piperidin-4-ol, the title compound was obtained as described for the example 172.</p><p id="p-0719" num="0000"><chemistry id="CHEM-US-00183" num="00183"><img id="EMI-C00183" he="39.03mm" wi="104.31mm" file="US20230002353A1-20230105-C00183.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0720" num="0534"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.59-1.68 (m, 1H) 1.74-1.87 (m, 3H) 1.92 (br s, 1H) 2.03 (dt, J=13.35, 6.53 Hz, 1H) 2.10-2.23 (m, 1H) 3.07 (br s, 1H) 3.51 (br d, J=10.56 Hz, 1H) 3.82 (br s, 1H) 3.89-3.92 (m, 3H) 3.98-4.03 (m, 1H) 4.08 (br s, 1H) 4.34 (br s, 2H) 4.39-4.45 (m, 1H) 4.67 (s, 2H) 7.45 (d, J=8.22 Hz, 2H) 7.54 (br s, 2H) 7.57-7.61 (m, 2H) 7.59 (d, J=8.22 Hz, 2H) 7.69 (br d, J=8.22 Hz, 2H) 7.85 (s, 1H) 7.99 (s, 1H) 8.21 (s, 1H) 8.52 (d, J=1.76 Hz, 1H);</p><p id="p-0721" num="0535">MS (ESI, m/z): 581.3 [M+H]<sup>+</sup></p><heading id="h-0197" level="1">Example 181. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)-methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-0722" num="0536">Using 2-(piperazin-1-yl)ethan-1-ol, the title compound was obtained as described for the example 172.</p><p id="p-0723" num="0000"><chemistry id="CHEM-US-00184" num="00184"><img id="EMI-C00184" he="39.03mm" wi="113.88mm" file="US20230002353A1-20230105-C00184.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0724" num="0537"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.64 (br dd, J=13.50, 7.04 Hz, 1H) 1.76-1.86 (m, 3H) 2.00-2.08 (m, 1H) 2.14-2.22 (m, 1H) 3.19 (br s, 2H) 3.82-3.85 (m, 2H) 3.90 (s, 3H) 3.98-4.02 (m, 1H) 4.39-4.44 (m, 1H) 4.66 (s, 2H) 7.40-7.47 (m, 4H) 7.53-7.61 (m, 4H) 7.85 (s, 1H) 7.97 (s, 1H) 8.20 (d, J=2.35 Hz, 1H) 8.52 (d, J=2.35 Hz, 1H);</p><p id="p-0725" num="0538">MS (ESI, m/z): 610.3 [M+H]<sup>+</sup></p><heading id="h-0198" level="1">Example 182. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-(2-hydroxy-2-methylpropyl)-piperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0726" num="0539">Using 2-methyl-1-(piperazin-1-yl)propan-2-ol, the title compound was obtained as described for the example 172.</p><p id="p-0727" num="0000"><chemistry id="CHEM-US-00185" num="00185"><img id="EMI-C00185" he="39.03mm" wi="113.88mm" file="US20230002353A1-20230105-C00185.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0728" num="0540">MS (ESI, m/z): 638.4 [M+H]<sup>+</sup></p><heading id="h-0199" level="1">Example 183. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-ethylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0729" num="0541">Using 1-ethylpiperazine, the title compound was obtained as described for the example 172.</p><p id="p-0730" num="0000"><chemistry id="CHEM-US-00186" num="00186"><img id="EMI-C00186" he="39.71mm" wi="105.92mm" file="US20230002353A1-20230105-C00186.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0731" num="0542"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.32 (t, J=7.34 Hz, 3H) 1.59-1.68 (m, 1H) 1.74-1.88 (m, 3H) 2.04 (dq, J=13.50, 6.85 Hz, 1H) 2.13-2.21 (m, 1H) 3.18 (br d, J=7.63 Hz, 2H) 3.78-3.87 (m, 2H) 3.90 (s, 3H) 3.98-4.02 (m, 1H) 4.38-4.44 (m, 1H) 4.66 (d, =1.76 Hz, 2H) 7.38-7.46 (m, 4H) 7.51-7.60 (m, 4H) 7.85 (s, 1H) 7.97 (s, 1H) 8.19 (d, J=2.35 Hz, 1H) 8.51 (d, J=2.35 Hz, 1H); MS (ESI, m/z): 594.4 [M+H]<sup>+</sup></p><heading id="h-0200" level="1">Example 184. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-cyclopronylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0732" num="0543">Using 1-cyclopropylpiperazine, the title compound was obtained as described for the example 172.</p><p id="p-0733" num="0000"><chemistry id="CHEM-US-00187" num="00187"><img id="EMI-C00187" he="39.71mm" wi="107.27mm" file="US20230002353A1-20230105-C00187.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0734" num="0544">MS (ESI, m/z): 606.4 [M+H]<sup>+</sup></p><heading id="h-0201" level="1">Example 185. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(((R)-3-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0735" num="0545">Using tert-butyl(R)-2-methylpiperazine-1-carboxylate, the title compound was obtained as described for the example 172 and following deprotection with TFA.</p><p id="p-0736" num="0000"><chemistry id="CHEM-US-00188" num="00188"><img id="EMI-C00188" he="29.97mm" wi="74.93mm" file="US20230002353A1-20230105-C00188.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0737" num="0546">MS (ESI, m/z): 580.3 [M+H]<sup>+</sup></p><heading id="h-0202" level="1">Example 186. 2-amino-N-((1S,2S)-2-((4&#x2032;-(((R)-3,4-dimethylpiperazin-1-yl)-methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-0738" num="0547">Using (R)-1,2-dimethylpiperazine, the title compound was obtained as described for the example 172.</p><p id="p-0739" num="0000"><chemistry id="CHEM-US-00189" num="00189"><img id="EMI-C00189" he="29.38mm" wi="74.68mm" file="US20230002353A1-20230105-C00189.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0740" num="0548">MS (ESI, m/z): 594.4 [M+H]<sup>+</sup></p><heading id="h-0203" level="1">Example 187. 2-amino-N-((1S,2S)-2-((4&#x2032;-(((R)-2,4-dimethylpiperazin-1-yl)-methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1l-pyrazol-4-yl)-nicotinamide</heading><p id="p-0741" num="0549">Using (R)-1,3-dimethylpiperazine, the title compound was obtained as described for the example 172.</p><p id="p-0742" num="0000"><chemistry id="CHEM-US-00190" num="00190"><img id="EMI-C00190" he="33.44mm" wi="74.68mm" file="US20230002353A1-20230105-C00190.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0743" num="0550"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.34 (br d, J=5.09 Hz, 3H) 1.63 (br dd, J=15.06, 6.46 Hz, 1H) 1.81 (br d, J=7.43 Hz, 3H) 2.03 (br d, J=6.26 Hz, 1H) 2.18 (s, 1H) 2.55 (br s, 1H) 2.82 (s, 3H) 2.92 (br s, 1H) 3.02 (br d, J=12.52 Hz, 1H) 3.89 (s, 3H) 4.00 (br s, 1H) 4.30 (br d, J=11.35 Hz, 1H) 4.42 (br s, 1H) 4.65 (s, 2H) 7.41 (br d, J=7.43 Hz, 4H) 7.54 (br dd, J=7.63, 3.33 Hz, 4H) 7.84 (s, 1H) 7.96 (s, 1H) 8.19 (s, 1H) 8.50 (s, 1H);</p><p id="p-0744" num="0551">MS (ESI, m/z): 594.4 [M+H]<sup>+</sup></p><heading id="h-0204" level="1">Example 188. 2-amino-N-((1S,2S)-2-((4&#x2032;-((3-ethyl-4-methylpiperazin-1-yl)-methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-0745" num="0552">Using 2-ethyl-1-methylpiperazine, the title compound was obtained as described for the example 172.</p><p id="p-0746" num="0000"><chemistry id="CHEM-US-00191" num="00191"><img id="EMI-C00191" he="29.38mm" wi="74.68mm" file="US20230002353A1-20230105-C00191.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0747" num="0553"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 0.96 (br t, J=7.24 Hz, 3H) 1.62 (br d, J=14.48 Hz, 3H) 1.81 (br d, J=7.43 Hz, 3H) 1.92 (br s, 1H) 2.04 (br s, 1H) 2.16 (br d, J=7.04 Hz, 1H) 2.87 (s, 3H) 3.20 (br d, J=14.09 Hz, 1H) 3.45 (br d, J=13.30 Hz, 1H) 3.70 (br d, J=13.30 Hz, 1H) 3.81 (br d, J=12.91 Hz, 1H) 3.89 (s, 3H) 3.99 (br s, 1H) 4.42 (br s, 1H) 4.65 (s, 2H) 7.41 (br d, J=8.22 Hz, 4H) 7.55 (br d, J=7.43 Hz, 4H) 7.85 (s, 1H) 7.97 (s, 1H) 8.19 (s, 1H) 8.51 (s, 1H);</p><p id="p-0748" num="0554">MS (ESI, m/z): 608.4 [M+H]<sup>+</sup></p><heading id="h-0205" level="1">Example 189. 2-amino-N-((1S,2S)-2-((4&#x2032;-((cis-3,5-dimethylpiperazin-1-yl)-methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-0749" num="0555">Using tert-butyl cis-2,6-dimethylpiperazine-1-carboxylate, the title compound was obtained as described for the example 172 and following deprotection with TFA.</p><p id="p-0750" num="0000"><chemistry id="CHEM-US-00192" num="00192"><img id="EMI-C00192" he="31.67mm" wi="74.93mm" file="US20230002353A1-20230105-C00192.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0751" num="0556"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.27 (br d, J=6.26 Hz, 6H) 1.64 (br d, J=5.87 Hz, 1H) 1.81 (br d, J=7.04 Hz, 3H) 1.96-2.24 (m, 3H) 3.09 (d, J=12.91 Hz, 2H) 3.62 (br s, 5H) 3.68 (s, 3H) 3.89 (s, 3H) 4.00 (br s, 1H) 4.37-4.45 (m, 1H) 4.65 (s, 2H) 7.34-7.46 (m, 4H) 7.53 (br d, J=7.43 Hz, 4H) 7.83 (s, 1H) 7.95 (s, 1H) 8.20 (s, 1H) 8.45 (s, 1H);</p><p id="p-0752" num="0557">MS (ESI, m/z): 594.4 [M+H]<sup>+</sup></p><heading id="h-0206" level="1">Example 190. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((cis-3,4,5-trimethylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-nicotinamide</heading><p id="p-0753" num="0558">Using cis-1,2,6-trimethylpiperazine, the title compound was obtained as described for the example 172.</p><p id="p-0754" num="0000"><chemistry id="CHEM-US-00193" num="00193"><img id="EMI-C00193" he="31.07mm" wi="74.68mm" file="US20230002353A1-20230105-C00193.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0755" num="0559"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.30 (br d, J=6.46 Hz, 6H) 1.64 (br dd, J=13.50, 7.04 Hz, 1H) 1.74-1.90 (m, 3H) 2.00-2.09 (m, 1H) 2.18 (br dd, J=12.91, 5.87 Hz, 1H) 2.30 (br d, J=12.91 Hz, 3H) 3.22 (br s, 3H) 3.45 (br s, 2H) 3.84 (br d, J=19.37 Hz, 2H) 3.90 (s, 3H) 3.97-4.03 (m, 1H) 4.38-4.45 (m, 1H) 4.66 (s, 2H) 4.69 (s, 1H) 7.42 (br d, J=7.63 Hz, 4H) 7.49-7.62 (m, 4H) 7.85 (s, 1H) 7.97 (s, 1H) 8.20 (d, J=2.35 Hz, 1H) 8.52 (d, J=1.76 Hz, 1H);</p><p id="p-0756" num="0560">MS (ESI, m/z): 608.4 [M+H]<sup>+</sup></p><heading id="h-0207" level="1">Example 191. 2-amino-N-((1S,2S)-2-((4&#x2032;-((trans-2,5-dimethylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0757" num="0561">Using trans-2,5-dimethylpiperazine, the title compound was obtained as described for the example 172.</p><p id="p-0758" num="0000"><chemistry id="CHEM-US-00194" num="00194"><img id="EMI-C00194" he="31.67mm" wi="74.93mm" file="US20230002353A1-20230105-C00194.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0759" num="0562">MS (ESI, m/z): 594.4 [M+H]<sup>+</sup></p><heading id="h-0208" level="1">Example 192. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(((2R,5S)-2,4,5-trimethylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0760" num="0563">Using trans-1,2,5-trimethylpiperazine, the title compound was obtained as described for the example 172.</p><p id="p-0761" num="0000"><chemistry id="CHEM-US-00195" num="00195"><img id="EMI-C00195" he="31.07mm" wi="74.68mm" file="US20230002353A1-20230105-C00195.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0762" num="0564">MS (ESI, m/z): 608.4 [M+H]<sup>+</sup></p><heading id="h-0209" level="1">Example 193. 2-amino-N-((1S,2S)-2-((4&#x2032;-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0763" num="0565">Using N,N-Dimethyl-3-pyrrolidinamine, the title compound was obtained as described for the example 172.</p><p id="p-0764" num="0000"><chemistry id="CHEM-US-00196" num="00196"><img id="EMI-C00196" he="43.10mm" wi="104.31mm" file="US20230002353A1-20230105-C00196.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0765" num="0566">MS (ESI, m/z): 594.4 [M+H]<sup>+</sup></p><heading id="h-0210" level="1">Example 194. 3-amino-6-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)pyrazine-2-carboxamide</heading><p id="p-0766" num="0567">Using 3-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxylic acid, the title compound was obtained as described for the example 172.</p><p id="p-0767" num="0000"><chemistry id="CHEM-US-00197" num="00197"><img id="EMI-C00197" he="29.38mm" wi="74.68mm" file="US20230002353A1-20230105-C00197.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0768" num="0568"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.60-1.69 (m, 1H) 1.70-1.78 (m, 1H) 1.78-1.87 (m, 2H) 2.03-2.20 (m, 3H) 2.88 (d, J=1.76 Hz, 3H) 3.00 (br s, 4H) 3.34 (br d, J=11.74 Hz, 3H) 3.85 (s, 3H) 3.91 (br d, J=11.74 Hz, 2H) 3.99-4.06 (m, 1H) 4.33-4.40 (m, 1H) 4.59-4.70 (m, 2H) 7.38 (d, J=8.22 Hz, 2H) 7.42 (br d, J=8.22 Hz, 2H) 7.47 (d, J=8.22 Hz, 2H) 7.52 (br d, J=8.22 Hz, 2H) 7.99 (s, 1H) 8.12 (s, 1H) 8.41 (s, 1H);</p><p id="p-0769" num="0569">MS (ESI, m/z): 581.3 [M+H]<sup>+</sup></p><heading id="h-0211" level="1">Example 195. 2-amino-N-((1S,2S)-2-((3&#x2032;-fluoro-4&#x2032;-((4-methylpiperazin-1-yl)-methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-0770" num="0570">Using (3-fluoro-4-formylphenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 172.</p><p id="p-0771" num="0000"><chemistry id="CHEM-US-00198" num="00198"><img id="EMI-C00198" he="31.16mm" wi="74.68mm" file="US20230002353A1-20230105-C00198.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0772" num="0571"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.63 (br dd, J=13.69, 7.04 Hz, 1H) 1.72-1.90 (m, 3H) 1.96-2.09 (m, 1H) 2.10-2.23 (m, 1H) 2.90 (s, 3H) 3.05-3.27 (m, 4H) 3.34-3.51 (m, 4H) 3.89 (s, 3H) 3.94-4.01 (m, 1H) 4.07 (s, 2H) 4.34-4.47 (m, 1H) 4.60-4.73 (m, 2H) 5.47 (s, 1H) 7.35 (br d, J=11.35 Hz, 1H) 7.42 (br d, J=7.83 Hz, 3H) 7.50 (br t, J=7.83 Hz, 1H) 7.55 (d, J=8.22 Hz, 2H) 7.83 (s, 1H) 7.97 (s, 1H) 8.17 (d, J=1.96 Hz, 1H) 8.50 (d, J=1.96 Hz, 1H);</p><p id="p-0773" num="0572">MS (ESI, m/z): 598.7 [M+H]<sup>+</sup></p><heading id="h-0212" level="1">Example 196. 2-amino-N-((1S,2S)-2-((3&#x2032;,5&#x2032;-difluoro-4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0774" num="0573">Using ((3,5-difluoro-4-formylphenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 172.</p><p id="p-0775" num="0000"><chemistry id="CHEM-US-00199" num="00199"><img id="EMI-C00199" he="31.24mm" wi="74.68mm" file="US20230002353A1-20230105-C00199.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0776" num="0574"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.63 (br dd, J=13.30, 7.04 Hz, 1H) 1.71-1.91 (m, 3H) 2.03 (br dd, J=12.91, 5.48 Hz, 1H) 2.12-2.23 (m, 1H) 2.87 (s, 3H) 2.94 (br d, J=18.00 Hz, 3H) 3.32 (br s, 4H) 3.90 (s, 3H) 3.99 (br s, 1H) 4.40 (br d, J=3.91 Hz, 1H) 4.62-4.77 (m, 2H) 7.24 (br d, J=8.61 Hz, 2H) 7.44 (m, J=7.83 Hz, 2H) 7.57 (m, J=7.83 Hz, 2H) 7.83 (s, 1H) 7.98 (s, 1H) 8.19 (s, 1H) 8.50 (s, 1H);</p><p id="p-0777" num="0575">MS (ESI m/z): 616.8 [M+H]<sup>+</sup></p><heading id="h-0213" level="1">Example 197. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)-cyclopentyl)nicotinamide</heading><p id="p-0778" num="0576">Using (4-formyl-3-(trifluoromethyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 172.</p><p id="p-0779" num="0000"><chemistry id="CHEM-US-00200" num="00200"><img id="EMI-C00200" he="31.83mm" wi="74.68mm" file="US20230002353A1-20230105-C00200.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0780" num="0577"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.59-1.71 (m, 1H) 1.75-1.89 (m, 3H) 1.99-2.10 (m, 1H) 2.13-2.25 (m, 1H) 2.91 (s, 3H) 3.47 (br d, J=1.57 Hz, 2H) 3.81 (s, 2H) 3.91 (s, 3H) 4.02 (br d, J=4.30 Hz, 1H) 4.39-4.46 (m, 1H) 4.69 (s, 2H) 7.47 (m, J=8.22 Hz, 2H) 7.60 (m, J=8.22 Hz, 2H) 7.83 (d, J=8.22 Hz, 4H) 7.98 (s, 1H) 8.21 (d, J=1.96 Hz, 1H) 8.50 (d, J=2.35 Hz, 1H);</p><p id="p-0781" num="0578">MS (ESI, m/z): 648.32 [M+H]<sup>+</sup></p><heading id="h-0214" level="1">Example 198. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3&#x2032;-methyl-4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-nicotinamide</heading><p id="p-0782" num="0579">Using (4-formyl-3-methylphenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 172.</p><p id="p-0783" num="0000"><chemistry id="CHEM-US-00201" num="00201"><img id="EMI-C00201" he="46.23mm" wi="103.55mm" file="US20230002353A1-20230105-C00201.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0784" num="0580"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.64 (br dd, J=13.11, 6.85 Hz, 2H) 1.72-1.90 (m, 3H) 1.82 (br s, 1H) 1.94-2.09 (m, 2H) 2.10-2.24 (m, 2H) 2.43 (s, 1H) 2.88 (s, 3H) 3.29-3.31 (m, 1H) 3.69 (s, 1H) 3.90 (s, 2H) 3.93-3.96 (m, 1H) 4.01 (br d, J=4.70 Hz, 1H) 4.16 (s, 1H) 4.37-4.47 (m, 1H) 4.66 (d, J=3.13 Hz, 1H) 7.37-7.43 (m, 2H) 7.51-7.55 (m, 1H) 7.52-7.59 (m, 1H) 7.85 (d, J=0.78 Hz, 1H) 7.96 (s, 1H) 8.19 (d, J=1.96 Hz, 1H) 8.49 (d, J=2.35 Hz, 1H);</p><p id="p-0785" num="0581">MS (ESI, m/z): 594.4 [M+H]<sup>+</sup></p><heading id="h-0215" level="1">Example 199. 2-amino-N-((1S,2S)-2-((3&#x2032;-hydroxy-4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0786" num="0582">Using (4-formyl-3-hydroxyphenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 172.</p><p id="p-0787" num="0000"><chemistry id="CHEM-US-00202" num="00202"><img id="EMI-C00202" he="47.07mm" wi="103.55mm" file="US20230002353A1-20230105-C00202.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0788" num="0583"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.64 (br dd, J=12.72, 6.85 Hz, 1H) 1.74-1.90 (m, 3H) 2.05 (br s, 1H) 2.12-2.26 (m, 1H) 2.82 (d, J=3.13 Hz, 3H) 3.13 (br s, 5H) 3.91 (s, 3H) 4.01 (br d, J=6.26 Hz, 1H) 4.05 (s, 1H) 4.08 (s, 1H) 4.38-4.46 (m, 1H) 4.66 (s, 2H) 7.05 (s, 1H) 7.28 (br d, J=8.61 Hz, 1H) 7.25-7.34 (m, 1H) 7.32 (br d, J=7.83 Hz, 1H) 7.41 (d, J=8.22 Hz, 2H) 7.52 (d, J=8.22 Hz, 2H) 7.54-7.59 (m, 1H) 7.85 (s, 1H) 7.97 (s, 1H) 8.20 (d, J=2.35 Hz, 1H) 8.48 (d, J=2.35 Hz, 1H);</p><p id="p-0789" num="0584">MS (ESI, m/z): 596.3 [M+H]<sup>+</sup></p><heading id="h-0216" level="1">Example 200. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-3&#x2032;-nitro-[1,1&#x2032;-biphenyl]-4-yl)methoxy-cyclopentyl)nicotinamide</heading><p id="p-0790" num="0585">Using (4-formyl-3-nitrophenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 172.</p><p id="p-0791" num="0000"><chemistry id="CHEM-US-00203" num="00203"><img id="EMI-C00203" he="47.67mm" wi="103.55mm" file="US20230002353A1-20230105-C00203.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0792" num="0586"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.64 (dt, J=13.89, 7.14 Hz, 1H) 1.74-1.91 (m, 3H) 2.00-2.10 (m, 1H) 2.13-2.24 (m, 1H) 2.88 (s, 3H) 3.35-3.39 (m, 2H) 3.91 (s, 3H) 3.92-3.95 (m, 2H) 3.99-4.03 (m, 1H) 4.39-4.47 (m, 1H) 4.69 (d, J=3.13 Hz, 2H) 7.48 (d, J=8.22 Hz, 2H) 7.60-7.65 (m, 4H) 7.83 (s, 1H) 7.97 (s, 1H) 8.02 (d, J=1.96 Hz, 1H) 8.21 (d, J=2.35 Hz, 1H) 8.48 (d, J=2.35 Hz, 1H);</p><p id="p-0793" num="0587">MS (ESI, m/z): 625.3 [M+H]<sup>+</sup></p><heading id="h-0217" level="1">Example 201. 2-amino-N-((1S,2S)-2-((3&#x2032;-methoxy-4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0794" num="0588">Using (4-formyl-3-methoxyphenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 172.</p><p id="p-0795" num="0000"><chemistry id="CHEM-US-00204" num="00204"><img id="EMI-C00204" he="50.38mm" wi="103.46mm" file="US20230002353A1-20230105-C00204.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0796" num="0589"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.65 (br dd, J=13.50, 6.46 Hz, 1H) 1.74-1.91 (m, 3H) 1.99-2.10 (m, 1H) 2.19 (br d, J=6.65 Hz, 1H) 2.81 (s, 3H) 3.91 (s, 3H) 3.92 (s, 3H) 3.98-4.07 (m, 1H) 4.43 (br d, J=3.52 Hz, 1H) 4.68 (s, 2H) 7.15-7.24 (m, 2H) 7.37-7.47 (m, 3H) 7.59 (d, J=8.22 Hz, 2H) 7.86 (s, 1H) 7.98 (s, 1H) 8.21 (d, J=1.96 Hz, 1H) 8.51 (d, J=2.35 Hz, 1H);</p><p id="p-0797" num="0590">MS (ESI, m/z): 610.3 [M+H]<sup>+</sup></p><heading id="h-0218" level="1">Example 202. 2-amino-N-((1S,2S)-2-((2&#x2032;-chloro-4&#x2032;-((4-methylpiperazin-1-yl)-methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-0798" num="0591">Using (2-chloro-4-formylphenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 172.</p><p id="p-0799" num="0000"><chemistry id="CHEM-US-00205" num="00205"><img id="EMI-C00205" he="45.64mm" wi="103.46mm" file="US20230002353A1-20230105-C00205.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0800" num="0592">MS (ESI, m/z): 614.3 [M+H]<sup>+</sup></p><heading id="h-0219" level="1">Example 203. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(6-((4-methylpiperazin-1-yl)methyl)pyridin-3-yl)benzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0801" num="0593">Using ((6-formylpyridin-3-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 172.</p><p id="p-0802" num="0000"><chemistry id="CHEM-US-00206" num="00206"><img id="EMI-C00206" he="45.72mm" wi="103.46mm" file="US20230002353A1-20230105-C00206.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0803" num="0594"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.65 (dt, J=13.60, 7.09 Hz, 1H) 1.74-1.90 (m, 3H) 2.05 (br dd, J=13.11, 6.46 Hz, 1H) 2.13-2.26 (m, 1H) 2.90 (s, 3H) 3.91-3.94 (m, 3H) 3.99-4.06 (m, 1H) 4.43 (br dd, J=11.93, 6.85 Hz, 1H) 7.52 (d, J=8.22 Hz, 2H) 7.64-7.68 (m, 2H) 7.72 (br dd, J=12.33, 8.41 Hz, 2H) 7.85 (s, 1H) 7.99 (s, 1H) 8.22 (d, J=2.35 Hz, 1H) 8.51 (d, J=1.96 Hz, 1H) 8.82 (d, J=2.35 Hz, 1H);</p><p id="p-0804" num="0595">MS (ESI, m/z): 581.3 [M+H]<sup>+</sup></p><heading id="h-0220" level="1">Example 204. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(5-((4-methylpiperazin-1-yl)methyl)pyridin-2-yl)benzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-0805" num="0596">Using (5-formylpyridin-2-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 172.</p><p id="p-0806" num="0000"><chemistry id="CHEM-US-00207" num="00207"><img id="EMI-C00207" he="45.64mm" wi="103.46mm" file="US20230002353A1-20230105-C00207.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0807" num="0597"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.66 (td, J=14.09, 7.04 Hz, 1H) 1.76-1.92 (m, 3H) 1.98-2.11 (m, 1H) 2.19 (br s, 1H) 2.90 (s, 3H) 3.64 (s, 1H) 3.76 (s, 3H) 3.98-4.07 (m, 1H) 4.38-4.48 (m, 1H) 7.52 (d, J=8.22 Hz, 2H) 7.84 (s, 1H) 7.90 (dd, J=8.41, 1.76 Hz, 3H) 7.98 (s, 1H) 8.02 (br d, J=8.61 Hz, 1H) 8.21 (d, J=1.96 Hz, 1H) 8.50 (d, J=1.96 Hz, 1H) 8.60 (s, 1H);</p><p id="p-0808" num="0598">MS (ESI, m/z): 581.3 [M+H]<sup>+</sup></p><heading id="h-0221" level="1">Example 205. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0809" num="0599">Using (4-formyl-3-(trifluoromethyl)phenyl)boronic acid pinacol ester and 2-(piperazin-1-yl)ethan-1-ol, the title compound was obtained as described for the example 172.</p><p id="p-0810" num="0000"><chemistry id="CHEM-US-00208" num="00208"><img id="EMI-C00208" he="47.84mm" wi="115.65mm" file="US20230002353A1-20230105-C00208.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0811" num="0600"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.57-1.72 (m, 1H) 1.75-1.90 (m, 3H) 2.04 (dt, J=12.81, 6.70 Hz, 1H) 2.13-2.26 (m, 1H) 3.82 (s, 2H) 3.86-3.90 (m, 2H) 3.91 (s, 3H) 3.97-4.05 (m, 1H) 4.43 (br dd, J=11.93, 6.46 Hz, 1H) 4.69 (s, 2H) 7.48 (d, J=8.22 Hz, 2H) 7.60 (d, J=8.22 Hz, 2H) 7.81-7.87 (m, 3H) 7.99 (s, 1H) 8.22 (d, J=2.35 Hz, 1H) 8.51 (d, J=1.96 Hz, 1H);</p><p id="p-0812" num="0601">MS (ESI, m/z): 678.3[M+H]<sup>+</sup></p><heading id="h-0222" level="1">Example 206. 2-amino-N-((1S,2S)-2-((2&#x2032;-chloro-4&#x2032;-((4-(2-hydroxyethyl)-piperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0813" num="0602">Using (2-chloro-4-formylphenyl)boronic acid pinacol ester and 2-(piperazin-1-yl)ethan-1-ol, the title compound was obtained as described for the example 172.</p><p id="p-0814" num="0000"><chemistry id="CHEM-US-00209" num="00209"><img id="EMI-C00209" he="45.72mm" wi="115.65mm" file="US20230002353A1-20230105-C00209.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0815" num="0603">MS (ESI, m/z): 644.3 [M+H]<sup>+</sup></p><heading id="h-0223" level="1">Example 207. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methy-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0816" num="0604">Using 2-aminonicotinic acid and (4-formyl-3-(trifluoromethyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 172.</p><p id="p-0817" num="0000"><chemistry id="CHEM-US-00210" num="00210"><img id="EMI-C00210" he="43.01mm" wi="74.93mm" file="US20230002353A1-20230105-C00210.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0818" num="0605"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.53-1.69 (m, 1H) 1.76-1.89 (m, 3H) 2.01 (s, 1H) 2.18 (br dd, J=13.30, 5.87 Hz, 1H) 2.48 (br s, 2H) 2.91 (s, 3H) 3.82 (s, 2H) 3.99 (br d, J=4.30 Hz, 1H) 4.40 (br d, J=5.09 Hz, 1H) 4.68 (d, J=4.30 Hz, 2H) 6.95 (dd, J=7.43, 6.26 Hz, 1H) 7.47 (d, J=8.22 Hz, 2H) 7.62 (d, J=8.22 Hz, 2H) 7.84-7.92 (m, 3H) 7.98-8.05 (m, 1H) 8.32 (dd, J=7.43, 1.56 Hz, 1H);</p><p id="p-0819" num="0606">MS (ESI, m/z): 568.3 [M+H]<sup>+</sup></p><heading id="h-0224" level="1">Example 208. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0820" num="0607">Scheme for the Preparation of the Compound of Example 208:</p><p id="p-0821" num="0000"><chemistry id="CHEM-US-00211" num="00211"><img id="EMI-C00211" he="134.54mm" wi="108.71mm" file="US20230002353A1-20230105-C00211.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0822" num="0608">Intermediate 7. To a mixture of intermediate 4 (100 mg, 0.21 mmol) and (4-acetylphenyl)boronic acid (52 mg, 0.32 mmol) in 1.2 ml of 1,4-dioxane/water (3/1) was added K<sub>2</sub>CO<sub>3 </sub>(88 mg, 0.64 mmol) followed by Pd(PPh<sub>3</sub>)<sub>4 </sub>(12 mg, 0.01 mmol). The reaction mixture was heated at 100&#xb0; C. for 3 hrs, cooled to room temperature, and extracted with EtOAc, dried over anhydrous MgSO<sub>4</sub>. After concentration under vacuum, the crude product was purified by silicagel column chromatography to give 80 mg of off-white solid</p><p id="p-0823" num="0609"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.62 (br dd, J=13.21, 7.34 Hz, 1H) 1.74-1.88 (m, 3H) 2.05 (br dd, J=12.62, 7.34 Hz, 1H) 2.17 (br dd, J=13.21, 5.58 Hz, 1H) 2.62 (s, 3H) 3.89 (s, 3H) 3.96-4.01 (m, 1H) 4.38-4.45 (m, 1H) 4.61-4.73 (m, 2H) 7.45 (d, J=8.22 Hz, 2H) 7.60 (d, J=8.22 Hz, 2H) 7.66 (d, J=8.22 Hz, 2H) 7.82 (s, 1H) 7.94 (s, 1H) 8.01 (d, J=8.22 Hz, 2H) 8.18 (d, J=1.76 Hz, 1H) 8.44 (d, J=1.76 Hz, 1H);</p><p id="p-0824" num="0610">MS (ESI, m/z): 510.8[M+H]<sup>+</sup></p><heading id="h-0225" level="1">Example 208. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0825" num="0611">To a mixture of intermediate 7 (30 mg, 0.06 mmol) in 0.4 ml of methanol was added 1-methylpiperazine (14 &#x3bc;l, 0.12 mmol) followed by NaBH<sub>3</sub>CN (11 mg, 0.18 mmol). The mixture was stirred at room temperature for 4 hr and then water was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 17 mg of the title compound.</p><p id="p-0826" num="0612"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.40 (d, J=6.46 Hz, 3H) 1.59 (br dd, J=13.21, 7.34 Hz, 1H) 1.73-1.85 (m, 3H) 1.98-2.05 (m, 1H) 2.15 (br dd, J=13.21, 5.58 Hz, 1H) 2.31 (s, 3H) 2.35-2.77 (m, 8H) 3.41-3.48 (m, 1H) 3.86 (s, 3H) 3.90-3.99 (m, 1H) 4.37-4.44 (m, 1H) 4.61-4.70 (m, 2H) 7.34 (d, J=7.63 Hz, 2H) 7.39 (br d, J=7.63 Hz, 2H) 7.48 (br d, J=7.63 Hz, 2H) 7.50 (br d, J=8.22 Hz, 2H) 7.74 (s, 1H) 7.82 (d, J=2.93 Hz, 1H) 7.96 (s, 1H) 8.22-8.26 (m, 1H);</p><p id="p-0827" num="0613">MS (ESI, m/z): 594.7 [M+H]<sup>+</sup></p><heading id="h-0226" level="1">Example 209. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(1-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)-cyclopentyl)nicotinamide</heading><p id="p-0828" num="0614">Using (2S,6R)-1,2,6-trimethylpiperazine, title compound was obtained as described for the example 208.</p><p id="p-0829" num="0000"><chemistry id="CHEM-US-00212" num="00212"><img id="EMI-C00212" he="48.77mm" wi="103.46mm" file="US20230002353A1-20230105-C00212.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0830" num="0615">MS (ESI, m/z): 622.4 [M+H]<sup>+</sup></p><heading id="h-0227" level="1">Example 210. 2-amino-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl)piperazin-1-yl)-ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-0831" num="0616">Using 1-(2-hydroxyethyl)piperazine, title compound was obtained as described for the example 208.</p><p id="p-0832" num="0000"><chemistry id="CHEM-US-00213" num="00213"><img id="EMI-C00213" he="48.01mm" wi="115.65mm" file="US20230002353A1-20230105-C00213.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0833" num="0617"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.64 (br dd, J=13.50, 7.04 Hz, 1H) 1.69 (d, J=7.04 Hz, 3H) 1.75-1.88 (m, 3H) 2.00-2.08 (m, 1H) 2.18 (br dd, J=13.50, 5.87 Hz, 1H) 3.16-3.23 (m, 2H) 3.23-3.27 (m, 2H) 3.53 (br s, 4H) 3.84 (br t, J=4.99 Hz, 2H) 3.90 (s, 3H) 3.98-4.03 (m, 1H) 4.25 (br d, J=7.04 Hz, 1H) 4.38-4.45 (m, 1H) 4.64-4.70 (m, 2H) 7.43 (d, J=7.63 Hz, 2H) 7.51 (m, J=8.22 Hz, 2H) 7.56 (m, J=8.22 Hz, 2H) 7.64 (d, J=8.22 Hz, 2H) 7.85 (s, 1H) 7.98 (s, 1H) 8.19 (s, 1H) 8.53 (s, 1H);</p><p id="p-0834" num="0618">MS (ESI, m/z): 624.4 [M+H]<sup>+</sup></p><heading id="h-0228" level="1">Example 211. 2-amino-N-((1S,2S)-2-((4&#x2032;-(1-((3S,5R)-4-(2-hydroxyethyl)-3,5-dimethylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0835" num="0619">Using 2-(cis-2,6-dimethylpiperazin-1-yl)ethan-1-ol, title compound was obtained as described for the example 208.</p><p id="p-0836" num="0000"><chemistry id="CHEM-US-00214" num="00214"><img id="EMI-C00214" he="48.68mm" wi="115.65mm" file="US20230002353A1-20230105-C00214.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0837" num="0620">MS (ESI, m/z): 652.4 [M+H]<sup>+</sup></p><heading id="h-0229" level="1">Example 212. 2-amino-N-((1S,2S)-2-((3&#x2032;,5&#x2032;-difluoro-4&#x2032;-(1-(4-(2-hydroxyethyl)-piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0838" num="0621">Using (4-acetyl-3,5-difluorophenyl)boronic acid pinacol ester and 2-(piperazin-1-yl)ethan-1-ol, the title compound was obtained as described for the example 208.</p><p id="p-0839" num="0000"><chemistry id="CHEM-US-00215" num="00215"><img id="EMI-C00215" he="48.01mm" wi="115.65mm" file="US20230002353A1-20230105-C00215.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0840" num="0622">MS (ESI, m/z): 660.32 [M+H]<sup>+</sup></p><p id="p-0841" num="0623">Scheme for the Preparation of the Intermediate 9:</p><p id="p-0842" num="0000"><chemistry id="CHEM-US-00216" num="00216"><img id="EMI-C00216" he="80.18mm" wi="75.86mm" file="US20230002353A1-20230105-C00216.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0843" num="0624">Intermediate 8. A mixture of (S)-1-(4-Bromophenyl)ethylamine (300 mg, 1.50 mmol) and (N,N-bis(2-chloroethyl)-4-methylbenzenesulfonamide (533 mg, 1.80 mmol) in 3 ml of DIPEA was heated at 120&#xb0; C. for 24 hrs, cooled to room temperature, and extracted with EtOAc, dried over anhydrous MgSO<sub>4</sub>. After concentration under vacuum, the crude product was purified by silicagel column chromatography to give 500 mg of off-white solid</p><p id="p-0844" num="0625"><sup>1</sup>H NMR (600 MHz, DMSO-d<sub>6</sub>) &#x3b4; ppm 1.16 (d, J=6.46 Hz, 3H) 2.27-2.33 (m, 2H) 2.39 (s, 5H) 2.78 (br s, 4H) 3.37-3.44 (m, 1H) 7.16 (d, J=7.87 Hz, 2H) 7.43 (t, J=7.59 Hz, 4H) 7.55-7.60 (m, 2H):</p><p id="p-0845" num="0626">MS (ESI, m/z): 423.1/425.2[M+H]<sup>+</sup></p><heading id="h-0230" level="1">Intermediate 9. (S)-1-(1-(4-bromophenyl)ethyl)piperazine</heading><p id="p-0846" num="0627">Intermediate 8 (0.5 g, 1.1 mmol) in 5 ml of HBr in AcOH was stirred at room temperature for 24 hrs. After concentration under vacuum, the crude product was diluted with EtOAC and the solid was collected by filtration to give 0.5 g of off-white solid</p><p id="p-0847" num="0628"><sup>1</sup>H NMR (600 MHz, DMSO-d<sub>6</sub>) &#x3b4; ppm 1.63 (br s, 3H) 3.40 (br s, 1H) 3.47-3.72 (br s, 8H) 7.54 (br s, 2H) 7.69 (br d, J=7.63 Hz, 2H);</p><p id="p-0848" num="0629">MS (ESI, m/z): 269.1/271.4 [M+H]<sup>+</sup></p><heading id="h-0231" level="1">Intermediate 10. (R)-1-(1-(4-bromophenyl)ethyl)piperazine</heading><p id="p-0849" num="0630">Using (R)-1-(4-Bromophenyl)ethylamine, the title compound was obtained as described for the intermediate 9.</p><p id="p-0850" num="0000"><chemistry id="CHEM-US-00217" num="00217"><img id="EMI-C00217" he="17.86mm" wi="39.12mm" file="US20230002353A1-20230105-C00217.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0851" num="0631">MS (ESI, m/z): 269.1/271.4 [M+H]<sup>+</sup></p><heading id="h-0232" level="1">Intermediate 11. 1-(1-(4-bromophenyl)cyclopropyl)piperazine</heading><p id="p-0852" num="0632">Using 1-(4-Bromophenyl)cyclopropan-1-amine, the title compound was obtained as described for the intermediate 9.</p><p id="p-0853" num="0000"><chemistry id="CHEM-US-00218" num="00218"><img id="EMI-C00218" he="17.19mm" wi="39.12mm" file="US20230002353A1-20230105-C00218.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0854" num="0633">MS (ESI, m/z): 281.1/283.4 [M+H]<sup>+</sup></p><heading id="h-0233" level="1">Intermediate 12. 1-(2-(4-bromophenyl)propan-2-yl)piperazine</heading><p id="p-0855" num="0634">Using 2-(4-Bromophenyl)propan-2-amine, the title compound was obtained as described for the intermediate 9.</p><p id="p-0856" num="0000"><chemistry id="CHEM-US-00219" num="00219"><img id="EMI-C00219" he="17.10mm" wi="39.12mm" file="US20230002353A1-20230105-C00219.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0857" num="0635">MS (ESI, m/z): 283.1/285.4 [M+H]<sup>+</sup></p><heading id="h-0234" level="1">Example 213 and 214</heading><p id="p-0858" num="0636">Scheme for the Preparation of the Compounds of Example 213 and 214;</p><p id="p-0859" num="0000"><chemistry id="CHEM-US-00220" num="00220"><img id="EMI-C00220" he="188.38mm" wi="125.73mm" file="US20230002353A1-20230105-C00220.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0860" num="0637">Intermediate 13. To a mixture of intermediate 4 (0.56 g, 1.19 mmol) and bis(pinacalato)diboron (0.6 g, 2.38 mmol) in 6 ml of 1,4-dioxane was added KOAc (0.35 g, 3.51 mmol) followed by Pd(PPh<sub>3</sub>)<sub>4 </sub>(69 mg, 0.06 mmol). The reaction mixture was heated at 110&#xb0; C. for 5 hrs, cooled to room temperature, and partitioned between water and EtOAc, dried over anhydrous MgSO<sub>4</sub>. After concentration under vacuum, the crude product was purified by silicagel column chromatography to give 0.5 g of light yellow solid</p><p id="p-0861" num="0638"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.19 (s, 6H) 1.30 (s, 6H) 1.60 (br dd, J=13.30, 7.04 Hz, 1H) 1.68-1.88 (m, 3H) 1.93-2.06 (m, 1H) 2.15 (br dd, J=13.11, 6.06 Hz, 1H) 3.90 (s, 3H) 3.92-3.99 (m, 1H) 4.32-4.44 (m, 1H) 4.64 (s, 2H) 7.33 (m, J=7.83 Hz, 2H) 7.66 (m, J=7.83 Hz, 2H) 7.75 (s, 1H) 7.85 (s, 1H) 7.97 (d, J=1.96 Hz, 1H) 8.20-8.30 (m, 1H);</p><p id="p-0862" num="0639">MS (ESI, m/z): 518.3 [M+H]<sup>+</sup></p><heading id="h-0235" level="1">Example 213. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((R)-1-(piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0863" num="0640">To a mixture of intermediate 13 (150 mg, 0.29 mmol) and intermediate 10 (100 mg, 0.29 mmol) in 1.5 ml of 1,4-dioxane/water (3/1) was added K<sub>2</sub>CO<sub>3 </sub>(120 mg, 0.87 mmol) followed by Pd(PPh<sub>3</sub>)<sub>4 </sub>(17 mg, 0.01 mmol). The reaction mixture was heated at 100&#xb0; C. for 3 hrs, cooled to room temperature, and extracted with EtOAc, dried over anhydrous MgSO<sub>4</sub>. After concentration under vacuum, the crude product was purified by silicagel column chromatography to give 130 mg of off-white solid</p><p id="p-0864" num="0641"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.40 (d, J=6.46 Hz, 3H) 1.54-1.63 (m, 1H) 1.73-1.86 (m, 3H) 1.98-2.05 (m, 1H) 2.12-2.19 (m, 1H) 2.40 (br s, 2H) 2.82 (t, J=4.99 Hz, 4H) 3.40 (q, J=6.46 Hz, 1H) 3.86 (s, 3H) 3.95 (dt, J=6.90, 4.48 Hz, 1H) 4.41 (td, J=7.63, 4.70 Hz, 1H) 4.61-4.70 (m, 2H) 5.48 (s, 1H) 7.33 (d, J=8.22 Hz, 2H) 7.39 (d, J=8.22 Hz, 2H) 7.44-7.49 (m, 2H) 7.49-7.55 (m, 2H) 7.74 (s, 1H) 7.83 (s, 1H) 7.97 (d, J=2.35 Hz, 1H) 8.23 (d, J=2.35 Hz, 1H);</p><p id="p-0865" num="0642">MS (ESI, m/z): 580.6[M+H]<sup>+</sup></p><heading id="h-0236" level="1">Example 214. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((R)-1-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0866" num="0643"><chemistry id="CHEM-US-00221" num="00221"><img id="EMI-C00221" he="32.26mm" wi="75.35mm" file="US20230002353A1-20230105-C00221.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0867" num="0644">To compound 213 (20 mg, 0.03 mmol) in 0.2 ml of 1,2-dichloroethane was added formaldehyde (0.005 ml, 0.06 mmol) followed by NaBH(OAc)<sub>3 </sub>(13 mg, 0.09 mmol). The mixture was stirred at room temperature for 1 hr and then water was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude residue was purified by preparative HPLC to afford 15 mg of the title compound.</p><p id="p-0868" num="0645"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.64 (dd, J=13.50, 7.04 Hz, 1H) 1.71 (d, J=7.04 Hz, 3H) 1.75-1.88 (m, 3H) 2.00-2.10 (m, 1H) 2.12-2.23 (m, 1H) 2.91 (s, 3H) 3.20-3.28 (m, 2H) 3.52 (br s, 4H) 3.90 (s, 3H) 4.00 (dt, J=6.46, 4.40 Hz, 1H) 4.32 (q, J=6.65 Hz, 1H) 4.42 (td, J=7.34, 4.11 Hz, 1H) 4.63-4.71 (m, 2H) 7.43 (d, J=8.22 Hz, 2H) 7.52 (d, J=8.22 Hz, 2H) 7.56 (d, J=8.22 Hz, 2H) 7.64 (d, J=8.22 Hz, 2H) 7.85 (s, 1H) 7.98 (s, 1H) 8.20 (d, J=1.76 Hz, 1H) 8.53 (d, J=2.35 Hz, 1H);</p><p id="p-0869" num="0646">MS (ESI, m/z): 594.8 [M+H]<sup>+</sup></p><heading id="h-0237" level="1">Example 215. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((S)-1-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0870" num="0647">Using intermediate 9, the title compound was obtained as described for the example</p><p id="p-0871" num="0000"><chemistry id="CHEM-US-00222" num="00222"><img id="EMI-C00222" he="32.26mm" wi="75.35mm" file="US20230002353A1-20230105-C00222.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0872" num="0648"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.51 (d, J=7.04 Hz, 3H) 1.64 (br dd, J=13.21, 6.75 Hz, 1H) 1.76-1.85 (m, 3H) 2.01-2.06 (m, 1H) 2.14 (s, 1H) 2.15-2.20 (m, 1H) 2.84 (s, 3H) 3.82 (br d, J=6.46 Hz, 1H) 3.90 (s, 3H) 3.98-4.02 (m, 1H) 4.42 (br dd, J=6.75, 3.23 Hz, 1H) 4.66 (s, 2H) 7.42 (dd, J=8.22, 1.76 Hz, 4H) 7.54-7.59 (m, 4H) 7.86 (s, 1H) 7.98 (s, 1H) 8.20 (d, J=2.35 Hz, 1H) 8.53 (d, J=1.76 Hz, 1H);</p><p id="p-0873" num="0649">MS (ESI, m/z): 594.8 [M+H]<sup>+</sup></p><heading id="h-0238" level="1">Example 216. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)cyclopropyl)-[1,1&#x2032;-biphenyl]-4-ylmethoxy)cyclopentyl)-nicotinamide</heading><p id="p-0874" num="0650">Using intermediate 11, the title compound was obtained as described for the example 214.</p><p id="p-0875" num="0000"><chemistry id="CHEM-US-00223" num="00223"><img id="EMI-C00223" he="31.67mm" wi="74.34mm" file="US20230002353A1-20230105-C00223.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0876" num="0651"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 0.85-0.88 (m, 1H) 0.89-0.92 (m, 1H) 0.99-1.01 (m, 1H) 1.01-1.04 (m, 1H) 1.64 (br dd, J13.50, 6.46 Hz, 1H) 1.75-1.88 (m, 3H) 2.01-2.07 (m, 1H) 2.16-2.24 (m, 2H) 2.79 (d, J1.76 Hz, 3H) 3.00 (br s, 21H) 3.15-3.21 (m, 2H) 3.34-3.43 (m, 4H) 3.90 (s, 3H) 4.00 (dt, J=6.46, 4.11 Hz, 1H) 4.42 (td, J=7.34, 4.70 Hz, 1H) 4.66 (s, 2H) 7.26 (d, J=8.31 Hz, 2H) 7.37-7.40 (m, 2H) 7.40-7.43 (m, 2H) 7.49-7.52 (m, 1H) 7.86 (s, 1H) 7.98 (s, 1H) 8.20 (d, J=1.76 Hz, 1H) 8.54 (d, J=&#x2212;235 Hz, 1H);</p><p id="p-0877" num="0652">MS (ESI, m/z): 606.3 [M+H]<sup>+</sup></p><heading id="h-0239" level="1">Example 217. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-(2-(4-methylpiperazin-1-yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-nicotinamide</heading><p id="p-0878" num="0653">Using intermediate 12, the title compound was obtained as described for the example 214.</p><p id="p-0879" num="0000"><chemistry id="CHEM-US-00224" num="00224"><img id="EMI-C00224" he="31.58mm" wi="74.34mm" file="US20230002353A1-20230105-C00224.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0880" num="0654"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.49 (s, 5H) 1.60-1.61 (m, 1H) 1.60-1.66 (m, 1H) 1.80-1.88 (m, 3H) 2.02-2.08 (m, 1H) 2.17 (br s, 1H) 2.87 (s, 3H) 3.90 (s, 3H) 4.02 (br s, 1H) 4.40-4.47 (m, 1H) 4.67 (s, 2H) 7.42 (d, J=8.22 Hz, 2H) 7.51-7.58 (m, 4H) 7.58-7.62 (m, 2H) 7.85 (d, J=0.78 Hz, 1H) 7.98 (s, 1H) 8.20 (d, J=2.35 Hz, 1H) 8.51 (d, J=1.96 Hz, 1H);</p><p id="p-0881" num="0655">MS (ESI, m/z): 608.2 [M+H]<sup>+</sup></p><heading id="h-0240" level="1">Example 218. 2-amino-N-((1S,2S)-2-((4&#x2032;-((R)-1-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-0882" num="0656">Scheme for the Preparation of the Compound of Example 218;</p><p id="p-0883" num="0000"><chemistry id="CHEM-US-00225" num="00225"><img id="EMI-C00225" he="92.37mm" wi="123.27mm" file="US20230002353A1-20230105-C00225.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0884" num="0657">To a mixture of compound 213 (20 mg, 0.03 mmol) and K<sub>2</sub>CO<sub>3 </sub>(14 mg, 0.1 mmol) in 0.3 ml of methanol was added 2-bromothanol (4 &#x3bc;l, 0.05 mmol). The reaction mixture was stirred at room temperature for 3 hrs, After concentration under vacuum, the crude product was purified by HPLC to give 10 mg of off-white solid</p><p id="p-0885" num="0658"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.60-1.71 (m, 1H) 1.75 (d, J=7.04 Hz, 3H) 1.76-1.85 (m, 3H) 2.00-2.09 (m, 1H) 2.14-2.23 (m, 1H) 3.33-3.44 (m, 2H) 3.56-3.73 (m, 4H) 3.83-3.87 (m, 2H) 3.90 (s, 3H) 4.00 (dt, J=6.60, 4.33 Hz, 1H) 4.38-4.45 (m, 2H) 4.64-4.70 (m, 2H) 7.43 (d, J=8.22 Hz, 2H) 7.54 (d, J=8.22 Hz, 2H) 7.56-7.61 (m, 2H) 7.64-7.71 (m, 2H) 7.85 (s, 1H) 7.98 (s, 1H) 8.20 (d, J=1.76 Hz, 1H) 8.53 (s, 1H);</p><p id="p-0886" num="0659">MS (ESI, m/z): 624.8 [M+H]<sup>+</sup></p><heading id="h-0241" level="1">Example 219. 2-amino-N-((1S,2S)-2-((4&#x2032;-((S)-1-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-0887" num="0660">Using intermediate 9, the title compound was obtained as described for the example 213 and 218.</p><p id="p-0888" num="0000"><chemistry id="CHEM-US-00226" num="00226"><img id="EMI-C00226" he="43.18mm" wi="113.88mm" file="US20230002353A1-20230105-C00226.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0889" num="0661"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.58 (d, J=7.04 Hz, 3H) 1.64 (br dd, J=13.21, 6.75 Hz, 1H) 1.72-1.87 (m, 3H) 2.00-2.07 (m, 1H) 2.15-2.23 (m, 1H) 2.99 (brs, 2H) 3.17-3.22 (m, 3H) 3.35-3.44 (m, 4H) 3.80-3.85 (m, 3H) 3.90 (s, 3H) 3.96-4.03 (m, 2H) 4.42 (td, J=7.34, 4.11 Hz, 1H) 4.66 (s, 2H) 7.42 (d, J=8.22 Hz, 2H) 7.46 (d, J=8.22 Hz, 2H) 7.55-7.57 (m, 2H) 7.60 (d, J=8.22 Hz, 2H) 7.86 (s, 1H) 7.98 (s, 1H) 8.20 (d, J=2.35 Hz, 1H) 8.52 (d, J=2.35 Hz, 1H);</p><p id="p-0890" num="0662">MS (ESI, m/z): 624.8 [M+H]<sup>+</sup></p><heading id="h-0242" level="1">Example 220. 2-amino-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl)piperazin-1-yl)cyclopropyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0891" num="0663">Using intermediate 11, the title compound was obtained as described for the example 213 and 218.</p><p id="p-0892" num="0000"><chemistry id="CHEM-US-00227" num="00227"><img id="EMI-C00227" he="43.10mm" wi="113.88mm" file="US20230002353A1-20230105-C00227.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0893" num="0664"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 0.85-0.88 (m, 1H) 0.91-0.94 (m, 1H) 1.00-1.03 (m, 1H) 1.05-1.07 (m, 1H) 1.64 (dd, J=13.21, 6.75 Hz, 1H) 1.74-1.86 (m, 2H) 1.99-2.07 (m, 1H) 2.15-2.21 (m, 1H) 3.13-3.18 (m, 3H) 3.76-3.81 (m, 2H) 3.90 (s, 3H) 3.97-4.04 (m, 1H) 4.39-4.45 (m, 1H) 4.61-4.71 (m, 2H) 7.25-7.28 (m, 1H) 7.35-7.43 (m, 3H) 7.49-7.58 (m, 4H) 7.85 (s, 1H) 7.98 (s, 1H) 8.19 (d, J=1.76 Hz, 1H) 8.53 (d, J=1.76 Hz, 1H);</p><p id="p-0894" num="0665">MS (ESI, m/z): 636.5 [M+H]<sup>+</sup></p><heading id="h-0243" level="1">Example 221. 2-amino-N-((1S,2S)-2-((4&#x2032;-(2-(4-(2-hydroxyethyl)piperazin-1-yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-0895" num="0666">Using intermediate 12, the title compound was obtained as described for the example 213 and 218.</p><p id="p-0896" num="0000"><chemistry id="CHEM-US-00228" num="00228"><img id="EMI-C00228" he="42.93mm" wi="113.88mm" file="US20230002353A1-20230105-C00228.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0897" num="0667"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.35-1.44 (m, 6H) 1.60 (br dd, J=12.91, 7.43 Hz, 1H) 1.73-1.89 (m, 3H) 2.03 (br dd, J=13.50, 6.46 Hz, 1H) 2.11-2.21 (m, 1H) 2.48-2.62 (m, 9H) 3.67 (t, J=6.06 Hz, 2H) 3.86 (s, 3H) 3.96 (dt, J=6.95, 4.55 Hz, 1H) 4.36-4.46 (m, 1H) 4.59-4.72 (m, 2H) 7.40 (d, J=7.83 Hz, 2H) 7.43-7.49 (m, 2H) 7.53 (dd, J=12.72, 8.41 Hz, 4H) 7.75 (s, 1H) 7.83 (s, 1H) 7.97 (d, J=2.35 Hz, 1H) 8.24 (d, J=1.96 Hz, 1H);</p><p id="p-0898" num="0668">MS (ESI, m/z): 624.8 [M+H]<sup>+</sup></p><heading id="h-0244" level="1">Example 222. 6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((S)-1-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0899" num="0669">Scheme for the Preparation of the Compound of Example 222:</p><p id="p-0900" num="0000"><chemistry id="CHEM-US-00229" num="00229"><img id="EMI-C00229" he="234.53mm" wi="145.63mm" file="US20230002353A1-20230105-C00229.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0901" num="0670">Intermediate 14.</p><p id="p-0902" num="0671">Using 6-fluoropyridine-3-boronic acid, the title compound was obtained as described for the intermediate 2.</p><p id="p-0903" num="0672"><sup>1</sup>H NMR (600 MHz, DMSO-d<sub>6</sub>) &#x3b4; ppm 7.20 (dd, J=8.51, 2.64 Hz, 1H) 8.20 (td, J=8.22, 2.35 Hz, 1H) 8.27 (d, J=2.93 Hz, 1H) 8.45 (d, J=2.93 Hz, 1H) 8.48 (d, J=2.35 Hz, 1H);</p><p id="p-0904" num="0673">MS (ESI+) m/z 234.1 [M+H]<sup>+</sup></p><p id="p-0905" num="0674">Intermediate 15.</p><p id="p-0906" num="0675">Using intermediate 14, the title compound was obtained as described for the intermediate 4.</p><p id="p-0907" num="0676"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.60 (br dd, J=13.30, 7.04 Hz, 1H) 1.71-1.84 (m, 3H) 2.00 (br dd, J=13.30, 6.26 Hz, 1H) 2.10-2.21 (m, 1H) 3.92 (dt, J=6.55, 4.35 Hz, 1H) 4.39 (td, J=7.34, 4.50 Hz, 1H) 4.58 (s, 2H) 7.15 (dd, J=8.41, 2.54 Hz, 1H) 7.26 (d, J=8.22 Hz, 2H) 7.38-7.43 (m, 2H) 8.08 (d, J2.35 Hz, 1H) 8.12-8.21 (m, 1H) 8.35 (d, J=2.35 Hz, 1H) 8.43 (d, =2.35 Hz, 1H);</p><p id="p-0908" num="0677">MS (ESI+) m/z 485.2/487.3 [M+H]<sup>+</sup></p><p id="p-0909" num="0678">Intermediate 16.</p><p id="p-0910" num="0679">Using intermediate 15, the title compound was obtained as described for the intermediate 13.</p><p id="p-0911" num="0680"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.18 (s, 12H) 1.58 (br dd, J=13.21, 7.34 Hz, 1H) 1.69-1.84 (m, 3H) 1.96-2.03 (m, 1H) 2.15 (br d, J=7.63 Hz, 1H) 3.93 (br d, J=6.46 Hz, 1H) 4.39 (br d, J=4.70 Hz, 1H) 4.63 (s, 2H) 7.13 (dd, J=8.51, 2.64 Hz, 1H) 7.32 (d, J=7.63 Hz, 2H) 7.49-7.57 (m, 1H) 7.64 (d, J=7.63 Hz, 2H) 8.07 (d, J=2.35 Hz, 1H) 8.10-8.18 (m, 1H) 8.33 (d, J=1.76 Hz, 1H) 8.41 (d, J=2.35 Hz, 1H);</p><p id="p-0912" num="0681">MS (ESI+) m/z 533.3 [M+H]<sup>+</sup></p><p id="p-0913" num="0682">Intermediate 17.</p><p id="p-0914" num="0683">Using intermediate 16, the title compound was obtained as described for the compound 213.</p><p id="p-0915" num="0684"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.61 (d, J=6.65 Hz, 3H) 1.64 (br s, 1H) 1.77-1.86 (m, 3H) 2.02-2.08 (m, 1H) 2.16-2.22 (m, 1H) 3.02 (br s, 2H) 3.13 (br s, 2H) 3.32-3.40 (m, 4H) 3.97-4.02 (m, 2H) 4.05 (br d, J=6.26 Hz, 1H) 4.41-4.46 (m, 1H) 4.67 (d, J=3.91 Hz, 2H) 7.16 (br dd, J=8.41, 2.54 Hz, 1H) 7.43 (br d, J=8.22 Hz, 2H) 7.48 (d, J=8.22 Hz, 2H) 7.55 (d, J=7.83 Hz, 2H) 7.60 (d, J=7.83 Hz, 2H) 8.19 (td, J=8.02, 2.74 Hz, 1H) 8.35 (d, J=2.35 Hz, 1H) 8.47 (br d, J=2.74 Hz, 1H) 8.52 (d, J=2.35 Hz, 1H);</p><p id="p-0916" num="0685">MS (ESI+) m/z 595.3 [M+H]<sup>+</sup></p><heading id="h-0245" level="1">Example 222. 6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((S)-1-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0917" num="0686">Using intermediate 17, the title compound was obtained as described for the example 214.</p><p id="p-0918" num="0687"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.57 (d, J=6.65 Hz, 3H) 1.63 (br dd, J=13.50, 6.85 Hz, 1H) 1.72-1.89 (m, 3H) 2.00-2.08 (m, 1H) 2.14-2.23 (m, 1H) 2.87 (s, 3H) 3.90-3.97 (m, 1H) 3.97-4.05 (m, 1H) 4.40-4.47 (m, 1H) 4.63-4.71 (m, 2H) 7.16 (dd, J=8.61, 2.74 Hz, 1H) 7.32-7.50 (m, 4H) 7.55 (br d, J=8.22 Hz, 2H) 7.58 (br d, J=8.22 Hz, 2H) 8.19 (ddd, J=8.61, 7.43, 2.74 Hz, 1H) 8.35 (d, J=2.35 Hz, 1H) 8.48 (d, J=2.74 Hz, 1H) 8.56 (d, J=2.35 Hz, 1H);</p><p id="p-0919" num="0688">MS (ESI+) m/z 609.3 [M+H]<sup>+</sup></p><heading id="h-0246" level="1">Example 223. 6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((R)-1-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0920" num="0689">Using intermediate 10, the title compound was obtained as described for the example 222.</p><p id="p-0921" num="0000"><chemistry id="CHEM-US-00230" num="00230"><img id="EMI-C00230" he="43.18mm" wi="102.45mm" file="US20230002353A1-20230105-C00230.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0922" num="0690"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.49 (d, J=7.04 Hz, 3H) 1.63 (br d, J=6.65 Hz, 1H) 1.84 (br d, J=15.65 Hz, 3H) 2.06 (br s, 1H) 2.19 (br d, J=8.61 Hz, 1H) 2.84 (s, 3H) 3.74 (br d, J=6.26 Hz, 1H) 4.00 (br s, 1H) 4.43 (br s, 1H) 4.67 (d, J=3.13 Hz, 2H) 7.15 (br dd, J=9.00, 2.74 Hz, 1H) 7.42 (dd, J=7.83, 3.52 Hz, 4H) 7.54 (br dd, J=7.83, 5.09 Hz, 4H) 8.15-8.22 (m, 1H) 8.35 (br d, J=2.35 Hz, 1H) 8.46 (s, 1H) 8.50 (br d, J=1.96 Hz, 1H);</p><p id="p-0923" num="0691">MS (ESI+) m/z 609.4 [M+H]<sup>+</sup></p><heading id="h-0247" level="1">Example 224. 6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)cyclopropyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0924" num="0692">Using intermediate 11, the title compound was obtained as described for the example 222.</p><p id="p-0925" num="0000"><chemistry id="CHEM-US-00231" num="00231"><img id="EMI-C00231" he="43.10mm" wi="102.45mm" file="US20230002353A1-20230105-C00231.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0926" num="0693"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 0.91-0.95 (m, 2H) 1.01-1.06 (m, 2H) 1.64 (br dd, J=13.21, 6.75 Hz, 1H) 1.76-1.85 (m, 3H) 2.01-2.06 (m, 1H) 2.14 (s, 1H) 2.15-2.20 (m, 1H) 2.80 (s, 3H) 3.34 (s, 2H) 3.99 (br d, J=4.30 Hz, 1H) 4.43 (br d, J=4.70 Hz, 1H) 4.67 (d, J=3.52 Hz, 2H) 7.12-7.16 (m, 1H) 7.40 (dd, J=14.28, 8.41 Hz, 4H) 7.52 (br dd, J=8.22, 3.91 Hz, 4H) 8.18 (s, 1H) 8.35 (d, J=2.35 Hz, 1H) 8.42 (d, J=2.35 Hz, 1H) 8.45 (s, 1H);</p><p id="p-0927" num="0694">MS (ESI+) m/z 621.5 [M+H]<sup>+</sup></p><heading id="h-0248" level="1">Example 225. 6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(2-(4-methylpiperazin-1-yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0928" num="0695">Using intermediate 12, the title compound was obtained as described for the example 222.</p><p id="p-0929" num="0000"><chemistry id="CHEM-US-00232" num="00232"><img id="EMI-C00232" he="42.50mm" wi="102.45mm" file="US20230002353A1-20230105-C00232.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0930" num="0696">MS (ESI+) m/z 623.3 [M+H]<sup>+</sup></p><heading id="h-0249" level="1">Example 226. 6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((S)-1-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0931" num="0697">Scheme for the Preparation of the Compound of Example 226:</p><p id="p-0932" num="0000"><chemistry id="CHEM-US-00233" num="00233"><img id="EMI-C00233" he="98.30mm" wi="126.15mm" file="US20230002353A1-20230105-C00233.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0933" num="0698">Using intermediate 17, the title compound was obtained as described for the example 218.</p><p id="p-0934" num="0699"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.58-1.68 (m, 4H) 1.77-1.87 (m, 3H) 2.02-2.09 (m, 1H) 2.15-2.23 (m, 1H) 3.13 (br s, 2H) 3.17-3.26 (m, 2H) 3.46 (br s, 4H) 3.77 (br s, 1H) 3.82-3.87 (m, 2H) 4.02 (br d, J=4.70 Hz, 2H) 4.11 (br d, J=6.26 Hz, 1H) 4.44 (br dd, J=11.74, 7.43 Hz, 1H) 4.67 (d, J=2.74 Hz, 2H) 7.17 (dd, J=8.61, 2.74 Hz, 1 H) 7.43 (d, J=8.22 Hz, 2H) 7.49 (d, J=8.22 Hz, 2H) 7.56 (d, J=8.22 Hz, 2H) 7.62 (d, J=8.61 Hz, 2H) 8.20 (td, J=8.02, 2.74 Hz, 1H) 8.36 (d, J=2.35 Hz, 1H) 8.48 (br d, J=2.74 Hz, 1H) 8.57 (d, J=1.96 Hz, 1H);</p><p id="p-0935" num="0700">MS (ESI+) m/z 639.4 [M+H]<sup>+</sup></p><heading id="h-0250" level="1">Example 227. 6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((R)-1-(4-(2-hydroxyethyl)-piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0936" num="0701">Using intermediate 10, the title compound was obtained as described for the example 226.</p><p id="p-0937" num="0000"><chemistry id="CHEM-US-00234" num="00234"><img id="EMI-C00234" he="43.18mm" wi="114.64mm" file="US20230002353A1-20230105-C00234.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0938" num="0702">MS (ESI+) m/z 639.1 [M+H]<sup>+</sup></p><heading id="h-0251" level="1">Example 228. 6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl)-piperazin-1-yl)cyclopropyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0939" num="0703">Using intermediate 11, the title compound was obtained as described for the example 226.</p><p id="p-0940" num="0000"><chemistry id="CHEM-US-00235" num="00235"><img id="EMI-C00235" he="43.10mm" wi="114.64mm" file="US20230002353A1-20230105-C00235.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0941" num="0704">MS (ESI+) m/z 651.6 [M+H]<sup>+</sup></p><heading id="h-0252" level="1">Example 229. 6-amino-6&#x2032;-fluoro-N-(1S,2S)-2-((4&#x2032;-(2-(4-(2-hydroxyethyl)-piperazin-1-yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0942" num="0705">Using intermediate 12, the title compound was obtained as described for the example 226.</p><p id="p-0943" num="0000"><chemistry id="CHEM-US-00236" num="00236"><img id="EMI-C00236" he="43.01mm" wi="114.64mm" file="US20230002353A1-20230105-C00236.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0944" num="0706">MS (ESI+) m/z 653.4 [M+H]<sup>+</sup></p><heading id="h-0253" level="1">Example 230. 6-amino-5&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0945" num="0707">Scheme for the Preparation of the Compound of Example 230:</p><p id="p-0946" num="0000"><chemistry id="CHEM-US-00237" num="00237"><img id="EMI-C00237" he="242.74mm" wi="118.03mm" file="US20230002353A1-20230105-C00237.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0947" num="0708">Intermediate 18.</p><p id="p-0948" num="0709">Using (1S,2S)-2-((4-bromobenzyl)oxy)cyclopentan-1-amine, the title compound was obtained as described for the intermediate 7.</p><p id="p-0949" num="0710"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.58-1.65 (m, 1H) 1.74-1.85 (m, 3H) 2.01-2.08 (m, 1H) 2.12-2.18 (m, 1H) 2.60 (s, 3H) 3.41-3.48 (m, 1H) 3.92 (q, J=5.87 Hz, 1H) 4.45-4.55 (m, 2H) 7.27 (d, J=8.22 Hz, 2H) 7.43-7.50 (m, 3H) 7.65 (d, J=8.22 Hz, 1H) 7.73 (d, J=8.22 Hz, 1H) 8.03 (d, J=8.22 Hz, 1H);</p><p id="p-0950" num="0711">MS (ESI+) m/z 310.1 [M+H]<sup>+</sup></p><p id="p-0951" num="0712">Intermediate 19.</p><p id="p-0952" num="0713">Using intermediate 18, the title compound was obtained as described for the intermediate 4.</p><p id="p-0953" num="0714"><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) &#x3b4; ppm 1.45-1.54 (m, 1H) 1.71-1.82 (m, 2H) 1.84-1.92 (m, 1H) 1.92-2.02 (m, 1H) 2.23-2.33 (m, 1H) 2.63 (s, 3H) 3.81-3.91 (m, 1H) 4.29-4.44 (m, 1H) 4.63-4.75 (m, 2H) 5.90 (br d, J=6.46 Hz, 1H) 6.35 (br s, 2H) 7.44 (d, J=8.22 Hz, 2H) 7.56-7.62 (m, 3H) 7.66 (d, J=8.22 Hz, 2H) 8.01 (d, J=8.22 Hz, 2H) 8.15 (d, J=1.76 Hz, 1H);</p><p id="p-0954" num="0715">MS (ESI+) m/Z 508.1/510.2 [M+H]<sup>+</sup></p><p id="p-0955" num="0716">Intermediate 20.</p><p id="p-0956" num="0717">To intermediate 19 (300 mg, 0.59 mmol) in 3 ml of THE was added 1-methylpiperazine (0.13 ml, 1.18 mmol) followed by Ti(OiPr)<sub>4 </sub>(0.7 ml, 2.36 mmol). The mixture was stirred at 60&#xb0; C. for 4 hr and then NaBH<sub>3</sub>CN (0.11 g, 1.18 mmol) was added. The mixture was stirred for 1 h and extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>. After concentration under vacuum, the crude product was purified by silicagel column chromatography to give 200 mg of off-white solid.</p><p id="p-0957" num="0718"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.55-1.61 (m, 1H) 1.64 (d, J=7.04 Hz, 3H) 1.72-1.84 (m, 3H) 1.97-2.05 (m, 1H) 2.09-2.17 (m, 1H) 2.88 (s, 3H) 3.11 (br s, 2H) 3.36-3.49 (m, 4H) 3.95 (dt, J=6.75, 4.26 Hz, 1H) 4.14 (br d, J=6.46 Hz, 1H) 4.35 (td, J=7.34, 4.70 Hz, 1H) 4.61-4.68 (m, 2H) 7.42 (d, J=8.22 Hz, 2H) 7.50 (d, J=8.22 Hz, 2H) 7.57 (d, J=8.22 Hz, 2H) 7.65 (d, J=8.22 Hz, 2H) 8.13 (d, J=2.35 Hz, 1H) 8.20 (d, J=2.35 Hz, 1H);</p><p id="p-0958" num="0719">MS (ESI+) m/z 592.2/594.3 [M+H]<sup>+</sup></p><heading id="h-0254" level="1">Example 230. 6-amino-5&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopeutyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0959" num="0720">Using intermediate 20 and 5-fluoropyridine-3-boronic acid, the title compound was obtained as described for the intermediate 14.</p><p id="p-0960" num="0721"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.54 (d, J=7.04 Hz, 3H) 1.63 (br dd, J=13.21, 6.75 Hz, 1H) 1.77-1.86 (m, 3H) 2.04 (br dd, J=12.91, 7.04 Hz, 1H) 2.16-2.23 (m, 1H) 2.85 (s, 3H) 3.88 (br d, J=7.04 Hz, 1H) 3.97-4.03 (m, 1H) 4.43 (br d, J=4.70 Hz, 1H) 4.64-4.70 (m, 2H) 7.42 (br dd, J=8.22, 4.11 Hz, 4H) 7.53 (br d, J=8.22 Hz, 2H) 7.56 (br d, J=8.22 Hz, 2H) 7.96 (br d, J=9.39 Hz, 1H) 8.42 (s, 1H) 8.50 (d, J=2.35 Hz, 1H) 8.56 (s, 1H) 8.70 (br s, 1H);</p><p id="p-0961" num="0722">MS (ESI+) m/z 609.3 [M+H]<sup>+</sup></p><heading id="h-0255" level="1">Example 231. 2-amino-5-chloro-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)-ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0962" num="0723">Using 2-amino-5-chloronicotinic acid, the title compound was obtained as described for the synthesis of intermediate 20.</p><p id="p-0963" num="0000"><chemistry id="CHEM-US-00238" num="00238"><img id="EMI-C00238" he="30.82mm" wi="75.27mm" file="US20230002353A1-20230105-C00238.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0964" num="0724"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.60 (dt, J=13.60, 7.09 Hz, 1H) 1.66 (d, J=6.65 Hz, 3H) 1.73-1.87 (m, 3H) 1.98-2.06 (m, 1H) 2.10-2.20 (m, 1H) 2.90 (s, 2H) 3.15 (br s, 2H) 3.45 (br s, 4H) 3.96 (dt, J=6.65, 4.30 Hz, 1H) 4.18 (q, J=6.65 Hz, 1H) 4.37 (td, J=7.24, 4.30 Hz, 1H) 4.61-4.71 (m, 2H) 7.43 (m, J=8.22 Hz, 2H) 7.52 (d, J=8.22 Hz, 2H) 7.59 (d, J=8.22 Hz, 2H) 7.67 (m, J=8.22 Hz, 2H) 8.09 (d, J=2.74 Hz, 1H) 8.14 (d, J=2.74 Hz, 1H);</p><p id="p-0965" num="0725">MS (ESI+) m/z 548.3 [M+H]<sup>+</sup></p><heading id="h-0256" level="1">Example 232. 2-amino-5-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)-ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0966" num="0726">Using 2-amino-5-fluoronicotinic acid, the title compound was obtained as described for the synthesis of intermediate 20.</p><p id="p-0967" num="0000"><chemistry id="CHEM-US-00239" num="00239"><img id="EMI-C00239" he="31.24mm" wi="74.76mm" file="US20230002353A1-20230105-C00239.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0968" num="0727">MS (ESI, m/z): 532.3 [M+H]<sup>+</sup></p><heading id="h-0257" level="1">Example 233. 2-amino-5-cyano-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)-ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0969" num="0728">Using 2-amino-5-cyanonicotinic acid, the title compound was obtained as described for the synthesis of intermediate 20.</p><p id="p-0970" num="0000"><chemistry id="CHEM-US-00240" num="00240"><img id="EMI-C00240" he="30.65mm" wi="75.27mm" file="US20230002353A1-20230105-C00240.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0971" num="0729">MS (ESI, m/z): 539.3 [M+H]<sup>+</sup></p><heading id="h-0258" level="1">Example 234. 2-amino-6-chloro-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)-ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0972" num="0730">Using 2-amino-6-chloronicotinic acid, the title compound was obtained as described for the synthesis of intermediate 20.</p><p id="p-0973" num="0000"><chemistry id="CHEM-US-00241" num="00241"><img id="EMI-C00241" he="30.82mm" wi="74.93mm" file="US20230002353A1-20230105-C00241.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0974" num="0731"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.56 (br dd, J=13.11, 7.24 Hz, 1H) 1.66 (d, J=7.04 Hz, 3H) 1.70-1.85 (m, 3H) 2.01 (br dd, J=13.11, 6.46 Hz, 1H) 2.07-2.19 (m, 2H) 2.90 (s, 3H) 3.09-3.21 (m, 2H) 3.39-3.58 (m, 4H) 3.87-3.96 (m, 1H) 4.19 (br d, J=6.65 Hz, 1H) 4.35 (br d, J=4.70 Hz, 1H) 4.57-4.73 (m, 2H) 6.56 (d, J=7.83 Hz, 1H) 7.42 (m, J=8.22 Hz, 2H) 7.52 (d, J=8.22 Hz, 2H) 7.56 (d, J=8.22 Hz, 2H) 7.66 (m, J=8.22 Hz, 2H) 7.73 (d, J=8.22 Hz, 1H);</p><p id="p-0975" num="0732">MS (ESI, m/z): 548.3 [M+H]<sup>+</sup></p><heading id="h-0259" level="1">Example 235. 2-amino-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0976" num="0733">Using 2-aminonicotinic acid, the title compound was obtained as described for the synthesis of intermediate 20.</p><p id="p-0977" num="0000"><chemistry id="CHEM-US-00242" num="00242"><img id="EMI-C00242" he="33.19mm" wi="74.93mm" file="US20230002353A1-20230105-C00242.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0978" num="0734"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.58-1.64 (m, 1H) 1.66 (d, J=7.04 Hz, 3H) 1.74-1.85 (m, 3H) 1.97-2.05 (m, 1H) 2.13-2.20 (m, 1H) 2.89 (s, 3H) 3.02-3.27 (m, 4H) 3.46 (br s, 4H) 3.93-4.00 (m, 1H) 4.20 (q, J=6.46 Hz, 1H) 4.35-4.42 (m, 1H) 4.65 (s, 2H) 6.95 (t, J=6.75 Hz, 1H) 7.43 (d, J=8.22 Hz, 2H) 7.52 (m, J=8.22 Hz, 2H) 7.58 (m, J=8.22 Hz, 2H) 7.67 (d, J=8.22 Hz, 2H) 7.99 (dd, J=6.46, 1.17 Hz, 1H) 8.33 (dd, J=7.34, 1.47 Hz, 1H);</p><p id="p-0979" num="0735">MS (ESI, m/z): 514.3 [M+H]<sup>+</sup></p><heading id="h-0260" level="1">Example 236. 6-amino-5&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl)-piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0980" num="0736">Scheme for the Preparation of the Compound of Example 236:</p><p id="p-0981" num="0000"><chemistry id="CHEM-US-00243" num="00243"><img id="EMI-C00243" he="143.76mm" wi="130.56mm" file="US20230002353A1-20230105-C00243.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0982" num="0737">Intermediate 21. Using 1-(2-hydroxyethyl)piperazine, the title compound was obtained as described for the intermediate 20.</p><p id="p-0983" num="0738"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.42 (d, J=6.46 Hz, 2H) 1.51-1.58 (m, 1H) 1.71-1.81 (m, 3H) 1.97-2.04 (m, 1H) 2.08-2.15 (m, 1H) 2.61 (br s, 2H) 3.47 (br d, J=5.28 Hz, 1H) 3.67 (t, J=5.87 Hz, 2H) 3.91 (dt, J=6.46, 4.70 Hz, 1H) 4.35 (td, J=7.34, 4.70 Hz, 1H) 4.59-4.67 (m, 2H) 7.37 (br d, J=8.22 Hz, 2H) 7.39 (br d, J=8.22 Hz, 2H) 7.54 (d, J=7.63 Hz, 4H) 7.90 (d, J=2.35 Hz, 1H) 8.05 (d, J=2.35 Hz, 1H);</p><p id="p-0984" num="0739">MS (ESI+) m/z 622.2/624.2 [M+H]<sup>+</sup></p><heading id="h-0261" level="1">Example 236. 6-amino-5&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0985" num="0740">Using intermediate 21, the title compound was obtained as described for the example 230.</p><p id="p-0986" num="0741"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.63 (br dd, J=13.89, 6.85 Hz, 1H) 1.72 (br d, J=6.65 Hz, 3H) 1.76-1.87 (m, 3H) 2.04 (br dd, J=12.72, 6.46 Hz, 1H) 2.13-2.23 (m, 1H) 3.52-3.68 (m, 4H) 3.84 (br t, J=4.89 Hz, 2H) 4.00 (br d, J=3.91 Hz, 1H) 4.35 (br d, J=6.65 Hz, 1H) 4.39-4.49 (m, 2H) 4.61-4.73 (m, 2H) 7.43 (br d, J=7.83 Hz, 2H) 7.53 (br t, J=9.39 Hz, 4H) 7.63 (br d, J=8.22 Hz, 2H) 7.98 (br d, J=9.78 Hz, 1H) 8.43 (s, 1H) 8.52 (s, 1H) 8.61 (s, 1H) 8.71 (s, 1H);</p><p id="p-0987" num="0742">MS (ESI+) m/z 639.3 [M+H]<sup>+</sup></p><heading id="h-0262" level="1">Example 237. 6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl)-piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0988" num="0743">Using 6-fluoropyridine-3-boronic acid, the title compound was obtained as described for the example 236.</p><p id="p-0989" num="0000"><chemistry id="CHEM-US-00244" num="00244"><img id="EMI-C00244" he="37.34mm" wi="116.92mm" file="US20230002353A1-20230105-C00244.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0990" num="0744"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.62 (br dd, J=13.30, 6.65 Hz, 1H) 1.68 (br d, J=7.04 Hz, 3H) 1.81 (br d, J=7.43 Hz, 3H) 1.98-2.08 (m, 1H) 2.12-2.23 (m, 1H) 3.17-3.28 (m, 4H) 3.53 (br s, 4H) 3.84 (br d, J=4.30 Hz, 2H) 3.99 (br s, 1H) 4.25 (br d, J=7.04 Hz, 1H) 4.42 (br d, J=4.70 Hz, 1H) 4.62-4.72 (m, 2H) 7.16 (br d, J=7.83 Hz, 1H) 7.42 (br d, J=7.83 Hz, 2H) 7.47-7.59 (m, 4H) 7.62 (br d, J=7.83 Hz, 2H) 8.19 (br t, J=8.02 Hz, 1H) 8.34 (s, 1H) 8.47 (br s, 1H) 8.56 (s, 1H);</p><p id="p-0991" num="0745">MS (ESI+) n/z 639.3 [M+H]<sup>+</sup></p><heading id="h-0263" level="1">Example 238. 6-amino-2&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl)-piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-0992" num="0746">Using 2-fluoropyridine-3-boronic acid, the title compound was obtained as described for the example 236.</p><p id="p-0993" num="0000"><chemistry id="CHEM-US-00245" num="00245"><img id="EMI-C00245" he="37.34mm" wi="112.18mm" file="US20230002353A1-20230105-C00245.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0994" num="0747">MS (ESI+) m/z 639.3 [M+H]<sup>+</sup></p><heading id="h-0264" level="1">Example 239. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((1-methylpiperidin-4-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-0995" num="0748">Scheme for the Preparation of the Compound of Example 239:</p><p id="p-0996" num="0000"><chemistry id="CHEM-US-00246" num="00246"><img id="EMI-C00246" he="150.62mm" wi="135.47mm" file="US20230002353A1-20230105-C00246.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0997" num="0749">Intermediate 22.</p><p id="p-0998" num="0750">Using 4-(4-(1-trifluoroacetylpiperidino)methyl)phenylboronic acid pinacol ester, the title compound was obtained as described for the example 134.</p><p id="p-0999" num="0751"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.39-1.48 (m, 2H) 1.63 (br dd, J=13.50, 7.04 Hz, 1H) 1.76-1.86 (m, 4H) 1.86-1.95 (m, 3H) 2.04 (br dd, J=13.21, 6.75 Hz, 1H) 2.18 (br dd, J=13.50, 5.87 Hz, 1H) 2.64 (br d, J=6.46 Hz, 2H) 2.90-2.98 (m, 2H) 3.33 (s, 3H) 3.36 (br d, J=12.33 Hz, 3H) 3.89 (s, 3H) 3.97-4.03 (m, 1H) 4.37-4.45 (m, 1H) 4.63-4.70 (m, 2H) 7.23 (br d, J=8.22 Hz, 2H) 7.40 (d, J=8.22 Hz, 2H) 7.48 (d, J=8.22 Hz, 2H) 7.52 (d, J=8.22 Hz, 2H) 7.85 (s, 1H) 7.97 (s, 1H) 8.19 (d, J=1.76 Hz, 1H) 8.51 (d, J=2.35 Hz, 1H);</p><p id="p-1000" num="0752">MS (ESI, m/z): 564.8 [M+H]<sup>+</sup></p><heading id="h-0265" level="1">Example 239. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(1S,2S)-2-((4&#x2032;-((1-methylpiperidin-4-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-1001" num="0753">Using intermediate 22 and formaldehyde, the title compound was obtained as described for the example 214.</p><p id="p-1002" num="0754"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.42-1.54 (m, 2H) 1.63 (br dd, J=13.50, 7.04 Hz, 1H) 1.75-1.88 (m, 4H) 1.92 (br d, J=14.67 Hz, 2H) 2.00-2.08 (m, 1H) 2.17 (br dd, J=13.50, 5.87 Hz, 1H) 2.64 (br d, J=7.04 Hz, 2H) 2.82 (s, 3H) 2.89-2.98 (m, 2H) 3.47 (br d, J=12.33 Hz, 2H) 3.89 (s, 3H) 3.94-4.05 (m, 1H) 4.36-4.46 (m, 1H) 4.61-4.69 (m, 2H) 7.22 (d, J=8.22 Hz, 2H) 7.39 (br d, J=8.22 Hz, 2H) 7.47 (br d, J=8.22 Hz, 2H) 7.51 (br d, J=8.22 Hz, 2H) 7.84 (s, 1H) 7.96 (s, 1H) 8.18 (d, J=1.76 Hz, 1H) 8.49 (d, J=2.35 Hz, 1H);</p><p id="p-1003" num="0755">MS (ESI, m/z): 579.8 [M+H]<sup>+</sup></p><heading id="h-0266" level="1">Example 240. 2-amino-N-((1S,2S)-2-((4&#x2032;-((1-(2-hydroxyethyl)piperidin-4-yl)-methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-1004" num="0756">Scheme for the Preparation of the Compound of Example 240:</p><p id="p-1005" num="0000"><chemistry id="CHEM-US-00247" num="00247"><img id="EMI-C00247" he="92.29mm" wi="120.14mm" file="US20230002353A1-20230105-C00247.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1006" num="0757">To a mixture of intermediate 22 (30 mg, 0.05 mmol) and K<sub>2</sub>CO<sub>3 </sub>(22 mg, 0.16 mmol) in 0.4 ml of DMF was added 2-bromoethanol (6 &#x3bc;l, 0.08 mmol). The mixture was stirred at room temperature for 4 hr and then water was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 27 mg of the title compound.</p><p id="p-1007" num="0758"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.26 (br d, J=13.50 Hz, 2H) 1.56-1.74 (m, 4H) 1.74-1.89 (m, 4H) 2.04 (br dd, J=13.21, 6.16 Hz, 1H) 2.20 (br dd, J=13.50, 7.04 Hz, 1H) 2.64 (br d, J=7.04 Hz, 2H) 2.77 (br t, J=12.62 Hz, 2H) 3.05-3.13 (m, 2H) 3.47 (br d, J=12.33 Hz, 2H) 3.75-3.81 (m, 2H) 3.92 (s, 3H) 4.01-4.07 (m, 1H) 4.40-4.47 (m, 1H) 4.62-4.72 (m, 2H) 7.10 (br d, J=7.63 Hz, 1H) 7.20-7.26 (m, 3H) 7.27-7.33 (m, 2H) 7.41 (br d, J=7.63 Hz, 2H) 7.87-7.90 (m, 1H) 7.88 (s, 1H) 8.03 (s, 1H) 8.23 (d, J=1.76 Hz, 1H) 8.60 (br s, 1H);</p><p id="p-1008" num="0759">MS (ESI, m/z): 609.8 [M+H]<sup>+</sup></p><heading id="h-0267" level="1">Example 241. methyl 2-(4-((4&#x2032;-((((1S,2S)-2-(2-amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinamido)cyclopentyl)oxy)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methyl)piperidin-1-yl)-acetate</heading><p id="p-1009" num="0760">Using intermediate 22 and methyl bromoacetate, the title compound was obtained as described for the example 240.</p><p id="p-1010" num="0000"><chemistry id="CHEM-US-00248" num="00248"><img id="EMI-C00248" he="33.44mm" wi="118.28mm" file="US20230002353A1-20230105-C00248.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1011" num="0761"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.32 (br s, 2H) 1.61-1.71 (m, 4H) 1.79-1.89 (m, 4H) 2.01-2.06 (m, 1H) 2.20 (br dd, J=13.79, 6.75 Hz, 1H) 2.66 (br s, 2H) 2.85 (br s, 2H) 3.49 (br s, 2H) 3.79 (s, 3H) 3.92 (s, 3H) 4.01 (br s, 2H) 4.02-4.06 (m, 1H) 4.44 (br dd, J=11.15, 7.04 Hz, 1H) 4.63-4.73 (m, 2H) 7.11 (br d, J=7.63 Hz, 1H) 7.23-7.30 (m, 4H) 7.41 (br d, J=8.22 Hz, 2H) 7.88 (s, 1H) 8.02-8.04 (m, 1H) 8.23 (d, J=1.76 Hz, 1H) 8.60 (s, 1H);</p><p id="p-1012" num="0762">MS (ESI, m/z): 637.7 [M+H]<sup>+</sup></p><heading id="h-0268" level="1">Example 242. 2-amino-N-((1S,2S)-2-((4&#x2032;-((1-(2-amino-2-oxoethyl)piperidin-4-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-1013" num="0763">Using intermediate 22 and bromoacetamide, the title compound was obtained as described for the example 240.</p><p id="p-1014" num="0000"><chemistry id="CHEM-US-00249" num="00249"><img id="EMI-C00249" he="33.44mm" wi="117.77mm" file="US20230002353A1-20230105-C00249.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1015" num="0764">MS (ESI, m/z): 622.8 [M+H]<sup>+</sup></p><heading id="h-0269" level="1">Example 243. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-(4-(3-(4-methylpiperazin-1-yl)propyl)benzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1016" num="0765">Scheme for the Preparation of the Compound of Example 243</p><p id="p-1017" num="0000"><chemistry id="CHEM-US-00250" num="00250"><img id="EMI-C00250" he="126.41mm" wi="109.14mm" file="US20230002353A1-20230105-C00250.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1018" num="0766">Intermediate 23.</p><p id="p-1019" num="0767">A mixture of intermediate 4 (300 mg, 0.64 mmol), Pd(dba)<sub>2 </sub>(7 mg, 0.01 mmol), P(t-bu)<sub>3 </sub>(8 mg, 0.04 mmol) in DMF (3 ml) was degassed with nitrogen and TEA (0.133 ml, 0.96 mmol), allyl alcohol (0.11 ml, 1.28 mmol) were added. The mixture was heated at 100&#xb0; C. for 1h. After cooling, the mixture was partitioned between EA and water. The organic layer was separated and washed with water, brine dried over MgSO<sub>4 </sub>and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with Et<sub>2</sub>O-hexane mixtures as eluents to give 150 mg of off-white solid.</p><p id="p-1020" num="0768"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.64 (br dd, J=13.21, 6.75 Hz, 1H) 1.75 (br d, J=7.63 Hz, 1H) 1.79-1.85 (m, 2H) 1.94-2.04 (m, 3H) 2.16 (br d, J=6.46 Hz, 1H) 2.64 (br t, J=7.63 Hz, 2H) 2.89 (s, 3H) 3.02-3.07 (m, 2H) 3.40 (br s, 2H) 3.46 (br s, 4H) 3.93 (s, 3H) 3.96-4.00 (m, 1H) 4.36-4.42 (m, 1H) 4.54-4.65 (m, 3H) 7.16 (d, J=8.22 Hz, 2H) 7.27 (d, J=8.22 Hz, 2H) 7.84-7.89 (m, 1H) 8.03 (s, 1H) 8.23 (d, J=1.76 Hz, 1H) 8.56 (d, J=2.35 Hz, 1H);</p><p id="p-1021" num="0769">MS (ESI, m/z): 532.5 [M+H]<sup>+</sup></p><heading id="h-0270" level="1">Example 243. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(3-(4-methylpiperazin-1-yl)propyl)benzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1022" num="0770">Using intermediate 23, the title compound was obtained as described for the example 172.</p><p id="p-1023" num="0771"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.64 (br dd, J=13.21, 6.75 Hz, 1H) 1.75 (br d, J=7.63 Hz, 1H) 1.79-1.85 (m, 2H) 1.94-2.04 (m, 3H) 2.16 (br d, J=6.46 Hz, 1H) 2.64 (br t, J=7.63 Hz, 2H) 2.89 (s, 3H) 3.02-3.07 (m, 2H) 3.40 (br s, 2H) 3.46 (br s, 4H) 3.93 (s, 3H) 3.96-4.00 (m, 1H) 4.36-4.42 (m, 1H) 4.54-4.65 (m, 3H) 7.16 (d, J=8.22 Hz, 2H) 7.27 (d, J=8.22 Hz, 2H) 7.84-7.89 (m, 1H) 8.03 (s, 1H) 8.23 (d, J=1.76 Hz, 1H) 8.56 (d, J=2.35 Hz, 1H);</p><p id="p-1024" num="0772">MS (ESI, m/z): 532.4 [M+H]<sup>+</sup></p><heading id="h-0271" level="1">Example 244. 2-amino-N-((1S,2S)-2-((4-(3-(dimethylamino)propyl)benzyl)oxy)-cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1025" num="0773">Using intermediate 23 and dimethylamine (50% in THF), the title compound was obtained as described for the example 243.</p><p id="p-1026" num="0000"><chemistry id="CHEM-US-00251" num="00251"><img id="EMI-C00251" he="23.45mm" wi="74.59mm" file="US20230002353A1-20230105-C00251.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1027" num="0774"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.63-1.68 (m, 1H) 1.73-1.78 (m, 1H) 1.80-1.83 (m, 3H) 1.96-2.05 (m, 3H) 2.17 (br d, J=6.46 Hz, 1H) 2.65 (br t, J=7.63 Hz, 2H) 2.84 (s, 6H) 3.06-3.14 (m, 2H) 3.94 (s, 3H) 3.98 (br s, 1H) 4.39 (br s, 1H) 4.55-4.67 (m, 3H) 7.18 (br d, J=7.63 Hz, 2H) 7.29 (br d, J=7.63 Hz, 2H) 7.87-7.89 (m, 1H) 8.04 (s, 1H) 8.23 (d, J=1.76 Hz, 1H) 8.57 (d, J=2.35 Hz, 1H);</p><p id="p-1028" num="0775">MS (ESI, m/z): 477.5 [M+H]<sup>+</sup></p><heading id="h-0272" level="1">Example 245. 2-amino-N-((1S,2S)-2-((4&#x2032;-(2-(dimethylamino)ethoxy)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1029" num="0776">Scheme for the Preparation of the Compound of Example 245</p><p id="p-1030" num="0000"><chemistry id="CHEM-US-00252" num="00252"><img id="EMI-C00252" he="140.97mm" wi="112.27mm" file="US20230002353A1-20230105-C00252.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1031" num="0777">Intermediate 24.</p><p id="p-1032" num="0778">To a mixture of intermediate 4 (300 mg 0.64 mmol) and (4-hydroxyphenyl)boronic acid (132 mg, 0.96 mmol) in 4 ml of 1,4-dioxane/water (3/1) was added K<sub>2</sub>CO<sub>3 </sub>(264 mg, 1.91 mmol) followed by Pd(PPh<sub>3</sub>)<sub>4 </sub>(37 mg, 0.03 mmol). The reaction mixture was heated at 100&#xb0; C. for 3 hrs, cooled to room temperature, and extracted with EtOAc, dried over anhydrous MgSO<sub>4 </sub>and concentrated under vacuum. After concentration under vacuum, the crude material was purified by flash chromatography on silica gel with DCM-MeOH mixtures as eluents to give 250 mg of off-white solid.</p><p id="p-1033" num="0779"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.60 (br dd, J=13.21, 7.34 Hz, 1H) 1.74-1.87 (m, 3H) 2.04 (br dd, J=12.62, 7.34 Hz, 1H) 2.10-2.20 (m, 1H) 3.88 (s, 3H) 3.92-4.00 (m, 1H) 4.35-4.44 (m, 1H) 4.57 (d, J=12.33 Hz, 1H) 4.66 (d, J=12.33 Hz, 2H) 6.78 (m, J=8.22 Hz, 2H) 7.33 (t, J=9.10 Hz, 4H) 7.43 (m, J=8.22 Hz, 2H) 7.82 (s, 1H) 7.91 (s, 1H) 8.15 (d, J=2.35 Hz, 1H) 8.43 (d, J=1.76 Hz, 1H);</p><p id="p-1034" num="0780">MS (ESI, m/z): 484.3 [M+H]<sup>+</sup></p><heading id="h-0273" level="1">Example 245. 2-amino-N-((1S,2S)-2-((4&#x2032;-(2-(dimethylamino)ethoxy)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1035" num="0781">A mixture of intermediate 24 (30 mg, 0.06 mmol) and K<sub>2</sub>CO<sub>3 </sub>(43 mg, 0.31 mmol) was heated at 60&#xb0; C. for 12 hrs, cooled to room temperature, and extracted with EtOAc, dried over anhydrous MgSO<sub>4 </sub>and concentrated under vacuum. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 30 mg of the title compound</p><p id="p-1036" num="0782"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.57-1.68 (m, 1H) 1.81 (br d, J=7.83 Hz, 3H) 2.01 (br d, J=19.56 Hz, 1H) 2.16 (br d, J=12.91 Hz, 1H) 2.99 (s, 6H) 3.61 (br s, 2H) 3.89 (s, 3H) 3.99 (br s, 1H) 4.37 (br d, J=3.52 Hz, 3H) 4.64 (s, 2H) 7.05 (br d, J=8.22 Hz, 2H) 7.38 (br d, J=7.83 Hz, 2H) 7.50 (br t, J=7.43 Hz, 3H) 7.84 (s, 1H) 7.96 (s, 1H) 8.19 (br s, 1H) 8.48 (s, 1H);</p><p id="p-1037" num="0783">MS (ESI, m/z): 555.4 [M+H]<sup>+</sup></p><heading id="h-0274" level="1">Example 246. 2-amino-N-((1S,2S)-2-((4&#x2032;-(3-(dimethylamino)propoxy)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1038" num="0784">Using (3-chloropropyl)dimethylamine, title compound was obtained as described for the example 245.</p><p id="p-1039" num="0000"><chemistry id="CHEM-US-00253" num="00253"><img id="EMI-C00253" he="42.25mm" wi="107.70mm" file="US20230002353A1-20230105-C00253.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1040" num="0785"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.62 (br dd, J=13.21, 7.34 Hz, 1H) 1.73-1.86 (m, 3H) 2.04 (br dd, J=12.91, 7.63 Hz, 1H) 2.16 (br dd, J=13.21, 6.16 Hz, 1H) 2.19-2.28 (m, 2H) 2.94 (s, 6H) 3.32-3.41 (m, 2H) 3.88 (s, 3H) 3.93-4.05 (m, 1H) 4.13 (t, J=5.87 Hz, 2H) 4.36-4.43 (m, 1H) 4.58-4.68 (m, 2H) 6.97 (d, J=8.80 Hz, 2H) 7.37 (d, J=8.22 Hz, 2H) 7.46 (t, J=8.51 Hz, 4H) 7.82 (s, 1H) 7.93 (s, 1H) 8.17 (d, J=2.35 Hz, 1H) 8.43 (d, J=1.76 Hz, 1H);</p><p id="p-1041" num="0786">MS (ESI, m/z): 569.4 [M+H]<sup>+</sup></p><heading id="h-0275" level="1">Example 247. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4&#x2032;-((1-methylpiperidin-4-yl)oxy)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-1042" num="0787">Using 4-bromo-1-methylpiperidine, title compound was obtained as described for the example 245.</p><p id="p-1043" num="0000"><chemistry id="CHEM-US-00254" num="00254"><img id="EMI-C00254" he="33.44mm" wi="103.80mm" file="US20230002353A1-20230105-C00254.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1044" num="0788">MS (ESI, m/z): 581.5 [M+H]<sup>+</sup></p><heading id="h-0276" level="1">Example 248. 2-amino-N-((1S,2S)-2-((4-(3-(dimethylamino)prop-1-yn-1-yl)benzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1045" num="0789">Scheme for the Preparation of the Compound of Example 248</p><p id="p-1046" num="0000"><chemistry id="CHEM-US-00255" num="00255"><img id="EMI-C00255" he="79.84mm" wi="105.83mm" file="US20230002353A1-20230105-C00255.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1047" num="0790">A mixture of intermediate 4 (40 mg, 0.09 mmol), Pd(dba)<sub>2 </sub>(1 mg, 2 mol %), P(t-bu)<sub>3 </sub>(1 mg, 6 mol %) in DMF (3 ml) was degassed with nitrogen and TEA (0.018 ml, 0.13 mmol), N,N-dimethylpropargylamine (0.016 ml, 0.17 mmol) were added. The mixture was heated at 100&#xb0; C. for 12 hrs. After cooling, the mixture was partitioned between EA and water. The organic layer was separated and washed with water, brine dried over MgSO<sub>4 </sub>and concentrated in vacuo. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 10 mg of the title compound.</p><p id="p-1048" num="0791"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.63 (s, 2H) 1.78 (br dd, J=14.28, 6.85 Hz, 2H) 1.99 (br dd, J=12.91, 6.65 Hz, 1H) 2.09-2.18 (m, 1H) 2.35 (s, 3H) 3.12-3.18 (m, 1H) 3.32-3.34 (m, 4H) 3.42-3.50 (m, 2H) 3.58 (br d, J=7.04 Hz, 1H) 3.90 (s, 3H) 4.32-4.42 (m, 1H) 4.61 (s, 2H) 7.27-7.40 (m, 4H) 7.76 (s, 1H) 7.87 (s, 1H) 7.98 (s, 1H) 8.24 (s, 1H);</p><p id="p-1049" num="0792">MS (ESI, m/z): 473.4 [M+H]<sup>+</sup></p><heading id="h-0277" level="1">Example 249. 2-amino-N-((1S,2S)-2-((4-(4-hydroxybut-1-yn-1-yl)benzyl)oxy)-cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1050" num="0793">Using 3-butyn-1-ol, title compound was obtained as described for the example 248.</p><p id="p-1051" num="0000"><chemistry id="CHEM-US-00256" num="00256"><img id="EMI-C00256" he="25.74mm" wi="75.10mm" file="US20230002353A1-20230105-C00256.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1052" num="0794"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.62 (br dd, J=13.21, 7.34 Hz, 1H) 1.70-1.77 (m, 1H) 1.77-1.84 (m, 3H) 2.01 (br dd, J=12.62, 7.34 Hz, 1H) 2.15 (br dd, J=13.21, 6.16 Hz, 1H) 2.57 (t, J=6.75 Hz, 2H) 3.69 (t, J=6.75 Hz, 2H) 3.94 (s, 3H) 4.32-4.40 (m, 1H) 4.54-4.63 (m, 2H) 7.23-7.31 (m, 4H) 7.87 (s, 1H) 8.01 (s, 1H) 8.23 (d, J=2.35 Hz, 1H) 8.50 (d, J=1.76 Hz, 1H);</p><p id="p-1053" num="0795">MS (ESI, m/z): 460.6 [M+H]<sup>+</sup></p><heading id="h-0278" level="1">Example 250. 2-amino-N-((1S,2S)-2-((4-(5-hydroxypent-1-yn-1-yl)-benzyl)oxy)-cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1054" num="0796">Using 4-pentyn-1-ol, title compound was obtained as described for the example 248.</p><p id="p-1055" num="0000"><chemistry id="CHEM-US-00257" num="00257"><img id="EMI-C00257" he="28.02mm" wi="74.76mm" file="US20230002353A1-20230105-C00257.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1056" num="0797"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.62 (br dd, J=12.91, 7.04 Hz, 1H) 1.69-1.78 (m, 3H) 1.78-1.86 (m, 2H) 2.01 (br dd, J=12.91, 7.63 Hz, 1H) 2.16 (br d, J=5.87 Hz, 1H) 2.45 (t, J=7.04 Hz, 2H) 3.66 (t, J=6.46 Hz, 2H) 3.88-4.00 (m, 4H) 4.31-4.41 (m, 1H) 4.51-4.65 (m, 2H) 7.26 (s, 4H) 7.87 (s, 1H) 8.01 (s, 1H) 8.23 (d, J=1.76 Hz, 1H) 8.51 (d, J=2.35 Hz, 1H);</p><p id="p-1057" num="0798">MS (ESI, m/z): 474.2 [M+H]<sup>+</sup></p><heading id="h-0279" level="1">Example 251. 2-amino-N-((1S,2S)-2-((4-(6-hydroxyhex-1-yn-1-yl)benzyl)oxy)-cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1058" num="0799">Using 5-hexyn-1-ol, title compound was obtained as described for the example 248.</p><p id="p-1059" num="0000"><chemistry id="CHEM-US-00258" num="00258"><img id="EMI-C00258" he="25.06mm" wi="74.42mm" file="US20230002353A1-20230105-C00258.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1060" num="0800"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 0.00-0.00 (m, 1H) 1.54-1.69 (m, 8H) 1.72-1.78 (m, 1H) 1.78-1.86 (m, 3H) 1.91 (br d, J=7.63 Hz, 1H) 1.97-2.05 (m, 1H) 2.12-2.20 (m, 1H) 2.24-2.30 (m, 2H) 2.32 (br d, J=3.52 Hz, 1H) 2.40 (t, J=7.04 Hz, 1H) 2.45 (t, J=6.75 Hz, 1H) 2.43-2.43 (m, 1H) 3.55 (t, J=6.46 Hz, 2H) 3.56-3.60 (m, 1H) 3.94 (d, J=1.17 Hz, 3H) 4.35-4.41 (m, 2H) 4.43 (t, J=6.46 Hz, 1H) 4.54-4.65 (m, 2H) 4.68-4.68 (m, 1H) 4.69-4.69 (m, 1H) 7.26 (d, J=7.04 Hz, 3H) 7.87 (s, 1H) 8.01 (s, 1H) 8.19-8.26 (m, 1H) 8.48-8.53 (m, 1H);</p><p id="p-1061" num="0801">MS (ESI, m/z): 488.3 [M+H]<sup>+</sup></p><heading id="h-0280" level="1">Example 252. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((4-(4-(4-methylpiperazin-1-yl)but-1-yn-1-yl)benzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1062" num="0802">Scheme for the Preparation of the Compound of Example 252</p><p id="p-1063" num="0000"><chemistry id="CHEM-US-00259" num="00259"><img id="EMI-C00259" he="94.57mm" wi="130.13mm" file="US20230002353A1-20230105-C00259.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1064" num="0803">To a mixture of compound 249 (30 mg, 0.07 mmol) and triethylamine (27 &#x3bc;L, 0.2 mmol) in DCM (0.3 mL) was added methanesulfonyl chloride (12 &#x3bc;L, 0.16 mmol). The mixture was stirred at room temperature for 2 hrs. After completion of conversion, the volatile was removed under reduced pressure. The crude residue was diluted with EtOH (0.3 mL) and 1-methylpiperazine (16 &#x3bc;L, 0.13 mmol) was added. The mixture was refluxed for 2 hrs. After cooling, the crude residue was purified by preparative HPLC to afford 20 mg of the title compound.</p><p id="p-1065" num="0804"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.63 (br dd, J=13.21, 6.75 Hz, 1H) 1.75 (br d, J=5.28 Hz, 1H) 1.80-1.84 (m, 2H) 1.98-2.02 (m, 1H) 2.16 (br dd, J=13.79, 6.75 Hz, 1H) 2.78 (brs, 2H) 2.89-2.93 (m, 3H) 3.44 (brs, 4H) 3.55 (brs, 2H) 3.94 (s, 3H) 3.95-3.99 (m, 1H) 4.38 (br dd, J=11.15, 7.04 Hz, 1H) 4.60 (s, 2H) 7.26-7.35 (m, 4H) 7.88 (s, 1H) 8.02 (s, 1H) 8.23 (d, J=2.35 Hz, 1H) 8.55 (d, J=1.76 Hz, 1H);</p><p id="p-1066" num="0805">MS (ESI, m/z): 542.5 [M+H]<sup>+</sup></p><heading id="h-0281" level="1">Example 253. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1067" num="0806">Scheme for the Preparation of the Compound of Example 253:</p><p id="p-1068" num="0000"><chemistry id="CHEM-US-00260" num="00260"><img id="EMI-C00260" he="101.85mm" wi="75.78mm" file="US20230002353A1-20230105-C00260.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1069" num="0807">Intermediate 25.</p><p id="p-1070" num="0808">To a mixture of intermediate 3 (300 mg, 1.38 mmol) and triethylamine (168 mg, 1.66 mmol) in 7 ml of DMF was added HATU (524 mg, 1.66 mmol) followed by (1S,2S)-2-(benzyloxy)cyclopentan-1-amine (263 mg, 1.38 mmol). The mixture was stirred at room temperature for 1 hr and then saturated sodium bicarbonate solution was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude product was purified through silicagel column chromatography to give 326 mg of off-white solid.</p><p id="p-1071" num="0809"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; ppm 1.47 (dt, J=13.99, 6.90 Hz, 1H) 1.72-1.82 (m, 2H) 1.83-1.92 (m, 1H) 1.92-2.01 (m, 2H) 2.22-2.34 (m, 1H) 3.79-3.88 (m, 1H) 4.32 (dd, J=7.04, 4.70 Hz, 1H) 4.56-4.68 (m, 2H) 5.81 (br d, J=6.65 Hz, 1H) 6.35 (br s, 2H) 7.26-7.38 (m, 4H) 7.53 (d, J=2.35 Hz, 1H) 8.17 (d, J=2.35 Hz, 1H);</p><p id="p-1072" num="0810">MS (ESI, m/z): 390.2/392.2 [M+H]<sup>+</sup></p><heading id="h-0282" level="1">Example 253. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1073" num="0811">To a mixture of intermediate 25 (40 mg, 0.1 mmol) and (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid pinacol ester (51 mg, 0.16 mmol) in 1 ml of 1,4-dioxane was added 0.15 ml of aq. 2N K<sub>3</sub>PO<sub>4 </sub>followed by Pd(PPh<sub>3</sub>)<sub>4 </sub>(8 mg, 0.007 mmol). The reaction mixture was heated at 100&#xb0; C. for 3 hrs, cooled to room temperature, and extracted with EtOAc, dried over anhydrous MgSO<sub>4 </sub>and concentrated under vacuum. The crude residue was purified by preparative HPLC to afford 23 mg of the title compound.</p><p id="p-1074" num="0812"><sup>1</sup>H NMR (400 MHz, METHANOL-d<sub>4</sub>) &#x3b4; ppm 1.57 (br dd, J=13.30, 7.04 Hz, 1H) 1.66-1.87 (m, 3H) 1.97 (dt, J=13.01, 6.60 Hz, 1H) 2.13 (br dd, J=13.11, 6.85 Hz, 1H) 2.95 (s, 3H) 3.44-3.62 (m, 4H) 3.87-3.97 (m, 1H) 4.17 (s, 2H) 4.31-4.39 (m, 1H) 4.60 (s, 2H) 6.25 (d, J=9.00 Hz, 1H) 7.21-7.35 (m, 5H) 7.43 (d, J=8.22 Hz, 2H) 7.58 (d, J=8.61 Hz, 2H) 8.08 (d, J=9.00 Hz, 1H);</p><p id="p-1075" num="0813">MS (ESI, m/z): 500.3 [M+H]<sup>+</sup></p><heading id="h-0283" level="1">Example 254. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1076" num="0814">Using (1-(piperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 201.</p><p id="p-1077" num="0000"><chemistry id="CHEM-US-00261" num="00261"><img id="EMI-C00261" he="26.25mm" wi="74.93mm" file="US20230002353A1-20230105-C00261.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1078" num="0815">MS (ESI, m/z): 461.3 [M+H]<sup>+</sup></p><heading id="h-0284" level="1">Example 255. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1079" num="0816">Using (1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1080" num="0000"><chemistry id="CHEM-US-00262" num="00262"><img id="EMI-C00262" he="30.65mm" wi="75.10mm" file="US20230002353A1-20230105-C00262.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><heading id="h-0285" level="1">Example 256. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(1-(1-ethylpiperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1081" num="0817">Using (1-(1-ethylpiperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1082" num="0000"><chemistry id="CHEM-US-00263" num="00263"><img id="EMI-C00263" he="24.64mm" wi="75.69mm" file="US20230002353A1-20230105-C00263.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1083" num="0818">MS (ESI, m/z): 489.3 [M+H]<sup>+</sup></p><heading id="h-0286" level="1">Example 257. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(1-(1-isopropylpiperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1084" num="0819">Using (1-(1-isopropylpiperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1085" num="0000"><chemistry id="CHEM-US-00264" num="00264"><img id="EMI-C00264" he="24.72mm" wi="75.69mm" file="US20230002353A1-20230105-C00264.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1086" num="0820">MS (ESI, m/z): 503.3 [M+H]<sup>+</sup></p><heading id="h-0287" level="1">Example 258. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(1-(1-(pyrrolidin-3-ylmethyl)piperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1087" num="0821">Using (1-(1-(pyrrolidin-3-ylmethyl)piperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1088" num="0000"><chemistry id="CHEM-US-00265" num="00265"><img id="EMI-C00265" he="21.76mm" wi="74.76mm" file="US20230002353A1-20230105-C00265.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1089" num="0822">MS (ESI, m/z): 544.3 [M+H]<sup>+</sup></p><heading id="h-0288" level="1">Example 259. 2-amino-N-((1R,2R)-2-(benzyloxy)cyclopentyl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1090" num="0823">Using (1R,2R)-2-(benzyloxy)cyclopentan-1-amine and (1-(piperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1091" num="0000"><chemistry id="CHEM-US-00266" num="00266"><img id="EMI-C00266" he="26.33mm" wi="74.93mm" file="US20230002353A1-20230105-C00266.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1092" num="0824">MS (ESI, m/z): 461.3 [M+H]<sup>+</sup></p><heading id="h-0289" level="1">Example 260. 2-amino-N-((1S,2S)-2-((3,4-dichlorobenzyl)oxy)cyclopentyl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1093" num="0825">Using (1S,2S)-2-((3,4-dichlorobenzyl)oxy)cyclopentan-1-amine and (1-(piperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1094" num="0000"><chemistry id="CHEM-US-00267" num="00267"><img id="EMI-C00267" he="24.21mm" wi="75.69mm" file="US20230002353A1-20230105-C00267.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1095" num="0826">MS (ESI, m/z): 529.2 [M+H]<sup>+</sup></p><heading id="h-0290" level="1">Example 261. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(3-(hydroxymethyl)-1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1096" num="0827">Using (3-(hydroxymethyl)-1-methyl-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1097" num="0000"><chemistry id="CHEM-US-00268" num="00268"><img id="EMI-C00268" he="27.94mm" wi="64.69mm" file="US20230002353A1-20230105-C00268.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1098" num="0828">MS (ESI, m/z): 422.2 [M+H]<sup>+</sup></p><heading id="h-0291" level="1">Example 262. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(3-(((2-hydroxyethyl)amino)methyl)-1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1099" num="0829">Using (3-(((2-hydroxyethyl)amino)methyl)-1-methyl-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1100" num="0000"><chemistry id="CHEM-US-00269" num="00269"><img id="EMI-C00269" he="41.06mm" wi="64.69mm" file="US20230002353A1-20230105-C00269.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1101" num="0830">MS (ESI, m/z): 465.3 [M+H]<sup>+</sup></p><heading id="h-0292" level="1">Example 263. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(3-((3-hydroxypiperidin-1-yl)methyl)-1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1102" num="0831">Using (3-((3-hydroxypiperidin-1-yl)methyl)-1-methyl-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1103" num="0000"><chemistry id="CHEM-US-00270" num="00270"><img id="EMI-C00270" he="39.79mm" wi="59.18mm" file="US20230002353A1-20230105-C00270.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1104" num="0832">MS (ESI, m/z): 505.3 [M+H]<sup>+</sup></p><heading id="h-0293" level="1">Example 264. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(4-cyanophenyl)-nicotinamide</heading><p id="p-1105" num="0833">Using (4-cyanophenyl)boronic acid, the title compound was obtained as described for</p><p id="p-1106" num="0000"><chemistry id="CHEM-US-00271" num="00271"><img id="EMI-C00271" he="30.23mm" wi="69.26mm" file="US20230002353A1-20230105-C00271.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1107" num="0834"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; 1.59 (m, 2H) 1.85 (m, 4H) 2.10 (m, 2H) 2.24 (m, 1H) 4.17 (br d, J=7.04 Hz, 1H) 4.28 (br d, J=7.04 Hz, 1H) 4.43-4.54 (m, 1H) 4.56-4.67 (m, 2H) 7.13-7.19 (m, 1H) 7.13-7.19 (m, 1H) 7.13-7.19 (m, 2H) 7.19-7.24 (m, 2H) 7.35 (br d, J=7.43 Hz, 2H) 7.64 (m, J=8.22 Hz, 2H) 7.73 (m, J=8.22 Hz, 2H) 7.80 (s, 1H) 7.85-7.91 (m, 1H) 8.27 (s, 1H) 8.58 (br s, 2H) 11.76-11.97 (m, 2H);</p><p id="p-1108" num="0835">MS (ESI, m/z): 413.2 [M+H]<sup>+</sup></p><heading id="h-0294" level="1">Example 265. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(3-cyanophenyl)-nicotinamide</heading><p id="p-1109" num="0836">Using (3-cyanophenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1110" num="0000"><chemistry id="CHEM-US-00272" num="00272"><img id="EMI-C00272" he="24.64mm" wi="61.89mm" file="US20230002353A1-20230105-C00272.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1111" num="0837"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x25a1;&#x25a1; 1.54-1.70 (m, 2H) 1.70-1.95 (m, 4H) 2.07 (br s, 2H) 2.23 (br s, 2H) 4.08 (br d, J=5.87 Hz, 1H) 4.33 (br s, 1H) 4.61 (q, J=11.74 Hz, 2H) 7.14-7.20 (m, 1H) 7.20-7.29 (m, 2H) 7.29-7.38 (m, 2H) 7.53-7.63 (m, 1H) 7.70 (br d, J=7.43 Hz, 1H) 7.75 (br d, J=7.43 Hz, 1H) 7.87 (s, 1H) 7.91 (s, 1H) 8.26 (s, 1H) 8.87 (br s, 2H) 11.40-11.54 (m, 1H);</p><p id="p-1112" num="0838">MS (ESI, m/z): 413.2 [M+H]<sup>+</sup></p><heading id="h-0295" level="1">Example 266. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(4-(cyanomethyl)phenyl)nicotinamide</heading><p id="p-1113" num="0839">Using (4-(cyanomethyl)phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1114" num="0000"><chemistry id="CHEM-US-00273" num="00273"><img id="EMI-C00273" he="27.60mm" wi="72.22mm" file="US20230002353A1-20230105-C00273.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1115" num="0840"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x25a1;&#x25a1; 1.54-1.64 (m, 1H) 1.70 (br s, 1H) 1.83 (br s, 2H) 1.97-2.05 (m, 2H) 3.11 (br s, 1H) 3.79 (s, 2H) 4.35 (br s, 1H) 4.64 (s, 2H) 7.14 (br s, 1H) 7.18-7.24 (m, 3H) 7.39 (br t, J=7.83 Hz, 2H) 7.55 (br d, J=7.83 Hz, 1H) 7.59 (s, 1H) 8.00 (br s, 1H) 8.34 (s, 1H) 8.55-8.67 (m, 1H);</p><p id="p-1116" num="0841">MS (ESI, m/z): 427.2 [M+H]<sup>+</sup></p><heading id="h-0296" level="1">Example 267. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(4-phenoxyphenyl)nicotinamide</heading><p id="p-1117" num="0842">Using (4-phenoxyphenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1118" num="0000"><chemistry id="CHEM-US-00274" num="00274"><img id="EMI-C00274" he="25.91mm" wi="74.51mm" file="US20230002353A1-20230105-C00274.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1119" num="0843"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x25a1; 1.23 (m, 2H) 1.56 (m, 2H) 1.75 (m, 4H) 2.07 (br s, 2H) 2.24 (br s, 2H) 4.12 (br d, J=5.87 Hz, 1H) 4.29 (br s, 1H) 4.56-4.66 (m, 2H) 7.04 (br t, J=6.85 Hz, 3H) 7.17 (br d, J=7.43 Hz, 1H) 7.22-7.26 (m, 4H) 7.30-7.39 (m, 3H) 7.39-7.44 (m, 2H) 7.50 (s, 1H) 7.74 (s, 1H) 8.18 (s, 1H) 8.45 (br s, 2H) 11.28 (br s, 1H);</p><p id="p-1120" num="0844">MS (ESI m/z): 480.2 [M+H]<sup>+</sup></p><heading id="h-0297" level="1">Example 268. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5-(3-((1-methylpiperidin-4-yl)carbamoyl)phenyl)nicotinamide</heading><p id="p-1121" num="0845">Using (3-((1-methylpiperidin-4-yl)carbamoyl)phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1122" num="0000"><chemistry id="CHEM-US-00275" num="00275"><img id="EMI-C00275" he="23.37mm" wi="74.51mm" file="US20230002353A1-20230105-C00275.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1123" num="0846">MS (ESI m/z): 528.3 [M+H]<sup>+</sup></p><heading id="h-0298" level="1">Example 269. 6-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6&#x2032;-(hydroxymethyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-1124" num="0847">Using (6-(hydroxymethyl)pyridin-3-yl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1125" num="0000"><chemistry id="CHEM-US-00276" num="00276"><img id="EMI-C00276" he="27.60mm" wi="72.31mm" file="US20230002353A1-20230105-C00276.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1126" num="0848">MS (ESI, m/z): 420.2 [M+H]<sup>+</sup></p><heading id="h-0299" level="1">Example 270. 2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1127" num="0849">Using (1S,2S)-2-((3-methylbenzyl)oxy)cyclopentan-1-amine and (4-((4-methyl-piperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1128" num="0000"><chemistry id="CHEM-US-00277" num="00277"><img id="EMI-C00277" he="23.37mm" wi="75.69mm" file="US20230002353A1-20230105-C00277.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1129" num="0850">MS (ESI, m/z): 514.3 [M+H]<sup>+</sup></p><heading id="h-0300" level="1">Example 271. 2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(3-(4-methylpiperazine-1-carbonyl)phenyl)nicotinamide</heading><p id="p-1130" num="0851">Using (1S,2S)-2-((3-methylbenzyl)oxy)cyclopentan-1-amine and (4-methylpiperazin-1-yl)(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone, the title compound was obtained as described for the example 253.</p><p id="p-1131" num="0000"><chemistry id="CHEM-US-00278" num="00278"><img id="EMI-C00278" he="23.45mm" wi="75.69mm" file="US20230002353A1-20230105-C00278.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1132" num="0852">MS (ESI, m/z): 528.3 [M+H]<sup>+</sup></p><heading id="h-0301" level="1">Example 272. 2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(3-(4-(pyrrolidin-1-yl)piperidine-1-carbonyl)phenyl)nicotinamide</heading><p id="p-1133" num="0853">Using (1S,2S)-2-((3-methylbenzyl)oxy)cyclopentan-1-amine and (4-(pyrrolidin-1-yl)piperidin-1-yl)(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone, the title compound was obtained as described for the example 253.</p><p id="p-1134" num="0000"><chemistry id="CHEM-US-00279" num="00279"><img id="EMI-C00279" he="21.34mm" wi="75.52mm" file="US20230002353A1-20230105-C00279.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1135" num="0854">MS (ESI, m/z): 582.3 [M+H]<sup>+</sup></p><heading id="h-0302" level="1">Example 273. 2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(3-((4-methylpiperazin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1136" num="0855">Using (1S,2S)-2-((3-methylbenzyl)oxy)cyclopentan-1-amine and 1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine, the title compound was obtained as described for the example 253.</p><p id="p-1137" num="0000"><chemistry id="CHEM-US-00280" num="00280"><img id="EMI-C00280" he="22.61mm" wi="72.81mm" file="US20230002353A1-20230105-C00280.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1138" num="0856">MS (ESI, m/z): 514.3 [M+H]<sup>+</sup></p><heading id="h-0303" level="1">Example 274. 2-amino-5-(3-fluoro-4-((4-methylpiperazin-1-yl)methyl)phenyl)-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1139" num="0857">Using (1S,2S)-2-((3-methylbenzyl)oxy)cyclopentan-1-amine and 1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-4-methylpiperazine, the title compound was obtained as described for the example 253.</p><p id="p-1140" num="0000"><chemistry id="CHEM-US-00281" num="00281"><img id="EMI-C00281" he="23.45mm" wi="75.69mm" file="US20230002353A1-20230105-C00281.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1141" num="0858">MS (ESI, m/z): 532.3 [M+H]<sup>+</sup></p><heading id="h-0304" level="1">Example 275. 2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-((4-(pyrrolidin-1-yl)piperidin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1142" num="0859">Using (1S,2S)-2-((3-methylbenzyl)oxy)cyclopentan-1-amine and 4-(pyrrolidin-1-yl)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperidine, the title compound was obtained as described for the example 253.</p><p id="p-1143" num="0000"><chemistry id="CHEM-US-00282" num="00282"><img id="EMI-C00282" he="20.83mm" wi="74.00mm" file="US20230002353A1-20230105-C00282.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1144" num="0860">MS (ESI, m/z): 568.4 [M+H]<sup>+</sup></p><heading id="h-0305" level="1">Example 276. 2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-(4-methylpiperazine-1-carbonyl)phenyl)nicotinamide</heading><p id="p-1145" num="0861">Using (1S,2S)-2-((3-methylbenzyl)oxy)cyclopentan-1-amine and (4-methylpiperazin-1-yl)(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone, the title compound was obtained as described for the example 253.</p><p id="p-1146" num="0000"><chemistry id="CHEM-US-00283" num="00283"><img id="EMI-C00283" he="23.45mm" wi="75.69mm" file="US20230002353A1-20230105-C00283.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1147" num="0862">MS (ESI, m/z): 528.3 [M+H]<sup>+</sup></p><heading id="h-0306" level="1">Example 277. 2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-(4-(pyrrolidin-1-yl)piperidine-1-carbonyl)phenyl)nicotinamide</heading><p id="p-1148" num="0863">Using (1S,2S)-2-((3-methylbenzyl)oxy)cyclopentan-1-amine and (4-(pyrrolidin-1-yl)piperidin-1-yl)(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone, the title compound was obtained as described for the example 253.</p><p id="p-1149" num="0000"><chemistry id="CHEM-US-00284" num="00284"><img id="EMI-C00284" he="20.91mm" wi="74.00mm" file="US20230002353A1-20230105-C00284.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1150" num="0864">MS (ESI, m/z): 582.3 [M+H]<sup>+</sup></p><heading id="h-0307" level="1">Example 278. 2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-(2-((1-methylpiperidin-4-yl)amino)-2-oxoethyl)phenyl)nicotinamide</heading><p id="p-1151" num="0865">Using (1S,2S)-2-((3-methylbenzyl)oxy)cyclopentan-1-amine and N-(1-methylpiperidin-4-yl)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide, the title compound was obtained as described for the example 253.</p><p id="p-1152" num="0000"><chemistry id="CHEM-US-00285" num="00285"><img id="EMI-C00285" he="20.91mm" wi="74.59mm" file="US20230002353A1-20230105-C00285.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1153" num="0866">MS (ESI, m/z): 556.3 [M+H]<sup>+</sup></p><heading id="h-0308" level="1">Example 279. 2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-(2-(4-methylpiperazin-1-yl)acetyl)phenyl)nicotinamide</heading><p id="p-1154" num="0867">Using (1S,2S)-2-((3-methylbenzyl)oxy)cyclopentan-1-amine and 2-(4-methylpiperazin-1-yl)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethan-1-one, the title compound was obtained as described for the example 253.</p><p id="p-1155" num="0000"><chemistry id="CHEM-US-00286" num="00286"><img id="EMI-C00286" he="23.03mm" wi="73.83mm" file="US20230002353A1-20230105-C00286.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1156" num="0868">MS (ESI, m/z): 542.3 [M+H]<sup>+</sup></p><heading id="h-0309" level="1">Example 280. 2-amino-5-(3-fluoro-4-((4-(pyrrolidin-1-yl)piperidin-1-yl)-methyl)phenyl)-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1157" num="0869">(1S,2S)-2-((3-methylbenzyl)oxy)cyclopentan-1-amine and 1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-4-(pyrrolidin-1-yl)piperidine, the title compound was obtained as described for the example 253.</p><p id="p-1158" num="0000"><chemistry id="CHEM-US-00287" num="00287"><img id="EMI-C00287" he="20.91mm" wi="74.00mm" file="US20230002353A1-20230105-C00287.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1159" num="0870">MS (ESI, m/z): 586.4 [M+H]<sup>+</sup></p><heading id="h-0310" level="1">Example 281. 2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)phenyl)nicotinamide</heading><p id="p-1160" num="0871">Using (1S,2S)-2-((3-methylbenzyl)oxy)cyclopentan-1-amine and (4-(4-methyl-piperazin-1-yl)piperidin-1-yl)(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-methanone, the title compound was obtained as described for the example 253.</p><p id="p-1161" num="0000"><chemistry id="CHEM-US-00288" num="00288"><img id="EMI-C00288" he="27.60mm" wi="104.31mm" file="US20230002353A1-20230105-C00288.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1162" num="0872">MS (ESI, m/z): 611.4 [M+H]<sup>+</sup></p><heading id="h-0311" level="1">Example 282. 2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy)cyclopentyl)-5-(4-(piperazin-1-ylmethyl)phenyl)nicotinamide</heading><p id="p-1163" num="0873">Using (1S,2S)-2-((3-methylbenzyl)oxy)cyclopentan-1-amine and 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine, the title compound was obtained as described for the example 253.</p><p id="p-1164" num="0000"><chemistry id="CHEM-US-00289" num="00289"><img id="EMI-C00289" he="22.52mm" wi="71.46mm" file="US20230002353A1-20230105-C00289.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1165" num="0874">MS (ESI, m/z): 500.3 [M+H]<sup>+</sup></p><heading id="h-0312" level="1">Example 283. 2-amino-N-((1S,2S)-2-((4-methylbenzyl)oxy)cyclopentyl)-5-(4-(4-methylpiperazine-1-carbonyl)phenyl)nicotinamide</heading><p id="p-1166" num="0875">Using (1S,2S)-2-((4-methylbenzyl)oxy)cyclopentan-1-amine and (4-methylpiperazin-1-yl)(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone, the title compound was obtained as described for the example 253.</p><p id="p-1167" num="0000"><chemistry id="CHEM-US-00290" num="00290"><img id="EMI-C00290" he="23.45mm" wi="73.66mm" file="US20230002353A1-20230105-C00290.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1168" num="0876">MS (ESI, m/z): 528.3 [M+H]<sup>+</sup></p><heading id="h-0313" level="1">Example 284. 2-amino-N-((1S,2S)-2-((4-methylbenzyl)oxy)cyclopentyl)-5-(4-(4-(pyrrolidin-1-yl)piperidine-1-carbonyl)phenyl)nicotinamide</heading><p id="p-1169" num="0877">Using (1S,2S)-2-((4-methylbenzyl)oxy)cyclopentan-1-amine and (4-(pyrrolidin-1-yl)piperidin-1-yl)(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone, the title compound was obtained as described for the example 253.</p><p id="p-1170" num="0000"><chemistry id="CHEM-US-00291" num="00291"><img id="EMI-C00291" he="21.76mm" wi="74.76mm" file="US20230002353A1-20230105-C00291.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1171" num="0878">MS (ESI, m/z): 582.3 [M+H]<sup>+</sup></p><heading id="h-0314" level="1">Example 285. 2-amino-5-(1,5-dimethyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1172" num="0879">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (1,5-dimethyl-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1173" num="0000"><chemistry id="CHEM-US-00292" num="00292"><img id="EMI-C00292" he="27.52mm" wi="69.77mm" file="US20230002353A1-20230105-C00292.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1174" num="0880">MS (ESI, m/z): 434.3 [M+H]<sup>+</sup></p><heading id="h-0315" level="1">Example 286. 2-amino-5-(1,3-dimethyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1175" num="0881">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (1,3-dimethyl-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1176" num="0000"><chemistry id="CHEM-US-00293" num="00293"><img id="EMI-C00293" he="27.52mm" wi="69.85mm" file="US20230002353A1-20230105-C00293.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1177" num="0882">MS (ESI, m/z): 434.3 [M+H]<sup>+</sup></p><heading id="h-0316" level="1">Example 287. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(2-(2-hydroxypropan-2-yl)-4-methylthiazol-5-yl)nicotinamide</heading><p id="p-1178" num="0883">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (2-(2-hydroxypropan-2-yl)-4-methylthiazol-5-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1179" num="0000"><chemistry id="CHEM-US-00294" num="00294"><img id="EMI-C00294" he="28.79mm" wi="69.17mm" file="US20230002353A1-20230105-C00294.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1180" num="0884">MS (ESI, m/z): 495.2 [M+H]<sup>+</sup></p><heading id="h-0317" level="1">Example 288. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(2-(3-hydroxytetrahydrofuran-3-yl)-4-methylthiazol-5-yl)nicotinamide</heading><p id="p-1181" num="0885">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (2-(3-hydroxytetrahydrofuran-3-yl)-4-methylthiazol-5-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1182" num="0000"><chemistry id="CHEM-US-00295" num="00295"><img id="EMI-C00295" he="34.12mm" wi="69.51mm" file="US20230002353A1-20230105-C00295.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1183" num="0886">MS (ESI, m/z): 523.2 [M+H]<sup>+</sup></p><heading id="h-0318" level="1">Example 289. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1184" num="0887">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (4-((4-methyl-piperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1185" num="0000"><chemistry id="CHEM-US-00296" num="00296"><img id="EMI-C00296" he="23.45mm" wi="75.52mm" file="US20230002353A1-20230105-C00296.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1186" num="0888">MS (ESI, m/z): 528.3 [M+H]<sup>+</sup></p><heading id="h-0319" level="1">Example 290. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)phenyl)nicotinamide</heading><p id="p-1187" num="0889">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-(4-methyl-piperazin-1-yl)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethan-1-one, the title compound was obtained as described for the example 253.</p><p id="p-1188" num="0000"><chemistry id="CHEM-US-00297" num="00297"><img id="EMI-C00297" he="23.54mm" wi="75.27mm" file="US20230002353A1-20230105-C00297.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1189" num="0890">MS (ESI, m/z): 556.3 [M+H]<sup>+</sup></p><heading id="h-0320" level="1">Example 291. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-(morpholinomethyl)phenyl)nicotinamide</heading><p id="p-1190" num="0891">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine, the title compound was obtained as described for the example 253.</p><p id="p-1191" num="0000"><chemistry id="CHEM-US-00298" num="00298"><img id="EMI-C00298" he="24.21mm" wi="74.93mm" file="US20230002353A1-20230105-C00298.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1192" num="0892">MS (ESI, m/z): 515.3 [M+H]<sup>+</sup></p><heading id="h-0321" level="1">Example 292. 2-amino-5-(4-((dimethylamino)methyl)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1193" num="0893">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (4-((dimethyl-amino)methyl)phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1194" num="0000"><chemistry id="CHEM-US-00299" num="00299"><img id="EMI-C00299" he="25.91mm" wi="74.76mm" file="US20230002353A1-20230105-C00299.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1195" num="0894">MS (ESI, m/z): 473.3 [M+H]<sup>+</sup></p><heading id="h-0322" level="1">Example 293. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1196" num="0895">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 2-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazin-1-yl)ethan-1-ol, the title compound was obtained as described for the example 253.</p><p id="p-1197" num="0000"><chemistry id="CHEM-US-00300" num="00300"><img id="EMI-C00300" he="20.49mm" wi="75.61mm" file="US20230002353A1-20230105-C00300.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1198" num="0896">MS (ESI, m/z): 558.3 [M+H]<sup>+</sup></p><heading id="h-0323" level="1">Example 294. 6-amino-N-((1S,2S)-2-((3,4-dimethyl benzyl)oxy)cyclopentyl)-2&#x2032;-methoxy-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-1199" num="0897">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (2-methoxy-pyridin-3-yl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1200" num="0000"><chemistry id="CHEM-US-00301" num="00301"><img id="EMI-C00301" he="27.52mm" wi="65.79mm" file="US20230002353A1-20230105-C00301.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1201" num="0898">MS (ESI, m/z): 447.2 [M+H]<sup>+</sup></p><heading id="h-0324" level="1">Example 295. 2-amino-5-(4-(dimethylamino)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1202" num="0899">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (4-(dimethyl-amino)phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1203" num="0000"><chemistry id="CHEM-US-00302" num="00302"><img id="EMI-C00302" he="27.52mm" wi="74.76mm" file="US20230002353A1-20230105-C00302.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1204" num="0900">MS (ESI, m/z): 459.3 [M+H]<sup>+</sup></p><heading id="h-0325" level="1">Example 296. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-hydroxyphenyl)nicotinamide</heading><p id="p-1205" num="0901">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (3-hydroxy-phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1206" num="0000"><chemistry id="CHEM-US-00303" num="00303"><img id="EMI-C00303" he="27.52mm" wi="72.56mm" file="US20230002353A1-20230105-C00303.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1207" num="0902">MS (ESI, m/z): 432.2 [M+H]<sup>+</sup></p><heading id="h-0326" level="1">Example 297. 2-amino-5-(3-aminophenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)-oxy)cyclopentyl)nicotinamide</heading><p id="p-1208" num="0903">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (3-amino-phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1209" num="0000"><chemistry id="CHEM-US-00304" num="00304"><img id="EMI-C00304" he="27.60mm" wi="73.41mm" file="US20230002353A1-20230105-C00304.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1210" num="0904">MS (ESI, m/z): 431.2 [M+H]<sup>+</sup></p><heading id="h-0327" level="1">Example 298. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-(methylsulfonamido)phenyl)nicotinamide</heading><p id="p-1211" num="0905">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (3-(methyl-sulfonamido)phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1212" num="0000"><chemistry id="CHEM-US-00305" num="00305"><img id="EMI-C00305" he="25.91mm" wi="74.76mm" file="US20230002353A1-20230105-C00305.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1213" num="0906">MS (ESI, m/z): 509.2 [M+H]<sup>+</sup></p><heading id="h-0328" level="1">Example 299. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-(hydroxymethyl)phenyl)nicotinamide</heading><p id="p-1214" num="0907">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (3-(hydroxy-methyl)phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1215" num="0000"><chemistry id="CHEM-US-00306" num="00306"><img id="EMI-C00306" he="27.77mm" wi="72.56mm" file="US20230002353A1-20230105-C00306.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1216" num="0908">MS (ESI m/z): 446.2 [M+H]<sup>+</sup></p><heading id="h-0329" level="1">Example 300. 2-amino-5-(3-(aminomethyl)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1217" num="0909">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (3-(amino-methyl)phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1218" num="0000"><chemistry id="CHEM-US-00307" num="00307"><img id="EMI-C00307" he="27.77mm" wi="73.41mm" file="US20230002353A1-20230105-C00307.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1219" num="0910">MS (ESI m/z): 445.3 [M+H]<sup>+</sup></p><heading id="h-0330" level="1">Example 301. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-(3-hydroxypropyl)phenyl)nicotinamide</heading><p id="p-1220" num="0911">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (3-(3-hydroxy-propyl)phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1221" num="0000"><chemistry id="CHEM-US-00308" num="00308"><img id="EMI-C00308" he="25.15mm" wi="73.74mm" file="US20230002353A1-20230105-C00308.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1222" num="0912">MS (ESI, m/z): 474.3 [M+H]<sup>+</sup></p><heading id="h-0331" level="1">Example 302. 2-amino-N-(1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-((((1r,4S)-4-hydroxycyclohexyl)amino)methyl)phenyl)nicotinamide</heading><p id="p-1223" num="0913">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (1r,4r)-4-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)amino)cyclohexan-1-ol, the title compound was obtained as described for the example 253</p><p id="p-1224" num="0000"><chemistry id="CHEM-US-00309" num="00309"><img id="EMI-C00309" he="22.52mm" wi="73.24mm" file="US20230002353A1-20230105-C00309.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1225" num="0914">MS (ESI, m/z): 543.3 [M+H]<sup>+</sup></p><heading id="h-0332" level="1">Example 303. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-(((1-methylpiperidin-4-yl)amino)methyl)phenyl)nicotinamide</heading><p id="p-1226" num="0915">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-methyl-N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperidin-4-amine, the title compound was obtained as described for the example 253.</p><p id="p-1227" num="0000"><chemistry id="CHEM-US-00310" num="00310"><img id="EMI-C00310" he="23.28mm" wi="73.58mm" file="US20230002353A1-20230105-C00310.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1228" num="0916">MS (ESI, m/z): 542.3 [M+H]<sup>+</sup></p><heading id="h-0333" level="1">Example 304. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-((((S)-piperidin-3-yl)amino)methyl)phenyl)nicotinamide</heading><p id="p-1229" num="0917">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (S)&#x2014;N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperidin-3-amine, the title compound was obtained as described for the example 253.</p><p id="p-1230" num="0000"><chemistry id="CHEM-US-00311" num="00311"><img id="EMI-C00311" he="23.28mm" wi="72.22mm" file="US20230002353A1-20230105-C00311.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1231" num="0918">MS (ESI, m/z): 528.3 [M+H]<sup>+</sup></p><heading id="h-0334" level="1">Example 305. 3-(6-amino-5-(((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-carbamoyl)pyridin-3-yl)-5-hydroxybenzoic Acid</heading><p id="p-1232" num="0919">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 3-borono-5-hydroxybenzoic acid, the title compound was obtained as described for the example 253.</p><p id="p-1233" num="0000"><chemistry id="CHEM-US-00312" num="00312"><img id="EMI-C00312" he="30.06mm" wi="72.22mm" file="US20230002353A1-20230105-C00312.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1234" num="0920">MS (ESL, m/z): 476.2 [M+H]<sup>+</sup></p><heading id="h-0335" level="1">Example 306. 4-(6-amino-5-(((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-carbamoyl)pyridin-3-yl)-2-methylbenzoic Acid</heading><p id="p-1235" num="0921">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 4-borono-2-methylbenzoic acid, the title compound was obtained as described for the example 253.</p><p id="p-1236" num="0000"><chemistry id="CHEM-US-00313" num="00313"><img id="EMI-C00313" he="28.62mm" wi="74.76mm" file="US20230002353A1-20230105-C00313.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1237" num="0922">MS (ESI, m/z): 474.2 [M+H]<sup>+</sup></p><heading id="h-0336" level="1">Example 307. 2-amino-5-(4-aminophenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)-oxy)cyclopentyl)nicotinamide</heading><p id="p-1238" num="0923">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (4-amino-phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1239" num="0000"><chemistry id="CHEM-US-00314" num="00314"><img id="EMI-C00314" he="29.63mm" wi="73.07mm" file="US20230002353A1-20230105-C00314.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1240" num="0924">MS (ESI, m/z): 431.2 [M+H]<sup>+</sup></p><heading id="h-0337" level="1">Example 308. 3-(6-amino-5-(((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-carbamoyl)pyridin-3-yl)benzoic Acid</heading><p id="p-1241" num="0925">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 3-boronobenzoic acid, the title compound was obtained as described for the example 253.</p><p id="p-1242" num="0000"><chemistry id="CHEM-US-00315" num="00315"><img id="EMI-C00315" he="30.06mm" wi="67.31mm" file="US20230002353A1-20230105-C00315.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1243" num="0926">MS (ESI, m/z): 460.2 [M+H]<sup>+</sup></p><heading id="h-0338" level="1">Example 309. 3-amino-5-(6-amino-5-(((1S,2S)-2-((3,4-dimethylbenzyl)oxy)-cyclopentyl)carbamoyl)pyridin-3-yl)benzoic Acid</heading><p id="p-1244" num="0927">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 3-amino-5-boronobenzoic acid, the title compound was obtained as described for the example 253.</p><p id="p-1245" num="0000"><chemistry id="CHEM-US-00316" num="00316"><img id="EMI-C00316" he="29.97mm" wi="73.07mm" file="US20230002353A1-20230105-C00316.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1246" num="0928">MS (ESI, m/z): 475.2 [M+H]<sup>+</sup></p><heading id="h-0339" level="1">Example 310. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(2-methyl-5-(4-(pyrrolidin-1-yl)piperidine-1-carbonyl)phenyl)nicotinamide</heading><p id="p-1247" num="0929">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)(4-(pyrrolidin-1-yl)piperidin-1-yl)methanone, the title compound was obtained as described for the example 253.</p><p id="p-1248" num="0000"><chemistry id="CHEM-US-00317" num="00317"><img id="EMI-C00317" he="37.08mm" wi="74.76mm" file="US20230002353A1-20230105-C00317.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1249" num="0930">MS (ESI, m/z): 610.4 [M+H]<sup>+</sup></p><heading id="h-0340" level="1">Example 311. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-methyl-4-(4-methylpiperazine-1-carbonyl)phenyl)nicotinamide</heading><p id="p-1250" num="0931">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)(4-methylpiperazin-1-yl)methanone, the title compound was obtained as described for the example 253.</p><p id="p-1251" num="0000"><chemistry id="CHEM-US-00318" num="00318"><img id="EMI-C00318" he="24.21mm" wi="72.47mm" file="US20230002353A1-20230105-C00318.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1252" num="0932">MS (ESI, m/z): 556.3 [M+H]<sup>+</sup></p><heading id="h-0341" level="1">Example 312. 2-amino-5-(3-amino-5-(4-(pyrrolidin-1-yl)piperidine-1-carbonyl)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1253" num="0933">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (3-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)(4-(pyrrolidin-1-yl)piperidin-1-yl)methanone, the title compound was obtained as described for the example 253.</p><p id="p-1254" num="0000"><chemistry id="CHEM-US-00319" num="00319"><img id="EMI-C00319" he="35.81mm" wi="72.05mm" file="US20230002353A1-20230105-C00319.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1255" num="0934">MS (ESI, m/z): 611.4 [M+H]<sup>+</sup></p><heading id="h-0342" level="1">Example 313. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-(hydroxymethyl)phenyl)nicotinamide</heading><p id="p-1256" num="0935">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (4-(hydroxymethyl)phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1257" num="0000"><chemistry id="CHEM-US-00320" num="00320"><img id="EMI-C00320" he="28.70mm" wi="74.76mm" file="US20230002353A1-20230105-C00320.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1258" num="0936">MS (ESI, m/z): 446.2 [M+H]<sup>+</sup></p><heading id="h-0343" level="1">Example 314. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-formylphenyl)nicotinamide</heading><p id="p-1259" num="0937">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (4-formyl-phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1260" num="0000"><chemistry id="CHEM-US-00321" num="00321"><img id="EMI-C00321" he="28.28mm" wi="75.01mm" file="US20230002353A1-20230105-C00321.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1261" num="0938">MS (ESI, m/z): 444.2 [M+H]<sup>+</sup></p><heading id="h-0344" level="1">Example 315. 4-(6-amino-5-(((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-carbamoyl)pyridin-3-yl)benzoic Acid</heading><p id="p-1262" num="0939">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 4-boronobenzoic acid, the title compound was obtained as described for the example 253.</p><p id="p-1263" num="0000"><chemistry id="CHEM-US-00322" num="00322"><img id="EMI-C00322" he="28.28mm" wi="75.01mm" file="US20230002353A1-20230105-C00322.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1264" num="0940">MS (ESI, m/z): 460.2 [M+H]<sup>+</sup></p><heading id="h-0345" level="1">Example 316. 3-(4-(6-amino-5-(((1S,2S)-2-((3,4-dimethylbenzyl)oxy)-cyclopentyl)carbamoyl)pyridin-3-yl)phenyl)propanoic Acid</heading><p id="p-1265" num="0941">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 3-(4-boronophenyl)propanoic acid, the title compound was obtained as described for the example 253.</p><p id="p-1266" num="0000"><chemistry id="CHEM-US-00323" num="00323"><img id="EMI-C00323" he="24.55mm" wi="75.18mm" file="US20230002353A1-20230105-C00323.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1267" num="0942">MS (ESI, m/z): 488.3 [M+H]<sup>+</sup></p><heading id="h-0346" level="1">Example 317. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(2-hydroxyphenyl)nicotinamide</heading><p id="p-1268" num="0943">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (2-hydroxyphenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1269" num="0000"><chemistry id="CHEM-US-00324" num="00324"><img id="EMI-C00324" he="28.70mm" wi="65.62mm" file="US20230002353A1-20230105-C00324.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1270" num="0944">MS (ESI, m/z): 432.22 [M+H]<sup>+</sup></p><heading id="h-0347" level="1">Example 318. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((1-methylpiperidin-4-yl)carbamoyl)phenyl)nicotinamide</heading><p id="p-1271" num="0945">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and N-(1-methylpiperidin-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide, the title compound was obtained as described for the example 253.</p><p id="p-1272" num="0000"><chemistry id="CHEM-US-00325" num="00325"><img id="EMI-C00325" he="23.37mm" wi="75.10mm" file="US20230002353A1-20230105-C00325.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1273" num="0946">MS (ESI, m/z): 556.3 [M+H]<sup>+</sup></p><heading id="h-0348" level="1">Example 319. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-(dimethylcarbamoyl)phenyl)nicotinamide</heading><p id="p-1274" num="0947">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (4-(dimethyl-carbamoyl)phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1275" num="0000"><chemistry id="CHEM-US-00326" num="00326"><img id="EMI-C00326" he="26.92mm" wi="75.01mm" file="US20230002353A1-20230105-C00326.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1276" num="0948">MS (ESI m/z): 487.3 [M+H]<sup>+</sup></p><heading id="h-0349" level="1">Example 320. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-(((1-methylpiperidin-4-yl)amino)methyl)phenyl)nicotinamide</heading><p id="p-1277" num="0949">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-methyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperidin-4-amine, the title compound was obtained as described for the example 253.</p><p id="p-1278" num="0000"><chemistry id="CHEM-US-00327" num="00327"><img id="EMI-C00327" he="23.20mm" wi="74.59mm" file="US20230002353A1-20230105-C00327.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1279" num="0950">MS (ESI, m/z): 542.3 [M+H]<sup>+</sup></p><heading id="h-0350" level="1">Example 321. 6-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-6&#x2032;-(hydroxymethyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-1280" num="0951">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (6-(hydroxy-methyl)pyridin-3-yl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1281" num="0000"><chemistry id="CHEM-US-00328" num="00328"><img id="EMI-C00328" he="27.86mm" wi="75.61mm" file="US20230002353A1-20230105-C00328.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1282" num="0952">MS (ESI, m/z): 447.2 [M+H]<sup>+</sup></p><heading id="h-0351" level="1">Example 322. 2-amino-4-(6-amino-5-(((1S,2S)-2-((3,4-dimethylbenzyl)oxy)-cyclopentyl)carbamoyl)pyridin-3-yl)benzoic Acid</heading><p id="p-1283" num="0953">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 2-amino-4-boronobenzoic acid, the title compound was obtained as described for the example 253.</p><p id="p-1284" num="0000"><chemistry id="CHEM-US-00329" num="00329"><img id="EMI-C00329" he="27.86mm" wi="73.83mm" file="US20230002353A1-20230105-C00329.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1285" num="0954">MS (ESI, m/z): 475.2 [M+H]<sup>+</sup></p><heading id="h-0352" level="1">Example 323. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-(hydroxymethyl)-3-methoxyphenyl)nicotinamide</heading><p id="p-1286" num="0955">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol, the title compound was obtained as described for the example 253.</p><p id="p-1287" num="0000"><chemistry id="CHEM-US-00330" num="00330"><img id="EMI-C00330" he="27.86mm" wi="75.61mm" file="US20230002353A1-20230105-C00330.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1288" num="0956">MS (ESI, m/z): 476.3 [M+H]<sup>+</sup></p><heading id="h-0353" level="1">Example 324. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-fluoro-4-(hydroxymethyl)phenyl)nicotinamide</heading><p id="p-1289" num="0957">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (3-fluoro-4-(hydroxymethyl)phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1290" num="0000"><chemistry id="CHEM-US-00331" num="00331"><img id="EMI-C00331" he="27.86mm" wi="75.61mm" file="US20230002353A1-20230105-C00331.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1291" num="0958">MS (ESI, m/z): 464.2 [M+H]<sup>+</sup></p><heading id="h-0354" level="1">Example 325. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-fluoro-4-((4-(pyrrolidin-1-yl)piperidin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1292" num="0959">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-4-(pyrrolidin-1-yl)piperidine, the title compound was obtained as described for the example 253.</p><p id="p-1293" num="0000"><chemistry id="CHEM-US-00332" num="00332"><img id="EMI-C00332" he="21.93mm" wi="74.85mm" file="US20230002353A1-20230105-C00332.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1294" num="0960">MS (ESI, m/z): 600.4 [M+H]<sup>+</sup></p><heading id="h-0355" level="1">Example 326. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-(1-hydroxyethyl)phenyl)nicotinamide</heading><p id="p-1295" num="0961">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (4-(1-hydroxyethyl)phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1296" num="0000"><chemistry id="CHEM-US-00333" num="00333"><img id="EMI-C00333" he="27.86mm" wi="75.61mm" file="US20230002353A1-20230105-C00333.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1297" num="0962">MS (ESI, m/z): 460.3 [M+H]<sup>+</sup></p><heading id="h-0356" level="1">Example 327. 2-amino-5-(4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1298" num="0963">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and N,N-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-amine, the title compound was obtained as described for the example 253.</p><p id="p-1299" num="0000"><chemistry id="CHEM-US-00334" num="00334"><img id="EMI-C00334" he="23.28mm" wi="75.10mm" file="US20230002353A1-20230105-C00334.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1300" num="0964">MS (ESI, m/z): 542.3 [M+H]<sup>+</sup></p><heading id="h-0357" level="1">Example 328. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((4-hydroxypiperidin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1301" num="0965">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperidin-4-ol, the title compound was obtained as described for the example 253.</p><p id="p-1302" num="0000"><chemistry id="CHEM-US-00335" num="00335"><img id="EMI-C00335" he="23.28mm" wi="75.10mm" file="US20230002353A1-20230105-C00335.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1303" num="0966">MS (ESI, m/z): 529.3 [M+H]<sup>+</sup></p><heading id="h-0358" level="1">Example 329. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((((1-methylpiperidin-4-yl)methyl)amino)methyl)phenyl)nicotinamide</heading><p id="p-1304" num="0967">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-(1-methyl-piperidin-4-yl)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)methanamine, the title compound was obtained as described for the example 253.</p><p id="p-1305" num="0000"><chemistry id="CHEM-US-00336" num="00336"><img id="EMI-C00336" he="22.27mm" wi="75.52mm" file="US20230002353A1-20230105-C00336.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1306" num="0968">MS (ESI, m/z): 556.4 [M+H]<sup>+</sup></p><heading id="h-0359" level="1">Example 330. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-methyl-4-(4-(pyrrolidin-1-yl)piperidine-1-carbonyl)phenyl)nicotinamide</heading><p id="p-1307" num="0969">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)(4-(pyrrolidin-1-yl)piperidin-1-yl)methanone, the title compound was obtained as described for the example 253.</p><p id="p-1308" num="0000"><chemistry id="CHEM-US-00337" num="00337"><img id="EMI-C00337" he="22.52mm" wi="75.52mm" file="US20230002353A1-20230105-C00337.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1309" num="0970">MS (ESI, m/z): 610.4 [M+H]<sup>+</sup></p><heading id="h-0360" level="1">Example 331. 2-amino-5-(3-amino-4-(4-(pyrrolidin-1-yl)piperidine-1-carbonyl)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1310" num="0971">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (2-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)(4-(pyrrolidin-1-yl)piperidin-1-yl)methanone, the title compound was obtained as described for the example 253.</p><p id="p-1311" num="0000"><chemistry id="CHEM-US-00338" num="00338"><img id="EMI-C00338" he="22.44mm" wi="75.52mm" file="US20230002353A1-20230105-C00338.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1312" num="0972">MS (ESI, m/z): 611.4 [M+H]<sup>+</sup></p><heading id="h-0361" level="1">Example 332. 2-amino-5-(3-amino-4-((4-(pyrrolidin-1-yl)piperidin-1-yl)methyl)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1313" num="0973">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 2-((4-(pyrrolidin-1-yl)piperidin-1-yl)methyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-aniline, the title compound was obtained as described for the example 253.</p><p id="p-1314" num="0000"><chemistry id="CHEM-US-00339" num="00339"><img id="EMI-C00339" he="22.52mm" wi="75.52mm" file="US20230002353A1-20230105-C00339.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1315" num="0974">MS (ESI, m/z): 597.4 [M+H]<sup>+</sup></p><heading id="h-0362" level="1">Example 333. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-(hydroxymethyl)-3-methylphenyl)nicotinamide</heading><p id="p-1316" num="0975">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol, the title compound was obtained as described for the example 253.</p><p id="p-1317" num="0000"><chemistry id="CHEM-US-00340" num="00340"><img id="EMI-C00340" he="28.19mm" wi="75.18mm" file="US20230002353A1-20230105-C00340.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1318" num="0976">MS (ESI, m/z): 460.3 [M+H]<sup>+</sup></p><heading id="h-0363" level="1">Example 334. 2-amino-5-(3-chlorophenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)-oxy)cyclopentyl)nicotinamide</heading><p id="p-1319" num="0977">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (3-chloro-phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1320" num="0000"><chemistry id="CHEM-US-00341" num="00341"><img id="EMI-C00341" he="29.21mm" wi="72.39mm" file="US20230002353A1-20230105-C00341.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1321" num="0978">MS (ESI, m/z): 450 [M+H]<sup>+</sup></p><heading id="h-0364" level="1">Example 335. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(m-tolyl)nicotinamide</heading><p id="p-1322" num="0979">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and m-tolylboronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1323" num="0000"><chemistry id="CHEM-US-00342" num="00342"><img id="EMI-C00342" he="29.21mm" wi="70.44mm" file="US20230002353A1-20230105-C00342.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1324" num="0980">MS (ESI, m/z): 430.2 [M+H]<sup>+</sup></p><heading id="h-0365" level="1">Example 336. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3,5-dimethylphenyl)nicotinamide</heading><p id="p-1325" num="0981">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (3,5-dimethylphenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1326" num="0000"><chemistry id="CHEM-US-00343" num="00343"><img id="EMI-C00343" he="29.21mm" wi="70.44mm" file="US20230002353A1-20230105-C00343.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1327" num="0982">MS (ESI, m/z): 444.3 [M+H]<sup>+</sup></p><heading id="h-0366" level="1">Example 337. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((3-morpholinopyrrolidin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1328" num="0983">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 4-(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-yl)morpholine, the title compound was obtained as described for the example 253.</p><p id="p-1329" num="0000"><chemistry id="CHEM-US-00344" num="00344"><img id="EMI-C00344" he="29.21mm" wi="102.02mm" file="US20230002353A1-20230105-C00344.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1330" num="0984">MS (ESI, m/z): 584.4 [M+H]<sup>+</sup></p><heading id="h-0367" level="1">Example 338. 2-amino-5-(4-((4-aminopiperidin-1-yl)methyl)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1331" num="0985">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperidin-4-amine, the title compound was obtained as described for the example 253.</p><p id="p-1332" num="0000"><chemistry id="CHEM-US-00345" num="00345"><img id="EMI-C00345" he="23.62mm" wi="75.52mm" file="US20230002353A1-20230105-C00345.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1333" num="0986">MS (ESI, m/z): 528.3 [M+H]<sup>+</sup></p><heading id="h-0368" level="1">Example 339. 2-amino-5-(4-((3-aminopiperidin-1-yl)methyl)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1334" num="0987">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperidin-3-amine, the title compound was obtained as described for the example 253</p><p id="p-1335" num="0000"><chemistry id="CHEM-US-00346" num="00346"><img id="EMI-C00346" he="23.54mm" wi="75.52mm" file="US20230002353A1-20230105-C00346.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1336" num="0988">MS (ESI, m/z): 528.3 [M+H]<sup>+</sup></p><heading id="h-0369" level="1">Example 340. 2-amino-5-(4-((3-aminopyrrolidin-1-yl)methyl)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1337" num="0989">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-amine, the title compound was obtained as described for the example 253.</p><p id="p-1338" num="0000"><chemistry id="CHEM-US-00347" num="00347"><img id="EMI-C00347" he="23.62mm" wi="75.44mm" file="US20230002353A1-20230105-C00347.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1339" num="0990">MS (ESI, m/z): 514.3 [M+H]<sup>+</sup></p><heading id="h-0370" level="1">Example 341. 2-amino-5-(4-((3-aminopyrrolidin-1-yl)methyl)-3-fluorophenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1340" num="0991">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-amine, the title compound was obtained as described for the example 253.</p><p id="p-1341" num="0000"><chemistry id="CHEM-US-00348" num="00348"><img id="EMI-C00348" he="23.54mm" wi="75.44mm" file="US20230002353A1-20230105-C00348.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1342" num="0992">MS (ESI, m/z): 532.3 [M+H]<sup>+</sup></p><heading id="h-0371" level="1">Example 342. 2-amino-5-(4-((3-aminopyrrolidin-1-yl)methyl)-3,5-difluorophenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1343" num="0993">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-(2,6-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-amine, the title compound was obtained as described for the example 253.</p><p id="p-1344" num="0000"><chemistry id="CHEM-US-00349" num="00349"><img id="EMI-C00349" he="23.54mm" wi="75.44mm" file="US20230002353A1-20230105-C00349.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1345" num="0994">MS (ESI, m/z): 550.3 [M+H]<sup>+</sup></p><heading id="h-0372" level="1">Example 343. 2-amino-5-(3-((3-(dimethylamino)pyrrolidin-1-yl)methyl)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1346" num="0995">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and N,N-dimethyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-amine, the title compound was obtained as described for the example 253.</p><p id="p-1347" num="0000"><chemistry id="CHEM-US-00350" num="00350"><img id="EMI-C00350" he="23.71mm" wi="75.18mm" file="US20230002353A1-20230105-C00350.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1348" num="0996">MS (ESI, m/z): 542.3 [M+H]<sup>+</sup></p><heading id="h-0373" level="1">Example 344. 2-amino-5-(3-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-4-methoxyphenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1349" num="0997">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-N,N-dimethylpyrrolidin-3-amine, the title compound was obtained as described for the example 253.</p><p id="p-1350" num="0000"><chemistry id="CHEM-US-00351" num="00351"><img id="EMI-C00351" he="22.44mm" wi="75.44mm" file="US20230002353A1-20230105-C00351.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1351" num="0998">MS (ESI, m/z): 572.4 [M+H]<sup>+</sup></p><heading id="h-0374" level="1">Example 345. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((3-hydroxyazetidin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1352" num="0999">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)azetidin-3-ol, the title compound was obtained as described for the example 253.</p><p id="p-1353" num="0000"><chemistry id="CHEM-US-00352" num="00352"><img id="EMI-C00352" he="22.52mm" wi="73.24mm" file="US20230002353A1-20230105-C00352.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1354" num="1000">MS (ESI, m/z): 501.3 [M+H]<sup>+</sup></p><heading id="h-0375" level="1">Example 346. 2-amino-5-(4-(((R)-3-(dimethylamino)pyrrolidin-1-yl)methyl)-phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1355" num="1001">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (R)&#x2014;N,N-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-amine, the title compound was obtained as described for the example 253.</p><p id="p-1356" num="0000"><chemistry id="CHEM-US-00353" num="00353"><img id="EMI-C00353" he="22.52mm" wi="75.44mm" file="US20230002353A1-20230105-C00353.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1357" num="1002">MS (ESI, m/z): 542.3 [M+H]<sup>+</sup></p><heading id="h-0376" level="1">Example 347. 2-amino-5-(4-(((S)-3-(dimethylamino)pyrrolidin-1-yl)methyl)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1358" num="1003">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (S)&#x2014;N,N-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-amine, the title compound was obtained as described for the example 253.</p><p id="p-1359" num="0000"><chemistry id="CHEM-US-00354" num="00354"><img id="EMI-C00354" he="22.61mm" wi="75.44mm" file="US20230002353A1-20230105-C00354.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1360" num="1004">MS (ESI, m/z): 542.3 [M+H]<sup>+</sup></p><heading id="h-0377" level="1">Example 348. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-(((R)-3-hydroxypyrrolidin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1361" num="1005">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (R)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-ol, the title compound was obtained as described for the example 253.</p><p id="p-1362" num="0000"><chemistry id="CHEM-US-00355" num="00355"><img id="EMI-C00355" he="22.52mm" wi="75.44mm" file="US20230002353A1-20230105-C00355.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1363" num="1006">MS (ESI, m/z): 515.3 [M+H]<sup>+</sup></p><heading id="h-0378" level="1">Example 349. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-(((S)-3-hydroxypyrrolidin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1364" num="1007">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-ol, the title compound was obtained as described for the example 253.</p><p id="p-1365" num="0000"><chemistry id="CHEM-US-00356" num="00356"><img id="EMI-C00356" he="22.10mm" wi="74.76mm" file="US20230002353A1-20230105-C00356.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1366" num="1008">MS (ESI, m/z): 515.3 [M+H]<sup>+</sup></p><heading id="h-0379" level="1">Example 350. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-((3-hydroxypiperidin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1367" num="1009">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperidin-3-ol, the title compound was obtained as described for the example 253.</p><p id="p-1368" num="0000"><chemistry id="CHEM-US-00357" num="00357"><img id="EMI-C00357" he="22.61mm" wi="75.44mm" file="US20230002353A1-20230105-C00357.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1369" num="1010">MS (ESI, m/z): 529.3 [M+H]<sup>+</sup></p><heading id="h-0380" level="1">Example 351. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-hydroxyphenyl)nicotinamide</heading><p id="p-1370" num="1011">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (4-hydroxy-phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1371" num="0000"><chemistry id="CHEM-US-00358" num="00358"><img id="EMI-C00358" he="22.52mm" wi="61.55mm" file="US20230002353A1-20230105-C00358.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1372" num="1012">MS (ESI, m/z): 432.2 [M+H]<sup>+</sup></p><heading id="h-0381" level="1">Example 352. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(4-hydroxy-3-methoxyphenyl)nicotinamide</heading><p id="p-1373" num="1013">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (4-hydroxy-3-methoxyphenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1374" num="0000"><chemistry id="CHEM-US-00359" num="00359"><img id="EMI-C00359" he="27.18mm" wi="74.76mm" file="US20230002353A1-20230105-C00359.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1375" num="1014">MS (ESI, m/z): 462.23 [M+H]<sup>+</sup></p><heading id="h-0382" level="1">Example 353. 2-amino-5-(3,4-dimethoxyphenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1376" num="1015">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (3,4-dimethoxy-phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1377" num="0000"><chemistry id="CHEM-US-00360" num="00360"><img id="EMI-C00360" he="22.61mm" wi="60.88mm" file="US20230002353A1-20230105-C00360.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1378" num="1016">MS (ESI, m/z): 476.3 [M+H]<sup>+</sup></p><heading id="h-0383" level="1">Example 354. 2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)-5-(3-(pyrrolidin-1-yl)phenyl)nicotinamide</heading><p id="p-1379" num="1017">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and (3-(pyrrolidin-1-yl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1380" num="0000"><chemistry id="CHEM-US-00361" num="00361"><img id="EMI-C00361" he="22.61mm" wi="66.89mm" file="US20230002353A1-20230105-C00361.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1381" num="1018">MS (ESI, m/z): 485.3 [M+H]<sup>+</sup></p><heading id="h-0384" level="1">Example 355. 2-amino-5-(5-amino-1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1382" num="1019">Using (1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentan-1-amine and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-5-amine, the title compound was obtained as described for the example 253.</p><p id="p-1383" num="0000"><chemistry id="CHEM-US-00362" num="00362"><img id="EMI-C00362" he="22.61mm" wi="59.52mm" file="US20230002353A1-20230105-C00362.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1384" num="1020">MS (ESI, m/z): 435.2 [M+H]<sup>+</sup></p><heading id="h-0385" level="1">Example 356. 2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentyl)-5-(4-(hydroxymethyl)phenyl)nicotinamide</heading><p id="p-1385" num="1021">Using (1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentan-1-amine and (4-(hydroxy-methyl)phenyl)boronic acid, the title compound was obtained as described for the example 253.</p><p id="p-1386" num="0000"><chemistry id="CHEM-US-00363" num="00363"><img id="EMI-C00363" he="22.52mm" wi="67.82mm" file="US20230002353A1-20230105-C00363.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1387" num="1022">MS (ESI, m/z): 460.3 [M+H]<sup>+</sup></p><heading id="h-0386" level="1">Example 357. 2-amino-5-(4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)phenyl)-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentyl)nicotinamide</heading><p id="p-1388" num="1023">Using (1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentan-1-amine and N,N-dimethyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-amine, the title compound was obtained as described for the example 253.</p><p id="p-1389" num="0000"><chemistry id="CHEM-US-00364" num="00364"><img id="EMI-C00364" he="21.76mm" wi="75.95mm" file="US20230002353A1-20230105-C00364.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1390" num="1024">MS (ESI, m/z): 556.4 [M+H]<sup>+</sup></p><heading id="h-0387" level="1">Example 358. 2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentyl)-5-(4-((3-hydroxypyrrolidin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1391" num="1025">Using (1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentan-1-amine and 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-ol, the title compound was obtained as described for the example 253.</p><p id="p-1392" num="0000"><chemistry id="CHEM-US-00365" num="00365"><img id="EMI-C00365" he="21.76mm" wi="75.95mm" file="US20230002353A1-20230105-C00365.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1393" num="1026">MS (ESI, m/z): 529.3 [M+H]<sup>+</sup></p><heading id="h-0388" level="1">Example 359. 2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentyl)-5-(4-(2-(piperazin-1-yl)propan-2-yl)phenyl)nicotinamide</heading><p id="p-1394" num="1027">Using (1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentan-1-amine and 1-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl)piperazine, the title compound was obtained as described for the example 253.</p><p id="p-1395" num="0000"><chemistry id="CHEM-US-00366" num="00366"><img id="EMI-C00366" he="23.03mm" wi="74.93mm" file="US20230002353A1-20230105-C00366.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1396" num="1028"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.11 (t, J=7.63 Hz, 3H) 1.50 (s, 6H) 1.58-1.67 (m, 1H) 1.70-1.88 (m, 3H) 1.98-2.06 (m, 1H) 2.10-2.17 (m, 1H) 2.17 (s, 3H) 2.49-2.57 (q, J=7.63 Hz, 2H) 2.84 (br s, 4H) 3.24 (t, J=4.70 Hz, 4H) 3.91-4.00 (m, 1H) 4.40 (br d, J=4.70 Hz, 1H) 4.49-4.61 (m, 2H) 6.98-7.05 (m, 2H) 7.09 (s, 1H) 7.64-7.80 (m, 4H) 8.31 (d, J=2.35 Hz, 1H) 8.57 (d, J=1.96 Hz, 1H);</p><p id="p-1397" num="1029">MS (ESI, m/z): 556.4 [M+H]<sup>+</sup></p><heading id="h-0389" level="1">Example 360. 2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentyl)-5-(4-(2-(4-(2-hydroxyethyl)piperazin-1-yl)propan-2-yl)phenyl)nicotinamide</heading><p id="p-1398" num="1030">Using (1S,2S)-2-((3-ethyl-4-methylbenzyl)oxy)cyclopentan-1-amine and 2-(4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl)piperazin-1-yl)ethan-1-ol, the title compound was obtained as described for the example 253.</p><p id="p-1399" num="0000"><chemistry id="CHEM-US-00367" num="00367"><img id="EMI-C00367" he="19.98mm" wi="75.27mm" file="US20230002353A1-20230105-C00367.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1400" num="1031"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.11 (t, J=7.43 Hz, 3H) 1.57 (s, 3H) 1.61-1.64 (m, 1H) 1.64 (s, 3H) 1.69-1.89 (m, 3H) 2.01 (br dd, J=13.11, 6.06 Hz, 1H) 2.10-2.29 (m, 4H) 2.53 (q, J=7.56 Hz, 2H) 2.88-3.13 (m, 4H) 3.22-3.28 (m, 1H) 3.33-3.39 (m, 2H) 3.43 (br s, 2H) 3.83-3.90 (m, 1H) 3.92-4.00 (m, 1H) 4.35-4.45 (m, 1H) 4.47-4.62 (m, 2H) 6.95-7.07 (m, 2H) 7.09 (s, 1H) 7.65-7.84 (m, 4H) 8.29-8.36 (m, 1H) 8.56-8.64 (m, 1H);</p><p id="p-1401" num="1032">MS (ESI, m/z): 600.3 [M+H]<sup>+</sup></p><heading id="h-0390" level="1">Example 361. 3-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazine-2-carboxamide</heading><p id="p-1402" num="1033">Using 3-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6-bromopyrazine-2-carboxamide and (1-(piperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1403" num="0000"><chemistry id="CHEM-US-00368" num="00368"><img id="EMI-C00368" he="26.84mm" wi="74.93mm" file="US20230002353A1-20230105-C00368.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1404" num="1034">MS (ESI, m/z): 462.3 [M+H]<sup>+</sup></p><heading id="h-0391" level="1">Example 362. (S)-3-amino-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazine-2-carboxamide</heading><p id="p-1405" num="1035">Using (S)-3-amino-6-bromo-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazine-2-carboxamide and (1-(piperidin-4-yl)-1H-pyrazol-4-yl)boronic acid pinacol ester, the title compound was obtained as described for the example 253.</p><p id="p-1406" num="0000"><chemistry id="CHEM-US-00369" num="00369"><img id="EMI-C00369" he="37.17mm" wi="62.31mm" file="US20230002353A1-20230105-C00369.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1407" num="1036">MS (ESI, m/z): 418.2 [M+H]<sup>+</sup></p><heading id="h-0392" level="1">Example 363. 2-amino-5-(4-fluorophenyl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-1408" num="1037">Scheme for the Preparation of the Compound of Example 363:</p><p id="p-1409" num="0000"><chemistry id="CHEM-US-00370" num="00370"><img id="EMI-C00370" he="218.44mm" wi="154.86mm" file="US20230002353A1-20230105-C00370.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1410" num="1038">Intermediate 26.</p><p id="p-1411" num="1039">To a solution of trans-(1S,2S)-2-Aminocyclopentanol hydrochloride (8.0 mmol) in DMF (5 ml) was added 1M potassium tert-butoxide in THF (20 ml) at room temperature. The mixture was allowed to stir for 30 min. After being allowed to stir for 30 min, 4-bromobenzyl bromide (9.6 mmol) was added to the mixture, and then allowed to stir for additional 2 h at room temperature. The reaction mixture was then quenched with water and extracted with EtOAc. The separated organic layer was dried over MgSO<sub>4</sub>, filtered and concentrated in vacuo. The concentrated residue was used in the next step without further purification.</p><p id="p-1412" num="1040"><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) &#x3b4; ppm 1.29-1.35 (m, 1H) 1.57-1.65 (m, 1H) 1.65-1.77 (m, 2H) 1.96 (br dd, J=12.62, 6.75 Hz, 2H) 3.20-3.27 (m, 1H) 3.51 (br d, J=5.28 Hz, 1H) 4.40-4.46 (m, 1H) 4.46-4.54 (m, 1H) 7.21 (br t, J=7.63 Hz, 2H) 7.40-7.48 (m, 2H);</p><p id="p-1413" num="1041">MS (ESI+) m/z 270 [M+H]<sup>+</sup></p><p id="p-1414" num="1042">Intermediate 27.</p><p id="p-1415" num="1043">To a solution of intermediate 26 (0.851 mmol) in 1,4-dioxane (4 ml) and water (1 ml) was added 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine (0.851 mmol), tetrakis(triphenylphosphine)palladium(0) (0.0851 mmol) and potassium carbonate (0.851 mmol). The mixture was heated to 100&#xb0; C. and allowed to stir for overnight. After being cooled to room temperature, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL). The separated organic layer was dried over MgSO<sub>4</sub>, filtered and concentrated in vacuo. The concentrated residue was purified by flash column chromatography to afford the desired compound (265 mg, 0.7 mmol).</p><p id="p-1416" num="1044"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.36-1.45 (m, 1H) 1.63-1.78 (m, 3H) 1.97-2.07 (m, 2H) 2.26 (s, 3H) 2.30-2.71 (br s, 8H) 3.24 (td, J=7.48, 4.99 Hz, 1H) 3.55 (s, 2H) 3.67-3.74 (m, 1H) 4.53 (d, J=11.74 Hz, 1H) 4.60 (d, J=11.74 Hz, 1H) 7.38 (d, J=8.22 Hz, 2H) 7.42 (d, J=8.22 Hz, 2H) 7.55-7.58 (m, 2H) 7.58-7.61 (m, 2H);</p><p id="p-1417" num="1045">MS (ESI+) m/z 380 [M+H]<sup>+</sup></p><p id="p-1418" num="1046">Intermediate 28.</p><p id="p-1419" num="1047">To a solution of intermediate 27 (0.685 mmol) and 2-amino-5-bromonicotinic acid (0.685 mmol) in N,N-dimethylformamide (5 mL) was added diisopropylethylamine (3.425 mmol) and HATU (1.027 mmol) at room temperature. The reaction mixture was allowed to stir for overnight, concentrated in vacuo, diluted with EtOAc and washed with brine. The separated organic layer was dried over MgSO<sub>4</sub>, filtered and concentrated in vacuo. The concentrated residue was purified by flash column chromatography to afford the desired compound (0.653 mmol) as a pale yellow oil.</p><p id="p-1420" num="1048"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.49-1.57 (m, 1H) 1.68-1.78 (m, 3H) 1.95-2.01 (m, 1H) 2.07-2.13 (m, 1H) 2.41 (s, 3H) 2.49-2.79 (br s, 8H) 3.56 (s, 2H) 3.91 (dt, J=6.90, 4.48 Hz, 1H) 4.34 (td, J=7.48, 4.40 Hz, 1H) 4.57-4.65 (m, 2H) 7.35 (br d, J=8.22 Hz, 2H) 7.37 (br d, J=8.22 Hz, 2H) 7.52 (d, J=7.63 Hz, 4H) 7.90 (d, J=2.35 Hz, 1H) 8.04 (d, J=2.35 Hz, 1H);</p><p id="p-1421" num="1049">MS (ESI+) m/z 579 [M+H]<sup>+</sup></p><heading id="h-0393" level="1">Example 363. 2-amino-5-(4-fluorophenyl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-1422" num="1050">To a solution of intermediate 28 (0.076 mmol) in 1,4-dioxane (4 ml) and water (1 ml) was added (4-fluorophenyl)boronic acid (0.076 mmol), tetrakis(triphenylphosphine)-palladium(0) (0.0076 mmol) and potassium carbonate (0.076 mmol). The mixture was heated to 100&#xb0; C. and allowed to stir for overnight. After being cooled to room temperature, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL). The separated organic layer was dried over MgSO<sub>4</sub>, filtered and concentrated in vacuo. The concentrated residue was purified by preparative HPLC to afford the compound of Example 363.</p><p id="p-1423" num="1051"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; 8.57 (s, 1H), 8.23 (s, 1H), 7.64-7.47 (m, 8H), 7.42 (d, 2H), 7.17 (t, 2H), 4.66 (qd, 2H), 4.45-4.39 (m, 1H), 4.25 (s, 1H), 4.09-3.90 (m, 1H), 3.62 (s, 1H), 3.53 (br s, 2H), 3.39 (br s, 2H), 2.94 (s, 3H), 2.19-2.12 (m, 1H), 2.05-1.97 (m, 1H), 1.83-1.75 (m, 3H), 1.66-1.57 (m, 1H);</p><p id="p-1424" num="1052">MS (ESI+) n/z 594 [M+H]<sup>+</sup></p><heading id="h-0394" level="1">Example 364. 2-amino-5-(3,4-difluorophenyl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-1425" num="1053">Using 3,4-difluorophenylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1426" num="0000"><chemistry id="CHEM-US-00371" num="00371"><img id="EMI-C00371" he="31.67mm" wi="75.27mm" file="US20230002353A1-20230105-C00371.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1427" num="1054"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; 8.54 (s, 1H), 8.26 (s, 1H), 7.71-7.52 (m, 8H), 7.42-7.33 (m, 3H), 4.65 (qd, 2H), 4.41 (m, 1H), 4.32 (s, 2H), 3.98 (m, 1H), 3.57 (br s, 2H), 3.48 (br s, 2H), 2.94 (s, 3H), 2.18-2.05 (m, 1H), 2.04-1.99 (m, 1H), 1.81-1.73 (m, 3H), 1.66-1.59 (m, 1H);</p><p id="p-1428" num="1055">MS (ESI+) m/z 612 [M+H]<sup>+</sup></p><heading id="h-0395" level="1">Example 365. 2-amino-N-((1S,2S)-2-(4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(4-(trifluoromethyl)phenyl)nicotinamide</heading><p id="p-1429" num="1056">Using 4-trifluoromethylphenylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1430" num="0000"><chemistry id="CHEM-US-00372" num="00372"><img id="EMI-C00372" he="30.56mm" wi="75.01mm" file="US20230002353A1-20230105-C00372.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1431" num="1057"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; 8.65 (s, 1H), 8.36 (s, 1H), 7.83 (d, J=8.0 Hz, 2H), 7.75 (d, J=12.0 Hz, 2H), 7.62 (d, J=8.0 Hz, 2H), 7.54-7.50 (m, 4H), 7.42 (d, J=8.0 Hz, 2H), 4.69-4.62 (qd, 2H), 4.44-4.39 (m, 1H), 4.27 (s, 2H), 4.02-4.00 (m, 1H), 3.54 (br s, 2H), 3.42 (br s, 2H), 2.94 (s, 3H), 2.21-2.05 (m, 1H), 2.05-1.97 (m, 1H), 1.87-1.76 (m, 3H), 1.68-1.59 (m, 1H);</p><p id="p-1432" num="1058">MS (ESI+) m/z 644 [M+H]<sup>+</sup></p><heading id="h-0396" level="1">Example 366. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1433" num="1059">Using 1-methyl-4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]-piperidine, the title compound was obtained as described for the example 363.</p><p id="p-1434" num="0000"><chemistry id="CHEM-US-00373" num="00373"><img id="EMI-C00373" he="42.59mm" wi="117.77mm" file="US20230002353A1-20230105-C00373.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1435" num="1060"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; 8.57 (s, 1H), 8.21 (s, 1H), 8.15 (s, 1H), 7.92 (s, 1H), 7.63 (d, J=8.0 Hz, 2H), 7.57-7.50 (m, 4H), 7.42 (d, J=8.0 Hz, 2H), 4.66 (s, 2H), 4.59-4.53 (m, 1H), 4.43-4.38 (m, 1H), 4.25 (s, 2H), 4.12-4.01 (m, 2H), 3.69-3.66 (d, 2H), 3.53 (br s, 2H), 3.39 (br s, 2H), 3.25-3.20 (m, 1H), 2.93 (s, 3H), 2.92 (s, 3H), 2.41-2.33 (m, 4H), 2.19-1.97 (m, 2H), 1.84-1.76 (m, 3H), 1.69-1.60 (m, 1H);</p><p id="p-1436" num="1061">MS (ESI+) m/z 663 [M+H]<sup>+</sup></p><heading id="h-0397" level="1">Example 367. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(4-(4-methylpiperazin-1-yl)phenyl)-nicotinamide</heading><p id="p-1437" num="1062">Using 4-(4-Methylpiperazin-1-yl)phenylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1438" num="0000"><chemistry id="CHEM-US-00374" num="00374"><img id="EMI-C00374" he="42.59mm" wi="115.82mm" file="US20230002353A1-20230105-C00374.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1439" num="1063"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; 8.59 (s, 1H), 8.18 (s, 1H), 7.64-7.50 (m, 8H), 7.43 (d, J=8.0 Hz, 2H), 7.11 (d, J=8.0 Hz, 2H), 4.66 (s, 2H), 4.43-4.39 (m, 1H), 4.25 (s, 2H), 4.03-4.00 (m, 1H), 3.92 (d, J=1.2 Hz, 2H), 3.62 (d, J=1.2 Hz, 2H), 3.52 (br s, 2H), 3.39 (br s, 2H), 3.26-3.20 (m, 2H), 3.12-3.06 (m, 2H), 2.96 (s, 3H), 2.93 (s, 3H), 2.18-2.13 (m, 1H), 2.05-1.92 (m, 1H), 1.83-1.76 (m, 3H), 1.66-1.59 (m, 1H);</p><p id="p-1440" num="1064">MS (ESI+) n/z 674 [M+H]<sup>+</sup></p><heading id="h-0398" level="1">Example 368. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1441" num="1065">Using 4-((4-methylpiperazin-1-yl)methyl)phenylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1442" num="0000"><chemistry id="CHEM-US-00375" num="00375"><img id="EMI-C00375" he="42.59mm" wi="120.73mm" file="US20230002353A1-20230105-C00375.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1443" num="1066"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; 8.66 (s, 1H), 8.29 (s, 1H). 7.73 (d, J=8.0 Hz, 2H), 7.65-7.52 (m, 8H), 7.43 (d, J=8.0 Hz, 2H), 4.66 (s, 2H), 4.42 (m, 1H), 4.31 (s, 2H), 4.21 (s, 2H), 4.02 (m, 1H), 3.53 (br, 8H), 3.46 (br, 4H), 3.29 (br, 4H), 2.94 (s, 3H), 2.93 (s, 3H), 2.23-2.10 (m, 1H), 2.04-1.98 (m, 1H), 1.88-1.75 (m, 3H), 1.67-1.60 (m, 1H);</p><p id="p-1444" num="1067">MS (ESI+) m/z 688 [M+H]<sup>+</sup></p><heading id="h-0399" level="1">Example 369. 2-amino-5-(4-(hydroxymethyl)phenyl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-1445" num="1068">Using 4-(Hydroxymethyl)phenylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1446" num="0000"><chemistry id="CHEM-US-00376" num="00376"><img id="EMI-C00376" he="42.59mm" wi="108.71mm" file="US20230002353A1-20230105-C00376.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1447" num="1069"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; 8.63 (s, 1H), 8.26 (s, 1H), 7.70 (d, J=8.0 Hz, 1H), 7.61-7.53 (m, 5H), 7.46-7.41 (m, 6H), 4.66 (s, 2H), 4.64 (s, 2H), 4.42 (m, 1H), 3.99 (m, 1H), 3.91 (s, 2H), 3.35 (br s, 2H), 3.00 (br s, 2H), 2.88 (s, 3H), 2.22-2.10 (m, 1H), 2.04 (m, 1H), 1.85-1.74 (m, 3H), 1.63 (m, 1H);</p><p id="p-1448" num="1070">MS (ESI+) m/z 606 [M+H]<sup>+</sup></p><heading id="h-0400" level="1">Example 370. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(m-tolyl)nicotinamide</heading><p id="p-1449" num="1071">Using 3-tolylboronic acid, the title compound was obtained as described for the example 363</p><p id="p-1450" num="0000"><chemistry id="CHEM-US-00377" num="00377"><img id="EMI-C00377" he="31.92mm" wi="75.44mm" file="US20230002353A1-20230105-C00377.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1451" num="1072"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; 8.62 (s, 1H), 8.23 (s, 1H), 7.72-7.32 (m, 1H), 7.24 (d, J=8.0 Hz, 1H), 4.66 (s, 2H), 4.41 (m, 1H), 4.06 (s, 2H), 4.00 (m, 1H), 3.43 (br s, 2H), 3.17 (br s, 2H), 2.90 (s, 3H), 2.39 (s, 3H), 2.18 (m, 1H), 2.04 (m, 1H), 1.89-1.75 (m, 3H), 1.65-1.60 (m, 1H);</p><p id="p-1452" num="1073">MS (ESI+) m/z 590 [M+H]<sup>+</sup></p><heading id="h-0401" level="1">Example 371. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-phenylnicotinamide</heading><p id="p-1453" num="1074">Using phenylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1454" num="0000"><chemistry id="CHEM-US-00378" num="00378"><img id="EMI-C00378" he="33.36mm" wi="75.10mm" file="US20230002353A1-20230105-C00378.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1455" num="1075">MS (ESI+) m/z 576 [M+H]<sup>+</sup></p><heading id="h-0402" level="1">Example 372. 2-amino-5-(4-hydroxyphenyl)-N-((1S,2S)-2-((4&#x2032;-((4-methyl-piperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-1456" num="1076">Using 4-hydroxyphenylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1457" num="0000"><chemistry id="CHEM-US-00379" num="00379"><img id="EMI-C00379" he="30.73mm" wi="75.10mm" file="US20230002353A1-20230105-C00379.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1458" num="1077">MS (ESI+) m/z 592 [M+H]<sup>+</sup></p><heading id="h-0403" level="1">Example 373. 2-amino-5-(4-chloro-3-fluorophenyl)-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-1459" num="1078">Using 4-chloro-3-fluorophenylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1460" num="0000"><chemistry id="CHEM-US-00380" num="00380"><img id="EMI-C00380" he="31.16mm" wi="75.35mm" file="US20230002353A1-20230105-C00380.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1461" num="1079">MS (ESI+) m/z 629 [M+H]<sup>+</sup></p><heading id="h-0404" level="1">Example 374. 2-amino-5-methyl-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)-methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-1462" num="1080">Using trimethylboroxine, the title compound was obtained as described for the example 363.</p><p id="p-1463" num="0000"><chemistry id="CHEM-US-00381" num="00381"><img id="EMI-C00381" he="37.17mm" wi="75.27mm" file="US20230002353A1-20230105-C00381.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1464" num="1081">MS (ESI+) m/z 514 [M+H]<sup>+</sup></p><heading id="h-0405" level="1">Example 375. 6-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-1465" num="1082">Using 3-pyridylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1466" num="0000"><chemistry id="CHEM-US-00382" num="00382"><img id="EMI-C00382" he="32.94mm" wi="74.93mm" file="US20230002353A1-20230105-C00382.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1467" num="1083">MS (ESI+) n/z 577 [M+H]<sup>+</sup></p><heading id="h-0406" level="1">Example 376. 2-amino-5-(4-methoxyphenyl)-N-((1S,2S)-2-((4&#x2032;-((4-methyl-piperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-1468" num="1084">Using 4-methoxyphenylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1469" num="0000"><chemistry id="CHEM-US-00383" num="00383"><img id="EMI-C00383" he="30.14mm" wi="75.10mm" file="US20230002353A1-20230105-C00383.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1470" num="1085">MS (ESI+) m/z 606 [M+H]<sup>+</sup></p><heading id="h-0407" level="1">Example 377. 6-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,4&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-1471" num="1086">Using 4-pyridylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1472" num="0000"><chemistry id="CHEM-US-00384" num="00384"><img id="EMI-C00384" he="32.94mm" wi="74.93mm" file="US20230002353A1-20230105-C00384.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1473" num="1087">MS (ESI+) m/z 577 [M+H]<sup>+</sup></p><heading id="h-0408" level="1">Example 378. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(4-((4-methylpiperidin-1-yl)methyl)phenyl)-nicotinamide</heading><p id="p-1474" num="1088">Using (4-((4-methylpiperidin-1-yl)methyl)phenyl)boronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1475" num="0000"><chemistry id="CHEM-US-00385" num="00385"><img id="EMI-C00385" he="42.59mm" wi="120.82mm" file="US20230002353A1-20230105-C00385.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1476" num="1089">MS (ESI+) m/z 687 [M+H]<sup>+</sup></p><heading id="h-0409" level="1">Example 379. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(4-(morpholinomethyl)phenyl)nicotinamide</heading><p id="p-1477" num="1090">Using (4-(morpholinomethyl)phenyl)boronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1478" num="0000"><chemistry id="CHEM-US-00386" num="00386"><img id="EMI-C00386" he="42.59mm" wi="116.76mm" file="US20230002353A1-20230105-C00386.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1479" num="1091">MS (ESI+) n/z 675 [M+H]<sup>+</sup></p><heading id="h-0410" level="1">Example 380. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1480" num="1092">Using 1-(Tetrahydro-pyran-4-yl)-1H-pyrazole-4-boronic acid pinacol ester, the title compound was obtained as described for the example 363.</p><p id="p-1481" num="0000"><chemistry id="CHEM-US-00387" num="00387"><img id="EMI-C00387" he="42.59mm" wi="113.03mm" file="US20230002353A1-20230105-C00387.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1482" num="1093">MS (ESI+) m/z 650 [M+H]<sup>+</sup></p><heading id="h-0411" level="1">Example 381. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(4-morpholinophenyl)nicotinamide</heading><p id="p-1483" num="1094">Using 4-morpholinophenylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1484" num="0000"><chemistry id="CHEM-US-00388" num="00388"><img id="EMI-C00388" he="42.59mm" wi="111.84mm" file="US20230002353A1-20230105-C00388.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1485" num="1095">MS (ESI+) n/z 661 [M+H]<sup>+</sup></p><heading id="h-0412" level="1">Example 382. 2-amino-5-(cyclohex-1-en-1-yl)-N-((1S,2S)-2-((4&#x2032;-((4-methyl-piperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-1486" num="1096">Using 1-cyclohexenylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1487" num="0000"><chemistry id="CHEM-US-00389" num="00389"><img id="EMI-C00389" he="33.36mm" wi="75.18mm" file="US20230002353A1-20230105-C00389.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1488" num="1097">MS (ESI+) n/z 580 [M+H]<sup>+</sup></p><heading id="h-0413" level="1">Example 383. 2-amino-5-(3,4-dimethoxyphenyl)-N-((1S,2S)-2-((4&#x2032;-((4-methyl-piperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide</heading><p id="p-1489" num="1098">Using 3,4-dimethoxyphenylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1490" num="0000"><chemistry id="CHEM-US-00390" num="00390"><img id="EMI-C00390" he="30.14mm" wi="75.10mm" file="US20230002353A1-20230105-C00390.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1491" num="1099">MS (ESI+) m/z 636 [M+H]<sup>+</sup></p><heading id="h-0414" level="1">Example 384. 6-amino-2&#x2032;,6&#x2032;-difluoro-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,4&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-1492" num="1100">Using 2,6-difluoropyridine-4-boronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1493" num="0000"><chemistry id="CHEM-US-00391" num="00391"><img id="EMI-C00391" he="31.75mm" wi="75.44mm" file="US20230002353A1-20230105-C00391.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1494" num="1101">MS (ESI+) n/z 613 [M+H]<sup>+</sup></p><heading id="h-0415" level="1">Example 385. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxycyclopentyl)-5-(4-methylthiophen-3-yl)nicotinamide</heading><p id="p-1495" num="1102">Using 4-Methyl-3-thienylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1496" num="0000"><chemistry id="CHEM-US-00392" num="00392"><img id="EMI-C00392" he="33.53mm" wi="75.27mm" file="US20230002353A1-20230105-C00392.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1497" num="1103">MS (ESI+) m/z 596 [M+H]<sup>+</sup></p><heading id="h-0416" level="1">Example 386. 6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-1498" num="1104">Using 6-fluoro-3-pyridinylboronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1499" num="0000"><chemistry id="CHEM-US-00393" num="00393"><img id="EMI-C00393" he="31.58mm" wi="75.27mm" file="US20230002353A1-20230105-C00393.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1500" num="1105">MS (ESI+) m/z 595 [M+H]<sup>+</sup></p><heading id="h-0417" level="1">Example 387. 2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-(1,1,2,2-tetrafluoroethyl)-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-1501" num="1106">Using (1-(1,1,2,2-tetrafluoroethyl)-1H-pyrazol-4-yl)boronic acid, the title compound was obtained as described for the example 363.</p><p id="p-1502" num="0000"><chemistry id="CHEM-US-00394" num="00394"><img id="EMI-C00394" he="32.26mm" wi="113.37mm" file="US20230002353A1-20230105-C00394.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1503" num="1107"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.64 (br dd, J=14.09, 7.04 Hz, 1H) 1.75-1.88 (m, 3H) 2.04 (br dd, J=12.33, 7.63 Hz, 1H) 2.15-2.23 (m, 1H) 2.87 (s, 3H) 2.90-3.06 (m, 4H) 3.33 (br s, 4H) 3.86 (s, 2H) 3.98-4.04 (m, 1H) 4.39-4.44 (m, 1H) 4.62-4.69 (m, 2H) 6.75-6.98 (m, 1H) 7.39-7.45 (m, 4H) 7.55 (br d, J=8.22 Hz, 2H) 7.57 (br d, J=8.22 Hz, 2H) 8.20 (s, 1H) 8.33 (d, J=1.76 Hz, 1H) 8.58 (d, J=1.76 Hz, 1H) 8.60 (s, 1H);</p><p id="p-1504" num="1108">MS (ESI+) m/z 666.3 [M+H]<sup>+</sup></p><heading id="h-0418" level="1">Example 388. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1505" num="1109">Scheme for the Preparation of the Compound of Example 388:</p><p id="p-1506" num="0000"><chemistry id="CHEM-US-00395" num="00395"><img id="EMI-C00395" he="146.05mm" wi="75.86mm" file="US20230002353A1-20230105-C00395.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1507" num="1110">Intermediate 29.</p><p id="p-1508" num="1111">To a mixture of intermediate 3 (420 mg, 1.94 mmol) and triethylamine (0.40 ml, 2.90 mmol) in 10 ml of DMF was added HATU (884 mg, 2.32 mmol) followed by tert-butyl (3S,4S)-3-amino-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidine-1-carboxylate (647 mg, 1.94 mmol). The mixture was stirred at room temperature for 1 hr and then saturated sodium bicarbonate solution was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude product was purified through silicagel column chromatography to give 800 mg of off-white solid.</p><p id="p-1509" num="1112"><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) &#x3b4; ppm 1.14-1.22 (t, 3H) 1.41 (br s, 9H) 2.27 (s, 3H) 2.55-2.64 (q, 2H) 3.37-3.66 (m, 4H) 3.78 (dd, J=12.03, 5.58 Hz, 1H) 4.10 (br s, 1H) 4.50-4.79 (m, 2H) 6.74 (br s, 2H) 7.04-7.15 (m, 3H) 7.98 (d, J=1.76 Hz, 1H) 8.43 (br s, 1H);</p><p id="p-1510" num="1113">MS (ESI, m/z): 534.3 [M+H]<sup>+</sup></p><heading id="h-0419" level="1">Example 388. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1511" num="1114">To a mixture of intermediate 29 (40 mg, 0.07 mmol) and 1-methylpyrazole-4-boronic acid pinacol ester (23 mg, 0.11 mmol) in 0.4 ml of 1,4-dioxane/water (3/I) was added K<sub>2</sub>CO<sub>3 </sub>(31 mg, 0.22 mmol) followed by Pd(PPh<sub>3</sub>)<sub>4 </sub>(4 mg, 0.003 mmol). The reaction mixture was heated at 100&#xb0; C. for 3 hrs, cooled to room temperature, and extracted with EtOAc, dried over anhydrous MgSO<sub>4 </sub>and concentrated under vacuum. The crude residue was dissolved with 0.5 ml of CH<sub>2</sub>Cl<sub>2</sub>/TFA (10/1) and the mixture was stirred for 2 hrs. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 23 mg of the title compound.</p><p id="p-1512" num="1115"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) ppm 1.13 (t, J=7.34 Hz, 3H) 2.23 (s, 2H) 2.57 (q, J=7.24 Hz, 2H) 2.91 (dd, J=12.03, 4.40 Hz, 1H) 2.97-3.04 (m, 1H) 3.16-3.22 (m, 1H) 3.36-3.43 (m, 1H) 3.91 (s, 3H) 4.05-4.10 (m, 1H) 4.48 (br s, 1H) 4.57 (d, J=11.74 Hz, 1H) 4.65 (d, J=11.74 Hz, 1H) 7.06 (s, 2H) 7.12 (s, 1H) 7.76 (s, 1H) 7.89 (s, 1H) 8.02 (d, J=2.35 Hz, 1H) 8.26 (d, J=2.35 Hz, 1H),</p><p id="p-1513" num="1116">MS (ESI, m/z): 435.5 [M+H]<sup>+</sup></p><heading id="h-0420" level="1">Example 389. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(4-(hydroxymethyl)phenyl)nicotinamide</heading><p id="p-1514" num="1117">Using 4-hydroxymethylphenylboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1515" num="0000"><chemistry id="CHEM-US-00396" num="00396"><img id="EMI-C00396" he="28.36mm" wi="74.93mm" file="US20230002353A1-20230105-C00396.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1516" num="1118">MS (ES, m/z): 461.6 [M+H]<sup>+</sup></p><heading id="h-0421" level="1">Example 390. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1517" num="1119">Using (4-((4-methylpiperazin-1-yl)methyl)phenyl)boronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1518" num="0000"><chemistry id="CHEM-US-00397" num="00397"><img id="EMI-C00397" he="23.54mm" wi="75.35mm" file="US20230002353A1-20230105-C00397.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1519" num="1120">MS (ESI, m/z): 543.4 [M+H]<sup>+</sup></p><heading id="h-0422" level="1">Example 391. 2-amino-5-(4-carbamoylphenyl)-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</heading><p id="p-1520" num="1121">Using (4-carbamoylphenyl)boronic acid, the title compound was obtained as described for the example 388.4</p><p id="p-1521" num="0000"><chemistry id="CHEM-US-00398" num="00398"><img id="EMI-C00398" he="26.16mm" wi="74.93mm" file="US20230002353A1-20230105-C00398.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1522" num="1122"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.63 Hz, 3H) 2.25 (s, 3H) 2.19-2.19 (m, 1H) 2.60 (q, J=7.70 Hz, 2H) 3.33-3.35 (m, 1H) 3.43-3.64 (m, 2H) 3.77 (br dd, J=12.72, 7.24 Hz, 1H) 4.36 (br s, 1H) 4.55-4.73 (m, 3H) 7.10 (s, 2H) 7.17 (s, 1H) 7.78 (d, J=8.22 Hz, 2H) 7.99 (d, J=8.61 Hz, 2H) 8.44 (d, J=2.35 Hz, 1H) 8.62 (d, J=1.96 Hz, 1H);</p><p id="p-1523" num="1123">MS (ESI, m/z): 474.5 [M+H]<sup>+</sup></p><heading id="h-0423" level="1">Example 392. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(m-tolyl)nicotinamide</heading><p id="p-1524" num="1124">Using m-tolylboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1525" num="0000"><chemistry id="CHEM-US-00399" num="00399"><img id="EMI-C00399" he="28.28mm" wi="74.08mm" file="US20230002353A1-20230105-C00399.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1526" num="1125"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.43 Hz, 3H) 2.25 (s, 3H) 2.41 (s, 3H) 2.60 (q, J=7.56 Hz, 2H) 3.43-3.65 (m, 3H) 3.77 (dd, J=12.52, 7.04 Hz, 1H) 4.35 (br d, J=4.30 Hz, 1H) 4.62-4.74 (m, 3H) 7.09 (s, 2H) 7.16 (s, 1H) 7.25 (br d, J=7.43 Hz, 1H) 7.36 (t, J=7.63 Hz, 1H) 7.42-7.51 (m, 2H) 8.31 (d, J=1.96 Hz, 1H) 8.65 (d, J=1.96 Hz, 1H);</p><p id="p-1527" num="1126">MS (ESI, m/z): 445.3 [M+H]<sup>+</sup></p><heading id="h-0424" level="1">Example 393. 4-(6-amino-5-(((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)-pyrrolidin-3-yl)carbamoyl)pyridin-3-yl)benzoic acid</heading><p id="p-1528" num="1127">Using 4-carboxyphenylboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1529" num="0000"><chemistry id="CHEM-US-00400" num="00400"><img id="EMI-C00400" he="25.82mm" wi="74.25mm" file="US20230002353A1-20230105-C00400.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1530" num="1128"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.43 Hz, 3H) 2.23 (s, 3H) 2.59 (q, J=7.56 Hz, 2H) 3.34-3.51 (m, 2H) 3.52-3.67 (m, 1H) 3.76 (br d, J=7.43 Hz, 1H) 4.13 (br s, 1H) 4.57-4.69 (m, 3H) 7.02-7.10 (m, 2H) 7.14 (s, 1H) 7.79 (br d, J=8.22 Hz, 2H) 8.13 (br d, J=8.22 Hz, 2H) 8.37-8.45 (m, 1H) 8.73 (d, J=1.56 Hz, 1H); MS (ESI, m/z): 475.4 [M+H]<sup>+</sup></p><heading id="h-0425" level="1">Example 394. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-phenylnicotinamide</heading><p id="p-1531" num="1129">Using phenylboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1532" num="0000"><chemistry id="CHEM-US-00401" num="00401"><img id="EMI-C00401" he="28.28mm" wi="69.17mm" file="US20230002353A1-20230105-C00401.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1533" num="1130"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.63 Hz, 3H) 2.25 (s, 3H) 2.61 (q, J=7.43 Hz, 2H) 3.42-3.51 (m, 1H) 3.51-3.65 (m, 2H) 3.77 (dd, J=12.91, 7.04 Hz, 1H) 4.35 (br d, J=4.30 Hz, 1H) 4.57-4.76 (m, 3H) 7.06-7.13 (m, 2H) 7.17 (s, 1H) 7.35-7.58 (m, 3H) 7.68 (d, J=7.04 Hz, 2H) 8.33 (d, J=2.35 Hz, 1H) 8.74 (d, J=2.35 Hz, 1H);</p><p id="p-1534" num="1131">MS (ESI, m/z): 431.5 [M+H]<sup>+</sup></p><heading id="h-0426" level="1">Example 395. 6-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-[3,4&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-1535" num="1132">Using pyridine-4-boronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1536" num="0000"><chemistry id="CHEM-US-00402" num="00402"><img id="EMI-C00402" he="28.28mm" wi="70.02mm" file="US20230002353A1-20230105-C00402.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1537" num="1133"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.17 (t, J=7.63 Hz, 3H) 2.26 (s, 3H) 2.62 (q, J=7.56 Hz, 2H) 3.47 (br d, J=12.52 Hz, 1H) 3.52-3.67 (m, 2H) 3.77 (br dd, J=12.72, 6.85 Hz, 1H) 4.34 (br d, J=3.91 Hz, 1H) 4.61-4.78 (m, 3H) 7.07-7.13 (m, 2H) 7.13-7.19 (m, 1H) 7.99 (dd, J=8.02, 5.67 Hz, 1H) 8.56 (d, J=1.96 Hz, 1H) 8.68-8.82 (m, 3H) 9.14 (s, 1H);</p><p id="p-1538" num="1134">MS (ESI, m/z): 432.3 [M+H]<sup>+</sup></p><heading id="h-0427" level="1">Example 396. 6-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-[3,3&#x2032;-bipyridine]-5-carboxamide</heading><p id="p-1539" num="1135">Using pyridine-3-boronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1540" num="0000"><chemistry id="CHEM-US-00403" num="00403"><img id="EMI-C00403" he="28.28mm" wi="70.02mm" file="US20230002353A1-20230105-C00403.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1541" num="1136"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.17 (t, J=7.63 Hz, 3H) 2.26 (s, 3H) 2.62 (q, J=7.56 Hz, 2H) 3.47 (br d, J=12.52 Hz, 1H) 3.52-3.67 (m, 2H) 3.77 (br dd, J=12.72, 6.85 Hz, 1H) 4.34 (br d, J=3.91 Hz, 1H) 4.60-4.78 (m, 3H) 7.07-7.13 (m, 2H) 7.17 (d, J=7.06 Hz, 1H) 7.18 (s, 1H) 7.99 (dd, J=8.02, 5.67 Hz, 1H) 8.56 (d, J=1.96 Hz, 1H) 8.67-8.83 (m, 3H) 9.14 (s, 1H);</p><p id="p-1542" num="1137">MS (ESI, m/z): 432.3 [M+H]<sup>+</sup></p><heading id="h-0428" level="1">Example 397. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-vinylnicotinamide</heading><p id="p-1543" num="1138">Using potassium vinyltrifluoroborate, the title compound was obtained as described for the example 388.</p><p id="p-1544" num="0000"><chemistry id="CHEM-US-00404" num="00404"><img id="EMI-C00404" he="28.36mm" wi="64.26mm" file="US20230002353A1-20230105-C00404.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1545" num="1139"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.17 (t, J=7.43 Hz, 3H) 2.26 (s, 3H) 2.61 (q, J=7.56 Hz, 2H) 3.44-3.65 (m, 3H) 3.76 (br dd, J=12.91, 7.04 Hz, 1H) 4.33 (br d, J=3.91 Hz, 1H) 4.59-4.74 (m, 3H) 5.42 (d, J=10.96 Hz, 1H) 5.94 (d, J=17.61 Hz, 1H) 6.66 (dd, J=17.80, 11.15 Hz, 1H) 7.10 (s, 2H) 7.16 (s, 1H) 8.02-8.08 (m, 1H) 8.66 (d, J=1.96 Hz, 1H);</p><p id="p-1546" num="1140">MS (ESI, m/z): 381.3 [M+H]<sup>+</sup></p><heading id="h-0429" level="1">Example 398. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(4-fluorophenyl)nicotinamide</heading><p id="p-1547" num="1141">Using 4-fluorophenylboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1548" num="0000"><chemistry id="CHEM-US-00405" num="00405"><img id="EMI-C00405" he="28.36mm" wi="74.59mm" file="US20230002353A1-20230105-C00405.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1549" num="1142"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.63 Hz, 3H) 2.25 (s, 3H) 2.60 (q, J=7.63 Hz, 2H) 3.44-3.59 (m, 2H) 3.76 (dd, J=12.62, 7.34 Hz, 2H) 4.25-4.38 (m, 1H) 4.61-4.71 (m, 3H) 7.03-7.12 (m, 2H) 7.14-7.24 (m, 3H) 7.60-7.69 (m, 2H) 8.32 (d, J=2.35 Hz, 1H) 8.48 (d, J=2.35 Hz, 1H);</p><p id="p-1550" num="1143">MS (ESI, m/z): 499.3 [M+H]<sup>+</sup></p><heading id="h-0430" level="1">Example 399. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(4-formylphenyl)nicotinamide</heading><p id="p-1551" num="1144">Using 4-formylphenylboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1552" num="0000"><chemistry id="CHEM-US-00406" num="00406"><img id="EMI-C00406" he="27.01mm" wi="74.93mm" file="US20230002353A1-20230105-C00406.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1553" num="1145"><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) &#x3b4; ppm 1.30 (t, J=7.63 Hz, 3H) 2.26 (br s, 3H) 2.58 (q, J=7.63 Hz, 2H), 3.43-3.49 (m, 1H) 3.50-3.65 (m, 2H) 3.77 (dd, J=12.62, 6.75 Hz, 1H), 4.17 (br s, 1H) 4.64 (br s, 2H) 4.77 (br s, 1H) 6.59 (br s, 2H) 7.05-7.20 (m, 3H) 7.55-7.73 (m, 2H) 7.86 (br d, J=5.28 Hz, 2H) 8.04 (br s, 1H) 8.46 (br s, 1H) 9.86 (br s, 1H);</p><p id="p-1554" num="1146">MS (ESI, m/z): 459.5 [M+H]<sup>+</sup></p><heading id="h-0431" level="1">Example 400. 2-amino-5-(4-cyanophenyl)-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</heading><p id="p-1555" num="1147">Using 4-cyanophenylboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1556" num="0000"><chemistry id="CHEM-US-00407" num="00407"><img id="EMI-C00407" he="27.94mm" wi="75.44mm" file="US20230002353A1-20230105-C00407.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1557" num="1148"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.34 Hz, 3H) 2.25 (s, 3H) 2.60 (q, J=7.63 Hz, 2H) 3.43-3.49 (m, 1H) 3.50-3.65 (m, 2H) 3.77 (dd, J=12.62, 6.75 Hz, 1H) 4.35 (br d, J=4.11 Hz, 1H) 4.62-4.74 (m, 3H) 7.04-7.14 (m, 2H) 7.16 (s, 1H) 7.78-7.84 (m, 2H) 7.84-7.88 (m, 2H) 8.39-8.52 (m, 1H) 8.59 (d, J=1.76 Hz, 1H);</p><p id="p-1558" num="1149">MS (ESI, m/z): 456.3 [M+H]<sup>+</sup></p><heading id="h-0432" level="1">Example 401. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(4-(methylsulfonamido)phenyl)nicotinamide</heading><p id="p-1559" num="1150">Using 4-methylsulfonylphenylboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1560" num="0000"><chemistry id="CHEM-US-00408" num="00408"><img id="EMI-C00408" he="25.40mm" wi="75.61mm" file="US20230002353A1-20230105-C00408.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1561" num="1151"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.34 Hz, 3H) 2.25 (s, 3H) 2.60 (q, J=7.63 Hz, 2H) 2.98 (s, 3H) 3.43-3.49 (m, 1H) 3.50-3.65 (m, 2H) 3.76 (dd, J=12.62, 7.34 Hz, 1H) 4.33-4.38 (m, 1H) 4.62-4.71 (m, 3H) 7.05-7.13 (m, 2H) 7.16 (s, 1H) 7.36 (d, J=8.80 Hz, 2H) 7.65 (d, J=8.22 Hz, 2H) 8.32 (d, J=1.76 Hz, 1H) 8.59 (d, J=1.76 Hz, 1H);</p><p id="p-1562" num="1152">MS (ESI, m/z):524.6 [M+H]<sup>+</sup></p><heading id="h-0433" level="1">Example 402. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(4-phenoxyphenyl)nicotinamide</heading><p id="p-1563" num="1153">Using 4-phenoxyphenylboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1564" num="0000"><chemistry id="CHEM-US-00409" num="00409"><img id="EMI-C00409" he="24.21mm" wi="74.93mm" file="US20230002353A1-20230105-C00409.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1565" num="1154"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.63 Hz, 3H) 2.25 (s, 3H) 2.56-2.65 (m, 2H) 3.46 (br d, J=12.33 Hz, 1H) 3.52-3.61 (m, 2H) 3.76 (s, 1H) 4.32-4.40 (m, 1H) 4.62-4.73 (m, 3H) 7.02 (d, J=7.63 Hz, 2H) 7.04-7.12 (m, 4H) 7.13-7.19 (m, 2H) 7.38 (t, J=7.92 Hz, 2H) 7.66 (d, J=8.80 Hz, 2H) 8.29-8.34 (m, 1H) 8.68 (d, J=1.76 Hz, 1H);</p><p id="p-1566" num="1155">MS (ESI, m/z):523.7 [M+H]<sup>+</sup></p><heading id="h-0434" level="1">Example 403. 5-([1,1&#x2032;-biphenyl]-4-yl)-2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</heading><p id="p-1567" num="1156">Using 4-biphenylboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1568" num="0000"><chemistry id="CHEM-US-00410" num="00410"><img id="EMI-C00410" he="26.16mm" wi="74.76mm" file="US20230002353A1-20230105-C00410.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1569" num="1157"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.63 Hz, 3H) 2.25 (s, 3H) 2.60 (q, J=7.63 Hz, 2H) 3.47 (br d, J=12.91 Hz, 1H) 3.51-3.62 (m, 2H) 3.77 (dd, J=12.33, 7.04 Hz, 1H) 4.31-4.40 (m, 1H) 4.63-4.73 (m, 3H) 7.05-7.14 (m, 2H) 7.17 (s, 1H) 7.34 (s, 1H) 7.36 (br d, J=7.63 Hz, 1H) 7.45 (t, J=7.63 Hz, 2H) 7.64 (d, J=7.63 Hz, 2H) 7.70-7.79 (m, 3H) 8.40 (d, J=1.76 Hz, 1H) 8.64 (d, J=2.35 Hz, 1H);</p><p id="p-1570" num="1158">MS (ESI, m/z):507.4 [M+H]<sup>+</sup></p><heading id="h-0435" level="1">Example 404. 2-amino-5-(4-(benzyloxy)phenyl)-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</heading><p id="p-1571" num="1159">Using 4-benzyloxyphenylboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1572" num="0000"><chemistry id="CHEM-US-00411" num="00411"><img id="EMI-C00411" he="23.54mm" wi="74.76mm" file="US20230002353A1-20230105-C00411.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1573" num="1160"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.63 Hz, 3H) 2.24 (s, 3H) 2.60 (q, J=7.63 Hz, 2H) 3.46 (br d, J=12.91 Hz, 1H) 3.49-3.60 (m, 2H) 3.76 (dd, J=12.91, 7.04 Hz, 1H) 4.28-4.36 (m, 1H) 4.60-4.73 (m, 3H) 5.13 (s, 2H) 7.03-7.13 (m, 4H) 7.16 (s, 1H) 7.23-7.32 (m, 1H) 7.36 (t, J=7.63 Hz, 2H) 7.43 (d, J=7.04 Hz, 2H) 7.59 (d, J=8.80 Hz, 2H) 8.23-8.29 (m, 1H) 8.60 (d, J=1.76 Hz, 1H);</p><p id="p-1574" num="1161">MS (ESI, m/z): 537.8 [M+H]<sup>+</sup></p><heading id="h-0436" level="1">Example 405. 2-amino-5-(4-(dimethylamino)phenyl)-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</heading><p id="p-1575" num="1162"><chemistry id="CHEM-US-00412" num="00412"><img id="EMI-C00412" he="27.09mm" wi="75.27mm" file="US20230002353A1-20230105-C00412.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1576" num="1163">Using 4-dimethylaminophenylboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1577" num="1164"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.63 Hz, 3H) 2.25 (s, 3H) 2.60 (q, J=7.24 Hz, 2H) 3.07 (s, 6H) 3.47 (br d, J=12.91 Hz, 1H) 3.57 (ddd, J=18.78, 12.91, 3.52 Hz, 2H) 3.76 (br dd, J=12.91, 7.04 Hz, 1H) 4.32-4.37 (m, 1H) 4.61-4.72 (m, 3H) 7.02-7.12 (m, 4H) 7.16 (s, 1H) 7.62 (d, J=8.80 Hz, 2H) 8.26 (d, J=1.76 Hz, 1H) 8.69 (d, J=1.76 Hz, 1H);</p><p id="p-1578" num="1165">MS (ESI, m/z): 474.4 [M+H]<sup>+</sup></p><heading id="h-0437" level="1">Example 406. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(quinolin-3-yl)nicotinamide</heading><p id="p-1579" num="1166"><chemistry id="CHEM-US-00413" num="00413"><img id="EMI-C00413" he="27.26mm" wi="74.42mm" file="US20230002353A1-20230105-C00413.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1580" num="1167">Using quinoline-3-boronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1581" num="1168"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.17 (t, J=7.34 Hz, 3H) 2.25 (s, 3H) 2.61 (q, J=7.24 Hz, 2H) 3.48 (br d, J=12.91 Hz, 1H) 3.57-3.69 (m, 2H) 3.78 (br dd, J=12.91, 7.04 Hz, 1H) 4.34-4.42 (m, 1H) 4.61-4.75 (m, 3H) 7.05-7.15 (m, 2H) 7.18 (s, 1H) 7.78-7.93 (m, 1H) 7.93-8.09 (m, 1H) 8.18 (br dd, J=8.22, 3.52 Hz, 2H) 8.63 (d, J=1.76 Hz, 1H) 8.86 (d, J=2.35 Hz, 1H) 8.99-9.07 (m, 1H) 9.37 (d, J=1.76 Hz, 1H);</p><p id="p-1582" num="1169">MS (ESI, m/z): 482.6 [M+H]<sup>+</sup></p><heading id="h-0438" level="1">Example 407. 2-amino-5-(benzofuran-2-yl)-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</heading><p id="p-1583" num="1170"><chemistry id="CHEM-US-00414" num="00414"><img id="EMI-C00414" he="28.11mm" wi="74.93mm" file="US20230002353A1-20230105-C00414.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1584" num="1171">Using benzo[b]furan-2-boronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1585" num="1172"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.63 Hz, 3H) 2.25 (s, 3H) 2.61 (q, J=7.63 Hz, 2H) 3.48 (br d, J=12.33 Hz, 1H) 3.53 (br dd, J=12.91, 2.93 Hz, 1H) 3.60 (br dd, J=12.91, 4.70 Hz, 1H) 3.78 (br dd, J=12.62, 7.34 Hz, 1H) 4.37 (br s, 1H) 4.63-4.72 (m, 3H) 7.04-7.14 (m, 2H) 7.15-7.20 (m, 2H) 7.20-7.26 (m, 1H) 7.29 (br t, J=7.63 Hz, 1H) 7.51 (d, J=8.22 Hz, 1H) 7.58 (br d, J=7.63 Hz, 1H) 8.57 (d, J=1.76 Hz, 1H) 8.60 (d, J=1.76 Hz, 1H);</p><p id="p-1586" num="1173">MS (ESI, m/z): 471.5 [M+H]<sup>+</sup></p><heading id="h-0439" level="1">Example 408. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(naphthalen-1-yl)nicotinamide</heading><p id="p-1587" num="1174">Using 2-naphthyleneboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1588" num="0000"><chemistry id="CHEM-US-00415" num="00415"><img id="EMI-C00415" he="28.87mm" wi="74.51mm" file="US20230002353A1-20230105-C00415.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1589" num="1175"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.63 Hz, 3H) 2.24 (s, 3H) 2.60 (q, J=7.43 Hz, 2H) 3.48 (br d, J=12.91 Hz, 1H) 3.53-3.69 (m, 2H) 3.78 (dd, J=12.91, 7.04 Hz, 1H) 4.31-4.46 (m, 1H) 4.55-4.72 (m, 3H) 7.05-7.14 (m, 2H) 7.17 (s, 1H) 7.47-7.58 (m, 2H) 7.79 (dd, J=8.22, 1.76 Hz, 1H) 7.85-8.02 (m, 3H) 8.16 (s, 1H) 8.47 (d, J=1.76 Hz, 1H) 8.78 (d, J=1.76 Hz, 1H);</p><p id="p-1590" num="1176">MS (ESI, m/z): 481.4 [M+H]<sup>+</sup></p><heading id="h-0440" level="1">Example 409, 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(4-(trifluoromethyl)phenyl)nicotinamide</heading><p id="p-1591" num="1177">Using 4-trifluoromethylbenzeneboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1592" num="0000"><chemistry id="CHEM-US-00416" num="00416"><img id="EMI-C00416" he="28.11mm" wi="75.27mm" file="US20230002353A1-20230105-C00416.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1593" num="1178"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.63 Hz, 3H) 2.25 (s, 3H) 2.61 (q, J=7.24 Hz, 2H) 3.45 (br d, J=12.32 Hz, 1H) 3.49-3.62 (m, 2H) 3.75 (dd, J=12.62, 6.75 Hz, 1H) 4.26-4.38 (m, 1H) 4.61-4.72 (m, 3H) 7.03-7.13 (m, 2H) 7.16 (s, 1H) 7.33 (td, J=10.12, 6.75 Hz, 2H) 7.53-7.69 (m, 2H) 8.29 (s, 1H) 8.48 (d, J=1.76 Hz, 1H);</p><p id="p-1594" num="1179">MS (ESI, m/z): 499.6 [M+H]<sup>+</sup></p><heading id="h-0441" level="1">Example 410. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(2,4,5-trifluorophenyl)nicotinamide</heading><p id="p-1595" num="1180">Using 2,4,5-trifluorophenylboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1596" num="0000"><chemistry id="CHEM-US-00417" num="00417"><img id="EMI-C00417" he="29.04mm" wi="75.27mm" file="US20230002353A1-20230105-C00417.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1597" num="1181"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.63 Hz, 3H) 2.25 (s, 3H) 2.61 (q, J=7.24 Hz, 2H) 3.45 (br d, J=12.32 Hz, 1H) 3.49-3.62 (m, 2H) 3.75 (dd, J=12.62, 6.75 Hz, 1H) 4.26-4.38 (m, 1H) 4.61-4.72 (m, 3H) 7.03-7.13 (m, 2H) 7.16 (s, 1H) 7.33 (td, J=10.12, 6.75 Hz, 1H) 7.53-7.63 (m, 1H) 8.29 (s, 1H) 8.48 (d, J=1.76 Hz, 1H);</p><p id="p-1598" num="1182">MS (ESI, m/z): 485.3 [M+H]<sup>+</sup></p><heading id="h-0442" level="1">Example 411. 2-amino-5-(4-(cyanomethyl)phenyl)-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</heading><p id="p-1599" num="1183">Using 4-cyanomethylphenylboronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1600" num="0000"><chemistry id="CHEM-US-00418" num="00418"><img id="EMI-C00418" he="26.59mm" wi="74.93mm" file="US20230002353A1-20230105-C00418.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1601" num="1184"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (td, J=7.63, 2.35 Hz, 3H) 2.24 (d, J=4.11 Hz, 3H) 2.59 (qd, J=7.53, 3.23 Hz, 2H) 3.45-3.56 (m, 1H) 3.67-3.74 (m, 1H) 3.77-3.88 (m, 1H) 3.93 (s, 2H) 3.98 (br dd, J=11.44, 6.16 Hz, 1H) 4.11-4.28 (m, 1H) 4.58-4.70 (m, 3H) 7.07 (s, 2H) 7.14 (s, 1H) 7.86 (d, J=2.93 Hz, 1H) 8.02 (s, 1H) 8.19 (d, J=11.15 Hz, 1H) 8.24 (d, J=1.76 Hz, 1H) 8.59 (dd, J=7.04, 2.35 Hz, 1H);</p><p id="p-1602" num="1185">MS (ESI, m/z): 470.8 [M+H]<sup>+</sup></p><heading id="h-0443" level="1">Example 412. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1603" num="1186">Using 1-(4-N-Boc-piperidine)pyrazole-4-boronic acid, the title compound was obtained as described for the example 388 and following deprotection with TFA.</p><p id="p-1604" num="0000"><chemistry id="CHEM-US-00419" num="00419"><img id="EMI-C00419" he="26.75mm" wi="75.27mm" file="US20230002353A1-20230105-C00419.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1605" num="1187">MS (ESL m/z): 504.3 [M+H]<sup>+</sup></p><heading id="h-0444" level="1">Example 413. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(1-(1-methylpieridin-4-yl)-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1606" num="1188">Using 1-(4-N-methylpiperidine)pyrazole-4-boronic acid, the title compound was obtained as described for the example 388.</p><p id="p-1607" num="0000"><chemistry id="CHEM-US-00420" num="00420"><img id="EMI-C00420" he="25.99mm" wi="75.10mm" file="US20230002353A1-20230105-C00420.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1608" num="1189">MS (ESI, m/z): 518.3 [M+H]<sup>+</sup></p><heading id="h-0445" level="1">Example 414. 2-amino-N-((3S,4S)-4-(benzyloxy)pyrrolidin-3-yl)-5-(1-methyl-1H1-pyrazol-4-yl)nicotinamide</heading><p id="p-1609" num="1190">Using tert-butyl (3S,4S)-3-amino-4-(benzyloxy)pyrrolidine-1-carboxylate, the title compound was obtained as described for the example 388.</p><p id="p-1610" num="0000"><chemistry id="CHEM-US-00421" num="00421"><img id="EMI-C00421" he="30.73mm" wi="64.69mm" file="US20230002353A1-20230105-C00421.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1611" num="1191">MS (ESL m/z): 393.2 [M+H]<sup>+</sup></p><heading id="h-0446" level="1">Example 415. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)-4-((4-methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</heading><p id="p-1612" num="1192">Using tert-butyl (3S,4S)-3-amino-4-((4-methylbenzyl)oxy)pyrolidine-1-carboxylate, the title compound was obtained as described for the example 388.</p><p id="p-1613" num="0000"><chemistry id="CHEM-US-00422" num="00422"><img id="EMI-C00422" he="28.87mm" wi="67.14mm" file="US20230002353A1-20230105-C00422.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1614" num="1193">MS (ESI, m/z): 407.2 [M+H]<sup>+</sup></p><heading id="h-0447" level="1">Example 416. 2-amino-N-((3S,4S)-4-((3-ethylbenzyl)oxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1615" num="1194">Using tert-butyl (3S,4S)-3-amino-4-((3-ethylbenzyl)oxy)pyrrolidine-1-carboxylate, the title compound was obtained as described for the example 388.</p><p id="p-1616" num="0000"><chemistry id="CHEM-US-00423" num="00423"><img id="EMI-C00423" he="28.87mm" wi="74.08mm" file="US20230002353A1-20230105-C00423.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1617" num="1195">MS (ESI, m/z): 421.2 [M+H]<sup>+</sup></p><heading id="h-0448" level="1">Example 417. 2-amino-N-((3S,4S)-4-((3-ethyl-4-fluorobenzyl)oxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1618" num="1196">Using tert-butyl (3S,4S)-3-amino-4-((3-ethyl-4-fluorobenzyl)oxy)pyrrolidine-1-carboxylate, the title compound was obtained as described for the example 388.</p><p id="p-1619" num="0000"><chemistry id="CHEM-US-00424" num="00424"><img id="EMI-C00424" he="28.87mm" wi="74.08mm" file="US20230002353A1-20230105-C00424.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1620" num="1197">MS (ESI, m/z): 439.2 [M+H]<sup>+</sup></p><heading id="h-0449" level="1">Example 418. 2-amino-N-(3S,4S)-4-((4-chloro-3-ethylbenzyl)oxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1621" num="1198">Using tert-butyl (3S,4S)-3-amino-4-((4-chloro-3-ethylbenzyl)oxy)pyrrolidine-1-carboxylate, the title compound was obtained as described for the example 388.</p><p id="p-1622" num="0000"><chemistry id="CHEM-US-00425" num="00425"><img id="EMI-C00425" he="30.73mm" wi="74.08mm" file="US20230002353A1-20230105-C00425.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1623" num="1199">MS (ESI, m/z): 455.2 [M+H]<sup>+</sup></p><heading id="h-0450" level="1">Example 419. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(4-((1-methylpiperidin-4-yl)carbamoyl)phenyl)nicotinamide</heading><p id="p-1624" num="1200">Scheme for the Preparation of the Compound of Example 419:</p><p id="p-1625" num="0000"><chemistry id="CHEM-US-00426" num="00426"><img id="EMI-C00426" he="120.48mm" wi="120.99mm" file="US20230002353A1-20230105-C00426.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1626" num="1201">Intermediate 30.</p><p id="p-1627" num="1202">To a mixture of intermediate 29 (400 mg, 0.7 mmol) and 4-carboxyphenylboronic acid (230 mg, 1.10 mmol) in 4 ml of 1,4-dioxane/water (3/1) was added K<sub>2</sub>CO<sub>3 </sub>(310 mg, 2.2 mmol) followed by Pd(PPh<sub>3</sub>)<sub>4 </sub>(40 mg, 0.03 mmol). The reaction mixture was heated at 100&#xb0; C. for 3 hrs, cooled to room temperature, and extracted with EtOAc, dried over anhydrous MgSO<sub>4 </sub>and concentrated under vacuum. The crude product was purified through silicagel column chromatography to give 350 mg of off-white solid</p><p id="p-1628" num="1203"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.43 Hz, 3H) 1.46 (br d, J=1.96 Hz, 9H) 2.23 (s, 3H) 2.59 (q, J=7.56 Hz, 2H) 3.40-3.51 (m, 2H) 3.52-3.65 (m, 1H) 3.76 (br d, J=7.43 Hz, 1H) 4.13 (br s, 1H) 4.57-4.74 (m, 3H) 7.06 (s, 2H) 7.14 (s, 1H) 7.79 (br d, J=8.22 Hz, 2H) 8.13 (br d, J=8.22 Hz, 2H) 8.37-8.45 (m, 1H) 8.73 (d, J=1.56 Hz, 1H);</p><p id="p-1629" num="1204">MS (ESI, m/z): 575.3 [M+H]<sup>+</sup></p><heading id="h-0451" level="1">Example 419. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(4-((1-methylpiperidin-4-yl)carbamoyl)phenyl)nicotinamide</heading><p id="p-1630" num="1205">To a mixture of intermediate 30 (12 mg, 0.02 mmol) and triethylamine (0.04 ml, 0.03 mmol) in 0.2 ml of DMF was added HATU (10 mg, 0.03 mmol) followed by 4-amino-1-methylpiperidine (0.03 ml, 0.02 mmol). The mixture was stirred at room temperature for 1 hr and then saturated sodium bicarbonate solution was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude residue was dissolved with 0.5 ml of CH<sub>2</sub>Cl<sub>2</sub>/TFA (10/1) and the mixture was stirred for 2 hrs. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 10 mg of the title compound.</p><p id="p-1631" num="1206"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.63 Hz, 3H) 1.86-1.98 (m, 2H) 2.23 (br s, 3H) 2.25 (s, 3H) 2.61 (q, J=7.70 Hz, 2H) 2.89 (s, 3H) 3.10-3.26 (m, 2H) 3.47 (br d, J=12.52 Hz, 1H) 3.52-3.66 (m, 3H) 3.77 (dd, J=12.72, 6.85 Hz, 1H) 4.11-4.23 (m, 1H) 4.32-4.43 (m, 1H) 4.53-4.77 (m, 3H) 7.05-7.14 (m, 2H) 7.17 (s, 1H) 7.81 (d, J=8.22 Hz, 2H) 7.88-7.99 (m, 2H) 8.42 (d, J=1.96 Hz, 1H) 8.74 (d, J=1.96 Hz, 1H);</p><p id="p-1632" num="1207">MS (ESI, m/z): 571.4 [M+H]<sup>+</sup></p><heading id="h-0452" level="1">Example 420. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(4-((4-methylcyclohexyl)carbamoyl)phenyl)nicotinamide</heading><p id="p-1633" num="1208">Using 4-methylcyclohexylamine, the title compound was obtained as described for the example 419.</p><p id="p-1634" num="0000"><chemistry id="CHEM-US-00427" num="00427"><img id="EMI-C00427" he="22.52mm" wi="75.44mm" file="US20230002353A1-20230105-C00427.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1635" num="1209"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 0.93 (d, J=6.46 Hz, 1H) 1.00 (d, J=6.46 Hz, 2H) 1.09 (br d, J=14.09 Hz, 1H) 1.16 (t, J=7.63 Hz, 3H) 1.38-1.48 (m, 2H) 1.59-1.73 (m, 3H) 1.75-1.84 (m, 2H) 1.96 (br d, J=11.15 Hz, 1H) 2.25 (s, 3H) 2.60 (q, J=7.63 Hz, 2H) 3.32-3.36 (m, 1H) 3.47 (br d, J=12.91 Hz, 1H) 3.51-3.61 (m, 2H) 3.76 (dd, J=12.91, 7.04 Hz, 2H) 3.99 (br s, 1H) 4.35 (br s, 1H) 4.62-4.72 (m, 3H) 7.03-7.14 (m, 2H) 7.16 (s, 1H) 7.76 (dd, J=8.51, 4.40 Hz, 2H) 7.91 (dd, J=8.22, 2.35 Hz, 2H) 8.42 (d, J=2.35 Hz, 1H) 8.58-8.62 (m, 1H);</p><p id="p-1636" num="1210">MS (ESI, m/z): 570.5 [M+H]<sup>+</sup></p><heading id="h-0453" level="1">Example 421. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(4-(4-methylpiperidine-1-carbonyl)phenyl)nicotinamide</heading><p id="p-1637" num="1211">Using 4-methylpiperidine, the title compound was obtained as described for the example 419.</p><p id="p-1638" num="0000"><chemistry id="CHEM-US-00428" num="00428"><img id="EMI-C00428" he="23.45mm" wi="75.27mm" file="US20230002353A1-20230105-C00428.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1639" num="1212"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 0.98 (d, J=6.46 Hz, 3H) 1.09-1.22 (m, 3H) 1.16 (t, J=7.63, 3H) 1.62 (br d, J=11.74 Hz, 1H) 1.66-1.74 (m, 2H) 1.79 (br d, J=12.91 Hz, 1H) 2.23 (s, 3H) 2.53-2.63 (q, J=7.63 Hz, 2H) 2.85 (br t, J=12.33 Hz, 1H) 3.11 (br t, J=12.33 Hz, 1H) 3.39-3.49 (m, 2H) 3.55-3.61 (m, 1H) 3.68 (br d, J=12.91 Hz, 1H) 3.75 (td, J=11.74, 7.04 Hz, 1H) 4.12 (br s, 1H) 4.58-4.64 (m, 3H) 7.02-7.11 (m, 2H) 7.13 (s, 1H) 7.51 (d, J=8.22 Hz, 2H) 7.76 (d, J=8.22 Hz, 2H) 8.36 (d, J=1.76 Hz, 1H) 8.70 (d, J=1.76 Hz, 1H);</p><p id="p-1640" num="1213">MS (ESI, m/z): 556.5 [M+H]<sup>+</sup></p><heading id="h-0454" level="1">Example 422. 2-amino-5-(4-(dimethylcarbamoyl)phenyl)-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</heading><p id="p-1641" num="1214">Using dimethylamine, the title compound was obtained as described for the example 419.</p><p id="p-1642" num="0000"><chemistry id="CHEM-US-00429" num="00429"><img id="EMI-C00429" he="25.40mm" wi="74.93mm" file="US20230002353A1-20230105-C00429.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1643" num="1215"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.15 (t, J=7.63 Hz, 3H) 2.22 (s, 3H) 2.58 (q, J=7.63 Hz, 2H) 3.01 (s, 3H) 3.11 (s, 3H) 3.38-3.50 (m, 2H) 3.52-3.66 (m, 1H) 3.67-3.81 (m, 1H) 4.12 (br s, 1H) 4.57-4.68 (m, 3H) 7.05 (s, 2H) 7.13 (s, 1H) 7.54 (d, J=8.80 Hz, 2H) 7.75 (d, J=8.22 Hz, 2H) 8.36 (d, J=1.76 Hz, 1H) 8.68 (d, J-=2.35 Hz, 1H);</p><p id="p-1644" num="1216">MS (ESI, m/z): 502.4 [M+H]<sup>+</sup></p><heading id="h-0455" level="1">Example 423. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(4-((4-methylpiperidin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1645" num="1217">Scheme for the Preparation of the Compound of Example 423:</p><p id="p-1646" num="0000"><chemistry id="CHEM-US-00430" num="00430"><img id="EMI-C00430" he="120.23mm" wi="117.69mm" file="US20230002353A1-20230105-C00430.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1647" num="1218">Intermediate 31.</p><p id="p-1648" num="1219">Using intermediate 29 and 4-formylphenylboronic acid, the title compound was obtained as described for the synthesis of intermediate 30.</p><p id="p-1649" num="1220"><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) &#x3b4; ppm 1.30 (t, J=7.63 Hz, 3H), 1.42 (s, 9H), 2.26 (br s, 3H) 2.58 (q, J=7.63 Hz, 2H) 3.37-3.84 (m, 4H) 4.17 (br s, 1H) 4.64 (br s, 2H) 4.77 (br s, 1H) 6.59 (br s, 2H) 7.05-7.20 (m, 3H) 7.55-7.73 (m, 2H) 7.86 (br d, J=5.28 Hz, 2H) 8.04 (br s, 1H) 8.46 (br s, 1H) 9.86 (br s, 1H);</p><p id="p-1650" num="1221">MS (ESI, m/z): 559.4 [M+H]<sup>+</sup></p><heading id="h-0456" level="1">Example 423. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(4-((4-methylpiperidin-1-yl)methyl)phenyl)nicotinamide</heading><p id="p-1651" num="1222">To a mixture of intermediate 31 (40 mg, 0.07 mmol) in 0.4 ml of dichloroethane was added 4-methylpiperidine (0.017 ml, 0.14 mmol) followed by NaBH(OAc)<sub>3 </sub>(30 mg, 0.21 mmol). The mixture was stirred at room temperature for 4 hr and then water was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude residue was dissolved with 0.5 ml of CH<sub>2</sub>Cl<sub>2</sub>/TFA (10/1) and the mixture was stirred for 2 hrs. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 10 mg of the title compound.</p><p id="p-1652" num="1223"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 0.99 (d, J=6.46 Hz, 3H) 1.16 (t, J=7.34 Hz, 3H) 1.34-1.46 (m, 2H) 1.91 (br d, J=14.09 Hz, 2H) 2.25 (s, 3H) 2.61 (q, J=7.63 Hz, 2H) 2.93-3.07 (m, 2H) 3.43-3.49 (m, 3H) 3.57 (ddd, J=16.43, 12.91, 3.52 Hz, 2H) 3.76 (dd, J=12.62, 6.75 Hz, 2H) 4.27-4.39 (m, 3H) 4.59-4.76 (m, 3H) 7.05-7.14 (m, 2H) 7.17 (s, 1H) 7.60 (d, J=8.22 Hz, 2H) 7.80 (d, J=8.22 Hz, 2H) 8.39 (d, J=1.76 Hz, 1H) 8.67 (d, J=1.76 Hz, 1H);</p><p id="p-1653" num="1224">MS (ESI, m/z): 542.3 [M+H]<sup>+</sup></p><heading id="h-0457" level="1">Example 424. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)-5-(4-(morpholinomethyl)phenyl)nicotinamide</heading><p id="p-1654" num="1225">Using morpholine, the title compound was obtained as described for the example 423.</p><p id="p-1655" num="0000"><chemistry id="CHEM-US-00431" num="00431"><img id="EMI-C00431" he="23.79mm" wi="74.51mm" file="US20230002353A1-20230105-C00431.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1656" num="1226"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.63 Hz, 3H) 2.25 (s, 3H) 2.61 (q, J=7.63 Hz, 2H) 3.09-3.27 (m, 2H) 3.31-3.40 (m, 2H) 3.46 (d, J=12.33 Hz, 1H) 3.52-3.67 (m, 2H) 3.76 (br dd, J=12.91, 7.04 Hz, 1H) 3.77 (br s, 2H) 4.03 (br s, 2H) 4.35 (br d, J=4.11 Hz, 1H) 4.41 (s, 2H) 4.63-4.71 (m, 2H) 4.72 (br d, J=6.46 Hz, 1H) 7.06-7.12 (m, 2H) 7.17 (s, 1H) 7.63 (d, J-=8.22 Hz, 2H) 7.82 (d, J=8.22 Hz, 2H) 8.40 (d, J=2.35 Hz, 1H) 8.66-8.70 (m, 1H);</p><p id="p-1657" num="1227">MS (ESI, m/z): 530.3 [M+H]<sup>+</sup></p><heading id="h-0458" level="1">Example 425. 2-amino-5-(4-((3,3-difluoropiperidin-1-yl)methyl)phenyl)-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide</heading><p id="p-1658" num="1228">Using 3,3-difluoropiperidine, the title compound was obtained as described for the example 423.</p><p id="p-1659" num="0000"><chemistry id="CHEM-US-00432" num="00432"><img id="EMI-C00432" he="22.86mm" wi="75.44mm" file="US20230002353A1-20230105-C00432.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1660" num="1229"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.16 (t, J=7.63 Hz, 3H) 1.97-2.09 (m, 2H) 2.15 (br s, 2H) 2.25 (s, 3H) 2.61 (q, J=7.63 Hz, 2H) 3.22-3.28 (m, 2H) 3.38-3.49 (m, 4H) 3.50-3.66 (m, 2H) 3.76 (dd, J=12.33, 7.04 Hz, 1H) 4.35 (br d, J=4.70 Hz, 1H) 4.40 (s, 2H) 4.62-4.73 (m, 3H) 7.07-7.12 (m, 2H) 7.17 (s, 1H) 7.61 (d, J=8.22 Hz, 2H) 7.81 (d, J=8.22 Hz, 2H) 8.40 (d, J=2.35 Hz, 1H) 8.61 (d, J=1.76 Hz, 1H);</p><p id="p-1661" num="1230">MS (ESI, m/z): 564.3 [M+H]<sup>+</sup></p><heading id="h-0459" level="1">Example 426. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)-1-methylpyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1662" num="1231">Scheme for the Preparation of the Compound of Example 426:</p><p id="p-1663" num="0000"><chemistry id="CHEM-US-00433" num="00433"><img id="EMI-C00433" he="71.54mm" wi="75.78mm" file="US20230002353A1-20230105-C00433.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1664" num="1232">To compound 388 (40 mg, 0.09 mmol) in 0.4 ml of 1,2-dichloroethane was added formaldehyde (0.015 ml, 0.18 mmol) followed by NaBH(OAc)<sub>3 </sub>(38 mg, 0.28 mmol). The mixture was stirred at room temperature for 1 hr and then water was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude residue was purified by preparative HPLC to afford 30 mg of the title compound.</p><p id="p-1665" num="1233"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.12-1.17 (m, 3H) 2.23 (s, 3H) 2.55-2.65 (m, 2H) 3.01 (s, 3H) 3.43-3.54 (m, 1H) 3.60-3.71 (m, 1H) 3.73-3.84 (m, 1H) 3.92 (s, 3H) 4.08-4.23 (m, 1H) 4.31-4.45 (m, 1H) 4.62-4.70 (m, 2H) 4.72 (br d, J=5.87 Hz, 1H) 7.04-7.11 (m, 2H) 7.15 (s, 1H) 7.88 (s, 1H) 8.05 (s, 1H) 8.26 (d, J=2.35 Hz, 1H) 8.66 (d, J=1.76 Hz, 1H);</p><p id="p-1666" num="1234">MS (ESI, m/z): 449.3 [M+H]<sup>+</sup></p><heading id="h-0460" level="1">Example 427. 2-amino-N-((3S,4S)-1-benzyl-4-((3-ethyl-4-methylbenzyl)oxy)-pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1667" num="1235">Using benzaldehyde, the title compound was obtained as described for the example 426.</p><p id="p-1668" num="0000"><chemistry id="CHEM-US-00434" num="00434"><img id="EMI-C00434" he="46.99mm" wi="74.17mm" file="US20230002353A1-20230105-C00434.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1669" num="1236">MS (ESI, m/z): 525.7 [M+H]<sup>+</sup></p><heading id="h-0461" level="1">Example 428. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)-1-(3-phenylpropyl)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1670" num="1237">Using 3-phenylpropanal, the title compound was obtained as described for the example 426.</p><p id="p-1671" num="0000"><chemistry id="CHEM-US-00435" num="00435"><img id="EMI-C00435" he="44.79mm" wi="74.17mm" file="US20230002353A1-20230105-C00435.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1672" num="1238"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.14 (t, J=7.63 Hz, 3H) 1.97-2.13 (m, 2H) 2.22 (s, 3H) 2.58 (q, J=7.63 Hz, 2H) 2.70 (t, J=7.63 Hz, 2H) 3.27 (t, J=7.63 Hz, 2H) 3.43-3.54 (m, 1H) 3.60-3.71 (m, 1H) 3.73-3.84 (m, 1H) 3.92 (s, 3H) 4.08-4.23 (m, 1H) 4.36 (br s, 1H) 4.6-4.72 (m, 3H) 7.01-7.10 (m, 2H) 7.12-7.15 (m, 1H) 7.15-7.30 (m, 5H) 7.87 (s, 1H) 8.04 (s, 1H) 8.25 (d, J=1.76 Hz, 1H) 8.64 (br s, 1H);</p><p id="p-1673" num="1239">MS (ESI, m/z): 553.3 [M+H]<sup>+</sup></p><heading id="h-0462" level="1">Example 429. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)-1-phenethylpyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1674" num="1240">Using phenylacetaldehyde, the title compound was obtained as described for the example 426.</p><p id="p-1675" num="0000"><chemistry id="CHEM-US-00436" num="00436"><img id="EMI-C00436" he="48.68mm" wi="74.17mm" file="US20230002353A1-20230105-C00436.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1676" num="1241">MS (ESI, m/z): 539.3[M+H]<sup>+</sup></p><heading id="h-0463" level="1">Example 430. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)-1-isobutylpyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1677" num="1242">Using isobutyraldehyde, the title compound was obtained as described for the example 426.</p><p id="p-1678" num="0000"><chemistry id="CHEM-US-00437" num="00437"><img id="EMI-C00437" he="38.35mm" wi="74.17mm" file="US20230002353A1-20230105-C00437.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1679" num="1243"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.04 (br d, J=3.52 Hz, 6H) 1.14 (t, J=7.63 Hz, 3H) 2.10 (dt, J=13.65, 6.97 Hz, 1H) 2.22 (s, 3H) 2.58 (q, J=7.63 Hz, 2H) 3.14 (br d, J=6.46 Hz, 2H) 3.32-3.42 (m, 1H) 3.52 (br s, 1H) 3.70-3.83 (m, 1H) 3.93 (s, 3H) 3.99-4.17 (m, 1H) 4.41 (br d, J=16.43 Hz, 1H) 4.59-4.75 (m, 3H) 7.02-7.12 (m, 2H) 7.15 (br s, 1H) 7.87 (br s, 1H) 8.05 (br d, J=11.15 Hz, 1H) 8.28 (d, J=1.76 Hz, 1H) 8.59 (br s, 1H);</p><p id="p-1680" num="1244">MS (ESI, m/z): 491.3 [M+H]<sup>+</sup></p><heading id="h-0464" level="1">Example 431. 2-amino-N-((3S,4S)-1-butyl-4-((3-ethyl-4-methylbenzyl)-oxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1681" num="1245">Using butyraldehyde, the title compound was obtained as described for the example 426.</p><p id="p-1682" num="0000"><chemistry id="CHEM-US-00438" num="00438"><img id="EMI-C00438" he="39.03mm" wi="74.17mm" file="US20230002353A1-20230105-C00438.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1683" num="1246">MS (ESI, m/z): 491.4 [M+H]<sup>+</sup></p><heading id="h-0465" level="1">Example 432. 2-amino-N-((3S,4S)-1-ethyl-4-((3-ethyl-4-methylbenzyl)oxy)-pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1684" num="1247">Using acetaldehyde, the title compound was obtained as described for the example 426.</p><p id="p-1685" num="0000"><chemistry id="CHEM-US-00439" num="00439"><img id="EMI-C00439" he="33.27mm" wi="74.17mm" file="US20230002353A1-20230105-C00439.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1686" num="1248">MS (ESI, m/z): 463.3 [M+H]<sup>+</sup></p><heading id="h-0466" level="1">Example 433. 2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)-1-methylpyrrolidin-3-yl)-5-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1687" num="1249">From compound 359, the title compound was obtained as described for the example 426.</p><p id="p-1688" num="0000"><chemistry id="CHEM-US-00440" num="00440"><img id="EMI-C00440" he="27.26mm" wi="75.35mm" file="US20230002353A1-20230105-C00440.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1689" num="1250">MS (ESI, m/z): 532.3 [M+H]<sup>+</sup></p><heading id="h-0467" level="1">Example 434 and Example 435</heading><p id="p-1690" num="1251">Scheme for the Preparation of the Compounds of Example 434 and 435:</p><p id="p-1691" num="0000"><chemistry id="CHEM-US-00441" num="00441"><img id="EMI-C00441" he="164.25mm" wi="130.73mm" file="US20230002353A1-20230105-C00441.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1692" num="1252">Intermediate 32.</p><p id="p-1693" num="1253">To a mixture of intermediate 2 (350 mg, 1.60 mmol) and triethylamine (0.34 ml, 2.41 mmol) in 4 ml of DMF was added HATU (732 mg, 1.92 mmol) followed by tert-butyl (3S,4S)-3-amino-4-((4-bromobenzyl)oxy)pyrrolidine-1-carboxylate (657 mg, 1.76 mmol). The mixture was stirred at room temperature for 1 hr and then saturated sodium bicarbonate solution was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude product was purified through silicagel column chromatography to give 700 mg of off-white solid.</p><p id="p-1694" num="1254"><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) &#x3b4; ppm 1.43 (br s, 9H) 3.42 (br d, J=10.56 Hz, 1H) 3.51-3.65 (m, 2H) 3.80 (dd, J=12.03, 5.58 Hz, 1H) 3.89 (s, 3H) 4.03-4.20 (m, 1H) 4.54-4.77 (m, 3H) 6.29 (br s, 2H) 7.25 (br d, J=8.22 Hz, 2H) 7.46 (br d, J=8.22 Hz, 2H) 7.53 (br s, 1H) 7.57-7.67 (m, 2H) 8.29 (d, J=1.76 Hz, 1H);</p><p id="p-1695" num="1255">MS (ESI, m/z): 571.2 [M+H]<sup>+</sup></p><heading id="h-0468" level="1">Example 434. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)-4-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)-nicotinamide</heading><p id="p-1696" num="1256">To a mixture of intermediate 32 (40 mg, 0.07 mmol) and 4-((4-methylpiperazin-1-yl)-methylphenylboronic acid pinacol ester (27 mg, 0.08 mmol) in 0.4 ml of 1,4-dioxane/water (3/1) was added K<sub>2</sub>CO<sub>3 </sub>(29 mg, 0.21 mmol) followed by Pd(PPh<sub>3</sub>)<sub>4 </sub>(4 mg, 0.003 mmol) Pd(PPh<sub>3</sub>)<sub>4</sub>. The reaction mixture was heated at 100&#xb0; C. for 3 hrs, cooled to room temperature, and extracted with EtOAc, dried over anhydrous MgSO<sub>4 </sub>and concentrated under vacuum. The crude residue was dissolved with 0.5 ml of CH<sub>2</sub>Cl<sub>2</sub>/TFA (10/1) and the mixture was stirred for 2 hrs. After concentration under vacuum, the crude residue was purified by preparative HPLC to afford 30 mg of the title compound.</p><p id="p-1697" num="1257"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 2.88 (s, 3H) 2.91-3.13 (m, 4H) 3.31-3.46 (m, 4H) 3.52-3.65 (m, 3H) 3.80 (dd, J=12.91, 7.04 Hz, 1H) 3.87-3.96 (m, 5H) 4.39-4.45 (m, 1H) 4.71-4.83 (m, 3H) 7.46 (br d, J=8.22 Hz, 2H) 7.49 (br d, J=8.22 Hz, 2H) 7.62 (dd, J=8.22, 2.35 Hz, 4H) 7.87 (s, 1H) 8.04 (s, 1H) 8.25 (d, J=1.76 Hz, 1H) 8.65 (d, J=1.76 Hz, 1H);</p><p id="p-1698" num="1258">MS (ESI, m/z): 581.4 [M+H]<sup>+</sup></p><heading id="h-0469" level="1">Example 435. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)-1-methyl-4-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)-nicotinamide</heading><p id="p-1699" num="1259">To a mixture of compound 434 (52 mg, 0.09 mmol) in 0.4 ml of 1,2-dichloroethane was added formaldehyde (0.015 ml, 0.18 mmol) followed by NaBH(OAc)<sub>3 </sub>(38 mg, 0.28 mmol). The mixture was stirred at room temperature for 1 hr and then water was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude residue was purified by preparative HPLC to afford 35 mg of the title compound.</p><p id="p-1700" num="1260"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 2.94 (s, 3H) 3.04 (s, 3H) 3.36-3.47 (m, 6H) 3.48-3.58 (m, 6H) 3.91 (s, 3H) 4.27 (s, 2H) 4.44 (br s, 1H) 4.72-4.83 (m, 3H) 7.49 (d, J=8.22 Hz, 2H) 7.53 (d, J=8.22 Hz, 2H) 7.61 (d, J=8.22 Hz, 2H) 7.66 (d, J=8.22 Hz, 2H) 7.86 (s, 1H) 8.03 (s, 1H) 8.22 (d, J=1.76 Hz, 1H) 8.67 (d, J=2.35 Hz, 1H);</p><p id="p-1701" num="1261">MS (ESI, m/z): 595.3 [M+H]<sup>+</sup></p><heading id="h-0470" level="1">Example 436. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)-4-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)-pyrrolidin-3-yl)nicotinamide</heading><p id="p-1702" num="1262">Using (4-formyl-3-(trifluoromethyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 434.</p><p id="p-1703" num="0000"><chemistry id="CHEM-US-00442" num="00442"><img id="EMI-C00442" he="31.83mm" wi="74.68mm" file="US20230002353A1-20230105-C00442.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1704" num="1263">MS (ESI, m/z): 649.3 [M+H]<sup>+</sup></p><heading id="h-0471" level="1">Example 437. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)-1-methyl-4-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)-methoxy)pyrrolidin-3-yl)nicotinamide</heading><p id="p-1705" num="1264">From compound 436, the title compound was obtained as described for the example 435.</p><p id="p-1706" num="0000"><chemistry id="CHEM-US-00443" num="00443"><img id="EMI-C00443" he="31.83mm" wi="74.68mm" file="US20230002353A1-20230105-C00443.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1707" num="1265">MS (ESI, m/z): 663.3 [M+H]<sup>+</sup></p><heading id="h-0472" level="1">Example 438. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)-4-((4&#x2032;-(1-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)-nicotinamide</heading><p id="p-1708" num="1266">Using (4-acetylphenyl)boronic acid, the title compound was obtained as described for the example 434.</p><p id="p-1709" num="0000"><chemistry id="CHEM-US-00444" num="00444"><img id="EMI-C00444" he="31.83mm" wi="74.68mm" file="US20230002353A1-20230105-C00444.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1710" num="1267">MS (ESI+) n/z 595.3 [M+H]<sup>+</sup></p><heading id="h-0473" level="1">Example 439. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)-1-methyl-4-((4&#x2032;-(1-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxypyrrolidin-3-yl)-nicotinamide</heading><p id="p-1711" num="1268">From compound 438, the title compound was obtained as described for the example 435.</p><p id="p-1712" num="0000"><chemistry id="CHEM-US-00445" num="00445"><img id="EMI-C00445" he="31.92mm" wi="74.68mm" file="US20230002353A1-20230105-C00445.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1713" num="1269"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.65 (d, J=7.04 Hz, 3H) 2.90 (s, 3H) 3.05 (s, 3H) 3.08-3.17 (m, 2H) 3.46 (br s, 4H) 3.93 (s, 3H) 4.16 (br d, J=6.65 Hz, 2H) 4.49 (s, 1H) 4.75-4.87 (m, 3H) 7.51 (dd, J=8.22, 4.70 Hz, 4H) 7.57-7.70 (m, 4H) 7.88 (s, 1H) 8.05 (s, 1H) 8.26 (d, J=1.96 Hz, 1H) 8.68 (d, J=1.96 Hz, 1H); MS (ESI+) n/z 609.4 [M+H]<sup>+</sup></p><heading id="h-0474" level="1">Example 440. 2-amino-N-((3S,4S)-4-((4&#x2032;-(2-(4-(2-hydroxyethyl)piperazin-1-yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1714" num="1270">Using (4-(2-(4-(2-hydroxyethyl)piperazin-1-yl)propan-2-yl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 434.</p><p id="p-1715" num="0000"><chemistry id="CHEM-US-00446" num="00446"><img id="EMI-C00446" he="42.93mm" wi="113.88mm" file="US20230002353A1-20230105-C00446.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1716" num="1271"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.77 (s, 6H) 3.50-3.68 (m, 6H) 3.80 (s, 1H) 3.83-3.89 (m, 2H) 3.92 (s, 3H) 4.42 (br d, J=4.30 Hz, 1H) 4.73-4.88 (m, 3H) 7.52 (d, J=8.22 Hz, 2H) 7.65 (d, J=8.22 Hz, 2H) 7.67-7.84 (m, 3H) 7.86-7.92 (m, 1H) 8.06 (s, 1H) 8.26 (d, J=2.35 Hz, 1H) 8.70 (d, J=2.35 Hz, 1H);</p><p id="p-1717" num="1272">MS (ESI, m/z): 639.4 [M+H]<sup>+</sup></p><heading id="h-0475" level="1">Example 441. 2-amino-N-((3S,4S)-4-((4&#x2032;-(2-(4-(2-hydroxyethyl)piperazin-1-yl)-propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)-1-methylpyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1718" num="1273">From compound 440, the title compound was obtained as described for the example 435.</p><p id="p-1719" num="0000"><chemistry id="CHEM-US-00447" num="00447"><img id="EMI-C00447" he="30.23mm" wi="75.44mm" file="US20230002353A1-20230105-C00447.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1720" num="1274">MS (ESI m/z): 653.4 [M+H]<sup>+</sup></p><heading id="h-0476" level="1">Example 442. 2-amino-N-((3S,4S)-4-((4&#x2032;-(1-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1721" num="1275">Using (4-(1-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 434.</p><p id="p-1722" num="0000"><chemistry id="CHEM-US-00448" num="00448"><img id="EMI-C00448" he="30.23mm" wi="75.44mm" file="US20230002353A1-20230105-C00448.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1723" num="1276">MS (ESI, m/z): 625.4 [M+H]<sup>+</sup></p><heading id="h-0477" level="1">Example 443. 2-amino-N-((3S,4S)-4-((4&#x2032;-(1-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)-1-methylpyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1724" num="1277">From compound 442, the title compound was obtained as described for the example 435.</p><p id="p-1725" num="0000"><chemistry id="CHEM-US-00449" num="00449"><img id="EMI-C00449" he="30.23mm" wi="75.44mm" file="US20230002353A1-20230105-C00449.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1726" num="1278">MS (ESI, m/z): 639.4 [M+H]<sup>+</sup></p><heading id="h-0478" level="1">Example 444. 2-amino-N-((3S,4S)-4-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)-methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1727" num="1279">Using (4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-boronic acid pinacol ester, the title compound was obtained as described for the example 434.</p><p id="p-1728" num="0000"><chemistry id="CHEM-US-00450" num="00450"><img id="EMI-C00450" he="30.06mm" wi="75.44mm" file="US20230002353A1-20230105-C00450.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1729" num="1280">MS (ESI, m/z): 679.3 [M+H]<sup>+</sup></p><heading id="h-0479" level="1">Example 445. 2-amino-N-((3S,4S)-4-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)-methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)-1-methylpyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1730" num="1281">Using 1-(4-bromo-2-(trifluoromethyl)benzyl)piperazine, the title compound was obtained as described for the example 435.</p><p id="p-1731" num="0000"><chemistry id="CHEM-US-00451" num="00451"><img id="EMI-C00451" he="30.06mm" wi="75.44mm" file="US20230002353A1-20230105-C00451.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1732" num="1282">MS (ESI, m/z): 693.3 [M+H]<sup>+</sup></p><heading id="h-0480" level="1">Example 446. 2-amino-N-((3S,4S)-4-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)-methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)-nicotinamide</heading><p id="p-1733" num="1283">Using (4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 434.</p><p id="p-1734" num="0000"><chemistry id="CHEM-US-00452" num="00452"><img id="EMI-C00452" he="28.45mm" wi="75.44mm" file="US20230002353A1-20230105-C00452.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1735" num="1284">MS (ESI, m/z): 611.3 [M+H]<sup>+</sup></p><heading id="h-0481" level="1">Example 447. 2-amino-N-((3S,4S)-4-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)-methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)-1-methylpyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1736" num="1285">From compound 446, the title compound was obtained as described for the example 435.</p><p id="p-1737" num="0000"><chemistry id="CHEM-US-00453" num="00453"><img id="EMI-C00453" he="28.45mm" wi="75.44mm" file="US20230002353A1-20230105-C00453.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1738" num="1286">MS (ESI, m/z): 625.4 [M+H]<sup>+</sup></p><heading id="h-0482" level="1">Example 448. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4R)-4-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl)-nicotinamide</heading><p id="p-1739" num="1287">Scheme for the Preparation of the Compound of Example 448:</p><p id="p-1740" num="0000"><chemistry id="CHEM-US-00454" num="00454"><img id="EMI-C00454" he="159.51mm" wi="106.00mm" file="US20230002353A1-20230105-C00454.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1741" num="1288">Intermediate 33.</p><p id="p-1742" num="1289">Using intermediate 2 and (3S,4R)-4-((4-bromobenzyl)oxy)tetrahydrofuran-3-amine, the title compound was obtained as described for the intermediate 4.</p><p id="p-1743" num="1290"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 3.81 (td, J=10.27, 2.35 Hz, 2H) 3.91 (s, 3H) 4.05 (dd, J=9.98, 5.28 Hz, 1H) 4.11 (dd, J=9.39, 5.87 Hz, 1H) 4.13-4.16 (m, 1H) 4.55 (dd, J=3.81, 2.05 Hz, 1H) 4.60 (s, 2H) 4.63 (d, J=12.33 Hz, 1H) 4.74 (d, J=12.33 Hz, 1H) 7.30 (m, J=8.22 Hz, 2H) 7.45-7.49 (m, 2H) 7.78 (s, 1H) 7.90 (s, 1H) 8.07 (d, J=2.35 Hz, 1H) 8.26 (d, J=1.76 Hz, 1H);</p><p id="p-1744" num="1291">MS (ESI, m/z): 472.1 [M+H]<sup>+</sup></p><heading id="h-0483" level="1">Example 448. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4R)-4-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl)-nicotinamide</heading><p id="p-1745" num="1292">Using intermediate 33, the title compound was obtained as described for the example 172.</p><p id="p-1746" num="1293"><sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 2.87 (s, 3H) 3.80-3.89 (m, 4H) 3.92 (s, 3H) 4.04-4.15 (m, 2H) 4.19-4.25 (m, 1H) 4.57-4.63 (m, 1H) 4.71 (d, J=11.74 Hz, 1H) 4.82 (d, J=11.74 Hz, 1H) 7.40-7.51 (m, 4H) 7.57-7.63 (m, 4H) 7.88 (s, 1H) 8.02 (s, 1H) 8.23 (s, 1H) 8.62 (s, 1H);</p><p id="p-1747" num="1294">MS (ESI, m/z): 582.3 [M+H]<sup>+</sup></p><heading id="h-0484" level="1">Example 449. 2-amino-5-(l-methyl-1_H-pyrazol-4-yl)-N-((3S,4R)-4-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)-tetrahydrofuran-3-yl)nicotinamide</heading><p id="p-1748" num="1295">Using (4-formyl-3-(trifluoromethyl)phenyl)boronic acid pinacol ester pinacol ester, the title compound was obtained as described for the example 448.</p><p id="p-1749" num="0000"><chemistry id="CHEM-US-00455" num="00455"><img id="EMI-C00455" he="33.61mm" wi="75.27mm" file="US20230002353A1-20230105-C00455.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1750" num="1296"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 2.91 (s, 3H) 3.80-3.91 (m, 3H) 3.94 (s, 2H) 4.12 (td, J=9.59, 5.48 Hz, 2H) 4.23 (br s, 1H) 4.62 (br s, 1H) 4.74 (d, J=12.13 Hz, 1H) 7.52 (d, J=8.61 Hz, 2H) 7.65 (d, J=8.22 Hz, 2H) 7.88 (d, J=13.30 Hz, 4H) 8.03 (s, 1H) 8.25 (d, J=1.96 Hz, 1H) 8.63 (d, J=1.96 Hz, 1H);</p><p id="p-1751" num="1297">MS (ESI, m/z): 650.3 [M+H]<sup>+</sup></p><heading id="h-0485" level="1">Example 450. 2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4R)-4-((4&#x2032;-(2-(4-methylpiperazin-1-yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl)nicotinamide</heading><p id="p-1752" num="1298">Using (4-formyl-3-(trifluoromethyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 448.</p><p id="p-1753" num="0000"><chemistry id="CHEM-US-00456" num="00456"><img id="EMI-C00456" he="34.04mm" wi="75.10mm" file="US20230002353A1-20230105-C00456.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1754" num="1299"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.62 (s, 6H) 2.89 (s, 3H) 3.04 (br s, 2H) 3.34-3.47 (m, 4H) 3.82-3.91 (m, 2H) 3.93 (s, 3H) 4.12 (td, J=10.56, 5.48 Hz, 2H) 4.22 (br s, 1H) 4.61 (br s, 1H) 4.66-4.77 (m, 1H) 4.81-4.88 (m, 1H) 7.47 (d, J=7.83 Hz, 2H) 7.58-7.70 (m, 6H) 7.89 (s, 1H) 8.03 (s, 1H) 8.24 (d, J=1.96 Hz, 1H) 8.65 (d, J=1.96 Hz, 1H);</p><p id="p-1755" num="1300">MS (ESI, m/z): 610.2 [M+H]<sup>+</sup></p><heading id="h-0486" level="1">Example 451. 2-amino-N-((3S,4R)-4-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1756" num="1301">Using (4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 448.</p><p id="p-1757" num="0000"><chemistry id="CHEM-US-00457" num="00457"><img id="EMI-C00457" he="28.36mm" wi="75.44mm" file="US20230002353A1-20230105-C00457.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1758" num="1302">MS (ESI, m/z): 612.3 [M+H]<sup>+</sup></p><heading id="h-0487" level="1">Example 452. 2-amino-N-((3S,4R)-4-((4&#x2032;-((4-(2-hydroxyethyl)piperazin-1-yl)-methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1759" num="1303">Using (4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-boronic acid pinacol ester, the title compound was obtained as described for the example 448.</p><p id="p-1760" num="0000"><chemistry id="CHEM-US-00458" num="00458"><img id="EMI-C00458" he="30.06mm" wi="75.44mm" file="US20230002353A1-20230105-C00458.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1761" num="1304"><sup>1</sup>H NMR (400 MHz, CD3OD) &#x3b4; ppm 2.62 (br s, 4H) 3.25-3.29 (m, 2H) 3.34-3.40 (m, 2H) 3.82-3.84 (m, 2H) 3.85-3.91 (m, 2H) 3.94 (s, 2H) 4.06-4.17 (m, 2H) 4.23 (br s, 1H) 4.62 (br s, 1H) 4.74 (m, 1H) 7.52 (m, J=8.22 Hz, 2H) 7.65 (m, J=8.22 Hz, 2H) 7.86 (s, 2H) 7.89 (s, 2H) 8.03 (s, 1H) 8.25 (d, J=1.96 Hz, 1H) 8.63 (d, J=1.96 Hz, 1H);</p><p id="p-1762" num="1305">MS (ESI, m/z): 680.3 [M+H]<sup>+</sup></p><heading id="h-0488" level="1">Example 453. 2-amino-N-((3S,4R)-4-((4&#x2032;-(2-(4-(2-hydroxyethyl)piperazin-1-yl)-propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide</heading><p id="p-1763" num="1306">Using (4-(2-(4-(2-hydroxyethyl)piperazin-1-yl)propan-2-yl)phenyl)boronic acid pinacol ester, the title compound was obtained as described for the example 448.</p><p id="p-1764" num="0000"><chemistry id="CHEM-US-00459" num="00459"><img id="EMI-C00459" he="30.23mm" wi="75.44mm" file="US20230002353A1-20230105-C00459.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1765" num="1307">MS (ESI, m/z): 640.2 [M+H]<sup>+</sup></p><heading id="h-0489" level="1">Example 454. 2-amino-5-(l-methyl-1H-pyrazol-4-yl)-N-(trans-4-((4&#x2032;-((4-methyl-piperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl-nicotinamide</heading><p id="p-1766" num="1308">Using trans-4-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)-tetrahydrofuran-3-amine, the title compound was obtained as described for the example 448.</p><p id="p-1767" num="0000"><chemistry id="CHEM-US-00460" num="00460"><img id="EMI-C00460" he="31.92mm" wi="75.10mm" file="US20230002353A1-20230105-C00460.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1768" num="1309"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 2.88 (s, 3H) 3.76-3.89 (m, 4H) 4.09 (ddd, J=16.92, 9.88, 5.28 Hz, 2H) 4.20 (br d, J=4.70 Hz, 1H) 4.57 (br s, 1H) 4.70 (br d, J=11.74 Hz, 1H) 6.98 (dd, J=7.43, 6.26 Hz, 1H) 7.46 (d, J=8.22 Hz, 4H) 7.56-7.67 (m, 4H) 7.99-8.06 (m, 1H) 8.40 (dd, J=7.43, 1.56 Hz, 1H);</p><p id="p-1769" num="1310">MS (ESI, m/z): 582.3 [M+H]<sup>+</sup></p><heading id="h-0490" level="1">Example 455. 2-amino-N-(trans-4-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl)nicotinamide</heading><p id="p-1770" num="1311">Using 2-aminonicotinic acid and trans-4-((4-bromobenzyl)oxy)tetrahydrofuran-3-amine, the title compound was obtained as described for the example 448.</p><p id="p-1771" num="0000"><chemistry id="CHEM-US-00461" num="00461"><img id="EMI-C00461" he="39.20mm" wi="75.10mm" file="US20230002353A1-20230105-C00461.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1772" num="1312"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 2.88 (s, 3H) 3.76-3.89 (m, 4H) 4.09 (ddd, J=16.92, 9.88, 5.28 Hz, 2H) 4.20 (br d, J=4.70 Hz, 1H) 4.57 (br s, 1H) 4.70 (br d, J=11.74 Hz, 1H) 6.98 (dd, J=7.43, 6.26 Hz, 1H) 7.46 (d, J=8.22 Hz, 4H) 7.56-7.67 (m, 4H) 7.99-8.06 (m, 1H) 8.40 (dd, J=7.43, 1.56 Hz, 1H);</p><p id="p-1773" num="1313">MS (ESI m/z): 502.3 [M+H]<sup>+</sup></p><heading id="h-0491" level="1">Example 456. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl-6-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)nicotinamide</heading><p id="p-1774" num="1314">Scheme for the Preparation of the Compound of Example 456:</p><p id="p-1775" num="0000"><chemistry id="CHEM-US-00462" num="00462"><img id="EMI-C00462" he="113.71mm" wi="75.78mm" file="US20230002353A1-20230105-C00462.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1776" num="1315">Intermediate 34.</p><p id="p-1777" num="1316">To a suspension of methyl 2-amino-6-chloronicotinate (100 mg, 0.54 mmol) in 3 ml of MeOH was added 2N NaOH (1 ml, 2 mmol) and the mixture was heated at 65&#xb0; C. for 1 hr, cooled to room temperature, neutralized (1 ml of 2N HCl), and the resulting precipitate was filtered, washed with MeOH, and dried to give 80 mg of off-white solid.</p><p id="p-1778" num="1317"><sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) &#x3b4; ppm 6.61 (d, J=7.83 Hz, 1H) 7.53 (br s, 2H) 8.01 (d, J=8.22 Hz, 1H); MS (ESI, m/z): 173.2 [M+H]<sup>+</sup></p><p id="p-1779" num="1318">Intermediate 35.</p><p id="p-1780" num="1319">To a mixture of intermediate 34 (50 mg, 0.29 mmol) and triethylamine (0.061 ml, 0.43 mmol) in 2 ml of DMF was added HATU (132 mg, 0.35 mmol) followed by (1S,2S)-2-(benzyloxy)cyclopentan-1-amine (55 mg, 0.29 mmol). The mixture was stirred at room temperature for 1 hr and then saturated sodium bicarbonate solution was added. The mixture was extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude residue was purified by preparative HPLC to afford 80 mg of the title compound.</p><p id="p-1781" num="1320"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3b4; ppm 1.39-1.52 (m, 1H) 1.68-1.81 (m, 2H) 1.83-1.89 (m, 1H) 1.89-2.02 (m, 1H). 2.27 (td, J=13.69, 7.83 Hz, 1H) 3.80-3.87 (m, 1H) 4.27-4.37 (m, 1H) 4.58-4.67 (m, 2H) 5.79 (br d, J=6.26 Hz, 1H) 6.51 (br s, 2H) 6.56 (d, J=7.83 Hz, 1H) 7.25-7.37 (m, 5H) 7.39 (d, J=7.83 Hz, 1H);</p><p id="p-1782" num="1321">MS (ESI, m/z): 345.3 [M+H]<sup>+</sup></p><heading id="h-0492" level="1">Example 456. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)nicotinamide</heading><p id="p-1783" num="1322">To a mixture of intermediate 35 (186 mg, 1 mmol) and 4-((4-methylpiperazine-1-yl)methyl)aniline (240 mg, 1.2 mmol) in 5 ml of 1,4-dioxane was added 480 mg of K<sub>2</sub>CO<sub>3 </sub>followed by Pd<sub>2</sub>(dba)<sub>3 </sub>(30 mg, 0.3 mmol). The reaction mixture was heated at 100&#xb0; C. for 3 hrs, cooled to room temperature, and extracted with EtOAc, dried over anhydrous MgSO<sub>4 </sub>and concentrated under vacuum. The crude product was purified by silicagel column chromatography to give 170 mg of off-white solid.</p><p id="p-1784" num="1323"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) &#x3b4; ppm 1.57 (br dd, J=13.30, 7.04 Hz, 1H) 1.66-1.87 (m, 3H) 1.97 (dt, J=13.01, 6.60 Hz, 1H) 2.13 (br dd, J=13.11, 6.85 Hz, 1H) 2.95 (s, 3H) 3.44-3.62 (m, 4H) 3.87-3.97 (m, 1H) 4.17 (s, 2H) 4.31-4.39 (m, 1H) 4.60 (s, 2H) 6.25 (d, J=9.00 Hz, 1H) 7.21-7.35 (m, 4H) 7.43 (d, J=8.22 Hz, 2H) 7.58 (d, J=8.61 Hz, 2H) 8.08 (d, J=9.00 Hz, 1H); MS (ESI, m/z): 515.3 [M+H]<sup>+</sup></p><heading id="h-0493" level="1">Example 457. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6-(phenylamino)-nicotinamide</heading><p id="p-1785" num="1324">Using aniline, the title compound was obtained as described for the example 456.</p><p id="p-1786" num="0000"><chemistry id="CHEM-US-00463" num="00463"><img id="EMI-C00463" he="30.06mm" wi="65.11mm" file="US20230002353A1-20230105-C00463.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1787" num="1325">MS (ESI, m/z): 403.2 [M+H]<sup>+</sup></p><heading id="h-0494" level="1">Example 458. 2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)nicotinamide</heading><p id="p-1788" num="1326">Using 4-(4-methylpiperazin-1-yl)aniline, the title compound was obtained as described for the example 456.</p><p id="p-1789" num="0000"><chemistry id="CHEM-US-00464" num="00464"><img id="EMI-C00464" he="26.75mm" wi="73.66mm" file="US20230002353A1-20230105-C00464.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-1790" num="1327">MS (ESI, m/z): 501.3 [M+H]<sup>+</sup></p><p id="p-1791" num="1328">Biochemical Assay</p><p id="p-1792" num="1329">For the SAR (structure-activity relationship) and compound screening, LanthaScreen&#x2122; TR-FRET (Time-Resolved fluorescence energy transfer) assay was employed using the phospho-tyrosine specific Terbium (Tb)-labeled antibody with a fluorescein labeled poly-GT (glutamate-tyrosine) as a substrate. Upon excitation at 340 nm by UV, the energy from Tb donor of the antibody is transferred to the fluorescein of the phosphorylated poly GT substrate, and fluorescein emits light at 520 nm. The ratio between the intensity of primary emission at 495 nm and that of secondary emission at 520 nm was used to quantify the level of kinase activity. The recombinant proteins of human c-MER and AXL catalytic domains, Fluorescein-labeled poly-GT substrate, Tb-labeled anti-phosphorylated tyrosine antibodies, the kinase assay buffer, and 0.5M EDTA solution were purchased (Life technologies, USA). The TR-FRET assays were carried out in the white low volume 384-well plate (Corning, USA). To measure the compound mediated inhibition of kinase activity, the recombinant kinases were pre-incubated with test compounds for 20 minutes prior to the addition of 200 nM fluorescein labeled poly-GT substrates and 10 uM ATP, and then the reaction was carried out for 1 hour at room temperature. 10 mM EDTA was added to terminate the enzyme reaction, and the level of phosphorylation of poly-GT substrate was determined following 30 min incubation with 2 nM Tb-labeled antibody. The fluorescence intensity was measured with Envision&#x2122; plate reader (PerkinElmer, USA).</p><p id="p-1793" num="1330">In Cell MER Kinase Assay Using BaF3 Cellular System</p><p id="p-1794" num="1331">CD8-MerTK is a chimeric fusion protein consisting of the extracellular and transmembrane domains of the human CD8&#x3b1; (amino acids 1 to 209) at its N-terminus and the kinase domain and intracellular parts of MerTK (amino acids 521-994) at its C-terminus. To establish an in cell kinase assay for MerTK kinase, the IL-3 dependent Ba/F3 cells of murine lymphoid origin was transfected with CD8-MerTK. The resulting Ba/F3-CDM line was then validated that Ba/F3-CDM cell proliferation is completely dependent on the activity of MerTK kinase activity when growing in the absence of IL-3. For a routine cellular assay, Ba/F3-CDM cells were seeded at 2,000 cells per well in 384-well cell culture plate containing DMEM/10% FBS culture media and incubated for 24 hours before addition of compounds pre-diluted in culture media. Following compound treatment, cells were further incubated for 48 hours and the proliferation was measured. To discriminate a Ba/F3 growth inhibition by a specific inhibition of MerTK kinase following compound treatment vs growth inhibition due to a non-specific unintended cytotoxicity of compounds, we routinely carried out control sets of Ba/F3 cells in parallel that grown in L3-supplemented growth media. In the presence of IL-3, the proliferation of Ba/F3 is no longer dependent on the MerTK activity. Cell growth and proliferation was measured with Celltiter-Glo&#x2122; system (Promega, USA) according to the manufacturer's instruction. The half-maximal growth inhibitory concentration (GI<sub>50</sub>) value was calculated with Prism6.0 software (GraphPad, USA).</p><p id="p-1795" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Biochemical IC50 and cell growth inhibitory GI50 values.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="center"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="84pt" align="center"/><tbody valign="top"><row><entry/><entry>Mer TK inhibition</entry><entry>Cell growth inhibition</entry></row><row><entry>Compound No.</entry><entry>(IC50)</entry><entry>(GI50)</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="70pt" align="char" char="."/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="84pt" align="center"/><tbody valign="top"><row><entry>1</entry><entry>+++</entry><entry>+</entry></row><row><entry>2</entry><entry>++</entry></row><row><entry>3</entry><entry>++</entry></row><row><entry>4</entry><entry>+</entry></row><row><entry>5</entry><entry>+</entry></row><row><entry>6</entry><entry>+++</entry></row><row><entry>7</entry><entry>+++</entry></row><row><entry>8</entry><entry>+++</entry></row><row><entry>9</entry><entry>+++</entry></row><row><entry>10</entry><entry>++</entry></row><row><entry>11</entry><entry>+++</entry></row><row><entry>12</entry><entry>++</entry></row><row><entry>13</entry><entry>+++</entry></row><row><entry>14</entry><entry>+++</entry></row><row><entry>15</entry><entry>+</entry><entry>+</entry></row><row><entry>16</entry><entry>+++</entry></row><row><entry>17</entry><entry>+++</entry></row><row><entry>18</entry><entry>+++</entry></row><row><entry>19</entry><entry>+++</entry></row><row><entry>20</entry><entry>+++</entry></row><row><entry>21</entry><entry>++++</entry><entry>+</entry></row><row><entry>22</entry><entry>+++</entry></row><row><entry>23</entry><entry>++</entry><entry>+</entry></row><row><entry>24</entry><entry>+++</entry></row><row><entry>25</entry><entry>+++</entry></row><row><entry>26</entry><entry>++</entry></row><row><entry>27</entry><entry>++</entry></row><row><entry>28</entry><entry>++</entry></row><row><entry>29</entry><entry>++</entry></row><row><entry>30</entry><entry>+</entry></row><row><entry>31</entry><entry>+</entry></row><row><entry>32</entry><entry>+</entry></row><row><entry>33</entry><entry>++</entry></row><row><entry>34</entry><entry>++</entry></row><row><entry>35</entry><entry>+</entry></row><row><entry>36</entry><entry>+</entry></row><row><entry>37</entry><entry>++</entry></row><row><entry>38</entry><entry>++</entry></row><row><entry>39</entry><entry>++</entry></row><row><entry>40</entry><entry>++</entry></row><row><entry>41</entry><entry>+++</entry></row><row><entry>42</entry><entry>+</entry></row><row><entry>43</entry><entry>++</entry></row><row><entry>44</entry><entry>++</entry><entry>+</entry></row><row><entry>45</entry><entry>++</entry></row><row><entry>46</entry><entry>++</entry></row><row><entry>47</entry><entry>++</entry></row><row><entry>48</entry><entry>++</entry></row><row><entry>49</entry><entry>++</entry></row><row><entry>50</entry><entry>+</entry></row><row><entry>51</entry><entry>+</entry></row><row><entry>52</entry><entry>++</entry></row><row><entry>53</entry><entry>+</entry></row><row><entry>54</entry><entry>++</entry></row><row><entry>55</entry><entry>+</entry></row><row><entry>56</entry><entry>+</entry></row><row><entry>57</entry><entry>+</entry></row><row><entry>58</entry><entry>+</entry></row><row><entry>59</entry><entry>+</entry></row><row><entry>60</entry><entry>++</entry></row><row><entry>61</entry><entry>++</entry></row><row><entry>62</entry><entry>+</entry></row><row><entry>63</entry><entry>+++</entry><entry>+</entry></row><row><entry>64</entry><entry>++</entry></row><row><entry>65</entry><entry>+++</entry><entry>++</entry></row><row><entry>66</entry><entry>+</entry></row><row><entry>67</entry><entry>++</entry></row><row><entry>68</entry><entry>+++</entry><entry>+</entry></row><row><entry>69</entry><entry>+</entry></row><row><entry>70</entry><entry>+</entry></row><row><entry>71</entry><entry>+</entry></row><row><entry>72</entry><entry>+</entry></row><row><entry>73</entry><entry>+</entry></row><row><entry>74</entry><entry>+</entry></row><row><entry>75</entry><entry>+</entry></row><row><entry>76</entry><entry>+</entry></row><row><entry>77</entry><entry>++</entry></row><row><entry>78</entry><entry>+++</entry><entry>+</entry></row><row><entry>79</entry><entry>+</entry></row><row><entry>80</entry><entry>++</entry></row><row><entry>81</entry><entry>+++</entry><entry>+</entry></row><row><entry>82</entry><entry>++</entry></row><row><entry>83</entry><entry>+</entry></row><row><entry>84</entry><entry>++</entry></row><row><entry>85</entry><entry>++</entry></row><row><entry>86</entry><entry>++++</entry><entry>+++</entry></row><row><entry>87</entry><entry>++</entry></row><row><entry>88</entry><entry>++</entry></row><row><entry>89</entry><entry>++</entry></row><row><entry>90</entry><entry>+</entry></row><row><entry>91</entry><entry>+</entry></row><row><entry>92</entry><entry>+</entry></row><row><entry>93</entry><entry>++</entry><entry>+</entry></row><row><entry>94</entry><entry>+</entry></row><row><entry>95</entry><entry>+</entry></row><row><entry>96</entry><entry>+</entry></row><row><entry>97</entry><entry>+</entry></row><row><entry>98</entry><entry>+</entry></row><row><entry>99</entry><entry>+</entry></row><row><entry>100</entry><entry>+</entry></row><row><entry>101</entry><entry>++</entry></row><row><entry>102</entry><entry>+</entry></row><row><entry>103</entry><entry>+</entry></row><row><entry>104</entry><entry>+</entry></row><row><entry>105</entry><entry>+</entry></row><row><entry>106</entry><entry>+</entry></row><row><entry>107</entry><entry>+</entry></row><row><entry>108</entry><entry>+</entry></row><row><entry>109</entry><entry>+</entry></row><row><entry>110</entry><entry>+</entry></row><row><entry>111</entry><entry>+</entry></row><row><entry>112</entry><entry>+</entry></row><row><entry>113</entry><entry>+</entry></row><row><entry>114</entry><entry>+</entry></row><row><entry>115</entry><entry>+</entry></row><row><entry>116</entry><entry>+</entry></row><row><entry>117</entry><entry>+</entry></row><row><entry>118</entry><entry>+</entry></row><row><entry>119</entry><entry>+</entry></row><row><entry>120</entry><entry>+</entry></row><row><entry>121</entry><entry>+</entry></row><row><entry>122</entry><entry>+</entry></row><row><entry>123</entry><entry>+</entry></row><row><entry>124</entry><entry>+</entry></row><row><entry>125</entry><entry>+</entry></row><row><entry>126</entry><entry>+</entry></row><row><entry>127</entry><entry>+</entry></row><row><entry>128</entry><entry>+</entry></row><row><entry>129</entry><entry>+</entry></row><row><entry>130</entry><entry>+++</entry><entry>+</entry></row><row><entry>131</entry><entry>+</entry></row><row><entry>132</entry><entry>++</entry></row><row><entry>133</entry><entry>+</entry></row><row><entry>134</entry><entry>+++</entry></row><row><entry>135</entry><entry>+++</entry><entry>+</entry></row><row><entry>136</entry><entry>++++</entry><entry>+++</entry></row><row><entry>137</entry><entry>++++</entry><entry>++++</entry></row><row><entry>138</entry><entry>++++</entry><entry>+</entry></row><row><entry>139</entry><entry>+</entry></row><row><entry>140</entry><entry>+++</entry></row><row><entry>141</entry><entry>+++</entry></row><row><entry>142</entry><entry>++++</entry><entry>+++</entry></row><row><entry>143</entry><entry>+</entry></row><row><entry>144</entry><entry>++++</entry><entry>++</entry></row><row><entry>145</entry><entry>++++</entry><entry>+</entry></row><row><entry>146</entry><entry>++++</entry><entry>++++</entry></row><row><entry>147</entry><entry>++++</entry><entry>+++</entry></row><row><entry>148</entry><entry>++++</entry><entry>+</entry></row><row><entry>149</entry><entry>+++</entry><entry>+</entry></row><row><entry>150</entry><entry>+++</entry><entry>+</entry></row><row><entry>151</entry><entry>+++</entry></row><row><entry>152</entry><entry>+++</entry></row><row><entry>153</entry><entry>++++</entry><entry>++</entry></row><row><entry>154</entry><entry>++</entry><entry>+</entry></row><row><entry>155</entry><entry>+++</entry><entry>+</entry></row><row><entry>156</entry><entry>++++</entry><entry>++++</entry></row><row><entry>157</entry><entry>++++</entry><entry>+++</entry></row><row><entry>158</entry><entry>++</entry><entry>+</entry></row><row><entry>159</entry><entry>++++</entry><entry>+++</entry></row><row><entry>160</entry><entry>+++</entry><entry>+++</entry></row><row><entry>161</entry><entry>++++</entry><entry>++++</entry></row><row><entry>162</entry><entry>+++</entry></row><row><entry>163</entry><entry>++</entry></row><row><entry>164</entry><entry>+</entry><entry>+</entry></row><row><entry>165</entry><entry>+</entry></row><row><entry>166</entry><entry>+</entry></row><row><entry>167</entry><entry>++++</entry></row><row><entry>168</entry><entry>++</entry><entry>+</entry></row><row><entry>169</entry><entry>+</entry></row><row><entry>170</entry><entry>+</entry></row><row><entry>171</entry><entry>+</entry></row><row><entry>172</entry><entry>++++</entry><entry>++++</entry></row><row><entry>173</entry><entry>+++</entry><entry>+</entry></row><row><entry>174</entry><entry>++++</entry><entry>+++</entry></row><row><entry>175</entry><entry>+++</entry><entry>+</entry></row><row><entry>176</entry><entry>+++</entry><entry>+</entry></row><row><entry>177</entry><entry>++++</entry><entry>+++</entry></row><row><entry>178</entry><entry>++</entry><entry>+</entry></row><row><entry>179</entry><entry>++++</entry><entry>+++</entry></row><row><entry>180</entry><entry>++++</entry><entry>+</entry></row><row><entry>181</entry><entry>++++</entry><entry>++++</entry></row><row><entry>182</entry><entry>++++</entry><entry>++++</entry></row><row><entry>183</entry><entry>++++</entry><entry>++++</entry></row><row><entry>184</entry><entry>++++</entry><entry>++++</entry></row><row><entry>185</entry><entry>++++</entry><entry>+++</entry></row><row><entry>186</entry><entry>++++</entry><entry>++++</entry></row><row><entry>187</entry><entry>++++</entry><entry>++++</entry></row><row><entry>188</entry><entry>++++</entry><entry>++++</entry></row><row><entry>189</entry><entry>++++</entry><entry>+++</entry></row><row><entry>190</entry><entry>++++</entry><entry>++++</entry></row><row><entry>191</entry><entry>++++</entry><entry>+++</entry></row><row><entry>192</entry><entry>++++</entry><entry>++++</entry></row><row><entry>193</entry><entry>++++</entry><entry>++++</entry></row><row><entry>194</entry><entry>++++</entry><entry>++++</entry></row><row><entry>195</entry><entry>++++</entry><entry>++++</entry></row><row><entry>196</entry><entry>++++</entry><entry>+++</entry></row><row><entry>197</entry><entry>++++</entry><entry>++++</entry></row><row><entry>198</entry><entry>++++</entry><entry>++++</entry></row><row><entry>199</entry><entry>++++</entry><entry>++++</entry></row><row><entry>200</entry><entry>++++</entry><entry>+++</entry></row><row><entry>201</entry><entry>+++</entry><entry>+++</entry></row><row><entry>202</entry><entry>++++</entry><entry>+++</entry></row><row><entry>203</entry><entry>++++</entry><entry>+++</entry></row><row><entry>204</entry><entry>++++</entry></row><row><entry>205</entry><entry>++++</entry><entry>++++</entry></row><row><entry>206</entry><entry>++++</entry><entry>+++</entry></row><row><entry>207</entry><entry>++++</entry></row><row><entry>208</entry><entry>++++</entry><entry>++++</entry></row><row><entry>209</entry><entry>++++</entry><entry>++++</entry></row><row><entry>210</entry><entry>++++</entry><entry>++++</entry></row><row><entry>211</entry><entry>++++</entry><entry>++++</entry></row><row><entry>212</entry><entry>++++</entry><entry>+</entry></row><row><entry>213</entry><entry>++++</entry><entry>+++</entry></row><row><entry>214</entry><entry>++++</entry><entry>++++</entry></row><row><entry>215</entry><entry>++++</entry><entry>++++</entry></row><row><entry>216</entry><entry>++++</entry><entry>++++</entry></row><row><entry>217</entry><entry>++++</entry><entry>++++</entry></row><row><entry>218</entry><entry>++++</entry><entry>++++</entry></row><row><entry>219</entry><entry>++++</entry><entry>++++</entry></row><row><entry>220</entry><entry>++++</entry><entry>++++</entry></row><row><entry>221</entry><entry>++++</entry><entry>++++</entry></row><row><entry>222</entry><entry>++++</entry><entry>++++</entry></row><row><entry>223</entry><entry>++++</entry><entry>+++</entry></row><row><entry>224</entry><entry>++++</entry><entry>+++</entry></row><row><entry>225</entry><entry>++++</entry><entry>+++</entry></row><row><entry>226</entry><entry>++++</entry><entry>++++</entry></row><row><entry>227</entry><entry>++++</entry><entry>++++</entry></row><row><entry>228</entry><entry>++++</entry><entry>+++</entry></row><row><entry>229</entry><entry>++++</entry><entry>++++</entry></row><row><entry>230</entry><entry>++++</entry><entry>++++</entry></row><row><entry>231</entry><entry>++++</entry></row><row><entry>232</entry><entry>++++</entry><entry>++</entry></row><row><entry>233</entry><entry>++++</entry><entry>+++</entry></row><row><entry>234</entry><entry>++</entry></row><row><entry>235</entry><entry>++++</entry><entry>++</entry></row><row><entry>236</entry><entry>++++</entry><entry>++++</entry></row><row><entry>237</entry><entry>++++</entry><entry>++++</entry></row><row><entry>238</entry><entry>++++</entry><entry>++++</entry></row><row><entry>239</entry><entry>++++</entry><entry>++++</entry></row><row><entry>240</entry><entry>++++</entry><entry>++++</entry></row><row><entry>241</entry><entry>++++</entry><entry>++</entry></row><row><entry>242</entry><entry>++++</entry><entry>++++</entry></row><row><entry>243</entry><entry>++</entry><entry>+</entry></row><row><entry>244</entry><entry>+</entry></row><row><entry>245</entry><entry>++++</entry><entry>++</entry></row><row><entry>246</entry><entry>++++</entry><entry>+++</entry></row><row><entry>247</entry><entry>++++</entry><entry>+++</entry></row><row><entry>248</entry><entry>+++</entry><entry>+</entry></row><row><entry>249</entry><entry>++++</entry><entry>+</entry></row><row><entry>250</entry><entry>++++</entry><entry>+++</entry></row><row><entry>251</entry><entry>++++</entry><entry>+</entry></row><row><entry>252</entry><entry>+++</entry><entry>+</entry></row><row><entry>253</entry><entry>+++</entry><entry>+</entry></row><row><entry>254</entry><entry>+++</entry><entry>+</entry></row><row><entry>255</entry><entry>+++</entry><entry>++</entry></row><row><entry>256</entry><entry>+++</entry></row><row><entry>257</entry><entry>+++</entry><entry>+</entry></row><row><entry>258</entry><entry>+++</entry></row><row><entry>259</entry><entry>++</entry></row><row><entry>260</entry><entry>+++</entry></row><row><entry>261</entry><entry>++</entry></row><row><entry>262</entry><entry>+</entry></row><row><entry>263</entry><entry>+</entry></row><row><entry>264</entry><entry>+</entry></row><row><entry>265</entry><entry>++</entry></row><row><entry>266</entry><entry>++</entry></row><row><entry>267</entry><entry>+</entry></row><row><entry>268</entry><entry>++</entry></row><row><entry>269</entry><entry>++</entry></row><row><entry>270</entry><entry>+++</entry></row><row><entry>271</entry><entry>+++</entry></row><row><entry>272</entry><entry>+++</entry></row><row><entry>273</entry><entry>+++</entry><entry>+</entry></row><row><entry>274</entry><entry>+++</entry></row><row><entry>275</entry><entry>+++</entry><entry>++</entry></row><row><entry>276</entry><entry>+++</entry></row><row><entry>277</entry><entry>+++</entry></row><row><entry>278</entry><entry>+++</entry></row><row><entry>279</entry><entry>+++</entry></row><row><entry>280</entry><entry>+++</entry></row><row><entry>281</entry><entry>+++</entry></row><row><entry>282</entry><entry>+++</entry></row><row><entry>283</entry><entry>+++</entry></row><row><entry>284</entry><entry>+++</entry></row><row><entry>285</entry><entry>+++</entry></row><row><entry>286</entry><entry>+++</entry></row><row><entry>287</entry><entry>++</entry><entry>+</entry></row><row><entry>288</entry><entry>++</entry></row><row><entry>289</entry><entry>+++</entry></row><row><entry>290</entry><entry>+++</entry></row><row><entry>291</entry><entry>+++</entry></row><row><entry>292</entry><entry>+++</entry></row><row><entry>293</entry><entry>+++</entry><entry>+</entry></row><row><entry>294</entry><entry>++</entry></row><row><entry>295</entry><entry>++</entry></row><row><entry>296</entry><entry>++</entry></row><row><entry>297</entry><entry>+++</entry><entry>+</entry></row><row><entry>298</entry><entry>++</entry></row><row><entry>299</entry><entry>+++</entry></row><row><entry>300</entry><entry>+++</entry></row><row><entry>301</entry><entry>+++</entry></row><row><entry>302</entry><entry>+++</entry><entry>+</entry></row><row><entry>303</entry><entry>+++</entry></row><row><entry>304</entry><entry>+++</entry></row><row><entry>305</entry><entry>++</entry></row><row><entry>306</entry><entry>+++</entry></row><row><entry>307</entry><entry>+++</entry></row><row><entry>308</entry><entry>++</entry></row><row><entry>309</entry><entry>++</entry></row><row><entry>310</entry><entry>++</entry></row><row><entry>311</entry><entry>+++</entry></row><row><entry>312</entry><entry>+++</entry></row><row><entry>313</entry><entry>+++</entry><entry>+</entry></row><row><entry>314</entry><entry>+++</entry></row><row><entry>315</entry><entry>+++</entry></row><row><entry>316</entry><entry>+++</entry></row><row><entry>317</entry><entry>++</entry></row><row><entry>318</entry><entry>++++</entry><entry>++</entry></row><row><entry>319</entry><entry>+++</entry></row><row><entry>320</entry><entry>+++</entry></row><row><entry>321</entry><entry>+++</entry><entry>+</entry></row><row><entry>322</entry><entry>+++</entry></row><row><entry>323</entry><entry>+++</entry></row><row><entry>324</entry><entry>+++</entry></row><row><entry>325</entry><entry>++++</entry><entry>+</entry></row><row><entry>326</entry><entry>+++</entry></row><row><entry>327</entry><entry>++++</entry><entry>+</entry></row><row><entry>328</entry><entry>++++</entry><entry>++</entry></row><row><entry>329</entry><entry>++++</entry></row><row><entry>330</entry><entry>++++</entry></row><row><entry>331</entry><entry>+++</entry><entry>+</entry></row><row><entry>332</entry><entry>+++</entry></row><row><entry>333</entry><entry>+++</entry><entry>+</entry></row><row><entry>334</entry><entry>++</entry></row><row><entry>335</entry><entry>++</entry></row><row><entry>336</entry><entry>++</entry></row><row><entry>337</entry><entry>++++</entry><entry>++</entry></row><row><entry>338</entry><entry>+++</entry><entry>+</entry></row><row><entry>339</entry><entry>+++</entry></row><row><entry>340</entry><entry>+++</entry><entry>+</entry></row><row><entry>341</entry><entry>+++</entry></row><row><entry>342</entry><entry>++++</entry></row><row><entry>343</entry><entry>+++</entry></row><row><entry>344</entry><entry>+++</entry></row><row><entry>345</entry><entry>+++</entry></row><row><entry>346</entry><entry>+++</entry><entry>+</entry></row><row><entry>347</entry><entry>++++</entry><entry>+</entry></row><row><entry>348</entry><entry>++++</entry><entry>+</entry></row><row><entry>349</entry><entry>+++</entry><entry>+</entry></row><row><entry>350</entry><entry>+++</entry></row><row><entry>351</entry><entry>+++</entry></row><row><entry>352</entry><entry>+++</entry><entry>+</entry></row><row><entry>353</entry><entry>+++</entry></row><row><entry>354</entry><entry>++</entry></row><row><entry>355</entry><entry>+++</entry><entry>+</entry></row><row><entry>356</entry><entry>+++</entry><entry>+</entry></row><row><entry>357</entry><entry>+++</entry><entry>+</entry></row><row><entry>358</entry><entry>+++</entry><entry>+</entry></row><row><entry>359</entry><entry>+++</entry><entry>+</entry></row><row><entry>360</entry><entry>++++</entry><entry>+</entry></row><row><entry>361</entry><entry>+++</entry><entry>+</entry></row><row><entry>362</entry><entry>+</entry></row><row><entry>363</entry><entry>++++</entry><entry>+++</entry></row><row><entry>364</entry><entry>++++</entry><entry>++++</entry></row><row><entry>365</entry><entry>+++</entry><entry>+</entry></row><row><entry>366</entry><entry>++++</entry><entry>++++</entry></row><row><entry>367</entry><entry>++++</entry><entry>++++</entry></row><row><entry>368</entry><entry>++++</entry><entry>++++</entry></row><row><entry>369</entry><entry>++++</entry><entry>++++</entry></row><row><entry>370</entry><entry>++++</entry><entry>++++</entry></row><row><entry>371</entry><entry>++++</entry><entry>++++</entry></row><row><entry>372</entry><entry>++++</entry><entry>++++</entry></row><row><entry>373</entry><entry>++++</entry><entry>+++</entry></row><row><entry>374</entry><entry>++++</entry><entry>+++</entry></row><row><entry>375</entry><entry>++++</entry><entry>++++</entry></row><row><entry>376</entry><entry>++++</entry><entry>++++</entry></row><row><entry>377</entry><entry>++++</entry><entry>++++</entry></row><row><entry>378</entry><entry>++++</entry><entry>++++</entry></row><row><entry>379</entry><entry>++++</entry><entry>++++</entry></row><row><entry>380</entry><entry>++++</entry><entry>++++</entry></row><row><entry>381</entry><entry>++++</entry><entry>++++</entry></row><row><entry>382</entry><entry>++++</entry></row><row><entry>383</entry><entry>++++</entry><entry>++++</entry></row><row><entry>384</entry><entry>++++</entry><entry>++++</entry></row><row><entry>385</entry><entry>++++</entry><entry>+++</entry></row><row><entry>386</entry><entry>++++</entry><entry>++++</entry></row><row><entry>387</entry><entry>++++</entry><entry>++++</entry></row><row><entry>388</entry><entry>++++</entry><entry>+++</entry></row><row><entry>389</entry><entry>++++</entry><entry>+++</entry></row><row><entry>390</entry><entry>++++</entry><entry>+++</entry></row><row><entry>391</entry><entry>++++</entry><entry>+</entry></row><row><entry>392</entry><entry>+++</entry><entry>+</entry></row><row><entry>393</entry><entry>++</entry><entry>+</entry></row><row><entry>394</entry><entry>++++</entry><entry>++</entry></row><row><entry>395</entry><entry>++++</entry><entry>++</entry></row><row><entry>396</entry><entry>++++</entry><entry>+</entry></row><row><entry>397</entry><entry>+++</entry><entry>+</entry></row><row><entry>398</entry><entry>+++</entry><entry>++</entry></row><row><entry>399</entry><entry>++++</entry><entry>++</entry></row><row><entry>400</entry><entry>++++</entry><entry>++</entry></row><row><entry>401</entry><entry>++++</entry><entry>+</entry></row><row><entry>402</entry><entry>++</entry><entry>+</entry></row><row><entry>403</entry><entry>++</entry><entry>++</entry></row><row><entry>404</entry><entry>++</entry><entry>+</entry></row><row><entry>405</entry><entry>++++</entry><entry>+++</entry></row><row><entry>406</entry><entry>+++</entry><entry>+</entry></row><row><entry>407</entry><entry>+++</entry><entry>++</entry></row><row><entry>408</entry><entry>+++</entry><entry>+</entry></row><row><entry>409</entry><entry>+++</entry><entry>+</entry></row><row><entry>410</entry><entry>+++</entry><entry>+</entry></row><row><entry>411</entry><entry>++++</entry><entry>+++</entry></row><row><entry>412</entry><entry>++++</entry><entry>+</entry></row><row><entry>413</entry><entry>++++</entry><entry>++</entry></row><row><entry>414</entry><entry>+++</entry><entry>+</entry></row><row><entry>415</entry><entry>++++</entry><entry>+</entry></row><row><entry>416</entry><entry>++++</entry><entry>+++</entry></row><row><entry>417</entry><entry>+++</entry><entry>++</entry></row><row><entry>418</entry><entry>+++</entry><entry>++</entry></row><row><entry>419</entry><entry>++++</entry><entry>+</entry></row><row><entry>420</entry><entry>+++</entry><entry>+</entry></row><row><entry>421</entry><entry>+++</entry><entry>+</entry></row><row><entry>422</entry><entry>+++</entry><entry>+</entry></row><row><entry>423</entry><entry>+++</entry><entry>++</entry></row><row><entry>424</entry><entry>+++</entry><entry>+</entry></row><row><entry>425</entry><entry>+++</entry><entry>++</entry></row><row><entry>426</entry><entry>++++</entry><entry>++</entry></row><row><entry>427</entry><entry>+++</entry><entry>+</entry></row><row><entry>428</entry><entry>+++</entry><entry>+</entry></row><row><entry>429</entry><entry>++</entry><entry>+</entry></row><row><entry>430</entry><entry>+++</entry><entry>+</entry></row><row><entry>431</entry><entry>+++</entry><entry>+</entry></row><row><entry>432</entry><entry>+++</entry></row><row><entry>433</entry><entry>++++</entry><entry>+++</entry></row><row><entry>434</entry><entry>++++</entry><entry>++</entry></row><row><entry>435</entry><entry>++++</entry><entry>+++</entry></row><row><entry>436</entry><entry>++++</entry><entry>++</entry></row><row><entry>437</entry><entry>++++</entry><entry>++++</entry></row><row><entry>438</entry><entry>++++</entry><entry>++</entry></row><row><entry>439</entry><entry>++++</entry><entry>+++</entry></row><row><entry>440</entry><entry>++++</entry><entry>+</entry></row><row><entry>441</entry><entry>++++</entry><entry>+++</entry></row><row><entry>442</entry><entry>++++</entry><entry>+</entry></row><row><entry>443</entry><entry>++++</entry><entry>++++</entry></row><row><entry>444</entry><entry>++++</entry><entry>+</entry></row><row><entry>445</entry><entry>++++</entry><entry>++++</entry></row><row><entry>446</entry><entry>++++</entry><entry>+</entry></row><row><entry>447</entry><entry>++++</entry><entry>++++</entry></row><row><entry>448</entry><entry>++++</entry><entry>++++</entry></row><row><entry>449</entry><entry>++++</entry><entry>++++</entry></row><row><entry>450</entry><entry>++++</entry><entry>++++</entry></row><row><entry>451</entry><entry>++++</entry><entry>++++</entry></row><row><entry>452</entry><entry>++++</entry><entry>++++</entry></row><row><entry>453</entry><entry>++++</entry><entry>+++</entry></row><row><entry>454</entry><entry>++++</entry></row><row><entry>455</entry><entry>+++</entry></row><row><entry>456</entry><entry>+</entry></row><row><entry>457</entry><entry>+</entry></row><row><entry>458</entry><entry>+</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry namest="1" nameend="3" align="left" id="FOO-00001">++++: IC50 &#x3c; 10,</entry></row><row><entry namest="1" nameend="3" align="left" id="FOO-00002">+++: 10 &#x2264; IC50 &#x3c; 100,</entry></row><row><entry namest="1" nameend="3" align="left" id="FOO-00003">++: 100 &#x2264; IC50 &#x3c; 1000,</entry></row><row><entry namest="1" nameend="3" align="left" id="FOO-00004">+: IC50 &#x2265; 1000 nM</entry></row><row><entry namest="1" nameend="3" align="left" id="FOO-00005">++++: GI50 &#x3c; 100,</entry></row><row><entry namest="1" nameend="3" align="left" id="FOO-00006">+++: 100 &#x2264; GI50 &#x3c; 500,</entry></row><row><entry namest="1" nameend="3" align="left" id="FOO-00007">++: 500 &#x2264; GI50 &#x3c; 1000,</entry></row><row><entry namest="1" nameend="3" align="left" id="FOO-00008">+: GI50 &#x2265; 1000 nM</entry></row></tbody></tgroup></table></tables></p><p id="p-1796" num="1332">As can be seen in Table 1 above, the heterocyclic compounds of the present invention showed the activity of Mer, which compounds are useful for the prevention and/or the treatment of cancer.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-chemistry idref="CHEM-US-00001" cdx-file="US20230002353A1-20230105-C00001.CDX" mol-file="US20230002353A1-20230105-C00001.MOL"/><us-chemistry idref="CHEM-US-00002" cdx-file="US20230002353A1-20230105-C00002.CDX" mol-file="US20230002353A1-20230105-C00002.MOL"/><us-chemistry idref="CHEM-US-00003" cdx-file="US20230002353A1-20230105-C00003.CDX" mol-file="US20230002353A1-20230105-C00003.MOL"/><us-chemistry idref="CHEM-US-00004" cdx-file="US20230002353A1-20230105-C00004.CDX" mol-file="US20230002353A1-20230105-C00004.MOL"/><us-chemistry idref="CHEM-US-00005" cdx-file="US20230002353A1-20230105-C00005.CDX" mol-file="US20230002353A1-20230105-C00005.MOL"/><us-chemistry idref="CHEM-US-00006" cdx-file="US20230002353A1-20230105-C00006.CDX" mol-file="US20230002353A1-20230105-C00006.MOL"/><us-chemistry idref="CHEM-US-00007" cdx-file="US20230002353A1-20230105-C00007.CDX" mol-file="US20230002353A1-20230105-C00007.MOL"/><us-chemistry idref="CHEM-US-00008" cdx-file="US20230002353A1-20230105-C00008.CDX" mol-file="US20230002353A1-20230105-C00008.MOL"/><us-chemistry idref="CHEM-US-00009" cdx-file="US20230002353A1-20230105-C00009.CDX" mol-file="US20230002353A1-20230105-C00009.MOL"/><us-chemistry idref="CHEM-US-00010" cdx-file="US20230002353A1-20230105-C00010.CDX" mol-file="US20230002353A1-20230105-C00010.MOL"/><us-chemistry idref="CHEM-US-00011" cdx-file="US20230002353A1-20230105-C00011.CDX" mol-file="US20230002353A1-20230105-C00011.MOL"/><us-chemistry idref="CHEM-US-00012" cdx-file="US20230002353A1-20230105-C00012.CDX" mol-file="US20230002353A1-20230105-C00012.MOL"/><us-chemistry idref="CHEM-US-00013" cdx-file="US20230002353A1-20230105-C00013.CDX" mol-file="US20230002353A1-20230105-C00013.MOL"/><us-chemistry idref="CHEM-US-00014" cdx-file="US20230002353A1-20230105-C00014.CDX" mol-file="US20230002353A1-20230105-C00014.MOL"/><us-chemistry idref="CHEM-US-00015" cdx-file="US20230002353A1-20230105-C00015.CDX" mol-file="US20230002353A1-20230105-C00015.MOL"/><us-chemistry idref="CHEM-US-00016" cdx-file="US20230002353A1-20230105-C00016.CDX" mol-file="US20230002353A1-20230105-C00016.MOL"/><us-chemistry idref="CHEM-US-00017" cdx-file="US20230002353A1-20230105-C00017.CDX" mol-file="US20230002353A1-20230105-C00017.MOL"/><us-chemistry idref="CHEM-US-00018" cdx-file="US20230002353A1-20230105-C00018.CDX" mol-file="US20230002353A1-20230105-C00018.MOL"/><us-chemistry idref="CHEM-US-00019" cdx-file="US20230002353A1-20230105-C00019.CDX" mol-file="US20230002353A1-20230105-C00019.MOL"/><us-chemistry idref="CHEM-US-00020" cdx-file="US20230002353A1-20230105-C00020.CDX" mol-file="US20230002353A1-20230105-C00020.MOL"/><us-chemistry idref="CHEM-US-00021" cdx-file="US20230002353A1-20230105-C00021.CDX" mol-file="US20230002353A1-20230105-C00021.MOL"/><us-chemistry idref="CHEM-US-00022" cdx-file="US20230002353A1-20230105-C00022.CDX" mol-file="US20230002353A1-20230105-C00022.MOL"/><us-chemistry idref="CHEM-US-00023" cdx-file="US20230002353A1-20230105-C00023.CDX" mol-file="US20230002353A1-20230105-C00023.MOL"/><us-chemistry idref="CHEM-US-00024" cdx-file="US20230002353A1-20230105-C00024.CDX" mol-file="US20230002353A1-20230105-C00024.MOL"/><us-chemistry idref="CHEM-US-00025" cdx-file="US20230002353A1-20230105-C00025.CDX" mol-file="US20230002353A1-20230105-C00025.MOL"/><us-chemistry idref="CHEM-US-00026" cdx-file="US20230002353A1-20230105-C00026.CDX" mol-file="US20230002353A1-20230105-C00026.MOL"/><us-chemistry idref="CHEM-US-00027" cdx-file="US20230002353A1-20230105-C00027.CDX" mol-file="US20230002353A1-20230105-C00027.MOL"/><us-chemistry idref="CHEM-US-00028" cdx-file="US20230002353A1-20230105-C00028.CDX" mol-file="US20230002353A1-20230105-C00028.MOL"/><us-chemistry idref="CHEM-US-00029" cdx-file="US20230002353A1-20230105-C00029.CDX" mol-file="US20230002353A1-20230105-C00029.MOL"/><us-chemistry idref="CHEM-US-00030" cdx-file="US20230002353A1-20230105-C00030.CDX" mol-file="US20230002353A1-20230105-C00030.MOL"/><us-chemistry idref="CHEM-US-00031" cdx-file="US20230002353A1-20230105-C00031.CDX" mol-file="US20230002353A1-20230105-C00031.MOL"/><us-chemistry idref="CHEM-US-00032" cdx-file="US20230002353A1-20230105-C00032.CDX" mol-file="US20230002353A1-20230105-C00032.MOL"/><us-chemistry idref="CHEM-US-00033" cdx-file="US20230002353A1-20230105-C00033.CDX" mol-file="US20230002353A1-20230105-C00033.MOL"/><us-chemistry idref="CHEM-US-00034" cdx-file="US20230002353A1-20230105-C00034.CDX" mol-file="US20230002353A1-20230105-C00034.MOL"/><us-chemistry idref="CHEM-US-00035" cdx-file="US20230002353A1-20230105-C00035.CDX" mol-file="US20230002353A1-20230105-C00035.MOL"/><us-chemistry idref="CHEM-US-00036" cdx-file="US20230002353A1-20230105-C00036.CDX" mol-file="US20230002353A1-20230105-C00036.MOL"/><us-chemistry idref="CHEM-US-00037" cdx-file="US20230002353A1-20230105-C00037.CDX" mol-file="US20230002353A1-20230105-C00037.MOL"/><us-chemistry idref="CHEM-US-00038" cdx-file="US20230002353A1-20230105-C00038.CDX" mol-file="US20230002353A1-20230105-C00038.MOL"/><us-chemistry idref="CHEM-US-00039" cdx-file="US20230002353A1-20230105-C00039.CDX" mol-file="US20230002353A1-20230105-C00039.MOL"/><us-chemistry idref="CHEM-US-00040" cdx-file="US20230002353A1-20230105-C00040.CDX" mol-file="US20230002353A1-20230105-C00040.MOL"/><us-chemistry idref="CHEM-US-00041" cdx-file="US20230002353A1-20230105-C00041.CDX" mol-file="US20230002353A1-20230105-C00041.MOL"/><us-chemistry idref="CHEM-US-00042" cdx-file="US20230002353A1-20230105-C00042.CDX" mol-file="US20230002353A1-20230105-C00042.MOL"/><us-chemistry idref="CHEM-US-00043" cdx-file="US20230002353A1-20230105-C00043.CDX" mol-file="US20230002353A1-20230105-C00043.MOL"/><us-chemistry idref="CHEM-US-00044" cdx-file="US20230002353A1-20230105-C00044.CDX" mol-file="US20230002353A1-20230105-C00044.MOL"/><us-chemistry idref="CHEM-US-00045" cdx-file="US20230002353A1-20230105-C00045.CDX" mol-file="US20230002353A1-20230105-C00045.MOL"/><us-chemistry idref="CHEM-US-00046" cdx-file="US20230002353A1-20230105-C00046.CDX" mol-file="US20230002353A1-20230105-C00046.MOL"/><us-chemistry idref="CHEM-US-00047" cdx-file="US20230002353A1-20230105-C00047.CDX" mol-file="US20230002353A1-20230105-C00047.MOL"/><us-chemistry idref="CHEM-US-00048" cdx-file="US20230002353A1-20230105-C00048.CDX" mol-file="US20230002353A1-20230105-C00048.MOL"/><us-chemistry idref="CHEM-US-00049" cdx-file="US20230002353A1-20230105-C00049.CDX" mol-file="US20230002353A1-20230105-C00049.MOL"/><us-chemistry idref="CHEM-US-00050" cdx-file="US20230002353A1-20230105-C00050.CDX" mol-file="US20230002353A1-20230105-C00050.MOL"/><us-chemistry idref="CHEM-US-00051" cdx-file="US20230002353A1-20230105-C00051.CDX" mol-file="US20230002353A1-20230105-C00051.MOL"/><us-chemistry idref="CHEM-US-00052" cdx-file="US20230002353A1-20230105-C00052.CDX" mol-file="US20230002353A1-20230105-C00052.MOL"/><us-chemistry idref="CHEM-US-00053" cdx-file="US20230002353A1-20230105-C00053.CDX" mol-file="US20230002353A1-20230105-C00053.MOL"/><us-chemistry idref="CHEM-US-00054" cdx-file="US20230002353A1-20230105-C00054.CDX" mol-file="US20230002353A1-20230105-C00054.MOL"/><us-chemistry idref="CHEM-US-00055" cdx-file="US20230002353A1-20230105-C00055.CDX" mol-file="US20230002353A1-20230105-C00055.MOL"/><us-chemistry idref="CHEM-US-00056" cdx-file="US20230002353A1-20230105-C00056.CDX" mol-file="US20230002353A1-20230105-C00056.MOL"/><us-chemistry idref="CHEM-US-00057" cdx-file="US20230002353A1-20230105-C00057.CDX" mol-file="US20230002353A1-20230105-C00057.MOL"/><us-chemistry idref="CHEM-US-00058" cdx-file="US20230002353A1-20230105-C00058.CDX" mol-file="US20230002353A1-20230105-C00058.MOL"/><us-chemistry idref="CHEM-US-00059" cdx-file="US20230002353A1-20230105-C00059.CDX" mol-file="US20230002353A1-20230105-C00059.MOL"/><us-chemistry idref="CHEM-US-00060" cdx-file="US20230002353A1-20230105-C00060.CDX" mol-file="US20230002353A1-20230105-C00060.MOL"/><us-chemistry idref="CHEM-US-00061" cdx-file="US20230002353A1-20230105-C00061.CDX" mol-file="US20230002353A1-20230105-C00061.MOL"/><us-chemistry idref="CHEM-US-00062" cdx-file="US20230002353A1-20230105-C00062.CDX" mol-file="US20230002353A1-20230105-C00062.MOL"/><us-chemistry idref="CHEM-US-00063" cdx-file="US20230002353A1-20230105-C00063.CDX" mol-file="US20230002353A1-20230105-C00063.MOL"/><us-chemistry idref="CHEM-US-00064" cdx-file="US20230002353A1-20230105-C00064.CDX" mol-file="US20230002353A1-20230105-C00064.MOL"/><us-chemistry idref="CHEM-US-00065" cdx-file="US20230002353A1-20230105-C00065.CDX" mol-file="US20230002353A1-20230105-C00065.MOL"/><us-chemistry idref="CHEM-US-00066" cdx-file="US20230002353A1-20230105-C00066.CDX" mol-file="US20230002353A1-20230105-C00066.MOL"/><us-chemistry idref="CHEM-US-00067" cdx-file="US20230002353A1-20230105-C00067.CDX" mol-file="US20230002353A1-20230105-C00067.MOL"/><us-chemistry idref="CHEM-US-00068" cdx-file="US20230002353A1-20230105-C00068.CDX" mol-file="US20230002353A1-20230105-C00068.MOL"/><us-chemistry idref="CHEM-US-00069" cdx-file="US20230002353A1-20230105-C00069.CDX" mol-file="US20230002353A1-20230105-C00069.MOL"/><us-chemistry idref="CHEM-US-00070" cdx-file="US20230002353A1-20230105-C00070.CDX" mol-file="US20230002353A1-20230105-C00070.MOL"/><us-chemistry idref="CHEM-US-00071" cdx-file="US20230002353A1-20230105-C00071.CDX" mol-file="US20230002353A1-20230105-C00071.MOL"/><us-chemistry idref="CHEM-US-00072" cdx-file="US20230002353A1-20230105-C00072.CDX" mol-file="US20230002353A1-20230105-C00072.MOL"/><us-chemistry idref="CHEM-US-00073" cdx-file="US20230002353A1-20230105-C00073.CDX" mol-file="US20230002353A1-20230105-C00073.MOL"/><us-chemistry idref="CHEM-US-00074" cdx-file="US20230002353A1-20230105-C00074.CDX" mol-file="US20230002353A1-20230105-C00074.MOL"/><us-chemistry idref="CHEM-US-00075" cdx-file="US20230002353A1-20230105-C00075.CDX" mol-file="US20230002353A1-20230105-C00075.MOL"/><us-chemistry idref="CHEM-US-00076" cdx-file="US20230002353A1-20230105-C00076.CDX" mol-file="US20230002353A1-20230105-C00076.MOL"/><us-chemistry idref="CHEM-US-00077" cdx-file="US20230002353A1-20230105-C00077.CDX" mol-file="US20230002353A1-20230105-C00077.MOL"/><us-chemistry idref="CHEM-US-00078" cdx-file="US20230002353A1-20230105-C00078.CDX" mol-file="US20230002353A1-20230105-C00078.MOL"/><us-chemistry idref="CHEM-US-00079" cdx-file="US20230002353A1-20230105-C00079.CDX" mol-file="US20230002353A1-20230105-C00079.MOL"/><us-chemistry idref="CHEM-US-00080" cdx-file="US20230002353A1-20230105-C00080.CDX" mol-file="US20230002353A1-20230105-C00080.MOL"/><us-chemistry idref="CHEM-US-00081" cdx-file="US20230002353A1-20230105-C00081.CDX" mol-file="US20230002353A1-20230105-C00081.MOL"/><us-chemistry idref="CHEM-US-00082" cdx-file="US20230002353A1-20230105-C00082.CDX" mol-file="US20230002353A1-20230105-C00082.MOL"/><us-chemistry idref="CHEM-US-00083" cdx-file="US20230002353A1-20230105-C00083.CDX" mol-file="US20230002353A1-20230105-C00083.MOL"/><us-chemistry idref="CHEM-US-00084" cdx-file="US20230002353A1-20230105-C00084.CDX" mol-file="US20230002353A1-20230105-C00084.MOL"/><us-chemistry idref="CHEM-US-00085" cdx-file="US20230002353A1-20230105-C00085.CDX" mol-file="US20230002353A1-20230105-C00085.MOL"/><us-chemistry idref="CHEM-US-00086" cdx-file="US20230002353A1-20230105-C00086.CDX" mol-file="US20230002353A1-20230105-C00086.MOL"/><us-chemistry idref="CHEM-US-00087" cdx-file="US20230002353A1-20230105-C00087.CDX" mol-file="US20230002353A1-20230105-C00087.MOL"/><us-chemistry idref="CHEM-US-00088" cdx-file="US20230002353A1-20230105-C00088.CDX" mol-file="US20230002353A1-20230105-C00088.MOL"/><us-chemistry idref="CHEM-US-00089" cdx-file="US20230002353A1-20230105-C00089.CDX" mol-file="US20230002353A1-20230105-C00089.MOL"/><us-chemistry idref="CHEM-US-00090" cdx-file="US20230002353A1-20230105-C00090.CDX" mol-file="US20230002353A1-20230105-C00090.MOL"/><us-chemistry idref="CHEM-US-00091" cdx-file="US20230002353A1-20230105-C00091.CDX" mol-file="US20230002353A1-20230105-C00091.MOL"/><us-chemistry idref="CHEM-US-00092" cdx-file="US20230002353A1-20230105-C00092.CDX" mol-file="US20230002353A1-20230105-C00092.MOL"/><us-chemistry idref="CHEM-US-00093" cdx-file="US20230002353A1-20230105-C00093.CDX" mol-file="US20230002353A1-20230105-C00093.MOL"/><us-chemistry idref="CHEM-US-00094" cdx-file="US20230002353A1-20230105-C00094.CDX" mol-file="US20230002353A1-20230105-C00094.MOL"/><us-chemistry idref="CHEM-US-00095" cdx-file="US20230002353A1-20230105-C00095.CDX" mol-file="US20230002353A1-20230105-C00095.MOL"/><us-chemistry idref="CHEM-US-00096" cdx-file="US20230002353A1-20230105-C00096.CDX" mol-file="US20230002353A1-20230105-C00096.MOL"/><us-chemistry idref="CHEM-US-00097" cdx-file="US20230002353A1-20230105-C00097.CDX" mol-file="US20230002353A1-20230105-C00097.MOL"/><us-chemistry idref="CHEM-US-00098" cdx-file="US20230002353A1-20230105-C00098.CDX" mol-file="US20230002353A1-20230105-C00098.MOL"/><us-chemistry idref="CHEM-US-00099" cdx-file="US20230002353A1-20230105-C00099.CDX" mol-file="US20230002353A1-20230105-C00099.MOL"/><us-chemistry idref="CHEM-US-00100" cdx-file="US20230002353A1-20230105-C00100.CDX" mol-file="US20230002353A1-20230105-C00100.MOL"/><us-chemistry idref="CHEM-US-00101" cdx-file="US20230002353A1-20230105-C00101.CDX" mol-file="US20230002353A1-20230105-C00101.MOL"/><us-chemistry idref="CHEM-US-00102" cdx-file="US20230002353A1-20230105-C00102.CDX" mol-file="US20230002353A1-20230105-C00102.MOL"/><us-chemistry idref="CHEM-US-00103" cdx-file="US20230002353A1-20230105-C00103.CDX" mol-file="US20230002353A1-20230105-C00103.MOL"/><us-chemistry idref="CHEM-US-00104" cdx-file="US20230002353A1-20230105-C00104.CDX" mol-file="US20230002353A1-20230105-C00104.MOL"/><us-chemistry idref="CHEM-US-00105" cdx-file="US20230002353A1-20230105-C00105.CDX" mol-file="US20230002353A1-20230105-C00105.MOL"/><us-chemistry idref="CHEM-US-00106" cdx-file="US20230002353A1-20230105-C00106.CDX" mol-file="US20230002353A1-20230105-C00106.MOL"/><us-chemistry idref="CHEM-US-00107" cdx-file="US20230002353A1-20230105-C00107.CDX" mol-file="US20230002353A1-20230105-C00107.MOL"/><us-chemistry idref="CHEM-US-00108" cdx-file="US20230002353A1-20230105-C00108.CDX" mol-file="US20230002353A1-20230105-C00108.MOL"/><us-chemistry idref="CHEM-US-00109" cdx-file="US20230002353A1-20230105-C00109.CDX" mol-file="US20230002353A1-20230105-C00109.MOL"/><us-chemistry idref="CHEM-US-00110" cdx-file="US20230002353A1-20230105-C00110.CDX" mol-file="US20230002353A1-20230105-C00110.MOL"/><us-chemistry idref="CHEM-US-00111" cdx-file="US20230002353A1-20230105-C00111.CDX" mol-file="US20230002353A1-20230105-C00111.MOL"/><us-chemistry idref="CHEM-US-00112" cdx-file="US20230002353A1-20230105-C00112.CDX" mol-file="US20230002353A1-20230105-C00112.MOL"/><us-chemistry idref="CHEM-US-00113" cdx-file="US20230002353A1-20230105-C00113.CDX" mol-file="US20230002353A1-20230105-C00113.MOL"/><us-chemistry idref="CHEM-US-00114" cdx-file="US20230002353A1-20230105-C00114.CDX" mol-file="US20230002353A1-20230105-C00114.MOL"/><us-chemistry idref="CHEM-US-00115" cdx-file="US20230002353A1-20230105-C00115.CDX" mol-file="US20230002353A1-20230105-C00115.MOL"/><us-chemistry idref="CHEM-US-00116" cdx-file="US20230002353A1-20230105-C00116.CDX" mol-file="US20230002353A1-20230105-C00116.MOL"/><us-chemistry idref="CHEM-US-00117" cdx-file="US20230002353A1-20230105-C00117.CDX" mol-file="US20230002353A1-20230105-C00117.MOL"/><us-chemistry idref="CHEM-US-00118" cdx-file="US20230002353A1-20230105-C00118.CDX" mol-file="US20230002353A1-20230105-C00118.MOL"/><us-chemistry idref="CHEM-US-00119" cdx-file="US20230002353A1-20230105-C00119.CDX" mol-file="US20230002353A1-20230105-C00119.MOL"/><us-chemistry idref="CHEM-US-00120" cdx-file="US20230002353A1-20230105-C00120.CDX" mol-file="US20230002353A1-20230105-C00120.MOL"/><us-chemistry idref="CHEM-US-00121" cdx-file="US20230002353A1-20230105-C00121.CDX" mol-file="US20230002353A1-20230105-C00121.MOL"/><us-chemistry idref="CHEM-US-00122" cdx-file="US20230002353A1-20230105-C00122.CDX" mol-file="US20230002353A1-20230105-C00122.MOL"/><us-chemistry idref="CHEM-US-00123" cdx-file="US20230002353A1-20230105-C00123.CDX" mol-file="US20230002353A1-20230105-C00123.MOL"/><us-chemistry idref="CHEM-US-00124" cdx-file="US20230002353A1-20230105-C00124.CDX" mol-file="US20230002353A1-20230105-C00124.MOL"/><us-chemistry idref="CHEM-US-00125" cdx-file="US20230002353A1-20230105-C00125.CDX" mol-file="US20230002353A1-20230105-C00125.MOL"/><us-chemistry idref="CHEM-US-00126" cdx-file="US20230002353A1-20230105-C00126.CDX" mol-file="US20230002353A1-20230105-C00126.MOL"/><us-chemistry idref="CHEM-US-00127" cdx-file="US20230002353A1-20230105-C00127.CDX" mol-file="US20230002353A1-20230105-C00127.MOL"/><us-chemistry idref="CHEM-US-00128" cdx-file="US20230002353A1-20230105-C00128.CDX" mol-file="US20230002353A1-20230105-C00128.MOL"/><us-chemistry idref="CHEM-US-00129" cdx-file="US20230002353A1-20230105-C00129.CDX" mol-file="US20230002353A1-20230105-C00129.MOL"/><us-chemistry idref="CHEM-US-00130" cdx-file="US20230002353A1-20230105-C00130.CDX" mol-file="US20230002353A1-20230105-C00130.MOL"/><us-chemistry idref="CHEM-US-00131" cdx-file="US20230002353A1-20230105-C00131.CDX" mol-file="US20230002353A1-20230105-C00131.MOL"/><us-chemistry idref="CHEM-US-00132" cdx-file="US20230002353A1-20230105-C00132.CDX" mol-file="US20230002353A1-20230105-C00132.MOL"/><us-chemistry idref="CHEM-US-00133" cdx-file="US20230002353A1-20230105-C00133.CDX" mol-file="US20230002353A1-20230105-C00133.MOL"/><us-chemistry idref="CHEM-US-00134" cdx-file="US20230002353A1-20230105-C00134.CDX" mol-file="US20230002353A1-20230105-C00134.MOL"/><us-chemistry idref="CHEM-US-00135" cdx-file="US20230002353A1-20230105-C00135.CDX" mol-file="US20230002353A1-20230105-C00135.MOL"/><us-chemistry idref="CHEM-US-00136" cdx-file="US20230002353A1-20230105-C00136.CDX" mol-file="US20230002353A1-20230105-C00136.MOL"/><us-chemistry idref="CHEM-US-00137" cdx-file="US20230002353A1-20230105-C00137.CDX" mol-file="US20230002353A1-20230105-C00137.MOL"/><us-chemistry idref="CHEM-US-00138" cdx-file="US20230002353A1-20230105-C00138.CDX" mol-file="US20230002353A1-20230105-C00138.MOL"/><us-chemistry idref="CHEM-US-00139" cdx-file="US20230002353A1-20230105-C00139.CDX" mol-file="US20230002353A1-20230105-C00139.MOL"/><us-chemistry idref="CHEM-US-00140" cdx-file="US20230002353A1-20230105-C00140.CDX" mol-file="US20230002353A1-20230105-C00140.MOL"/><us-chemistry idref="CHEM-US-00141" cdx-file="US20230002353A1-20230105-C00141.CDX" mol-file="US20230002353A1-20230105-C00141.MOL"/><us-chemistry idref="CHEM-US-00142" cdx-file="US20230002353A1-20230105-C00142.CDX" mol-file="US20230002353A1-20230105-C00142.MOL"/><us-chemistry idref="CHEM-US-00143" cdx-file="US20230002353A1-20230105-C00143.CDX" mol-file="US20230002353A1-20230105-C00143.MOL"/><us-chemistry idref="CHEM-US-00144" cdx-file="US20230002353A1-20230105-C00144.CDX" mol-file="US20230002353A1-20230105-C00144.MOL"/><us-chemistry idref="CHEM-US-00145" cdx-file="US20230002353A1-20230105-C00145.CDX" mol-file="US20230002353A1-20230105-C00145.MOL"/><us-chemistry idref="CHEM-US-00146" cdx-file="US20230002353A1-20230105-C00146.CDX" mol-file="US20230002353A1-20230105-C00146.MOL"/><us-chemistry idref="CHEM-US-00147" cdx-file="US20230002353A1-20230105-C00147.CDX" mol-file="US20230002353A1-20230105-C00147.MOL"/><us-chemistry idref="CHEM-US-00148" cdx-file="US20230002353A1-20230105-C00148.CDX" mol-file="US20230002353A1-20230105-C00148.MOL"/><us-chemistry idref="CHEM-US-00149" cdx-file="US20230002353A1-20230105-C00149.CDX" mol-file="US20230002353A1-20230105-C00149.MOL"/><us-chemistry idref="CHEM-US-00150" cdx-file="US20230002353A1-20230105-C00150.CDX" mol-file="US20230002353A1-20230105-C00150.MOL"/><us-chemistry idref="CHEM-US-00151" cdx-file="US20230002353A1-20230105-C00151.CDX" mol-file="US20230002353A1-20230105-C00151.MOL"/><us-chemistry idref="CHEM-US-00152" cdx-file="US20230002353A1-20230105-C00152.CDX" mol-file="US20230002353A1-20230105-C00152.MOL"/><us-chemistry idref="CHEM-US-00153" cdx-file="US20230002353A1-20230105-C00153.CDX" mol-file="US20230002353A1-20230105-C00153.MOL"/><us-chemistry idref="CHEM-US-00154" cdx-file="US20230002353A1-20230105-C00154.CDX" mol-file="US20230002353A1-20230105-C00154.MOL"/><us-chemistry idref="CHEM-US-00155" cdx-file="US20230002353A1-20230105-C00155.CDX" mol-file="US20230002353A1-20230105-C00155.MOL"/><us-chemistry idref="CHEM-US-00156" cdx-file="US20230002353A1-20230105-C00156.CDX" mol-file="US20230002353A1-20230105-C00156.MOL"/><us-chemistry idref="CHEM-US-00157" cdx-file="US20230002353A1-20230105-C00157.CDX" mol-file="US20230002353A1-20230105-C00157.MOL"/><us-chemistry idref="CHEM-US-00158" cdx-file="US20230002353A1-20230105-C00158.CDX" mol-file="US20230002353A1-20230105-C00158.MOL"/><us-chemistry idref="CHEM-US-00159" cdx-file="US20230002353A1-20230105-C00159.CDX" mol-file="US20230002353A1-20230105-C00159.MOL"/><us-chemistry idref="CHEM-US-00160" cdx-file="US20230002353A1-20230105-C00160.CDX" mol-file="US20230002353A1-20230105-C00160.MOL"/><us-chemistry idref="CHEM-US-00161" cdx-file="US20230002353A1-20230105-C00161.CDX" mol-file="US20230002353A1-20230105-C00161.MOL"/><us-chemistry idref="CHEM-US-00162" cdx-file="US20230002353A1-20230105-C00162.CDX" mol-file="US20230002353A1-20230105-C00162.MOL"/><us-chemistry idref="CHEM-US-00163" cdx-file="US20230002353A1-20230105-C00163.CDX" mol-file="US20230002353A1-20230105-C00163.MOL"/><us-chemistry idref="CHEM-US-00164" cdx-file="US20230002353A1-20230105-C00164.CDX" mol-file="US20230002353A1-20230105-C00164.MOL"/><us-chemistry idref="CHEM-US-00165" cdx-file="US20230002353A1-20230105-C00165.CDX" mol-file="US20230002353A1-20230105-C00165.MOL"/><us-chemistry idref="CHEM-US-00166" cdx-file="US20230002353A1-20230105-C00166.CDX" mol-file="US20230002353A1-20230105-C00166.MOL"/><us-chemistry idref="CHEM-US-00167" cdx-file="US20230002353A1-20230105-C00167.CDX" mol-file="US20230002353A1-20230105-C00167.MOL"/><us-chemistry idref="CHEM-US-00168" cdx-file="US20230002353A1-20230105-C00168.CDX" mol-file="US20230002353A1-20230105-C00168.MOL"/><us-chemistry idref="CHEM-US-00169" cdx-file="US20230002353A1-20230105-C00169.CDX" mol-file="US20230002353A1-20230105-C00169.MOL"/><us-chemistry idref="CHEM-US-00170" cdx-file="US20230002353A1-20230105-C00170.CDX" mol-file="US20230002353A1-20230105-C00170.MOL"/><us-chemistry idref="CHEM-US-00171" cdx-file="US20230002353A1-20230105-C00171.CDX" mol-file="US20230002353A1-20230105-C00171.MOL"/><us-chemistry idref="CHEM-US-00172" cdx-file="US20230002353A1-20230105-C00172.CDX" mol-file="US20230002353A1-20230105-C00172.MOL"/><us-chemistry idref="CHEM-US-00173" cdx-file="US20230002353A1-20230105-C00173.CDX" mol-file="US20230002353A1-20230105-C00173.MOL"/><us-chemistry idref="CHEM-US-00174" cdx-file="US20230002353A1-20230105-C00174.CDX" mol-file="US20230002353A1-20230105-C00174.MOL"/><us-chemistry idref="CHEM-US-00175" cdx-file="US20230002353A1-20230105-C00175.CDX" mol-file="US20230002353A1-20230105-C00175.MOL"/><us-chemistry idref="CHEM-US-00176" cdx-file="US20230002353A1-20230105-C00176.CDX" mol-file="US20230002353A1-20230105-C00176.MOL"/><us-chemistry idref="CHEM-US-00177" cdx-file="US20230002353A1-20230105-C00177.CDX" mol-file="US20230002353A1-20230105-C00177.MOL"/><us-chemistry idref="CHEM-US-00178" cdx-file="US20230002353A1-20230105-C00178.CDX" mol-file="US20230002353A1-20230105-C00178.MOL"/><us-chemistry idref="CHEM-US-00179" cdx-file="US20230002353A1-20230105-C00179.CDX" mol-file="US20230002353A1-20230105-C00179.MOL"/><us-chemistry idref="CHEM-US-00180" cdx-file="US20230002353A1-20230105-C00180.CDX" mol-file="US20230002353A1-20230105-C00180.MOL"/><us-chemistry idref="CHEM-US-00181" cdx-file="US20230002353A1-20230105-C00181.CDX" mol-file="US20230002353A1-20230105-C00181.MOL"/><us-chemistry idref="CHEM-US-00182" cdx-file="US20230002353A1-20230105-C00182.CDX" mol-file="US20230002353A1-20230105-C00182.MOL"/><us-chemistry idref="CHEM-US-00183" cdx-file="US20230002353A1-20230105-C00183.CDX" mol-file="US20230002353A1-20230105-C00183.MOL"/><us-chemistry idref="CHEM-US-00184" cdx-file="US20230002353A1-20230105-C00184.CDX" mol-file="US20230002353A1-20230105-C00184.MOL"/><us-chemistry idref="CHEM-US-00185" cdx-file="US20230002353A1-20230105-C00185.CDX" mol-file="US20230002353A1-20230105-C00185.MOL"/><us-chemistry idref="CHEM-US-00186" cdx-file="US20230002353A1-20230105-C00186.CDX" mol-file="US20230002353A1-20230105-C00186.MOL"/><us-chemistry idref="CHEM-US-00187" cdx-file="US20230002353A1-20230105-C00187.CDX" mol-file="US20230002353A1-20230105-C00187.MOL"/><us-chemistry idref="CHEM-US-00188" cdx-file="US20230002353A1-20230105-C00188.CDX" mol-file="US20230002353A1-20230105-C00188.MOL"/><us-chemistry idref="CHEM-US-00189" cdx-file="US20230002353A1-20230105-C00189.CDX" mol-file="US20230002353A1-20230105-C00189.MOL"/><us-chemistry idref="CHEM-US-00190" cdx-file="US20230002353A1-20230105-C00190.CDX" mol-file="US20230002353A1-20230105-C00190.MOL"/><us-chemistry idref="CHEM-US-00191" cdx-file="US20230002353A1-20230105-C00191.CDX" mol-file="US20230002353A1-20230105-C00191.MOL"/><us-chemistry idref="CHEM-US-00192" cdx-file="US20230002353A1-20230105-C00192.CDX" mol-file="US20230002353A1-20230105-C00192.MOL"/><us-chemistry idref="CHEM-US-00193" cdx-file="US20230002353A1-20230105-C00193.CDX" mol-file="US20230002353A1-20230105-C00193.MOL"/><us-chemistry idref="CHEM-US-00194" cdx-file="US20230002353A1-20230105-C00194.CDX" mol-file="US20230002353A1-20230105-C00194.MOL"/><us-chemistry idref="CHEM-US-00195" cdx-file="US20230002353A1-20230105-C00195.CDX" mol-file="US20230002353A1-20230105-C00195.MOL"/><us-chemistry idref="CHEM-US-00196" cdx-file="US20230002353A1-20230105-C00196.CDX" mol-file="US20230002353A1-20230105-C00196.MOL"/><us-chemistry idref="CHEM-US-00197" cdx-file="US20230002353A1-20230105-C00197.CDX" mol-file="US20230002353A1-20230105-C00197.MOL"/><us-chemistry idref="CHEM-US-00198" cdx-file="US20230002353A1-20230105-C00198.CDX" mol-file="US20230002353A1-20230105-C00198.MOL"/><us-chemistry idref="CHEM-US-00199" cdx-file="US20230002353A1-20230105-C00199.CDX" mol-file="US20230002353A1-20230105-C00199.MOL"/><us-chemistry idref="CHEM-US-00200" cdx-file="US20230002353A1-20230105-C00200.CDX" mol-file="US20230002353A1-20230105-C00200.MOL"/><us-chemistry idref="CHEM-US-00201" cdx-file="US20230002353A1-20230105-C00201.CDX" mol-file="US20230002353A1-20230105-C00201.MOL"/><us-chemistry idref="CHEM-US-00202" cdx-file="US20230002353A1-20230105-C00202.CDX" mol-file="US20230002353A1-20230105-C00202.MOL"/><us-chemistry idref="CHEM-US-00203" cdx-file="US20230002353A1-20230105-C00203.CDX" mol-file="US20230002353A1-20230105-C00203.MOL"/><us-chemistry idref="CHEM-US-00204" cdx-file="US20230002353A1-20230105-C00204.CDX" mol-file="US20230002353A1-20230105-C00204.MOL"/><us-chemistry idref="CHEM-US-00205" cdx-file="US20230002353A1-20230105-C00205.CDX" mol-file="US20230002353A1-20230105-C00205.MOL"/><us-chemistry idref="CHEM-US-00206" cdx-file="US20230002353A1-20230105-C00206.CDX" mol-file="US20230002353A1-20230105-C00206.MOL"/><us-chemistry idref="CHEM-US-00207" cdx-file="US20230002353A1-20230105-C00207.CDX" mol-file="US20230002353A1-20230105-C00207.MOL"/><us-chemistry idref="CHEM-US-00208" cdx-file="US20230002353A1-20230105-C00208.CDX" mol-file="US20230002353A1-20230105-C00208.MOL"/><us-chemistry idref="CHEM-US-00209" cdx-file="US20230002353A1-20230105-C00209.CDX" mol-file="US20230002353A1-20230105-C00209.MOL"/><us-chemistry idref="CHEM-US-00210" cdx-file="US20230002353A1-20230105-C00210.CDX" mol-file="US20230002353A1-20230105-C00210.MOL"/><us-chemistry idref="CHEM-US-00211" cdx-file="US20230002353A1-20230105-C00211.CDX" mol-file="US20230002353A1-20230105-C00211.MOL"/><us-chemistry idref="CHEM-US-00212" cdx-file="US20230002353A1-20230105-C00212.CDX" mol-file="US20230002353A1-20230105-C00212.MOL"/><us-chemistry idref="CHEM-US-00213" cdx-file="US20230002353A1-20230105-C00213.CDX" mol-file="US20230002353A1-20230105-C00213.MOL"/><us-chemistry idref="CHEM-US-00214" cdx-file="US20230002353A1-20230105-C00214.CDX" mol-file="US20230002353A1-20230105-C00214.MOL"/><us-chemistry idref="CHEM-US-00215" cdx-file="US20230002353A1-20230105-C00215.CDX" mol-file="US20230002353A1-20230105-C00215.MOL"/><us-chemistry idref="CHEM-US-00216" cdx-file="US20230002353A1-20230105-C00216.CDX" mol-file="US20230002353A1-20230105-C00216.MOL"/><us-chemistry idref="CHEM-US-00217" cdx-file="US20230002353A1-20230105-C00217.CDX" mol-file="US20230002353A1-20230105-C00217.MOL"/><us-chemistry idref="CHEM-US-00218" cdx-file="US20230002353A1-20230105-C00218.CDX" mol-file="US20230002353A1-20230105-C00218.MOL"/><us-chemistry idref="CHEM-US-00219" cdx-file="US20230002353A1-20230105-C00219.CDX" mol-file="US20230002353A1-20230105-C00219.MOL"/><us-chemistry idref="CHEM-US-00220" cdx-file="US20230002353A1-20230105-C00220.CDX" mol-file="US20230002353A1-20230105-C00220.MOL"/><us-chemistry idref="CHEM-US-00221" cdx-file="US20230002353A1-20230105-C00221.CDX" mol-file="US20230002353A1-20230105-C00221.MOL"/><us-chemistry idref="CHEM-US-00222" cdx-file="US20230002353A1-20230105-C00222.CDX" mol-file="US20230002353A1-20230105-C00222.MOL"/><us-chemistry idref="CHEM-US-00223" cdx-file="US20230002353A1-20230105-C00223.CDX" mol-file="US20230002353A1-20230105-C00223.MOL"/><us-chemistry idref="CHEM-US-00224" cdx-file="US20230002353A1-20230105-C00224.CDX" mol-file="US20230002353A1-20230105-C00224.MOL"/><us-chemistry idref="CHEM-US-00225" cdx-file="US20230002353A1-20230105-C00225.CDX" mol-file="US20230002353A1-20230105-C00225.MOL"/><us-chemistry idref="CHEM-US-00226" cdx-file="US20230002353A1-20230105-C00226.CDX" mol-file="US20230002353A1-20230105-C00226.MOL"/><us-chemistry idref="CHEM-US-00227" cdx-file="US20230002353A1-20230105-C00227.CDX" mol-file="US20230002353A1-20230105-C00227.MOL"/><us-chemistry idref="CHEM-US-00228" cdx-file="US20230002353A1-20230105-C00228.CDX" mol-file="US20230002353A1-20230105-C00228.MOL"/><us-chemistry idref="CHEM-US-00229" cdx-file="US20230002353A1-20230105-C00229.CDX" mol-file="US20230002353A1-20230105-C00229.MOL"/><us-chemistry idref="CHEM-US-00230" cdx-file="US20230002353A1-20230105-C00230.CDX" mol-file="US20230002353A1-20230105-C00230.MOL"/><us-chemistry idref="CHEM-US-00231" cdx-file="US20230002353A1-20230105-C00231.CDX" mol-file="US20230002353A1-20230105-C00231.MOL"/><us-chemistry idref="CHEM-US-00232" cdx-file="US20230002353A1-20230105-C00232.CDX" mol-file="US20230002353A1-20230105-C00232.MOL"/><us-chemistry idref="CHEM-US-00233" cdx-file="US20230002353A1-20230105-C00233.CDX" mol-file="US20230002353A1-20230105-C00233.MOL"/><us-chemistry idref="CHEM-US-00234" cdx-file="US20230002353A1-20230105-C00234.CDX" mol-file="US20230002353A1-20230105-C00234.MOL"/><us-chemistry idref="CHEM-US-00235" cdx-file="US20230002353A1-20230105-C00235.CDX" mol-file="US20230002353A1-20230105-C00235.MOL"/><us-chemistry idref="CHEM-US-00236" cdx-file="US20230002353A1-20230105-C00236.CDX" mol-file="US20230002353A1-20230105-C00236.MOL"/><us-chemistry idref="CHEM-US-00237" cdx-file="US20230002353A1-20230105-C00237.CDX" mol-file="US20230002353A1-20230105-C00237.MOL"/><us-chemistry idref="CHEM-US-00238" cdx-file="US20230002353A1-20230105-C00238.CDX" mol-file="US20230002353A1-20230105-C00238.MOL"/><us-chemistry idref="CHEM-US-00239" cdx-file="US20230002353A1-20230105-C00239.CDX" mol-file="US20230002353A1-20230105-C00239.MOL"/><us-chemistry idref="CHEM-US-00240" cdx-file="US20230002353A1-20230105-C00240.CDX" mol-file="US20230002353A1-20230105-C00240.MOL"/><us-chemistry idref="CHEM-US-00241" cdx-file="US20230002353A1-20230105-C00241.CDX" mol-file="US20230002353A1-20230105-C00241.MOL"/><us-chemistry idref="CHEM-US-00242" cdx-file="US20230002353A1-20230105-C00242.CDX" mol-file="US20230002353A1-20230105-C00242.MOL"/><us-chemistry idref="CHEM-US-00243" cdx-file="US20230002353A1-20230105-C00243.CDX" mol-file="US20230002353A1-20230105-C00243.MOL"/><us-chemistry idref="CHEM-US-00244" cdx-file="US20230002353A1-20230105-C00244.CDX" mol-file="US20230002353A1-20230105-C00244.MOL"/><us-chemistry idref="CHEM-US-00245" cdx-file="US20230002353A1-20230105-C00245.CDX" mol-file="US20230002353A1-20230105-C00245.MOL"/><us-chemistry idref="CHEM-US-00246" cdx-file="US20230002353A1-20230105-C00246.CDX" mol-file="US20230002353A1-20230105-C00246.MOL"/><us-chemistry idref="CHEM-US-00247" cdx-file="US20230002353A1-20230105-C00247.CDX" mol-file="US20230002353A1-20230105-C00247.MOL"/><us-chemistry idref="CHEM-US-00248" cdx-file="US20230002353A1-20230105-C00248.CDX" mol-file="US20230002353A1-20230105-C00248.MOL"/><us-chemistry idref="CHEM-US-00249" cdx-file="US20230002353A1-20230105-C00249.CDX" mol-file="US20230002353A1-20230105-C00249.MOL"/><us-chemistry idref="CHEM-US-00250" cdx-file="US20230002353A1-20230105-C00250.CDX" mol-file="US20230002353A1-20230105-C00250.MOL"/><us-chemistry idref="CHEM-US-00251" cdx-file="US20230002353A1-20230105-C00251.CDX" mol-file="US20230002353A1-20230105-C00251.MOL"/><us-chemistry idref="CHEM-US-00252" cdx-file="US20230002353A1-20230105-C00252.CDX" mol-file="US20230002353A1-20230105-C00252.MOL"/><us-chemistry idref="CHEM-US-00253" cdx-file="US20230002353A1-20230105-C00253.CDX" mol-file="US20230002353A1-20230105-C00253.MOL"/><us-chemistry idref="CHEM-US-00254" cdx-file="US20230002353A1-20230105-C00254.CDX" mol-file="US20230002353A1-20230105-C00254.MOL"/><us-chemistry idref="CHEM-US-00255" cdx-file="US20230002353A1-20230105-C00255.CDX" mol-file="US20230002353A1-20230105-C00255.MOL"/><us-chemistry idref="CHEM-US-00256" cdx-file="US20230002353A1-20230105-C00256.CDX" mol-file="US20230002353A1-20230105-C00256.MOL"/><us-chemistry idref="CHEM-US-00257" cdx-file="US20230002353A1-20230105-C00257.CDX" mol-file="US20230002353A1-20230105-C00257.MOL"/><us-chemistry idref="CHEM-US-00258" cdx-file="US20230002353A1-20230105-C00258.CDX" mol-file="US20230002353A1-20230105-C00258.MOL"/><us-chemistry idref="CHEM-US-00259" cdx-file="US20230002353A1-20230105-C00259.CDX" mol-file="US20230002353A1-20230105-C00259.MOL"/><us-chemistry idref="CHEM-US-00260" cdx-file="US20230002353A1-20230105-C00260.CDX" mol-file="US20230002353A1-20230105-C00260.MOL"/><us-chemistry idref="CHEM-US-00261" cdx-file="US20230002353A1-20230105-C00261.CDX" mol-file="US20230002353A1-20230105-C00261.MOL"/><us-chemistry idref="CHEM-US-00262" cdx-file="US20230002353A1-20230105-C00262.CDX" mol-file="US20230002353A1-20230105-C00262.MOL"/><us-chemistry idref="CHEM-US-00263" cdx-file="US20230002353A1-20230105-C00263.CDX" mol-file="US20230002353A1-20230105-C00263.MOL"/><us-chemistry idref="CHEM-US-00264" cdx-file="US20230002353A1-20230105-C00264.CDX" mol-file="US20230002353A1-20230105-C00264.MOL"/><us-chemistry idref="CHEM-US-00265" cdx-file="US20230002353A1-20230105-C00265.CDX" mol-file="US20230002353A1-20230105-C00265.MOL"/><us-chemistry idref="CHEM-US-00266" cdx-file="US20230002353A1-20230105-C00266.CDX" mol-file="US20230002353A1-20230105-C00266.MOL"/><us-chemistry idref="CHEM-US-00267" cdx-file="US20230002353A1-20230105-C00267.CDX" mol-file="US20230002353A1-20230105-C00267.MOL"/><us-chemistry idref="CHEM-US-00268" cdx-file="US20230002353A1-20230105-C00268.CDX" mol-file="US20230002353A1-20230105-C00268.MOL"/><us-chemistry idref="CHEM-US-00269" cdx-file="US20230002353A1-20230105-C00269.CDX" mol-file="US20230002353A1-20230105-C00269.MOL"/><us-chemistry idref="CHEM-US-00270" cdx-file="US20230002353A1-20230105-C00270.CDX" mol-file="US20230002353A1-20230105-C00270.MOL"/><us-chemistry idref="CHEM-US-00271" cdx-file="US20230002353A1-20230105-C00271.CDX" mol-file="US20230002353A1-20230105-C00271.MOL"/><us-chemistry idref="CHEM-US-00272" cdx-file="US20230002353A1-20230105-C00272.CDX" mol-file="US20230002353A1-20230105-C00272.MOL"/><us-chemistry idref="CHEM-US-00273" cdx-file="US20230002353A1-20230105-C00273.CDX" mol-file="US20230002353A1-20230105-C00273.MOL"/><us-chemistry idref="CHEM-US-00274" cdx-file="US20230002353A1-20230105-C00274.CDX" mol-file="US20230002353A1-20230105-C00274.MOL"/><us-chemistry idref="CHEM-US-00275" cdx-file="US20230002353A1-20230105-C00275.CDX" mol-file="US20230002353A1-20230105-C00275.MOL"/><us-chemistry idref="CHEM-US-00276" cdx-file="US20230002353A1-20230105-C00276.CDX" mol-file="US20230002353A1-20230105-C00276.MOL"/><us-chemistry idref="CHEM-US-00277" cdx-file="US20230002353A1-20230105-C00277.CDX" mol-file="US20230002353A1-20230105-C00277.MOL"/><us-chemistry idref="CHEM-US-00278" cdx-file="US20230002353A1-20230105-C00278.CDX" mol-file="US20230002353A1-20230105-C00278.MOL"/><us-chemistry idref="CHEM-US-00279" cdx-file="US20230002353A1-20230105-C00279.CDX" mol-file="US20230002353A1-20230105-C00279.MOL"/><us-chemistry idref="CHEM-US-00280" cdx-file="US20230002353A1-20230105-C00280.CDX" mol-file="US20230002353A1-20230105-C00280.MOL"/><us-chemistry idref="CHEM-US-00281" cdx-file="US20230002353A1-20230105-C00281.CDX" mol-file="US20230002353A1-20230105-C00281.MOL"/><us-chemistry idref="CHEM-US-00282" cdx-file="US20230002353A1-20230105-C00282.CDX" mol-file="US20230002353A1-20230105-C00282.MOL"/><us-chemistry idref="CHEM-US-00283" cdx-file="US20230002353A1-20230105-C00283.CDX" mol-file="US20230002353A1-20230105-C00283.MOL"/><us-chemistry idref="CHEM-US-00284" cdx-file="US20230002353A1-20230105-C00284.CDX" mol-file="US20230002353A1-20230105-C00284.MOL"/><us-chemistry idref="CHEM-US-00285" cdx-file="US20230002353A1-20230105-C00285.CDX" mol-file="US20230002353A1-20230105-C00285.MOL"/><us-chemistry idref="CHEM-US-00286" cdx-file="US20230002353A1-20230105-C00286.CDX" mol-file="US20230002353A1-20230105-C00286.MOL"/><us-chemistry idref="CHEM-US-00287" cdx-file="US20230002353A1-20230105-C00287.CDX" mol-file="US20230002353A1-20230105-C00287.MOL"/><us-chemistry idref="CHEM-US-00288" cdx-file="US20230002353A1-20230105-C00288.CDX" mol-file="US20230002353A1-20230105-C00288.MOL"/><us-chemistry idref="CHEM-US-00289" cdx-file="US20230002353A1-20230105-C00289.CDX" mol-file="US20230002353A1-20230105-C00289.MOL"/><us-chemistry idref="CHEM-US-00290" cdx-file="US20230002353A1-20230105-C00290.CDX" mol-file="US20230002353A1-20230105-C00290.MOL"/><us-chemistry idref="CHEM-US-00291" cdx-file="US20230002353A1-20230105-C00291.CDX" mol-file="US20230002353A1-20230105-C00291.MOL"/><us-chemistry idref="CHEM-US-00292" cdx-file="US20230002353A1-20230105-C00292.CDX" mol-file="US20230002353A1-20230105-C00292.MOL"/><us-chemistry idref="CHEM-US-00293" cdx-file="US20230002353A1-20230105-C00293.CDX" mol-file="US20230002353A1-20230105-C00293.MOL"/><us-chemistry idref="CHEM-US-00294" cdx-file="US20230002353A1-20230105-C00294.CDX" mol-file="US20230002353A1-20230105-C00294.MOL"/><us-chemistry idref="CHEM-US-00295" cdx-file="US20230002353A1-20230105-C00295.CDX" mol-file="US20230002353A1-20230105-C00295.MOL"/><us-chemistry idref="CHEM-US-00296" cdx-file="US20230002353A1-20230105-C00296.CDX" mol-file="US20230002353A1-20230105-C00296.MOL"/><us-chemistry idref="CHEM-US-00297" cdx-file="US20230002353A1-20230105-C00297.CDX" mol-file="US20230002353A1-20230105-C00297.MOL"/><us-chemistry idref="CHEM-US-00298" cdx-file="US20230002353A1-20230105-C00298.CDX" mol-file="US20230002353A1-20230105-C00298.MOL"/><us-chemistry idref="CHEM-US-00299" cdx-file="US20230002353A1-20230105-C00299.CDX" mol-file="US20230002353A1-20230105-C00299.MOL"/><us-chemistry idref="CHEM-US-00300" cdx-file="US20230002353A1-20230105-C00300.CDX" mol-file="US20230002353A1-20230105-C00300.MOL"/><us-chemistry idref="CHEM-US-00301" cdx-file="US20230002353A1-20230105-C00301.CDX" mol-file="US20230002353A1-20230105-C00301.MOL"/><us-chemistry idref="CHEM-US-00302" cdx-file="US20230002353A1-20230105-C00302.CDX" mol-file="US20230002353A1-20230105-C00302.MOL"/><us-chemistry idref="CHEM-US-00303" cdx-file="US20230002353A1-20230105-C00303.CDX" mol-file="US20230002353A1-20230105-C00303.MOL"/><us-chemistry idref="CHEM-US-00304" cdx-file="US20230002353A1-20230105-C00304.CDX" mol-file="US20230002353A1-20230105-C00304.MOL"/><us-chemistry idref="CHEM-US-00305" cdx-file="US20230002353A1-20230105-C00305.CDX" mol-file="US20230002353A1-20230105-C00305.MOL"/><us-chemistry idref="CHEM-US-00306" cdx-file="US20230002353A1-20230105-C00306.CDX" mol-file="US20230002353A1-20230105-C00306.MOL"/><us-chemistry idref="CHEM-US-00307" cdx-file="US20230002353A1-20230105-C00307.CDX" mol-file="US20230002353A1-20230105-C00307.MOL"/><us-chemistry idref="CHEM-US-00308" cdx-file="US20230002353A1-20230105-C00308.CDX" mol-file="US20230002353A1-20230105-C00308.MOL"/><us-chemistry idref="CHEM-US-00309" cdx-file="US20230002353A1-20230105-C00309.CDX" mol-file="US20230002353A1-20230105-C00309.MOL"/><us-chemistry idref="CHEM-US-00310" cdx-file="US20230002353A1-20230105-C00310.CDX" mol-file="US20230002353A1-20230105-C00310.MOL"/><us-chemistry idref="CHEM-US-00311" cdx-file="US20230002353A1-20230105-C00311.CDX" mol-file="US20230002353A1-20230105-C00311.MOL"/><us-chemistry idref="CHEM-US-00312" cdx-file="US20230002353A1-20230105-C00312.CDX" mol-file="US20230002353A1-20230105-C00312.MOL"/><us-chemistry idref="CHEM-US-00313" cdx-file="US20230002353A1-20230105-C00313.CDX" mol-file="US20230002353A1-20230105-C00313.MOL"/><us-chemistry idref="CHEM-US-00314" cdx-file="US20230002353A1-20230105-C00314.CDX" mol-file="US20230002353A1-20230105-C00314.MOL"/><us-chemistry idref="CHEM-US-00315" cdx-file="US20230002353A1-20230105-C00315.CDX" mol-file="US20230002353A1-20230105-C00315.MOL"/><us-chemistry idref="CHEM-US-00316" cdx-file="US20230002353A1-20230105-C00316.CDX" mol-file="US20230002353A1-20230105-C00316.MOL"/><us-chemistry idref="CHEM-US-00317" cdx-file="US20230002353A1-20230105-C00317.CDX" mol-file="US20230002353A1-20230105-C00317.MOL"/><us-chemistry idref="CHEM-US-00318" cdx-file="US20230002353A1-20230105-C00318.CDX" mol-file="US20230002353A1-20230105-C00318.MOL"/><us-chemistry idref="CHEM-US-00319" cdx-file="US20230002353A1-20230105-C00319.CDX" mol-file="US20230002353A1-20230105-C00319.MOL"/><us-chemistry idref="CHEM-US-00320" cdx-file="US20230002353A1-20230105-C00320.CDX" mol-file="US20230002353A1-20230105-C00320.MOL"/><us-chemistry idref="CHEM-US-00321" cdx-file="US20230002353A1-20230105-C00321.CDX" mol-file="US20230002353A1-20230105-C00321.MOL"/><us-chemistry idref="CHEM-US-00322" cdx-file="US20230002353A1-20230105-C00322.CDX" mol-file="US20230002353A1-20230105-C00322.MOL"/><us-chemistry idref="CHEM-US-00323" cdx-file="US20230002353A1-20230105-C00323.CDX" mol-file="US20230002353A1-20230105-C00323.MOL"/><us-chemistry idref="CHEM-US-00324" cdx-file="US20230002353A1-20230105-C00324.CDX" mol-file="US20230002353A1-20230105-C00324.MOL"/><us-chemistry idref="CHEM-US-00325" cdx-file="US20230002353A1-20230105-C00325.CDX" mol-file="US20230002353A1-20230105-C00325.MOL"/><us-chemistry idref="CHEM-US-00326" cdx-file="US20230002353A1-20230105-C00326.CDX" mol-file="US20230002353A1-20230105-C00326.MOL"/><us-chemistry idref="CHEM-US-00327" cdx-file="US20230002353A1-20230105-C00327.CDX" mol-file="US20230002353A1-20230105-C00327.MOL"/><us-chemistry idref="CHEM-US-00328" cdx-file="US20230002353A1-20230105-C00328.CDX" mol-file="US20230002353A1-20230105-C00328.MOL"/><us-chemistry idref="CHEM-US-00329" cdx-file="US20230002353A1-20230105-C00329.CDX" mol-file="US20230002353A1-20230105-C00329.MOL"/><us-chemistry idref="CHEM-US-00330" cdx-file="US20230002353A1-20230105-C00330.CDX" mol-file="US20230002353A1-20230105-C00330.MOL"/><us-chemistry idref="CHEM-US-00331" cdx-file="US20230002353A1-20230105-C00331.CDX" mol-file="US20230002353A1-20230105-C00331.MOL"/><us-chemistry idref="CHEM-US-00332" cdx-file="US20230002353A1-20230105-C00332.CDX" mol-file="US20230002353A1-20230105-C00332.MOL"/><us-chemistry idref="CHEM-US-00333" cdx-file="US20230002353A1-20230105-C00333.CDX" mol-file="US20230002353A1-20230105-C00333.MOL"/><us-chemistry idref="CHEM-US-00334" cdx-file="US20230002353A1-20230105-C00334.CDX" mol-file="US20230002353A1-20230105-C00334.MOL"/><us-chemistry idref="CHEM-US-00335" cdx-file="US20230002353A1-20230105-C00335.CDX" mol-file="US20230002353A1-20230105-C00335.MOL"/><us-chemistry idref="CHEM-US-00336" cdx-file="US20230002353A1-20230105-C00336.CDX" mol-file="US20230002353A1-20230105-C00336.MOL"/><us-chemistry idref="CHEM-US-00337" cdx-file="US20230002353A1-20230105-C00337.CDX" mol-file="US20230002353A1-20230105-C00337.MOL"/><us-chemistry idref="CHEM-US-00338" cdx-file="US20230002353A1-20230105-C00338.CDX" mol-file="US20230002353A1-20230105-C00338.MOL"/><us-chemistry idref="CHEM-US-00339" cdx-file="US20230002353A1-20230105-C00339.CDX" mol-file="US20230002353A1-20230105-C00339.MOL"/><us-chemistry idref="CHEM-US-00340" cdx-file="US20230002353A1-20230105-C00340.CDX" mol-file="US20230002353A1-20230105-C00340.MOL"/><us-chemistry idref="CHEM-US-00341" cdx-file="US20230002353A1-20230105-C00341.CDX" mol-file="US20230002353A1-20230105-C00341.MOL"/><us-chemistry idref="CHEM-US-00342" cdx-file="US20230002353A1-20230105-C00342.CDX" mol-file="US20230002353A1-20230105-C00342.MOL"/><us-chemistry idref="CHEM-US-00343" cdx-file="US20230002353A1-20230105-C00343.CDX" mol-file="US20230002353A1-20230105-C00343.MOL"/><us-chemistry idref="CHEM-US-00344" cdx-file="US20230002353A1-20230105-C00344.CDX" mol-file="US20230002353A1-20230105-C00344.MOL"/><us-chemistry idref="CHEM-US-00345" cdx-file="US20230002353A1-20230105-C00345.CDX" mol-file="US20230002353A1-20230105-C00345.MOL"/><us-chemistry idref="CHEM-US-00346" cdx-file="US20230002353A1-20230105-C00346.CDX" mol-file="US20230002353A1-20230105-C00346.MOL"/><us-chemistry idref="CHEM-US-00347" cdx-file="US20230002353A1-20230105-C00347.CDX" mol-file="US20230002353A1-20230105-C00347.MOL"/><us-chemistry idref="CHEM-US-00348" cdx-file="US20230002353A1-20230105-C00348.CDX" mol-file="US20230002353A1-20230105-C00348.MOL"/><us-chemistry idref="CHEM-US-00349" cdx-file="US20230002353A1-20230105-C00349.CDX" mol-file="US20230002353A1-20230105-C00349.MOL"/><us-chemistry idref="CHEM-US-00350" cdx-file="US20230002353A1-20230105-C00350.CDX" mol-file="US20230002353A1-20230105-C00350.MOL"/><us-chemistry idref="CHEM-US-00351" cdx-file="US20230002353A1-20230105-C00351.CDX" mol-file="US20230002353A1-20230105-C00351.MOL"/><us-chemistry idref="CHEM-US-00352" cdx-file="US20230002353A1-20230105-C00352.CDX" mol-file="US20230002353A1-20230105-C00352.MOL"/><us-chemistry idref="CHEM-US-00353" cdx-file="US20230002353A1-20230105-C00353.CDX" mol-file="US20230002353A1-20230105-C00353.MOL"/><us-chemistry idref="CHEM-US-00354" cdx-file="US20230002353A1-20230105-C00354.CDX" mol-file="US20230002353A1-20230105-C00354.MOL"/><us-chemistry idref="CHEM-US-00355" cdx-file="US20230002353A1-20230105-C00355.CDX" mol-file="US20230002353A1-20230105-C00355.MOL"/><us-chemistry idref="CHEM-US-00356" cdx-file="US20230002353A1-20230105-C00356.CDX" mol-file="US20230002353A1-20230105-C00356.MOL"/><us-chemistry idref="CHEM-US-00357" cdx-file="US20230002353A1-20230105-C00357.CDX" mol-file="US20230002353A1-20230105-C00357.MOL"/><us-chemistry idref="CHEM-US-00358" cdx-file="US20230002353A1-20230105-C00358.CDX" mol-file="US20230002353A1-20230105-C00358.MOL"/><us-chemistry idref="CHEM-US-00359" cdx-file="US20230002353A1-20230105-C00359.CDX" mol-file="US20230002353A1-20230105-C00359.MOL"/><us-chemistry idref="CHEM-US-00360" cdx-file="US20230002353A1-20230105-C00360.CDX" mol-file="US20230002353A1-20230105-C00360.MOL"/><us-chemistry idref="CHEM-US-00361" cdx-file="US20230002353A1-20230105-C00361.CDX" mol-file="US20230002353A1-20230105-C00361.MOL"/><us-chemistry idref="CHEM-US-00362" cdx-file="US20230002353A1-20230105-C00362.CDX" mol-file="US20230002353A1-20230105-C00362.MOL"/><us-chemistry idref="CHEM-US-00363" cdx-file="US20230002353A1-20230105-C00363.CDX" mol-file="US20230002353A1-20230105-C00363.MOL"/><us-chemistry idref="CHEM-US-00364" cdx-file="US20230002353A1-20230105-C00364.CDX" mol-file="US20230002353A1-20230105-C00364.MOL"/><us-chemistry idref="CHEM-US-00365" cdx-file="US20230002353A1-20230105-C00365.CDX" mol-file="US20230002353A1-20230105-C00365.MOL"/><us-chemistry idref="CHEM-US-00366" cdx-file="US20230002353A1-20230105-C00366.CDX" mol-file="US20230002353A1-20230105-C00366.MOL"/><us-chemistry idref="CHEM-US-00367" cdx-file="US20230002353A1-20230105-C00367.CDX" mol-file="US20230002353A1-20230105-C00367.MOL"/><us-chemistry idref="CHEM-US-00368" cdx-file="US20230002353A1-20230105-C00368.CDX" mol-file="US20230002353A1-20230105-C00368.MOL"/><us-chemistry idref="CHEM-US-00369" cdx-file="US20230002353A1-20230105-C00369.CDX" mol-file="US20230002353A1-20230105-C00369.MOL"/><us-chemistry idref="CHEM-US-00370" cdx-file="US20230002353A1-20230105-C00370.CDX" mol-file="US20230002353A1-20230105-C00370.MOL"/><us-chemistry idref="CHEM-US-00371" cdx-file="US20230002353A1-20230105-C00371.CDX" mol-file="US20230002353A1-20230105-C00371.MOL"/><us-chemistry idref="CHEM-US-00372" cdx-file="US20230002353A1-20230105-C00372.CDX" mol-file="US20230002353A1-20230105-C00372.MOL"/><us-chemistry idref="CHEM-US-00373" cdx-file="US20230002353A1-20230105-C00373.CDX" mol-file="US20230002353A1-20230105-C00373.MOL"/><us-chemistry idref="CHEM-US-00374" cdx-file="US20230002353A1-20230105-C00374.CDX" mol-file="US20230002353A1-20230105-C00374.MOL"/><us-chemistry idref="CHEM-US-00375" cdx-file="US20230002353A1-20230105-C00375.CDX" mol-file="US20230002353A1-20230105-C00375.MOL"/><us-chemistry idref="CHEM-US-00376" cdx-file="US20230002353A1-20230105-C00376.CDX" mol-file="US20230002353A1-20230105-C00376.MOL"/><us-chemistry idref="CHEM-US-00377" cdx-file="US20230002353A1-20230105-C00377.CDX" mol-file="US20230002353A1-20230105-C00377.MOL"/><us-chemistry idref="CHEM-US-00378" cdx-file="US20230002353A1-20230105-C00378.CDX" mol-file="US20230002353A1-20230105-C00378.MOL"/><us-chemistry idref="CHEM-US-00379" cdx-file="US20230002353A1-20230105-C00379.CDX" mol-file="US20230002353A1-20230105-C00379.MOL"/><us-chemistry idref="CHEM-US-00380" cdx-file="US20230002353A1-20230105-C00380.CDX" mol-file="US20230002353A1-20230105-C00380.MOL"/><us-chemistry idref="CHEM-US-00381" cdx-file="US20230002353A1-20230105-C00381.CDX" mol-file="US20230002353A1-20230105-C00381.MOL"/><us-chemistry idref="CHEM-US-00382" cdx-file="US20230002353A1-20230105-C00382.CDX" mol-file="US20230002353A1-20230105-C00382.MOL"/><us-chemistry idref="CHEM-US-00383" cdx-file="US20230002353A1-20230105-C00383.CDX" mol-file="US20230002353A1-20230105-C00383.MOL"/><us-chemistry idref="CHEM-US-00384" cdx-file="US20230002353A1-20230105-C00384.CDX" mol-file="US20230002353A1-20230105-C00384.MOL"/><us-chemistry idref="CHEM-US-00385" cdx-file="US20230002353A1-20230105-C00385.CDX" mol-file="US20230002353A1-20230105-C00385.MOL"/><us-chemistry idref="CHEM-US-00386" cdx-file="US20230002353A1-20230105-C00386.CDX" mol-file="US20230002353A1-20230105-C00386.MOL"/><us-chemistry idref="CHEM-US-00387" cdx-file="US20230002353A1-20230105-C00387.CDX" mol-file="US20230002353A1-20230105-C00387.MOL"/><us-chemistry idref="CHEM-US-00388" cdx-file="US20230002353A1-20230105-C00388.CDX" mol-file="US20230002353A1-20230105-C00388.MOL"/><us-chemistry idref="CHEM-US-00389" cdx-file="US20230002353A1-20230105-C00389.CDX" mol-file="US20230002353A1-20230105-C00389.MOL"/><us-chemistry idref="CHEM-US-00390" cdx-file="US20230002353A1-20230105-C00390.CDX" mol-file="US20230002353A1-20230105-C00390.MOL"/><us-chemistry idref="CHEM-US-00391" cdx-file="US20230002353A1-20230105-C00391.CDX" mol-file="US20230002353A1-20230105-C00391.MOL"/><us-chemistry idref="CHEM-US-00392" cdx-file="US20230002353A1-20230105-C00392.CDX" mol-file="US20230002353A1-20230105-C00392.MOL"/><us-chemistry idref="CHEM-US-00393" cdx-file="US20230002353A1-20230105-C00393.CDX" mol-file="US20230002353A1-20230105-C00393.MOL"/><us-chemistry idref="CHEM-US-00394" cdx-file="US20230002353A1-20230105-C00394.CDX" mol-file="US20230002353A1-20230105-C00394.MOL"/><us-chemistry idref="CHEM-US-00395" cdx-file="US20230002353A1-20230105-C00395.CDX" mol-file="US20230002353A1-20230105-C00395.MOL"/><us-chemistry idref="CHEM-US-00396" cdx-file="US20230002353A1-20230105-C00396.CDX" mol-file="US20230002353A1-20230105-C00396.MOL"/><us-chemistry idref="CHEM-US-00397" cdx-file="US20230002353A1-20230105-C00397.CDX" mol-file="US20230002353A1-20230105-C00397.MOL"/><us-chemistry idref="CHEM-US-00398" cdx-file="US20230002353A1-20230105-C00398.CDX" mol-file="US20230002353A1-20230105-C00398.MOL"/><us-chemistry idref="CHEM-US-00399" cdx-file="US20230002353A1-20230105-C00399.CDX" mol-file="US20230002353A1-20230105-C00399.MOL"/><us-chemistry idref="CHEM-US-00400" cdx-file="US20230002353A1-20230105-C00400.CDX" mol-file="US20230002353A1-20230105-C00400.MOL"/><us-chemistry idref="CHEM-US-00401" cdx-file="US20230002353A1-20230105-C00401.CDX" mol-file="US20230002353A1-20230105-C00401.MOL"/><us-chemistry idref="CHEM-US-00402" cdx-file="US20230002353A1-20230105-C00402.CDX" mol-file="US20230002353A1-20230105-C00402.MOL"/><us-chemistry idref="CHEM-US-00403" cdx-file="US20230002353A1-20230105-C00403.CDX" mol-file="US20230002353A1-20230105-C00403.MOL"/><us-chemistry idref="CHEM-US-00404" cdx-file="US20230002353A1-20230105-C00404.CDX" mol-file="US20230002353A1-20230105-C00404.MOL"/><us-chemistry idref="CHEM-US-00405" cdx-file="US20230002353A1-20230105-C00405.CDX" mol-file="US20230002353A1-20230105-C00405.MOL"/><us-chemistry idref="CHEM-US-00406" cdx-file="US20230002353A1-20230105-C00406.CDX" mol-file="US20230002353A1-20230105-C00406.MOL"/><us-chemistry idref="CHEM-US-00407" cdx-file="US20230002353A1-20230105-C00407.CDX" mol-file="US20230002353A1-20230105-C00407.MOL"/><us-chemistry idref="CHEM-US-00408" cdx-file="US20230002353A1-20230105-C00408.CDX" mol-file="US20230002353A1-20230105-C00408.MOL"/><us-chemistry idref="CHEM-US-00409" cdx-file="US20230002353A1-20230105-C00409.CDX" mol-file="US20230002353A1-20230105-C00409.MOL"/><us-chemistry idref="CHEM-US-00410" cdx-file="US20230002353A1-20230105-C00410.CDX" mol-file="US20230002353A1-20230105-C00410.MOL"/><us-chemistry idref="CHEM-US-00411" cdx-file="US20230002353A1-20230105-C00411.CDX" mol-file="US20230002353A1-20230105-C00411.MOL"/><us-chemistry idref="CHEM-US-00412" cdx-file="US20230002353A1-20230105-C00412.CDX" mol-file="US20230002353A1-20230105-C00412.MOL"/><us-chemistry idref="CHEM-US-00413" cdx-file="US20230002353A1-20230105-C00413.CDX" mol-file="US20230002353A1-20230105-C00413.MOL"/><us-chemistry idref="CHEM-US-00414" cdx-file="US20230002353A1-20230105-C00414.CDX" mol-file="US20230002353A1-20230105-C00414.MOL"/><us-chemistry idref="CHEM-US-00415" cdx-file="US20230002353A1-20230105-C00415.CDX" mol-file="US20230002353A1-20230105-C00415.MOL"/><us-chemistry idref="CHEM-US-00416" cdx-file="US20230002353A1-20230105-C00416.CDX" mol-file="US20230002353A1-20230105-C00416.MOL"/><us-chemistry idref="CHEM-US-00417" cdx-file="US20230002353A1-20230105-C00417.CDX" mol-file="US20230002353A1-20230105-C00417.MOL"/><us-chemistry idref="CHEM-US-00418" cdx-file="US20230002353A1-20230105-C00418.CDX" mol-file="US20230002353A1-20230105-C00418.MOL"/><us-chemistry idref="CHEM-US-00419" cdx-file="US20230002353A1-20230105-C00419.CDX" mol-file="US20230002353A1-20230105-C00419.MOL"/><us-chemistry idref="CHEM-US-00420" cdx-file="US20230002353A1-20230105-C00420.CDX" mol-file="US20230002353A1-20230105-C00420.MOL"/><us-chemistry idref="CHEM-US-00421" cdx-file="US20230002353A1-20230105-C00421.CDX" mol-file="US20230002353A1-20230105-C00421.MOL"/><us-chemistry idref="CHEM-US-00422" cdx-file="US20230002353A1-20230105-C00422.CDX" mol-file="US20230002353A1-20230105-C00422.MOL"/><us-chemistry idref="CHEM-US-00423" cdx-file="US20230002353A1-20230105-C00423.CDX" mol-file="US20230002353A1-20230105-C00423.MOL"/><us-chemistry idref="CHEM-US-00424" cdx-file="US20230002353A1-20230105-C00424.CDX" mol-file="US20230002353A1-20230105-C00424.MOL"/><us-chemistry idref="CHEM-US-00425" cdx-file="US20230002353A1-20230105-C00425.CDX" mol-file="US20230002353A1-20230105-C00425.MOL"/><us-chemistry idref="CHEM-US-00426" cdx-file="US20230002353A1-20230105-C00426.CDX" mol-file="US20230002353A1-20230105-C00426.MOL"/><us-chemistry idref="CHEM-US-00427" cdx-file="US20230002353A1-20230105-C00427.CDX" mol-file="US20230002353A1-20230105-C00427.MOL"/><us-chemistry idref="CHEM-US-00428" cdx-file="US20230002353A1-20230105-C00428.CDX" mol-file="US20230002353A1-20230105-C00428.MOL"/><us-chemistry idref="CHEM-US-00429" cdx-file="US20230002353A1-20230105-C00429.CDX" mol-file="US20230002353A1-20230105-C00429.MOL"/><us-chemistry idref="CHEM-US-00430" cdx-file="US20230002353A1-20230105-C00430.CDX" mol-file="US20230002353A1-20230105-C00430.MOL"/><us-chemistry idref="CHEM-US-00431" cdx-file="US20230002353A1-20230105-C00431.CDX" mol-file="US20230002353A1-20230105-C00431.MOL"/><us-chemistry idref="CHEM-US-00432" cdx-file="US20230002353A1-20230105-C00432.CDX" mol-file="US20230002353A1-20230105-C00432.MOL"/><us-chemistry idref="CHEM-US-00433" cdx-file="US20230002353A1-20230105-C00433.CDX" mol-file="US20230002353A1-20230105-C00433.MOL"/><us-chemistry idref="CHEM-US-00434" cdx-file="US20230002353A1-20230105-C00434.CDX" mol-file="US20230002353A1-20230105-C00434.MOL"/><us-chemistry idref="CHEM-US-00435" cdx-file="US20230002353A1-20230105-C00435.CDX" mol-file="US20230002353A1-20230105-C00435.MOL"/><us-chemistry idref="CHEM-US-00436" cdx-file="US20230002353A1-20230105-C00436.CDX" mol-file="US20230002353A1-20230105-C00436.MOL"/><us-chemistry idref="CHEM-US-00437" cdx-file="US20230002353A1-20230105-C00437.CDX" mol-file="US20230002353A1-20230105-C00437.MOL"/><us-chemistry idref="CHEM-US-00438" cdx-file="US20230002353A1-20230105-C00438.CDX" mol-file="US20230002353A1-20230105-C00438.MOL"/><us-chemistry idref="CHEM-US-00439" cdx-file="US20230002353A1-20230105-C00439.CDX" mol-file="US20230002353A1-20230105-C00439.MOL"/><us-chemistry idref="CHEM-US-00440" cdx-file="US20230002353A1-20230105-C00440.CDX" mol-file="US20230002353A1-20230105-C00440.MOL"/><us-chemistry idref="CHEM-US-00441" cdx-file="US20230002353A1-20230105-C00441.CDX" mol-file="US20230002353A1-20230105-C00441.MOL"/><us-chemistry idref="CHEM-US-00442" cdx-file="US20230002353A1-20230105-C00442.CDX" mol-file="US20230002353A1-20230105-C00442.MOL"/><us-chemistry idref="CHEM-US-00443" cdx-file="US20230002353A1-20230105-C00443.CDX" mol-file="US20230002353A1-20230105-C00443.MOL"/><us-chemistry idref="CHEM-US-00444" cdx-file="US20230002353A1-20230105-C00444.CDX" mol-file="US20230002353A1-20230105-C00444.MOL"/><us-chemistry idref="CHEM-US-00445" cdx-file="US20230002353A1-20230105-C00445.CDX" mol-file="US20230002353A1-20230105-C00445.MOL"/><us-chemistry idref="CHEM-US-00446" cdx-file="US20230002353A1-20230105-C00446.CDX" mol-file="US20230002353A1-20230105-C00446.MOL"/><us-chemistry idref="CHEM-US-00447" cdx-file="US20230002353A1-20230105-C00447.CDX" mol-file="US20230002353A1-20230105-C00447.MOL"/><us-chemistry idref="CHEM-US-00448" cdx-file="US20230002353A1-20230105-C00448.CDX" mol-file="US20230002353A1-20230105-C00448.MOL"/><us-chemistry idref="CHEM-US-00449" cdx-file="US20230002353A1-20230105-C00449.CDX" mol-file="US20230002353A1-20230105-C00449.MOL"/><us-chemistry idref="CHEM-US-00450" cdx-file="US20230002353A1-20230105-C00450.CDX" mol-file="US20230002353A1-20230105-C00450.MOL"/><us-chemistry idref="CHEM-US-00451" cdx-file="US20230002353A1-20230105-C00451.CDX" mol-file="US20230002353A1-20230105-C00451.MOL"/><us-chemistry idref="CHEM-US-00452" cdx-file="US20230002353A1-20230105-C00452.CDX" mol-file="US20230002353A1-20230105-C00452.MOL"/><us-chemistry idref="CHEM-US-00453" cdx-file="US20230002353A1-20230105-C00453.CDX" mol-file="US20230002353A1-20230105-C00453.MOL"/><us-chemistry idref="CHEM-US-00454" cdx-file="US20230002353A1-20230105-C00454.CDX" mol-file="US20230002353A1-20230105-C00454.MOL"/><us-chemistry idref="CHEM-US-00455" cdx-file="US20230002353A1-20230105-C00455.CDX" mol-file="US20230002353A1-20230105-C00455.MOL"/><us-chemistry idref="CHEM-US-00456" cdx-file="US20230002353A1-20230105-C00456.CDX" mol-file="US20230002353A1-20230105-C00456.MOL"/><us-chemistry idref="CHEM-US-00457" cdx-file="US20230002353A1-20230105-C00457.CDX" mol-file="US20230002353A1-20230105-C00457.MOL"/><us-chemistry idref="CHEM-US-00458" cdx-file="US20230002353A1-20230105-C00458.CDX" mol-file="US20230002353A1-20230105-C00458.MOL"/><us-chemistry idref="CHEM-US-00459" cdx-file="US20230002353A1-20230105-C00459.CDX" mol-file="US20230002353A1-20230105-C00459.MOL"/><us-chemistry idref="CHEM-US-00460" cdx-file="US20230002353A1-20230105-C00460.CDX" mol-file="US20230002353A1-20230105-C00460.MOL"/><us-chemistry idref="CHEM-US-00461" cdx-file="US20230002353A1-20230105-C00461.CDX" mol-file="US20230002353A1-20230105-C00461.MOL"/><us-chemistry idref="CHEM-US-00462" cdx-file="US20230002353A1-20230105-C00462.CDX" mol-file="US20230002353A1-20230105-C00462.MOL"/><us-chemistry idref="CHEM-US-00463" cdx-file="US20230002353A1-20230105-C00463.CDX" mol-file="US20230002353A1-20230105-C00463.MOL"/><us-chemistry idref="CHEM-US-00464" cdx-file="US20230002353A1-20230105-C00464.CDX" mol-file="US20230002353A1-20230105-C00464.MOL"/><us-chemistry idref="CHEM-US-00465" cdx-file="US20230002353A1-20230105-C00465.CDX" mol-file="US20230002353A1-20230105-C00465.MOL"/><us-chemistry idref="CHEM-US-00466" cdx-file="US20230002353A1-20230105-C00466.CDX" mol-file="US20230002353A1-20230105-C00466.MOL"/><us-chemistry idref="CHEM-US-00467" cdx-file="US20230002353A1-20230105-C00467.CDX" mol-file="US20230002353A1-20230105-C00467.MOL"/><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A heterocyclic compound represented by the following Formula I, a stereoisomer thereof, an enantiomer thereof, or a pharmaceutically acceptable salt thereof:</claim-text><claim-text><chemistry id="CHEM-US-00465" num="00465"><img id="EMI-C00465" he="30.40mm" wi="63.58mm" file="US20230002353A1-20230105-C00465.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein:</claim-text><claim-text>X is CR<sup>7</sup>, or N;</claim-text><claim-text>Y is CHR<sup>8</sup>, NR<sup>8</sup>, or O;</claim-text><claim-text>Z is CH<sub>2</sub>, CH<sub>2</sub>O, C(&#x2550;O), C(&#x2550;O)O, C(&#x2550;O)NH, NR<sup>8</sup>, NHC(&#x2550;O), O or O(C&#x2550;O);</claim-text><claim-text>R<sup>1 </sup>is H, halogen, C<sub>1-3 </sub>alkyl, NHR<sup>8 </sup>or OR<sup>8</sup>;</claim-text><claim-text>R<sup>2 </sup>is H, halogen, C<sub>1-4 </sub>alkyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, C<sub>1-2 </sub>alkylheterocyclyl or -L-aryl, which C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, C<sub>1-2 </sub>alkylheterocyclyl or -L-aryl may optionally be substituted with one or more R<sup>9</sup>;</claim-text><claim-text>R<sup>3 </sup>is H, halogen, CN, C<sub>1-3 </sub>alkyl, cycloalkenyl, C<sub>2-6 </sub>alkenyl, aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, or C<sub>1-2 </sub>alkylheterocyclyl which aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, or C<sub>1-2 </sub>alkylheterocyclyl may optionally be substituted with one or more R<sup>9</sup>;</claim-text><claim-text>R<sup>4 </sup>and R<sup>5 </sup>each independently is H, C<sub>1-6 </sub>alkyl, C<sub>1-6</sub>alkoxy, C<sub>3-10 </sub>cycloalkyl, C(&#x2550;O)R<sup>6</sup>, C<sub>1-2 </sub>alkylaryl, aryl; or</claim-text><claim-text>R<sup>4 </sup>and R<sup>5 </sup>may be combined with each other to form a 3-7 membered cyclic ring or heterocyclic ring containing 1 or 2 of NR<sup>8</sup>, O or S, and the cyclic or heterocyclic ring may optionally be substituted with 1 or 2 halogen(s), C<sub>1-4 </sub>alkyl or C<sub>1-4 </sub>alkoxy;</claim-text><claim-text>R<sup>5&#x2032;</sup> is H or R<sup>5 </sup>and R<sup>5&#x2032;</sup> may be combined with each other to form carbonyl;</claim-text><claim-text>R<sup>6 </sup>is H, C<sub>1-4 </sub>alkyl, C<sub>1-6 </sub>alkoxy, &#x2014;NR<sup>15</sup>R<sup>16</sup>, aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, C<sub>1-2 </sub>alkylheterocyclyl, C<sub>1-2 </sub>alkylbiaryl, -L-aryl or -L-biaryl, which C<sub>1-4 </sub>alkyl, aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, C<sub>1-2 </sub>alkylheterocyclyl, C<sub>1-2 </sub>alkylbiaryl, -L-aryl or -L-biaryl, may optionally be substituted with one or more R<sup>9</sup>;</claim-text><claim-text>R<sup>7 </sup>is H, halogen or C<sub>1-3 </sub>alkyl;</claim-text><claim-text>R<sup>8 </sup>is H, C<sub>1-6 </sub>alkyl, C<sub>1-4 </sub>fluoroalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-3 </sub>alkylaryl or C(&#x2550;O)R<sup>10 </sup>which C<sub>1-6 </sub>alkyl or C<sub>1-3 </sub>alkylaryl may optionally be substituted with one or more R<sup>9</sup>;</claim-text><claim-text>when Z is NR<sup>8</sup>, R<sup>8 </sup>and R<sup>6 </sup>may be combined with each other to form a 3-7 membered heterocyclic ring comprising 1 to 2 N or 0 to 2 O heteroatoms;</claim-text><claim-text>R<sup>9 </sup>is halogen, hydroxyl, &#x2014;CN, &#x2014;NO<sub>2</sub>, &#x2014;COOH, &#x2014;(C&#x2550;O)H, C<sub>1-6 </sub>alkyl, C<sub>2-6 </sub>alkenyl, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-6 </sub>alkoxy, cycloalkenyl, aryl, heterocyclyl, heteroaryl, &#x2014;NR<sup>15</sup>R<sup>16</sup>, -L-NR<sup>15</sup>R<sup>16</sup>, -L-COOR<sup>17</sup>, -L-alkyl, -L-C<sub>3-10 </sub>cycloalkyl, -L-heterocyclyl, -L-heteroaryl, or -L-aryl which C<sub>1-6 </sub>alkyl, C<sub>2-6 </sub>alkenyl, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-6 </sub>alkoxy, cycloalkenyl, aryl, heterocyclyl, heteroaryl, -L-alkyl, -L-C<sub>3-10 </sub>cycloalkyl, -L-heterocyclyl, -L-heteroaryl, or -L-aryl may substituted with halogen, hydroxyl, &#x2014;CN, &#x2014;NR<sup>15</sup>R<sup>16</sup>, C<sub>1-6 </sub>alkyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>2-6 </sub>alkenyl, aryl, heterocyclyl, -L-heterocyclyl, or &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)&#x2014;NR<sup>15</sup>R<sup>16</sup>;</claim-text><claim-text>R<sup>10 </sup>is C<sub>1-3 </sub>alkyl or C<sub>1-3 </sub>alkylaryl;</claim-text><claim-text>R<sup>15 </sup>and R<sup>16 </sup>each independently is H, C<sub>1-6 </sub>alkyl, C<sub>3-10 </sub>cycloalkyl or SO<sub>2</sub>R<sup>17</sup>;</claim-text><claim-text>R<sup>17 </sup>is H, C<sub>1-3</sub>alkyl or C<sub>1-3 </sub>alkylaryl;</claim-text><claim-text>L is C<sub>1-3 </sub>alkyl, C<sub>1-3 </sub>alkylO, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, C(&#x2550;O)O, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)NH&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;NHC(&#x2550;O)&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, NR<sup>8</sup>, &#x2014;NH&#x2014;C(&#x2550;O)&#x2014;CR<sup>15</sup>R<sup>16</sup>&#x2014;NH&#x2014;C(&#x2550;O)&#x2014;, NHC(&#x2550;O), O, O(C&#x2550;O) S, S(&#x2550;O), or SO<sub>2</sub>; and</claim-text><claim-text>l and m each independently is an integer of 0 to 2.</claim-text></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The heterocyclic compound, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt thereof of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the heterocyclic compound represented formula I is represented by the following Formula Ia:</claim-text><claim-text><chemistry id="CHEM-US-00466" num="00466"><img id="EMI-C00466" he="34.97mm" wi="65.62mm" file="US20230002353A1-20230105-C00466.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein:</claim-text><claim-text>X is CH, or N;</claim-text><claim-text>Y is NR<sup>8</sup>, or O;</claim-text><claim-text>W is CH<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub>, NR<sup>11</sup>, or O;</claim-text><claim-text>Z is CH<sub>2</sub>, CH<sub>2</sub>O, C(&#x2550;O), C(&#x2550;O)O, C(&#x2550;O)NH, NR<sup>8</sup>, NHC(&#x2550;O), O or O(C&#x2550;O);</claim-text><claim-text>R<sup>3 </sup>is H, halogen, CN, C<sub>1-3 </sub>alkyl, cycloalkenyl, C<sub>2-6 </sub>alkenyl, aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, or C<sub>1-2 </sub>alkylheterocyclyl which aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, or C<sub>1-2 </sub>alkylheterocyclyl may optionally be substituted with one or more R<sup>9</sup>;</claim-text><claim-text>R<sup>6 </sup>is H, C<sub>1-4 </sub>alkyl, C<sub>1-6 </sub>alkoxy, &#x2014;NR<sup>15</sup>R<sup>16</sup>, aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, C<sub>1-2 </sub>alkylheterocyclyl, C<sub>1-2 </sub>alkylbiaryl, -L-aryl or -L-biaryl, which C<sub>1-4 </sub>alkyl, aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, C<sub>1-2 </sub>alkylheterocyclyl, C<sub>1-2 </sub>alkylbiaryl, -L-aryl or -L-biaryl, may optionally be substituted with one or more R<sup>9</sup>;</claim-text><claim-text>R<sup>8 </sup>is H, C<sub>1-6 </sub>alkyl, C<sub>1-4 </sub>fluoroalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-3 </sub>alkylaryl or C(&#x2550;O)R<sup>10 </sup>which C<sub>1-6 </sub>alkyl or C<sub>1-3 </sub>alkylaryl may optionally be substituted with one or more R<sup>9</sup>;</claim-text><claim-text>when Z is NR<sup>8</sup>, R<sup>8 </sup>and R<sup>6 </sup>may be combined with each other to form a 3-7 membered heterocyclic ring comprising 1 to 2 N or 0 to 2 O heteroatoms;</claim-text><claim-text>R<sup>9 </sup>is halogen, hydroxyl, &#x2014;CN, &#x2014;NO<sub>2</sub>, &#x2014;COOH, &#x2014;(C&#x2550;O)H, C<sub>1-6 </sub>alkyl, C<sub>2-6 </sub>alkenyl, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-6 </sub>alkoxy, cycloalkenyl, aryl, heterocyclyl, heteroaryl, &#x2014;NR<sup>15</sup>R<sup>16</sup>, -L-NR<sup>15</sup>R<sup>16</sup>, -L-COOR<sup>17</sup>, -L-alkyl, -L-C<sub>3-10 </sub>cycloalkyl, -L-heterocyclyl, -L-heteroaryl, or -L-aryl which C<sub>1-6 </sub>alkyl, C<sub>2-6 </sub>alkenyl, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-6 </sub>alkoxy, cycloalkenyl, aryl, heterocyclyl, heteroaryl, -L-alkyl, -L-C<sub>3-10 </sub>cycloalkyl, -L-heterocyclyl, -L-heteroaryl, or -L-aryl may substituted with halogen, hydroxyl, &#x2014;CN, &#x2014;NR<sup>15</sup>R<sup>16</sup>, C<sub>1-6 </sub>alkyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>2-6 </sub>alkenyl, aryl, heterocyclyl, -L-heterocyclyl, or &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)&#x2014;NR<sup>15</sup>R<sup>16</sup>;</claim-text><claim-text>R<sup>10 </sup>is C<sub>1-3 </sub>alkyl or C<sub>1-3 </sub>alkylaryl;</claim-text><claim-text>R<sup>11 </sup>is H, C<sub>1-6 </sub>alkyl, C<sub>1-4 </sub>fluoroalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-3 </sub>alkylaryl or C(&#x2550;O)R<sup>10 </sup>which C<sub>1-6 </sub>alkyl or C<sub>1-3 </sub>alkylaryl may optionally be substituted with one or more R<sup>9</sup>;</claim-text><claim-text>R<sup>15 </sup>and R<sup>16 </sup>each independently is H, C<sub>1-6 </sub>alkyl, C<sub>3-10 </sub>cycloalkyl or SO<sub>2</sub>R<sup>17</sup>;</claim-text><claim-text>R<sup>17 </sup>is H, C<sub>1-3 </sub>alkyl or C<sub>1-3 </sub>alkylaryl;</claim-text><claim-text>R<sup>18 </sup>to R<sup>21 </sup>are the same as or different from each other, and are each independently H or halogen; or</claim-text><claim-text>R<sup>18 </sup>and R<sup>19</sup>; or R<sup>20 </sup>and R<sup>21 </sup>may be combined with each other to form a 3-7 membered cyclic ring or heterocyclic ring containing 1 or 2 of NR<sup>8</sup>, O or S, and the cyclic or heterocyclic ring may optionally be substituted with 1 or 2 halogen(s), C<sub>1-4 </sub>alkyl or C<sub>1-4 </sub>alkoxy;</claim-text><claim-text>L is C<sub>1-3 </sub>alkyl, C<sub>1-3 </sub>alkylO, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, C(&#x2550;O)O, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)NH&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;NHC(&#x2550;O)&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, NR<sup>8</sup>, &#x2014;NH&#x2014;C(&#x2550;O)&#x2014;CR<sup>15</sup>R<sup>16</sup>&#x2014;NH&#x2014;C(&#x2550;O)&#x2014;NHC(&#x2550;O), O, O(C&#x2550;O) S, S, S(&#x2550;O), or SO<sub>2</sub>; and</claim-text><claim-text>l and m each independently is an integer of 0 to 2.</claim-text></claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The heterocyclic compound, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt thereof of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the heterocyclic compound represented formula I is represented by the following Formula Ib:</claim-text><claim-text><chemistry id="CHEM-US-00467" num="00467"><img id="EMI-C00467" he="35.64mm" wi="68.50mm" file="US20230002353A1-20230105-C00467.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein:</claim-text><claim-text>X is CH, or N;</claim-text><claim-text>W is CH<sub>2</sub>, NR<sup>11</sup>, or O;</claim-text><claim-text>V<sup>1 </sup>and V<sup>2 </sup>each independently is CR<sup>13</sup>R<sup>13&#x2032;</sup>, NR<sup>13</sup>, or O;</claim-text><claim-text>at least one of V<sub>1 </sub>and V<sub>2 </sub>is CR<sup>13</sup>R<sup>13&#x2032;</sup>;</claim-text><claim-text>X<sup>1 </sup>to X<sup>5 </sup>are the same as or different from each other, and are each independently CR<sup>14 </sup>or N;</claim-text><claim-text>at least one of X<sup>1 </sup>to X<sup>5 </sup>is CR<sup>14</sup>;</claim-text><claim-text>R<sup>3 </sup>is H, halogen, CN, C<sub>1-3 </sub>alkyl, cycloalkenyl, C<sub>2-6 </sub>alkenyl, aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, or C<sub>1-2 </sub>alkylheterocyclyl which aryl, biaryl, heteroaryl, heterobiaryl, heterocyclyl, C<sub>1-2 </sub>alkylaryl, C<sub>1-2 </sub>alkylheteroaryl, or C<sub>1-2 </sub>alkylheterocyclyl may optionally be substituted with one or more R<sup>9</sup>;</claim-text><claim-text>R<sup>9 </sup>is halogen, hydroxyl, &#x2014;CN, &#x2014;NO<sub>2</sub>, &#x2014;COOH, &#x2014;(C&#x2550;O)H, C<sub>1-6 </sub>alkyl, C<sub>2-4</sub>, alkenyl, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-6 </sub>alkoxy, cycloalkenyl, aryl, heterocyclyl, heteroaryl, &#x2014;NR<sup>15</sup>R<sup>16</sup>, -L-NR<sup>15</sup>R<sup>16</sup>, -L-COOR<sup>17</sup>, -L-alkyl, -L-C<sub>3-10 </sub>cycloalkyl, -L-heterocyclyl, -L-heteroaryl, or -L-aryl which C<sub>1-6 </sub>alkyl, C<sub>2-6 </sub>alkenyl, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-6 </sub>alkoxy, cycloalkenyl, aryl, heterocyclyl, heteroaryl, -L-alkyl, -L-C<sub>3-10 </sub>cycloalkyl, -L-heterocyclyl, -L-heteroaryl, or -L-aryl may substituted with halogen, hydroxyl, &#x2014;CN, &#x2014;NR<sup>15</sup>R<sup>16</sup>, C<sub>1-6 </sub>alkyl, C<sub>3-10 </sub>cycloalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>2-6 </sub>alkenyl, aryl, heterocyclyl, -L-heterocyclyl, or &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)&#x2014;NR<sup>15</sup>R<sup>16</sup>;</claim-text><claim-text>R<sup>10 </sup>is C<sub>1-3 </sub>alkyl or C<sub>1-3 </sub>alkylaryl;</claim-text><claim-text>R<sup>11 </sup>is H, C<sub>1-6 </sub>alkyl, C<sub>1-4 </sub>fluoroalkyl, C<sub>1-4 </sub>hydroxyalkyl, C<sub>1-3 </sub>alkylaryl or C(&#x2550;O)R<sup>10 </sup>which C<sub>1-6 </sub>alkyl or C<sub>1-3 </sub>alkylaryl may optionally be substituted with one or more R<sup>9</sup>;</claim-text><claim-text>R<sup>13 </sup>and R<sup>13&#x2032;</sup> each independently is H, C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>hydroxyalkyl;</claim-text><claim-text>each R<sup>14 </sup>is independently selected from H, halogen, hydroxyl, &#x2014;CN, &#x2014;NO<sub>2</sub>, C<sub>1-6 </sub>alkyl, C<sub>2-6 </sub>alkenyl, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, &#x2014;NR<sup>15</sup>R<sup>16</sup>, -L-alkyl, -L-heterocyclyl, -L-heteroaryl, or -L-aryl which C<sub>1-6 </sub>alkyl, aryl, heteroaryl, heterocyclyl may optionally be substituted with one or more R<sup>9</sup>; or adjacent groups among a plurality of R<sup>14</sup>s are bonded to each other to form a 3-7 membered cyclic ring or heterocyclic ring containing 1 or 2 of NR<sup>11 </sup>O or S, and the cyclic or heterocyclic ring may optionally be substituted with 1 or 2 halogen(s), C<sub>1-4 </sub>alkyl or C<sub>1-4 </sub>alkoxy;</claim-text><claim-text>R<sup>15 </sup>and R<sup>16 </sup>each independently is H, C<sub>1-6 </sub>alkyl, C<sub>3-10 </sub>cycloalkyl or SO<sub>2</sub>R<sup>17</sup>;</claim-text><claim-text>R<sup>17 </sup>is H, C<sub>1-3 </sub>alkyl or C<sub>1-3 </sub>alkylaryl;</claim-text><claim-text>L is C<sub>1-3 </sub>alkyl, C<sub>1-3 </sub>alkylO, C<sub>2-6 </sub>alkynyl, C<sub>3-10 </sub>cycloalkyl, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, C(&#x2550;O)O, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;C(&#x2550;O)NH&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;NHC(&#x2550;O)&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, &#x2014;(CH<sub>2</sub>)<sub>l</sub>&#x2014;NH&#x2014;(CH<sub>2</sub>)<sub>m</sub>&#x2014;, NR<sup>8</sup>, &#x2014;NH&#x2014;C(&#x2550;O)&#x2014;CR<sup>15</sup>R<sup>16</sup>&#x2014;NH&#x2014;C(&#x2550;O)&#x2014;, NHC(&#x2550;O), O, O(C&#x2550;O) S, S, S(&#x2550;O), or SO<sub>2</sub>; and</claim-text><claim-text>l and m each independently is an integer of 0 to 2.</claim-text></claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The heterocyclic compound, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt thereof of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the heterocyclic compound represented formula I is represented by any one of the following compounds:</claim-text><claim-text><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="168pt" align="left"/><thead><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>Example 1 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 2 </entry><entry>2-amino-N-((1R,2R)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 3 </entry><entry>2-amino-N-(trans-2-(benzyloxy)cyclopentyl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 4 </entry><entry>2-amino-N-((1R,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 5 </entry><entry>2-amino-N-(cis-2-(benzyloxy)cyclopentyl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 6 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((2-methylbenzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 7 </entry><entry>2-amino-N-((1S,2S)-2-((3-ethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 8 </entry><entry>2-amino-N-((1S,2S)-2-((4-ethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 9 </entry><entry>2-amino-N-(trans-2-((4-ethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 10 </entry><entry>2-amino-N-((1S,2S)-2-((4-isopropylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 11 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 12 </entry><entry>2-amino-N-((1R,2R)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 13 </entry><entry>2-amino-N-(trans-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 14 </entry><entry>2-amino-N-((1S,2S)-2-((2,3-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 15 </entry><entry>2-amino-N-((1S,2S)-2-((2,6-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 16 </entry><entry>2-amino-N-((1S,2S)-2-((2,5-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 17 </entry><entry>2-amino-N-((1S,2S)-2-((3,5-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 18 </entry><entry>2-amino-N-((1S,2S)-2-((2,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 19 </entry><entry>2-amino-N-((1S,2S)-2-((4-ethyl-3-methylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 20 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-diethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 21 </entry><entry>2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 22 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((3-propylbenzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 23 </entry><entry>2-amino-N-((1S,2S)-2-((3-cyclopentylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 24 </entry><entry>2-amino-N-((1S,2S)-2-((3-isopropylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 25 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((3-(prop-1-en-2-yl)benzyl)oxy)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 26 </entry><entry>2-amino-N-((1S,2S)-2-((3-cyclopropylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 27 </entry><entry>2-amino-N-((1S,2S)-2-((3-cyclobutylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 28 </entry><entry>2-amino-N-((1S,2S)-2-((3-ethynylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 29 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4-(trifluoromethyl)benzyl)oxy)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 30 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((3-nitrobenzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 31 </entry><entry>2-amino-N-((1S,2S)-2-((3-cyanobenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 32 </entry><entry>2-amino-N-((1S,2S)-2-((3-hydroxybenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 33 </entry><entry>2-amino-N-((1S,2S)-2-((3-methyloxybenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 34 </entry><entry>2-amino-N-((1R,2R)-2-((3-methoxybenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 35 </entry><entry>2-amino-N-((1S,2S)-2-((4-methoxybenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 36 </entry><entry>2-amino-N-((1R,2R)-2-((4-methoxybenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 37 </entry><entry>2-amino-N-(trans-2-((3,5-dimethoxybenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 38 </entry><entry>2-amino-N-((1S,2S)-2-((2,3-dimethoxybenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 39 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(1S,2S)- </entry></row><row><entry/><entry>2-((3-phenoxybenzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 40 </entry><entry>2-amino-N-((1S,2S)-2-(benzo[d][1,3]dioxol-5- </entry></row><row><entry/><entry>ylmethoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)nicotinamide </entry></row><row><entry>Example 41 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4-(methylthio)benzyl)oxy)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 42 </entry><entry>methyl 3-((((1S,2S)-2-(2-amino-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamido)cyclopentyl)oxy) </entry></row><row><entry/><entry>methyl)benzoate </entry></row><row><entry>Example 43 </entry><entry>2-amino-N-((1S,2S)-2-((3-chlorobenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 44 </entry><entry>2-amino-N-(trans-2-((3-chlorobenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 45 </entry><entry>2-amino-N-(trans-2-((4-chlorobenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 46 </entry><entry>2-amino-N-(trans-2-((3,4-dichlorobenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamid </entry></row><row><entry>Example 47 </entry><entry>2-amino-N-(trans-2-((2-fluorobenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 48 </entry><entry>2-amino-N-((1S,2S)-2-((3-fluorobenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 49 </entry><entry>2-amino-N-(trans-2-((4-bromo-2-fluorobenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 50 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(trans- </entry></row><row><entry/><entry>2-((2,4,5-trifluorobenzyl)oxy)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 51 </entry><entry>2-amino-N-((1S,2S)-2-((3-bromobenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 52 </entry><entry>2-amino-N-(trans-2-((3-bromo-4-fluorobenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 53 </entry><entry>2-amino-N-((1R,2R)-2-((3-bromo-4-fluorobenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 54 </entry><entry>2-amino-N-((1S,2S)-2-(1-(4-bromophenyl)ethoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 55 </entry><entry>methyl (3-((((1S,2S)-2-(2-amino-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamido)cyclopentyl)oxy)methyl) </entry></row><row><entry/><entry>benzoyl)glycinate </entry></row><row><entry>Example 56 </entry><entry>2-amino-N-((1S,2S)-2-((3-((2-hydroxyethyl) </entry></row><row><entry/><entry>carbamoyl)benzyl)-oxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 57 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((3-(piperidine-4-carboxamido)benzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)nicotinamide </entry></row><row><entry>Example 58 </entry><entry>2-amino-N-((1S,2S)-2-((3-((S)-2- </entry></row><row><entry/><entry>aminopropanamido)benzyl)oxy)-cyclopentyl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 59 </entry><entry>N-((1S,2S)-2-((3-((S)-2- </entry></row><row><entry/><entry>acetamidopropanamido)benzyl)oxy)-cyclopentyl)-2- </entry></row><row><entry/><entry>amino-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 60 </entry><entry>2-amino-N-((1S,2S)-2-((3-(3- </entry></row><row><entry/><entry>aminopropanamido)benzyl)oxy)-cyclopentyl)-5- </entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 61 </entry><entry>N-((1S,2S)-2-((3-(2H-1,2,3-triazol-2-yl)benzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-2-amino-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 62 </entry><entry>N-((1S,2S)-2-((4-(2H-1,2,3-triazol-2-yl)benzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-2-amino-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 63 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-(naphthalen-2-ylmethoxy)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 64 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-(quinolin-8-ylmethoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 65 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((2&#x2032;,3&#x2032;,4&#x2032;,5&#x2032;-tetrahydro-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 66 </entry><entry>N-(trans-2-([1,1&#x2032;-biphenyl]-2-ylmethoxy) </entry></row><row><entry/><entry>cyclopentyl)-2-amino-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 67 </entry><entry>N-((1S,2S)-2-([1,1&#x2032;-biphenyl]-3-ylmethoxy) </entry></row><row><entry/><entry>cyclopentyl)-2-amino-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 68 </entry><entry>N-((1S,2S)-2-([1,1&#x2032;-biphenyl]-4-ylmethoxy) </entry></row><row><entry/><entry>cyclopentyl)-2-amino-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 69 </entry><entry>2-amino-N-((1S,2S)-2-hydroxycyclopentyl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 70 </entry><entry>2-amino-N-(cis-2-hydroxycyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)-nicotinamide </entry></row><row><entry>Example 71 </entry><entry>N-((1S,2S)-2-(benzyloxy)cyclopentyl)-2- </entry></row><row><entry/><entry>(ethylamino)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 72 </entry><entry>N-((1S,2S)-2-(benzyloxy)cyclopentyl)-2-((3,4- </entry></row><row><entry/><entry>dimethylbenzyl)amino)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)nicotinamide </entry></row><row><entry>Example 73 </entry><entry>2-amino-N-((6R,7S)-6-(benzyloxy)-1,4-dioxaspiro </entry></row><row><entry/><entry>[4.4]nonan-7-yl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 74 </entry><entry>2-amino-N-(trans-2-(benzyloxy)cyclohexyl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 75 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclohexyl)-5- </entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 76 </entry><entry>2-amino-N-(trans-2-(benzyl(methyl)amino) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 77 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-(phenoxymethyl)cyclopentyl)nicotinamide </entry></row><row><entry>Example 78 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylphenoxy) </entry></row><row><entry/><entry>methyl)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 79 </entry><entry>2-amino-N-(trans-2,2-difluoro-5-(phenoxymethyl) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 80 </entry><entry>2-amino-N-((1S,2S)-2-(((2,3-dihydro-1H-inden-5- </entry></row><row><entry/><entry>yl)oxy)methyl)cyclopentyl)-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 81 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((3,4,5-trimethylphenoxy)methyl)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 82 </entry><entry>2-amino-N-((1S,2S)-2-((3-(dimethylamino) </entry></row><row><entry/><entry>phenoxy)methyl)-cyclopentyl)-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 83 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((3-(piperidine-1-carboxyl)phenoxy)methyl) </entry></row><row><entry/><entry>cyclopentyl)nicotinamide </entry></row><row><entry>Example 84 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4-phenoxyphenoxy)methyl)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 85 </entry><entry>2-amino-N-((1S,2S)-2-((benzyloxy)methyl) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 86 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((4-methyl-piperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)oxy)methyl)cyclopentyl)- </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 87 </entry><entry>(1S,2S)-2-(benzyloxy)cyclopentyl 2-amino-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinate </entry></row><row><entry>Example 88 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2R)- </entry></row><row><entry/><entry>2-phenethylcyclopentyl)nicotinamide </entry></row><row><entry>Example 89 </entry><entry>2-amino-N-(trans-4-(benzyloxy)tetrahydrofuran-3- </entry></row><row><entry/><entry>yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 90 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(trans-4- </entry></row><row><entry/><entry>morpholinotetrahydrofuran-3-yl)nicotinamide </entry></row><row><entry>Example 91 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(trans-4- </entry></row><row><entry/><entry>(pyrrolidin-1-yl)tetrahydrofuran-3-yl)nicotinamide </entry></row><row><entry>Example 92 </entry><entry>2-amino-N-(cis-4-hydroxytetrahydrofuran-3-yl)-5- </entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 93 </entry><entry>2-amino-N-(4-(benzyloxy)-1-methylpyrrolidin-3- </entry></row><row><entry/><entry>yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 94 </entry><entry>2-amino-N-(trans-4-(benzyloxy)-1- </entry></row><row><entry/><entry>isopropylpyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol- </entry></row><row><entry/><entry>4-yl)nicotinamide </entry></row><row><entry>Example 95 </entry><entry>(R)-2-amino-N-(2-(benzyloxy)propyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 96 </entry><entry>(S)-2-amino-N-(2-(benzyloxy)propyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 97 </entry><entry>(S)-2-amino-N-(1-(benzyloxy)propan-2-yl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 98 </entry><entry>(R)-2-amino-N-(1-(benzyloxy)propan-2-yl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 99 </entry><entry>2-amino-N-(1-(benzyloxy)-2-methylpropan-2-yl)-5- </entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 100 </entry><entry>(R)-2-amino-N-(1-((3,4-dimethylbenzyl)oxy)propan- </entry></row><row><entry/><entry>2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 101 </entry><entry>(S)-2-amino-N-(2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>propyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 102 </entry><entry>(R)-2-amino-N-(1-((4-chlorobenzyl)oxy)propan-2- </entry></row><row><entry/><entry>yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 103 </entry><entry>(S)-2-amino-N-(2-((4-chlorobenzyl)oxy)propyl)-5- </entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 104 </entry><entry>(R)-2-amino-N-(1-((3,4-dichlorobenzyl)oxy)propan- </entry></row><row><entry/><entry>2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 105 </entry><entry>(S)-2-amino-N-(2-((3,4-dichlorobenzyl)oxy)propyl)- </entry></row><row><entry/><entry>5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 106 </entry><entry>(R)-2-amino-N-(1-((3-methoxybenzyl)oxy)propan- </entry></row><row><entry/><entry>2-yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 107 </entry><entry>(S)-2-amino-N-(2-((3-methoxybenzyl)oxy)propyl)- </entry></row><row><entry/><entry>5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 108 </entry><entry>(R)-2-amino-N-(1-(benzyloxy)butan-2-yl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 109 </entry><entry>(S)-2-amino-N-(1-(benzyloxy)-3-methylbutan-2-yl)- </entry></row><row><entry/><entry>5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 110 </entry><entry>(R)-2-amino-N-(1-(benzyloxy)-3-methylbutan-2- </entry></row><row><entry/><entry>yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 111 </entry><entry>(S)-2-amino-N-(1-(benzyloxy)-4-methylpentan-2- </entry></row><row><entry/><entry>yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 112 </entry><entry>(R)-2-amino-N-(1-(benzyloxy)-4-methylpentan-2- </entry></row><row><entry/><entry>yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 113 </entry><entry>(R)-2-amino-N-(2-(benzyloxy)-1-cyclohexylethyl)- </entry></row><row><entry/><entry>5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 114 </entry><entry>(R)-2-amino-N-(1-cyclohexyl-2-hydroxyethyl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 115 </entry><entry>(S)-2-amino-N-(2-(benzyloxy)-1-phenylethyl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 116 </entry><entry>(R)-2-amino-N-(2-(benzyloxy)-1-phenylethyl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 117 </entry><entry>(S)-2-amino-N-(1-(benzyloxy)-3-phenylpropan-2- </entry></row><row><entry/><entry>yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 118 </entry><entry>(R)-2-amino-N-(1-(benzyloxy)-3-phenylpropan-2- </entry></row><row><entry/><entry>yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 119 </entry><entry>(R)-2-amino-N-(1-(cyclobutylmethoxy)propan-2- </entry></row><row><entry/><entry>yl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 120 </entry><entry>methyl N-(2-amino-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinoyl)-O-benzyl-L-serinate </entry></row><row><entry>Example 121 </entry><entry>methyl N-(2-amino-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinoyl)-O-benzyl-L-threoninate </entry></row><row><entry>Example 122 </entry><entry>2-amino-N-((2S,3R)-3-(benzyloxy)-1- </entry></row><row><entry/><entry>(methylamino)-1-oxobutan-2-yl)-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 123 </entry><entry>2-amino-N-((2S,3R)-3-(benzyloxy)-1-oxo-1- </entry></row><row><entry/><entry>(propylamino)butan-2-yl)-5-(1-methyl-1H-pyrazol- </entry></row><row><entry/><entry>4-yl)nicotinamide </entry></row><row><entry>Example 124 </entry><entry>2-amino-N-((2S,3R)-3-(benzyloxy)-1- </entry></row><row><entry/><entry>(cyclopentylamino)-1-oxobutan-2-yl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 125 </entry><entry>2-amino-N-((2S,3R)-3-(benzyloxy)-1-oxo-1- </entry></row><row><entry/><entry>(pyrrolidin-1-yl)butan-2-yl)-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 126 </entry><entry>benzyl (2-amino-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinoyl)-L-alaninate </entry></row><row><entry>Example 127 </entry><entry>benzyl (2-amino-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinoyl)-L-valinate </entry></row><row><entry>Example 128 </entry><entry>benzyl (2-amino-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinoyl)-L-serinate </entry></row><row><entry>Example 129 </entry><entry>3-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6- </entry></row><row><entry/><entry>(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxamide </entry></row><row><entry>Example 130 </entry><entry>3-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazine- </entry></row><row><entry/><entry>2-carboxamide </entry></row><row><entry>Example 131 </entry><entry>(S)-3-amino-6-(1-methyl-1H-pyrazol-4-yl)-N- </entry></row><row><entry/><entry>(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazine-2- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 132 </entry><entry>3-amino-N-(trans-4-(benzyloxy)tetrahydrofuran-3- </entry></row><row><entry/><entry>yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 133 </entry><entry>3-amino-N-(cis-4-(benzyloxy)tetrahydrofuran-3-yl)- </entry></row><row><entry/><entry>6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 134 </entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-amino-[1,1-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)nicotinamide </entry></row><row><entry>Example 135 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-amino-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)nicotinamide </entry></row><row><entry>Example 136 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-(methylamino)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)nicotinamide </entry></row><row><entry>Example 137 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(dimethylamino)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 138 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((dimethylamino) </entry></row><row><entry/><entry>methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)- </entry></row><row><entry/><entry>5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 139 </entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-amino-2&#x2032;-methyl-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 140 </entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-hydroxy-[1,1&#x2032;-biphenyl]- </entry></row><row><entry/><entry>4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol- </entry></row><row><entry/><entry>4-yl)nicotinamide </entry></row><row><entry>Example 141 </entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-(hydroxymethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 142 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(hydroxymethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl)-4-yl)methoxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 143 </entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-(aminomethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 144 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(aminomethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 145 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(2-aminoethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 146 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-(4-methylpiperazin-1-yl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 147 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4-(6-(piperazin-1-yl)pyridin-3-yl)benzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)nicotinamide </entry></row><row><entry>Example 148 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4-(6-(4-methylpiperazin-1-yl)pyridin-3-yl) </entry></row><row><entry/><entry>benzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 149 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((3&#x2032;-(piperazin-1-yl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 150 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((3&#x2032;-(4-methylpiperazin-1-yl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 151 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((3&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 152 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-(morpholine-4-carbonyl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 153 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-ethyl-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)nicotinamide </entry></row><row><entry>Example 154 </entry><entry>2-amino-N-((1S,2S)-2-[1,1&#x2032;-(cyanomethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 155 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-carbamoyl-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 156 </entry><entry>2-amino-N-((1S,2S)-2-((3-fluoro-4&#x2032;-((4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)nicotinamide </entry></row><row><entry>Example 157 </entry><entry>2-amino-N-((1S,2S)-2-((3-fluoro-4&#x2032;-((cis-3,4,5- </entry></row><row><entry/><entry>trimethylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)nicotinamide </entry></row><row><entry>Example 158 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-3- </entry></row><row><entry/><entry>(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)nicotinamide </entry></row><row><entry>Example 159 </entry><entry>2-amino-N-((1S,2S)-2-((2-chloro-4&#x2032;-((4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 160 </entry><entry>2-amino-N-((1S,2S)-2-((3-fluoro-4&#x2032;-((cis-4-(2- </entry></row><row><entry/><entry>hydroxyethyl)-3,5-dimethylpiperazin-1-yl)methyl)- </entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 161 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-(2-(4-methylpiperazin-1-yl)ethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 162 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)benzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 163 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>benzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 164 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2R)- </entry></row><row><entry/><entry>2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 165 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1R,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 166 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclohexyl)nicotinamide </entry></row><row><entry>Example 167 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(2-(4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)nicotinamide </entry></row><row><entry>Example 168 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-3-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 169 </entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-hydroxy-[1,1&#x2032;-biphenyl]- </entry></row><row><entry/><entry>3-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol- </entry></row><row><entry/><entry>4-yl)nicotinamide </entry></row><row><entry>Example 170 </entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-amino-[1,1&#x2032;-biphenyl]-3- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)nicotinamide </entry></row><row><entry>Example 171 </entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-(hydroxymethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-3-yl)methoxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 172 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 173 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(((2-hydroxyethyl) </entry></row><row><entry/><entry>amino)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 174 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-(morpholinomethyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 175 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((3,3-difluoropiperidin- </entry></row><row><entry/><entry>1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 176 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((4-methyl-piperidin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-nicotinamide </entry></row><row><entry>Example 177 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;(piperazin-1-ylmethyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 178 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((4-phenyl-piperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-nicotinamide </entry></row><row><entry>Example 179 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((4-(pyrrolidin-1-yl)piperidin-1-yl)methyl)- </entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)- </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 180 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-hydroxypiperidin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 181 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)-nicotinamide </entry></row><row><entry>Example 182 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-(2-hydroxy-2- </entry></row><row><entry/><entry>methylpropyl)piperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 183 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-ethylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 184 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4- </entry></row><row><entry/><entry>cyclopropylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]- </entry></row><row><entry/><entry>4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol- </entry></row><row><entry/><entry>4-yl)-nicotinamide </entry></row><row><entry>Example 185 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-(((R)-3-methyl-piperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-y])methoxy)cyclopentyl)-nicotinamide </entry></row><row><entry>Example 186 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(((R)-3,4- </entry></row><row><entry/><entry>dimethylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)-nicotinamide </entry></row><row><entry>Example 187 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(((R)-2,4- </entry></row><row><entry/><entry>dimethylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)-nicotinamide </entry></row><row><entry>Example 188 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((3-ethyl-4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)-nicotinamide </entry></row><row><entry>Example 189 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((cis-3,5- </entry></row><row><entry/><entry>dimethylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)-nicotinamide </entry></row><row><entry>Example 190 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((cis-3,4,5-trimethylpiperazin-1-yl)methyl)- </entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 191 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((trans-2,5- </entry></row><row><entry/><entry>dimethylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)-nicotinamide </entry></row><row><entry>Example 192 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-(((2R,5S)-2,4,5-trimethylpiperazin-1-yl) </entry></row><row><entry/><entry>methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)- </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 193 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((3- </entry></row><row><entry/><entry>(dimethylamino)pyrrolidin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)-nicotinamide </entry></row><row><entry>Example 194 </entry><entry>3-amino-6-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-pyrazine-2- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 195 </entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-fluoro-4&#x2032;-((4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)-nicotinamide </entry></row><row><entry>Example 196 </entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;,5&#x2032;-difluoro-4&#x2032;-((4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)-nicotinamide </entry></row><row><entry>Example 197 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-3&#x2032;- </entry></row><row><entry/><entry>(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)-methoxy) </entry></row><row><entry/><entry>cyclopentyl)nicotinamide </entry></row><row><entry>Example 198 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((3&#x2032;-methyl-4&#x2032;-((4-methylpiperazin-1-yl)methyl)- </entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)-methoxy)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 199 </entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-hydroxy-4&#x2032;-((4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)-nicotinamide </entry></row><row><entry>Example 200 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((4-methyl-piperazin-1-yl)methyl)-3&#x2032;-nitro- </entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)- </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 201 </entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;-methoxy-4&#x2032;-((4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)-nicotinamide </entry></row><row><entry>Example 202 </entry><entry>2-amino-N-((1S,2S)-2-((2&#x2032;-chloro-4&#x2032;-((4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)-nicotinamide </entry></row><row><entry>Example 203 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4-(6-((4-methyl-piperazin-1-yl)methyl)pyridin- </entry></row><row><entry/><entry>3-yl)benzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 204 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4-(5-((4-methyl-piperazin-1-yl)methyl)pyridin-2- </entry></row><row><entry/><entry>yl)benzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 205 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 206 </entry><entry>2-amino-N-((1S,2S)-2-((2&#x2032;-chloro-4&#x2032;-((4-(2- </entry></row><row><entry/><entry>hydroxyethyl)piperazin-1-yl)-methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 207 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-3&#x2032;-(trifluoro-methyl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 208 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-(1-(4-methyl-piperazin-1-yl)ethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 209 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-(1-((3S,5R)-3,4,5-trimethylpiperazin-1-yl) </entry></row><row><entry/><entry>ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)- </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 210 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl)- </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 211 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(1-((3S,5R)-4-(2- </entry></row><row><entry/><entry>hydroxyethyl)-3,5-dimethyl-piperazin-1-yl)ethyl)- </entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 212 </entry><entry>2-amino-N-((1S,2S)-2-((3&#x2032;,5&#x2032;-difluoro-4&#x2032;-(1-(4-(2- </entry></row><row><entry/><entry>hydroxyethyl)piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]- </entry></row><row><entry/><entry>4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol- </entry></row><row><entry/><entry>4-yl)nicotinamide </entry></row><row><entry>Example 213 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((R)-1-(piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]- </entry></row><row><entry/><entry>4-yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 214 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((R)-1-(4-methyl-piperazin-1-yl)ethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 215 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((4S)-1-(4-methyl-piperazin-1-yl)ethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 216 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-(1-(4-methyl-piperazin-1-yl)cyclopropyl)- </entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)- </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 217 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-(2-(4-methyl-piperazin-1-yl)propan-2-yl)- </entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl)- </entry></row><row><entry/><entry>nicodnamide </entry></row><row><entry>Example 218 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((R)-1-(4-(2- </entry></row><row><entry/><entry>hydroxyethyl)piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]- </entry></row><row><entry/><entry>4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol- </entry></row><row><entry/><entry>4-yl)-nicotinamide </entry></row><row><entry>Example 219 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((S)-1-(4-(2- </entry></row><row><entry/><entry>hydroxyethyl)piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]- </entry></row><row><entry/><entry>4-yl)methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol- </entry></row><row><entry/><entry>4-yl)-nicotinamide </entry></row><row><entry>Example 220 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)-cyclopropyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 221 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(2-(4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)-nicotinamide </entry></row><row><entry>Example 222 </entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((S)-1-(4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 223 </entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((4R)-1-(4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 224 </entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)cyclopropyl)-[1,1&#x2032;-biphenyl]- </entry></row><row><entry/><entry>4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 225 </entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(2-(4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)propan-2-yl)-[1,1&#x2032;-biphenyl]- </entry></row><row><entry/><entry>4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 226 </entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((S)-1-(4-(2- </entry></row><row><entry/><entry>hydroxyethyl)piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]- </entry></row><row><entry/><entry>4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 227 </entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-((R)-1-(4-(2- </entry></row><row><entry/><entry>hydroxyethyl)piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]- </entry></row><row><entry/><entry>4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 228 </entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2- </entry></row><row><entry/><entry>hydroxyethyl)piperazin-1-yl)cyclopropyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;- </entry></row><row><entry/><entry>bipyridine]-5-carboxamide </entry></row><row><entry>Example 229 </entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(2-(4-(2- </entry></row><row><entry/><entry>hydroxyethyl)piperazin-1-yl)-propan-2-yl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-[3,3&#x2032;- </entry></row><row><entry/><entry>bipyridine]-5-carboxamide </entry></row><row><entry>Example 230 </entry><entry>6-amino-5&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 231 </entry><entry>2-amino-5-chloro-N-((1S,2S)-2-((4&#x2032;-(1-(4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 232 </entry><entry>2-amino-5-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 233 </entry><entry>2-amino-5-cyano-N-((1S,2S)-2-((4&#x2032;-(1-(4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 234 </entry><entry>2-amino-6-chloro-N-((1S,2S)-2-((4&#x2032;-(1-(4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 235 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(1-(4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 236 </entry><entry>6-amino-5&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2- </entry></row><row><entry/><entry>hydroxyethyl)piperazin-1-yl)-ethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-((3,3&#x2032;- </entry></row><row><entry/><entry>bipyridine]-5-carboxamide </entry></row><row><entry>Example 237 </entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((4&#x2032;-(1-(4-(2- </entry></row><row><entry/><entry>hydroxyethyl)piperazin-1-yl)-ethyl)-[1,1&#x2032;-biphenyl]- </entry></row><row><entry/><entry>4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 238 </entry><entry>6-amino-2&#x2032;-fluoro-N-(1S,2S)-2-((4&#x2032;-(1-(4-(2- </entry></row><row><entry/><entry>hydroxyethyl)piperazin-1-yl)-ethyl)-[1,1&#x2032;-biphenyl]- </entry></row><row><entry/><entry>4-yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 239 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((1-methyl-piperidin-4-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-nicotinamide </entry></row><row><entry>Example 240 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((1-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperidin-4-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)-nicotinamide </entry></row><row><entry>Example 241 </entry><entry>methyl 2-(4-((4&#x2032;-((((1S,2S)-2-(2-amino-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)-nicotinamido)cyclopentyl)oxy) </entry></row><row><entry/><entry>methyl)-[1,1&#x2032;-biphenyl]-4-yl)methyl)piperidin-1-yl) </entry></row><row><entry/><entry>acetate </entry></row><row><entry>Example 242 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((1-(2-amino-2-oxoethyl) </entry></row><row><entry/><entry>piperidin-4-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)-nicotinamide </entry></row><row><entry>Example 243 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4-(3-(4-methyl-piperazin-1-yl)propyl)benzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 244 </entry><entry>2-amino-N-(1S,2S)-2-((4-(3-(dimethylamino)propyl) </entry></row><row><entry/><entry>benzyl)oxy)-cyclopentyl)-5-(1-methyl-1H-pyrazol- </entry></row><row><entry/><entry>4-yl)nicotinamide </entry></row><row><entry>Example 245 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(2-(dimethylamino) </entry></row><row><entry/><entry>ethoxy)-[1,1&#x2032;-biphenyl]-4-yl)-methoxy)cyclopentyl)- </entry></row><row><entry/><entry>5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 246 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-(3-(dimethylamino) </entry></row><row><entry/><entry>propoxy)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 247 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((1-methyl-piperidin-4-yl)oxy)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 248 </entry><entry>2-amino-N-((1S,2S)-2-((4-(3-(dimethylamino)prop-1- </entry></row><row><entry/><entry>yn-1-yl)benzyl)-oxy)cyclopentyl)-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 249 </entry><entry>2-amino-N-((1S,2S)-2-((4-(4-hydroxybut-1-yn-1-yl) </entry></row><row><entry/><entry>benzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)nicotinamide </entry></row><row><entry>Example 250 </entry><entry>2-amino-N-((1S,2S)-2-((4-(5-hydroxypent-1-yn-1- </entry></row><row><entry/><entry>yl)benzyl)oxy)-cyclopentyl)-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 251 </entry><entry>2-amino-N-((1S,2S)-2-((4-(6-hydroxyhex-1-yn-1-yl) </entry></row><row><entry/><entry>benzyl)oxy)cyclopentyl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)nicotinamide </entry></row><row><entry>Example 252 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(1S,2S)- </entry></row><row><entry/><entry>2-((4-(4-(4-methyl-piperazin-1-yl)but-1-yl)-1-yl) </entry></row><row><entry/><entry>benzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 253 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(4-((4-methylpiperazin-1-yl)methyl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 254 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(1-(piperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 255 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 256 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(1-(1-ethylpiperidin-4-yl)-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 257 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(1-(1-isopropylpiperidin-4-yl)-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 258 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(1-(1-(pyrrolidin-3-yl-methyl)piperidin-4-yl)-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 259 </entry><entry>2-amino-N-((1R,2R)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(1-(piperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 260 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dichlorobenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 261 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(3-(hydroxymethyl)-1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 262 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(3-(((2-hydroxyethyl)-amino)methyl)-1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 263 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(3-((3-hydroxypiperidin-1-yl)methyl)-1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 264 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(4-cyanophenyl)-nicotinamide </entry></row><row><entry>Example 265 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(3-cyanophenyl)-nicotinamide </entry></row><row><entry>Example 266 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(4-(cyanomethyl)-phenyl)nicotinamide </entry></row><row><entry>Example 267 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(4-phenoxyphenyl)-nicotinamide </entry></row><row><entry>Example 268 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-5- </entry></row><row><entry/><entry>(3-((1-methylpiperidin-4-yl)carbamoyl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 269 </entry><entry>6-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6&#x2032;- </entry></row><row><entry/><entry>(hydroxymethyl)-[3,3&#x2032;-bipyridine]-5-carboxamide </entry></row><row><entry>Example 270 </entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-((4-methyl-piperazin-1-yl)methyl) </entry></row><row><entry/><entry>phenyl)nicotinamide </entry></row><row><entry>Example 271 </entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(3-(4-methyl-piperazine-1-carbonyl) </entry></row><row><entry/><entry>phenyl)nicotinamide </entry></row><row><entry>Example 272 </entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(3-(4-(pyrrolidin-1-yl)piperidine-1- </entry></row><row><entry/><entry>carbonyl)phenyl)nicotinamide </entry></row><row><entry>Example 273 </entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(3-((4-methyl-piperazin-1-yl)methyl) </entry></row><row><entry/><entry>phenyl)nicotinamide </entry></row><row><entry>Example 274 </entry><entry>2-amino-5-(3-fluoro-4-((4-methylpiperazin-1-yl) </entry></row><row><entry/><entry>methyl)phenyl)-N-((1S,2S)-2-((3-methylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 275 </entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-((4-(pyrrolidin-1-yl)piperidin-1- </entry></row><row><entry/><entry>yl)methyl)phenyl)nicotinamide </entry></row><row><entry>Example 276 </entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(4-methyl-piperazine-1-carbonyl) </entry></row><row><entry/><entry>phenyl)nicotinamide </entry></row><row><entry>Example 277 </entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(4-(pyrrolidin-1-yl)piperidine-1- </entry></row><row><entry/><entry>carbonyl)phenyl)nicotinamide </entry></row><row><entry>Example 278 </entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(2-((1-methylpiperidin-4-yl) </entry></row><row><entry/><entry>amino)-2-oxoethyl)phenyl)nicotinamide </entry></row><row><entry>Example 279 </entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(2-(4-methylpiperazin-1-yl) </entry></row><row><entry/><entry>acetyl)phenyl)nicotinamide </entry></row><row><entry>Example 280 </entry><entry>2-amino-5-(3-fluoro-4-((4-(pyrrolidin-1-yl) </entry></row><row><entry/><entry>piperidin-1-yl)methyl)phenyl)-N-((1S,2S)-2-((3- </entry></row><row><entry/><entry>methylbenzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 281 </entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(4-(4-methylpiperazin-1-yl) </entry></row><row><entry/><entry>piperidine-1-carbonyl)phenyl)nicotinamide </entry></row><row><entry>Example 282 </entry><entry>2-amino-N-((1S,2S)-2-((3-methylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(piperazin-ylmethyl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 283 </entry><entry>2-amino-N-((1S,2S)-2-((4-methylbenzyl)oxy)- </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(4-methylpiperazine-1-carbonyl) </entry></row><row><entry/><entry>phenyl)nicotinamide </entry></row><row><entry>Example 284 </entry><entry>2-amino-N-((1S,2S)-2-((4-methylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(4-(pyrrolidin-1-yl)piperidine-1- </entry></row><row><entry/><entry>carbonyl)phenyl)nicotinamide </entry></row><row><entry>Example 285 </entry><entry>2-amino-5-(1,5-dimethyl-1H-pyrazol-4-yl)-N- </entry></row><row><entry/><entry>((1S,2S)-2-((3,4-dimethyl-benzyl)oxy)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 286 </entry><entry>2-amino-5-(1,3-dimethyl-1H-pyrazol-4-yl)-N- </entry></row><row><entry/><entry>((1S,2S)-2-((3,4-dimethyl-benzyl)oxy)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 287 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(2-(2-hydroxypropan-2-yl)-4- </entry></row><row><entry/><entry>methylthiazol-5-yl)nicotinamide </entry></row><row><entry>Example 288 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(2-(3-hydroxytetrahydrofuran-3-yl)- </entry></row><row><entry/><entry>4-methylthiazol-5-yl)nicotinamide </entry></row><row><entry>Example 289 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-5-(4-((4-methylpiperazin-1-yl) </entry></row><row><entry/><entry>methyl)phenyl)nicotinamide </entry></row><row><entry>Example 290 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(2-(4-methylpiperazin-1-yl)-2- </entry></row><row><entry/><entry>oxoethyl)phenyl)nicotinamide </entry></row><row><entry>Example 291 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(morpholinomethyl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 292 </entry><entry>2-amino-5-(4-((dimethylamino)methyl)phenyl)-N- </entry></row><row><entry/><entry>((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 293 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-((4-(2-hydroxyethyl)piperazin-1- </entry></row><row><entry/><entry>yl)methyl)phenyl)nicotinamide </entry></row><row><entry>Example 294 </entry><entry>6-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-2&#x2032;-methoxy-[3,3&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 295 </entry><entry>2-amino-5-(4-(dimethylamino)phenyl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((3,4-dimethylbenzyl)-oxy)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 296 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(3-hydroxy-phenyl)nicotinamide </entry></row><row><entry>Example 297 </entry><entry>2-amino-5-(3-aminophenyl)-N-((1S,2S)-2-((3,4- </entry></row><row><entry/><entry>dimethylbenzyl)oxy)-cyclopentyl)nicotinamide </entry></row><row><entry>Example 298 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(3-(methyl-sulfonamido)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 299 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(3-(hydroxy-methyl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 300 </entry><entry>2-amino-5-(3-(aminomethyl)phenyl)-N-((1S,2S)-2- </entry></row><row><entry/><entry>((3,4-dimethylbenzyl)-oxy)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 301 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(3-(3-hydroxypropyl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 302 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(3-((((1r,4S)-4-hydroxycyclohexyl) </entry></row><row><entry/><entry>amino)methyl)phenyl)nicotinamide </entry></row><row><entry>Example 303 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-((3-(((1-methylpiperidin-4-yl) </entry></row><row><entry/><entry>amino)methyl)phenyl)nicotinamide </entry></row><row><entry>Example 304 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(3-((((S)-piperidin-3-yl)amino) </entry></row><row><entry/><entry>methyl)phenyl)nicotinamide </entry></row><row><entry>Example 305 </entry><entry>3-(6-amino-5-(((1S,2S)-2-((3,4-dimethylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-carbamoyl)pyridin-3-yl)-5- </entry></row><row><entry/><entry>hydroxybenzoic acid </entry></row><row><entry>Example 306 </entry><entry>4-(6-amino-5-(((1S,2S)-2-((3,4-dimethylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)carbamoyl)-pyridin-3-yl)-2- </entry></row><row><entry/><entry>methylbenzoic acid </entry></row><row><entry>Example 307 </entry><entry>2-amino-5-(4-aminophenyl)-N-((1S,2S)-2-((3,4- </entry></row><row><entry/><entry>dimethylbenzyl)oxy-cyclopentyl)nicotinamide </entry></row><row><entry>Example 308 </entry><entry>3-(6-amino-5-(((1S,2S)-2-((3,4-dimethylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-carbamoyl)pyridin-3-yl)benzoic </entry></row><row><entry/><entry>acid </entry></row><row><entry>Example 309 </entry><entry>3-amino-5-(6-amino-5-(((1S,2S)-2-((3,4- </entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)-carbamoyl) </entry></row><row><entry/><entry>pyridin-3-yl)benzoic acid </entry></row><row><entry>Example 310 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(2-methyl-5-(4-(pyrrolidin-1-yl) </entry></row><row><entry/><entry>piperidine-1-carbonyl)phenyl)nicotinamide </entry></row><row><entry>Example 311 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-((3-methyl-4-(4-methylpiperazine-1- </entry></row><row><entry/><entry>carbonyl)phenyl)nicotinamide </entry></row><row><entry>Example 312 </entry><entry>2-amino-5-(3-amino-5-(4-(pyrrolidin-1-yl) </entry></row><row><entry/><entry>piperidine-1-carbonyl)phenyl)-N-((1S,2S)-2-((3,4- </entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 313 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-5-((4-(hydroxy-methyl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 314 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-((4-formyl-phenyl)nicotinamide </entry></row><row><entry>Example 315 </entry><entry>4-(6-amino-5-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)carbamoyl)pyridin-3-yl)benzoic acid </entry></row><row><entry>Example 316 </entry><entry>3-(4-(6-amino-5-(((1S,2S)-2-((3,4-dimethylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-carbamoyl)pyridin-3-yl)phenyl) </entry></row><row><entry/><entry>propanoic acid </entry></row><row><entry>Example 317 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(2-hydroxy-phenyl)nicotinamide </entry></row><row><entry>Example 318 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-((1-methylpiperidin-4-yl) </entry></row><row><entry/><entry>carbamoyl)phenyl)nicotinamide </entry></row><row><entry>Example 319 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-5-(4-(dimethylcarbamoyl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 320 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(((1-methylpiperidin-4-yl)amino) </entry></row><row><entry/><entry>methyl)phenyl)nicotinamide </entry></row><row><entry>Example 321 </entry><entry>6-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-6&#x2032;-(hydroxymethyl)-[3,3&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 322 </entry><entry>2-amino-4-(6-amino-5-(((1S,2S)-2-((3,4- </entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)carbamoyl) </entry></row><row><entry/><entry>pyridin-3-yl)benzoic acid </entry></row><row><entry>Example 323 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(hydroxymethyl)-3- </entry></row><row><entry/><entry>methoxyphenyl)nicotinamide </entry></row><row><entry>Example 324 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(3-fluoro-4-(hydroxymethyl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 325 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(3-fluoro-4-((4-(pyrrolidin-1-yl) </entry></row><row><entry/><entry>piperidin-1-yl)methyl)phenyl)nicotinamide </entry></row><row><entry>Example 326 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(1-hydroxyethyl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 327 </entry><entry>2-amino-5-(4-((3-(dimethylamino)pyrrolidin-1-yl) </entry></row><row><entry/><entry>methyl)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 328 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-((4-hydroxypiperidin-1-yl) </entry></row><row><entry/><entry>methyl)phenyl)nicotinamide </entry></row><row><entry>Example 329 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-((((1-methylpiperidin-4-yl)methyl) </entry></row><row><entry/><entry>amino)methyl)phenyl)nicotinamide </entry></row><row><entry>Example 330 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(3-methyl-4-(4-(pyrrolidin-1-yl) </entry></row><row><entry/><entry>piperidine-1-carbonyl)phenyl)nicotinamide </entry></row><row><entry>Example 331 </entry><entry>2-amino-5-(3-amino-4-(4-(pyrrolidin-1-yl) </entry></row><row><entry/><entry>piperidine-1-carbonyl)phenyl)-N-((1S,2S)-2-((3,4- </entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 332 </entry><entry>2-amino-5-(3-amino-4-((4-(pyrrolidin-1-yl) </entry></row><row><entry/><entry>piperidin-1-yl)methyl)phenyl)-N-((1S,2S)-2-((3,4- </entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 333 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(hydroxymethyl)-3-methylphenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 334 </entry><entry>2-amino-5-(3-chlorophenyl)-N-((1S,2S)-2-((3,4- </entry></row><row><entry/><entry>dimethylbenzyl)oxy)-cyclopentyl)nicotinamide </entry></row><row><entry>Example 335 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(m-tolyl)-nicotinamide </entry></row><row><entry>Example 336 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(3,5-dimethylphenyl)nicotinamide </entry></row><row><entry>Example 337 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-((3-morpholinopyrrolidin-1-yl) </entry></row><row><entry/><entry>methyl)phenyl)nicotinamide </entry></row><row><entry>Example 338 </entry><entry>2-amino-5-(4-((4-aminopiperidin-1-yl)methyl) </entry></row><row><entry/><entry>phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)nicotinamide </entry></row><row><entry>Example 339 </entry><entry>2-amino-5-(4-((3-aminopiperidin-1-yl)methyl) </entry></row><row><entry/><entry>phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)nicotinamide </entry></row><row><entry>Example 340 </entry><entry>2-amino-5-(4-((3-aminopyrrolidin-1-yl)methyl) </entry></row><row><entry/><entry>phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)nicotinamide </entry></row><row><entry>Example 341 </entry><entry>2-amino-5-(4-((3-aminopyrrolidin-1-yl)methyl)-3- </entry></row><row><entry/><entry>fluorophenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 342 </entry><entry>2-amino-5-(4-((3-aminopyrrolidin-1-yl)methyl)-3- </entry></row><row><entry/><entry>fluorophenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 343 </entry><entry>2-amino-5-(3-((3-(dimethylamino)pyrrolidin-1-yl) </entry></row><row><entry/><entry>methyl)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 344 </entry><entry>2-amino-5-(3-((3-(dimethylamino)pyrrolidin-1-yl) </entry></row><row><entry/><entry>methyl)-4-methoxyphenyl)-N-((1S,2S)-2-((3,4- </entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 345 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-((3-hydroxyazetidin-1-yl)methyl) </entry></row><row><entry/><entry>phenyl)nicotinamide </entry></row><row><entry>Example 346 </entry><entry>2-amino-5-(4-(((R)-3-(dimethylamino)pyrrolidin-1- </entry></row><row><entry/><entry>yl)methyl)phenyl)-N-((1S,2S)-2-((3,4- </entry></row><row><entry/><entry>dimethylbenzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 347 </entry><entry>2-amino-5-(4-(((S)-3-(dimethylamino)pyrrolidin-1-yl) </entry></row><row><entry/><entry>methyl)phenyl)-N-((1S,2S)-2-((3,4-dimethylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 348 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(((R)-3-hydroxypyrrolidin-1-yl) </entry></row><row><entry/><entry>methyl)phenyl)nicotinamide </entry></row><row><entry>Example 349 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(((S)-3-hydroxypyrrolidin-1-yl) </entry></row><row><entry/><entry>methyl)phenyl)nicotinamide </entry></row><row><entry>Example 350 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-((3-hydroxypiperidin-1-yl) </entry></row><row><entry/><entry>methyl)phenyl)nicotinamide </entry></row><row><entry>Example 351 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-((4-hydroxyphenyl)nicotinamide </entry></row><row><entry>Example 352 </entry><entry>2-amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-hydroxy-3-methoxyphenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 353 </entry><entry>2-amino-5-(3,4-dimethoxyphenyl)-N-((1S,2S)-2- </entry></row><row><entry/><entry>((3,4-dimethylbenzyl)oxy)-cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 354 </entry><entry>amino-N-((1S,2S)-2-((3,4-dimethylbenzyl)oxy) </entry></row><row><entry/><entry>cyclopentyl)-5-((3-(pyrrolidin-1-yl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 355 </entry><entry>2-amino-5-(5-amino-1-methyl-1H-pyrazol-4-yl)-N- </entry></row><row><entry/><entry>((1S,2S)-2-((3,4-dimethylbenzyl)oxy)cyclopentyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 356 </entry><entry>2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-5-((4-(hydroxymethyl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 357 </entry><entry>2-amino-5-(4-((3-(dimethylamino)pyrrolidin-1-yl) </entry></row><row><entry/><entry>methyl)phenyl)-N-((1S,2S)-2-((3-ethyl-4- </entry></row><row><entry/><entry>methylbenzyl)oxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 358 </entry><entry>2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-5-(4-((3-hydroxypyrrolidin-1- </entry></row><row><entry/><entry>yl)methyl)phenyl)nicotinamide </entry></row><row><entry>Example 359 </entry><entry>2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-5-(4-(2-(piperazin-1-yl)propan-2- </entry></row><row><entry/><entry>yl)phenyl)nicotinamide </entry></row><row><entry>Example 360 </entry><entry>2-amino-N-((1S,2S)-2-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)cyclopentyl)-5-(4-(2-(4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)propan-2-yl)phenyl)nicotinamide </entry></row><row><entry>Example 361 </entry><entry>3-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6- </entry></row><row><entry/><entry>(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazine-2- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 362 </entry><entry>(S)-3-amino-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)- </entry></row><row><entry/><entry>N-((1,2,3,4-tetrahydronaphthalen-1-yl)pyrazine-2- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 363 </entry><entry>2-amino-5-(4-fluorophenyl)-N-((1S,2S)-2-((4&#x2032;-((4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 364 </entry><entry>2-amino-5-(3,4-difluorophenyl)-N-((1S,2S)-2-((4&#x2032;- </entry></row><row><entry/><entry>((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 365 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(trifluoromethyl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 366 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-(1-methylpiperidin-4-yl)-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)-nicotinamide </entry></row><row><entry>Example 367 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(4-methylpiperazin-1-yl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 368 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-((4-methylpiperazin-1-yl)methyl) </entry></row><row><entry/><entry>phenyl)-nicotinamide </entry></row><row><entry>Example 369 </entry><entry>2-amino-5-(4-(hydroxymethyl)phenyl)-N-((1S,2S)- </entry></row><row><entry/><entry>2-((4&#x2032;-((4-methyl-piperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)-nicotinamide </entry></row><row><entry>Example 370 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(m-tolyl)nicotinamide </entry></row><row><entry>Example 371 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-phenylnicotinamide </entry></row><row><entry>Example 372 </entry><entry>2-amino-5-(4-hydroxyphenyl)-N-((1S,2S)-2-((4&#x2032;- </entry></row><row><entry/><entry>((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 373 </entry><entry>2-amino-5-(4-chloro-3-fluorophenyl)-N-((1S,2S)-2- </entry></row><row><entry/><entry>((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 374 </entry><entry>2-amino-5-methyl-N-((1S,2S)-2-((4&#x2032;-((4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 375 </entry><entry>6-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-[3,3&#x2032;-bipyridine]-5-carboxamide </entry></row><row><entry>Example 376 </entry><entry>2-amino-5-(4-methoxyphenyl)-N-((1S,2S)-2-((4&#x2032;- </entry></row><row><entry/><entry>((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 377 </entry><entry>6-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-[3,4&#x2032;-bipyridine]-5-carboxamide </entry></row><row><entry>Example 378 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-((4-methylpiperidin-1-yl)methyl) </entry></row><row><entry/><entry>phenyl)-nicotinamide </entry></row><row><entry>Example 379 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-(morpholinomethyl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 380 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-(tetrahydro-2H-pyran-4-yl)-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 381 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-morpholinophenyl)nicotinamide </entry></row><row><entry>Example 382 </entry><entry>2-amino-5-(cyclohex-1-en-1-yl)-N-((1S,2S)-2-((4&#x2032;- </entry></row><row><entry/><entry>((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 383 </entry><entry>2-amino-5-(3,4-dimethoxyphenyl)-N-((1S,2S)-2- </entry></row><row><entry/><entry>((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)cyclopentyl)nicotinamide </entry></row><row><entry>Example 384 </entry><entry>6-amino-2&#x2032;,6&#x2032;-difluoro-N-((1S,2S)-2-((4&#x2032;-((4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-[3,4&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 385 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(4-methylthiophen-3-yl)nicotinamide </entry></row><row><entry>Example 386 </entry><entry>6-amino-6&#x2032;-fluoro-N-((1S,2S)-2-((&#x2032;4-((4- </entry></row><row><entry/><entry>methylpiperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)cyclopentyl)-[3,3&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 387 </entry><entry>2-amino-N-((1S,2S)-2-((4&#x2032;-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>cyclopentyl)-5-(1-(1,1,2,2-tetrafluoroethyl)-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)-nicotinamide </entry></row><row><entry>Example 388 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)nicotinamide </entry></row><row><entry>Example 389 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(4-(hydroxymethyl) </entry></row><row><entry/><entry>phenyl)nicotinamide </entry></row><row><entry>Example 390 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(4-((4-methylpiperazin-1- </entry></row><row><entry/><entry>yl)methyl)phenyl)nicotinamide </entry></row><row><entry>Example 391 </entry><entry>2-amino-5-(4-carbamoylphenyl)-N-((3S,4S)-4-((3- </entry></row><row><entry/><entry>ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 392 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(m-tolyl)nicotinamide </entry></row><row><entry>Example 393 </entry><entry>4-(6-amino-5-(((3S,4S)-4-((3-ethyl-4- </entry></row><row><entry/><entry>methylbenzyl)oxy)pyrrolidin-3-yl)carbamoyl) </entry></row><row><entry/><entry>pyridin-3-yl)benzoic acid </entry></row><row><entry>Example 394 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-phenyl)nicotinamide </entry></row><row><entry>Example 395 </entry><entry>6-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-[3,4&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 396 </entry><entry>6-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-[3,3&#x2032;-bipyridine]-5- </entry></row><row><entry/><entry>carboxamide </entry></row><row><entry>Example 397 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-vinylnicotinamide </entry></row><row><entry>Example 398 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(4-fluorophenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 399 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(4-formylphenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 400 </entry><entry>2-amino-5-(4-cyanophenyl)-N-((3S,4S)-4-((3-ethyl- </entry></row><row><entry/><entry>4-methylbenzyl)oxy)pyrrolidin-3-yl)nicotinamide </entry></row><row><entry>Example 401 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(4-(methylsulfonamido) </entry></row><row><entry/><entry>phenyl)nicotinamide </entry></row><row><entry>Example 402 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(4-phenoxyphenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 403 </entry><entry>5-([1,1&#x2032;-biphenyl]-4-yl)-2-amino-N-((3S,4S)-4-((3- </entry></row><row><entry/><entry>ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 404 </entry><entry>2-amino-5-(4-(benzyloxy)phenyl)-N-((3S,4S)-4-((3- </entry></row><row><entry/><entry>ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 405 </entry><entry>2-amino-5-(4-(dimethylamino)phenyl)-N-((3S,4S)- </entry></row><row><entry/><entry>4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 406 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(quinolin-3-yl)nicotinamide </entry></row><row><entry>Example 407 </entry><entry>2-amino-5-(benzofuran-2-yl)-N-((3S,4S)-4-((3- </entry></row><row><entry/><entry>ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 408 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(naphthalen-1-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 409 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(4-(trifluoromethyl)phenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 410 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(2,4,5-trifluorophenyl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 411 </entry><entry>2-amino-5-(4-(cyanomethyl)phenyl)-N-((3S,4S)-4- </entry></row><row><entry/><entry>((3-ethyl-4-methylbenzyl)oxy)pyrrolidin-3-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 412 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(1-(piperidin-4-yl)-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 413 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(1-(1-methylpiperidin-4-yl)- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 414 </entry><entry>2-amino-N-((3S,4S)-4-(benzyloxy)pyrrolidin-3-yl)- </entry></row><row><entry/><entry>5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 415 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)- </entry></row><row><entry/><entry>4-((4-methylbenzyl)oxy)pyrrolidin-3-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 416 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethylbenzyl)oxy) </entry></row><row><entry/><entry>pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 417 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-fluorobenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 418 </entry><entry>2-amino-N-((3S,4S)-4-((4-chloro-3-ethylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 419 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(4-((1-methylpiperidin-4-yl) </entry></row><row><entry/><entry>carbamoyl)phenyl)nicotinamide </entry></row><row><entry>Example 420 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(4-((4-methylcyclohexyl) </entry></row><row><entry/><entry>carbamoyl)phenyl)nicotinamide </entry></row><row><entry>Example 421 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(4-(4-methylpiperidine-1- </entry></row><row><entry/><entry>carbonyl)phenyl)nicotinamide </entry></row><row><entry>Example 422 </entry><entry>2-amino-5-(4-(dimethylcarbamoyl)phenyl)-N- </entry></row><row><entry/><entry>((3S,4S)-4-((3-ethyl-4-methylbenzyl)oxy)pyrrolidin- </entry></row><row><entry/><entry>3-yl)nicotinamide </entry></row><row><entry>Example 423 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(4-((4-methylpiperidin-1-yl) </entry></row><row><entry/><entry>methyl)phenyl)nicotinamide </entry></row><row><entry>Example 424 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)-5-(4-(morpholinomethyl) </entry></row><row><entry/><entry>phenyl)nicotinamide </entry></row><row><entry>Example 425 </entry><entry>2-amino-5-(4-((3,3-difluoropiperidin-1-yl)methyl) </entry></row><row><entry/><entry>phenyl)-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)pyrrolidin-3-yl)nicotinamide </entry></row><row><entry>Example 426 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)-1-methylpyrrolidin-3-yl)-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 427 </entry><entry>2-amino-N-((3S,4S)-1-benzyl-4-((3-ethyl-4- </entry></row><row><entry/><entry>methylbenzyl)oxy)pyrrolidin-3-yl)-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 428 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)-1-(3-phenylpropyl)pyrrolidin-3-yl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 429 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)-1-phenethylpyrrolidin-3-yl)-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 430 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)-1-isobutylpyrrolidin-3-yl)-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 431 </entry><entry>2-amino-N-((3S,4S)-1-butyl-4-((3-ethyl-4- </entry></row><row><entry/><entry>methylbenzyl)oxy)pyrrolidin-3-yl)-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 432 </entry><entry>2-amino-N-((3S,4S)-1-ethyl-4-((3-ethyl-4- </entry></row><row><entry/><entry>methylbenzyl)oxy)pyrrolidin-3-yl)-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 433 </entry><entry>2-amino-N-((3S,4S)-4-((3-ethyl-4-methylbenzyl) </entry></row><row><entry/><entry>oxy)-1-methylpyrrolidin-3-yl)-5-(1-(1- </entry></row><row><entry/><entry>methylpiperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 434 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)- </entry></row><row><entry/><entry>4-((4&#x2032;-((4-methyl-piperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)- </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 435 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)- </entry></row><row><entry/><entry>1-methyl-4-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)- </entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-3- </entry></row><row><entry/><entry>yl)nicotinamide </entry></row><row><entry>Example 436 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)- </entry></row><row><entry/><entry>4-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-3&#x2032;- </entry></row><row><entry/><entry>(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>pyrrolidin-3-yl)nicotinamid </entry></row><row><entry>Example 437 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)- </entry></row><row><entry/><entry>1-methyl-4-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)- </entry></row><row><entry/><entry>3&#x2032;-(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>pyrrolidin-3-yl)nicotinamide </entry></row><row><entry>Example 438 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)- </entry></row><row><entry/><entry>4-((4&#x2032;-(1-(4-methyl-piperazin-1-yl)ethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)- </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 439 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4S)- </entry></row><row><entry/><entry>1-methyl-4-((4&#x2032;-(1-(4-methylpiperazin-1-yl)ethyl)- </entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)- </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 440 </entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-(2-(4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol- </entry></row><row><entry/><entry>4-yl)nicotinamide </entry></row><row><entry>Example 441 </entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-(2-(4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4- </entry></row><row><entry/><entry>yl)methoxy)-1-methylpyrrolidin-3-yl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 442 </entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-(1-(4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol- </entry></row><row><entry/><entry>4-yl)-nicotinamide </entry></row><row><entry>Example 443 </entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-(1-(4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)ethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)- </entry></row><row><entry/><entry>1-methylpyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol-4- </entry></row><row><entry/><entry>yl)nicotinamide </entry></row><row><entry>Example 444 </entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-((4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)pyrrolidin-3-yl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 445 </entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-((4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)-1-methylpyrrolidin-3-yl)- </entry></row><row><entry/><entry>5-(1-methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 446 </entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-((4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)pyrrolidin-3-yl)-5-(1-methyl-1H-pyrazol- </entry></row><row><entry/><entry>4-yl)nicotinamide </entry></row><row><entry>Example 447 </entry><entry>2-amino-N-((3S,4S)-4-((4&#x2032;-((4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)-1-methylpyrrolidin-3-yl)-5-(1-methyl- </entry></row><row><entry/><entry>1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 448 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4R)- </entry></row><row><entry/><entry>4-((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 449 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4R)- </entry></row><row><entry/><entry>4-((4&#x2032;-((4-methyl-piperazin-1-yl)methyl)-3&#x2032;- </entry></row><row><entry/><entry>(trifluoromethyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy)- </entry></row><row><entry/><entry>tetrahydrofuran-3-yl)nicotinamide </entry></row><row><entry>Example 450 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-((3S,4R)- </entry></row><row><entry/><entry>4-((4&#x2032;-(2-(4-methyl-piperazin-1-yl)propan-2-yl)- </entry></row><row><entry/><entry>[1,1&#x2032;-biphenyl]-4-yl)methoxy)tetrahydrofuran-3- </entry></row><row><entry/><entry>yl)nicotinamide </entry></row><row><entry>Example 451 </entry><entry>2-amino-N-((3S,4R)-4-((4&#x2032;-((4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)methyl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)tetrahydrofuran-3-yl)-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)-nicotinamide </entry></row><row><entry>Example 452 </entry><entry>2-amino-N-((3S,4R)-4-((4&#x2032;-((4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)methyl)-3&#x2032;-(trifluoromethyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl)-5-(1- </entry></row><row><entry/><entry>methyl-1H-pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 453 </entry><entry>2-amino-N-((3S,4R)-4-((4&#x2032;-(2-(4-(2-hydroxyethyl) </entry></row><row><entry/><entry>piperazin-1-yl)propan-2-yl)-[1,1&#x2032;-biphenyl]-4-yl) </entry></row><row><entry/><entry>methoxy)tetrahydrofuran-3-yl)-5-(1-methyl-1H- </entry></row><row><entry/><entry>pyrazol-4-yl)nicotinamide </entry></row><row><entry>Example 454 </entry><entry>2-amino-5-(1-methyl-1H-pyrazol-4-yl)-N-(trans-4- </entry></row><row><entry/><entry>((4&#x2032;-((4-methylpiperazin-1-yl)methyl)-[1,1&#x2032;- </entry></row><row><entry/><entry>biphenyl]-4-yl)methoxy)tetrahydrofuran-3-yl) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 455 </entry><entry>2-amino-N-(trans-4-((4&#x2032;-((4-methylpiperazin-1-yl) </entry></row><row><entry/><entry>methyl)-[1,1&#x2032;-biphenyl]-4-yl)methoxy) </entry></row><row><entry/><entry>tetrahydrofuran-3-yl)nicotinamide </entry></row><row><entry>Example 456 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6- </entry></row><row><entry/><entry>((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino) </entry></row><row><entry/><entry>nicotinamide </entry></row><row><entry>Example 457 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6- </entry></row><row><entry/><entry>(phenylamino)nicotinamide; and </entry></row><row><entry>Example 458 </entry><entry>2-amino-N-((1S,2S)-2-(benzyloxy)cyclopentyl)-6- </entry></row><row><entry/><entry>((4-(4-methylpiperazin-1-yl)phenyl)amino) </entry></row><row><entry/><entry>nicotinamide.</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. A pharmaceutical composition comprising the heterocyclic compound, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt thereof according to <claim-ref idref="CLM-00001">claim 1</claim-ref> together with a pharmaceutically acceptable carrier.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The pharmaceutical composition of <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein the composition comprises, as an active ingredient, the heterocyclic compound, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt thereof in an amount effective for prevention or treatment of a disease that is influenced by inhibition of Mer kinase.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The pharmaceutical composition of <claim-ref idref="CLM-00006">claim 6</claim-ref>, wherein the disease which is influenced by inhibition of Mer kinase is cancer or an immune-related disease.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The pharmaceutical composition of <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein the cancer is selected from the group consisting of: glioma, gliosarcoma, anaplastic astrocytoma, medulloblastoma, lung cancer, small cell lung carcinoma, cervical carcinoma, colon cancer, rectal cancer, chordoma, throat cancer, Kaposi's sarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, colorectal cancer, endometrium cancer, ovarian cancer, breast cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, hepatic carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, testicular tumor, Wilms' tumor, Ewing's tumor, bladder carcinoma, angiosarcoma, endotheliosarcoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland sarcoma, papillary sarcoma, papillary adenosarcoma, cystadenosarcoma, bronchogenic carcinoma, medullary carcinoma, mastocytoma, mesotheliorma, synovioma, melanoma, leiomyosarcoma, rhabdomyosarcoma, neuroblastoma, retinoblastoma, oligodentroglioma, acoustic neuroma, hemangioblastoma, meningioma, pinealoma, ependymoma, craniopharyngioma, epithelial carcinoma, embryonal carcinoma, squamous cell carcinoma, base cell carcinoma, fibrosarcoma, myxoma, myxosarcoma, liposarcorna, chondrosarcoma, osteogenic sarcoma, leukemia and metastatic lesions secondary to these primary tumors.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The pharmaceutical composition of <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein the immune-related disease is selected from the group consisting of infection and sepsis.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. A method of treating or preventing an immune-related disease or cancer, the method comprising administering to a mammal in need thereof compositions comprising, as active ingredients, the heterocyclic compounds, isomers thereof or pharmaceutically acceptable salts thereof according to <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The method of <claim-ref idref="CLM-00010">claim 10</claim-ref>, wherein the mammal is a human.</claim-text></claim></claims></us-patent-application>